# RGD-PIPELINE: ftp-file-extracts # MODULE: annotations-version-1.1.9 (Oct 10, 2019) # GENERATED-ON: 2025/02/01 # PURPOSE: annotations about active Human objects extracted from RGD database # ONTOLOGY: ChEBI: ChEBI Ontology # CONTACT: rgd.data@mcw.edu # FORMAT: tab delimited text # NOTES: multiple values in a single column are separated by '|' # #COLUMN INFORMATION: # #1 RGD_ID unique RGD_ID of the annotated object #2 OBJECT_SYMBOL official symbol of the annotated object #3 OBJECT_NAME official name of the annotated object #4 OBJECT_TYPE annotated object data type: one of ['gene','qtl','strain'] #5 TERM_ACC_ID ontology term accession id #6 TERM_NAME ontology term name #7 QUALIFIER optional qualifier #8 EVIDENCE evidence #9 WITH with info #10 ASPECT aspect #11 REFERENCES db references (Reference RGDID|PUBMED ID) #12 CREATED_DATE created date #13 ASSIGNED_BY assigned by #14 MESH_OMIM_ID MESH:xxx or OMIM:xxx id corresponding to RDO:xxx id found in TERM_ACC_ID column (RGD/CTD Disease Ontology annotations only) #15 CURATION_NOTES curation notes provided by RGD curators #16 ORIGINAL_REFERENCE original reference RGD_ID OBJECT_SYMBOL OBJECT_NAME OBJECT_TYPE TERM_ACC_ID TERM_NAME QUALIFIER EVIDENCE WITH ASPECT REFERENCES CREATED_DATE ASSIGNED_BY MESH_OMIM_ID CURATION_NOTES ORIGINAL_REFERENCE 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:132267 triptonide affects expression ISO RGD:408345430 E RGD:6480464 20241105 CTD MESH:C084079 triptonide affects the expression of TTC41 mRNA PMID:33045310 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:15600 (+)-catechin multiple interactions EXP E RGD:6480464 20150428 CTD MESH:D002392 [Catechin co-treated with Grape Seed Proanthocyanidins] results in decreased expression of TTC41P mRNA PMID:24763279 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20161025 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of TTC41P gene PMID:27153756 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of TTC41P mRNA PMID:34032870 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:29678 sodium arsenite multiple interactions ISO RGD:408345430 E RGD:6480464 20241105 CTD MESH:C017947 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TTC41 mRNA PMID:34876320 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:29852 methylarsonic acid multiple interactions ISO RGD:408345430 E RGD:6480464 20241105 CTD MESH:C020300 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TTC41 mRNA PMID:34876320 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:32234 titanium dioxide decreases expression ISO RGD:408345430 E RGD:6480464 20241105 CTD MESH:C009495 titanium dioxide results in decreased expression of TTC41 mRNA PMID:35295148 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:33216 bisphenol A decreases expression ISO RGD:1302940 E RGD:6480464 20211102 CTD MESH:C006780 bisphenol A results in decreased expression of TTC41P mRNA PMID:25181051 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:33216 bisphenol A decreases expression ISO RGD:408345430 E RGD:6480464 20241105 CTD MESH:C006780 bisphenol A results in decreased expression of TTC41 mRNA PMID:32156529 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:34575 bisphenol F decreases expression ISO RGD:408345430 E RGD:6480464 20241105 CTD MESH:C008745 bisphenol F results in decreased expression of TTC41 mRNA PMID:38685157 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of TTC41P mRNA PMID:38568856 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:48765 dimethylarsinic acid multiple interactions ISO RGD:408345430 E RGD:6480464 20241105 CTD MESH:D002101 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TTC41 mRNA PMID:34876320 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:63618 pravastatin decreases expression ISO RGD:408345430 E RGD:6480464 20241105 CTD MESH:D017035 Pravastatin results in decreased expression of TTC41 mRNA PMID:27225895 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:81520 2,3',4,4',5-Pentachlorobiphenyl increases expression ISO RGD:408345430 E RGD:6480464 20241105 CTD MESH:C070055 2,3',4,4',5-pentachlorobiphenyl results in increased expression of TTC41 mRNA PMID:31388691 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:8228 pioglitazone multiple interactions ISO RGD:408345430 E RGD:6480464 20241105 CTD MESH:C060836 [N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of TTC41 mRNA PMID:27935865 10002693 TTC41P tetratricopeptide repeat domain 41, pseudogene gene CHEBI:84070 sodium arsenate multiple interactions ISO RGD:408345430 E RGD:6480464 20241105 CTD MESH:C009277 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TTC41 mRNA PMID:34876320 10002854 MCPH1-AS1 MCPH1 antisense RNA 1 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in increased expression of MCPH1-AS1 mRNA PMID:29301061|PMID:38568856 10002854 MCPH1-AS1 MCPH1 antisense RNA 1 gene CHEBI:31835 methylparaben increases expression EXP E RGD:6480464 20200609 CTD MESH:C015358 methylparaben results in increased expression of MCPH1-AS1 mRNA PMID:31745603 10002854 MCPH1-AS1 MCPH1 antisense RNA 1 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of MCPH1-AS1 mRNA PMID:38568856 10002854 MCPH1-AS1 MCPH1 antisense RNA 1 gene CHEBI:53620 methylisothiazolinone increases expression EXP E RGD:6480464 20200714 CTD MESH:C011506 2-methyl-4-isothiazolin-3-one results in increased expression of MCPH1-AS1 mRNA PMID:31629900 10002876 LINC01608 long intergenic non-protein coding RNA 1608 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC01608 intron PMID:30157460 10002876 LINC01608 long intergenic non-protein coding RNA 1608 gene CHEBI:6402 leflunomide increases expression EXP E RGD:6480464 20180410 CTD MESH:C045463 leflunomide results in increased expression of LINC01608 mRNA PMID:28988120 10002894 UBR5-DT UBR5 divergent transcript gene CHEBI:28619 acrylamide increases expression EXP E RGD:6480464 20210406 CTD MESH:D020106 Acrylamide results in increased expression of UBR5-DT mRNA PMID:32763439 10002903 LINC01606 long intergenic non-protein coding RNA 1606 gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of LINC01606 intron PMID:30157460 10002903 LINC01606 long intergenic non-protein coding RNA 1606 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of LINC01606 intron PMID:30157460 10002903 LINC01606 long intergenic non-protein coding RNA 1606 gene CHEBI:6402 leflunomide increases expression EXP E RGD:6480464 20180410 CTD MESH:C045463 leflunomide results in increased expression of LINC01606 mRNA PMID:28988120 10002925 LINC01605 long intergenic non-protein coding RNA 1605 gene CHEBI:16236 ethanol decreases expression EXP E RGD:6480464 20180515 CTD MESH:D000431 Ethanol results in decreased expression of LINC01605 mRNA PMID:28986285 10002925 LINC01605 long intergenic non-protein coding RNA 1605 gene CHEBI:28358 rac-lactic acid decreases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in decreased expression of LINC01605 mRNA PMID:30851411 10002925 LINC01605 long intergenic non-protein coding RNA 1605 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in decreased expression of LINC01605 mRNA PMID:29301061 10002925 LINC01605 long intergenic non-protein coding RNA 1605 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01605 mRNA PMID:38568856 10002925 LINC01605 long intergenic non-protein coding RNA 1605 gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20200519 CTD MESH:C006780 bisphenol A results in decreased expression of LINC01605 mRNA PMID:31715268 10002925 LINC01605 long intergenic non-protein coding RNA 1605 gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of LINC01605 intron PMID:30157460 10002925 LINC01605 long intergenic non-protein coding RNA 1605 gene CHEBI:53620 methylisothiazolinone increases expression EXP E RGD:6480464 20200714 CTD MESH:C011506 2-methyl-4-isothiazolin-3-one results in increased expression of LINC01605 mRNA PMID:31629900 10002925 LINC01605 long intergenic non-protein coding RNA 1605 gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of LINC01605 intron PMID:30157460 10002925 LINC01605 long intergenic non-protein coding RNA 1605 gene CHEBI:78320 2-hydroxypropanoic acid decreases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in decreased expression of LINC01605 mRNA PMID:30851411 10002925 LINC01605 long intergenic non-protein coding RNA 1605 gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of LINC01605 mRNA PMID:38568856 10002948 MINCR MYC-induced long non-coding RNA gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of MINCR mRNA PMID:38218311 10002948 MINCR MYC-induced long non-coding RNA gene CHEBI:28112 nickel atom decreases expression EXP E RGD:6480464 20150609 CTD MESH:D009532 Nickel results in decreased expression of MINCR mRNA PMID:24768652 10002948 MINCR MYC-induced long non-coding RNA gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in decreased expression of MINCR mRNA PMID:38568856 10002959 CA3-AS1 CA3 antisense RNA 1 gene CHEBI:28358 rac-lactic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of CA3-AS1 mRNA PMID:30851411 10002959 CA3-AS1 CA3 antisense RNA 1 gene CHEBI:78320 2-hydroxypropanoic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of CA3-AS1 mRNA PMID:30851411 10002976 PKIA-AS1 PKIA antisense RNA 1 gene CHEBI:29865 benzo[a]pyrene multiple interactions EXP E RGD:6480464 20241105 CTD MESH:D001564 [AHR gene mutant form affects the susceptibility to Benzo(a)pyrene] which results in increased expression of PKIA-AS1 PMID:38036013 10002985 LINC01609 long intergenic non-protein coding RNA 1609 gene CHEBI:181914 Aflatoxin B2 alpha decreases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in decreased methylation of LINC01609 polyA tail PMID:30157460 10002985 LINC01609 long intergenic non-protein coding RNA 1609 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of LINC01609 polyA tail PMID:30157460 10002996 PARTICL promoter of MAT2A antisense radiation-induced circulating long non-coding RNA gene CHEBI:27899 cisplatin multiple interactions EXP E RGD:6480464 20170516 CTD MESH:D002945 [Cisplatin co-treated with jinfukang] results in increased expression of PARTICL mRNA PMID:27392435 10002996 PARTICL promoter of MAT2A antisense radiation-induced circulating long non-coding RNA gene CHEBI:34575 bisphenol F increases expression ISO RGD:1613016 E RGD:6480464 20241105 CTD MESH:C008745 bisphenol F results in increased expression of PARTICL mRNA PMID:38685157 10002996 PARTICL promoter of MAT2A antisense radiation-induced circulating long non-coding RNA gene CHEBI:9753 troglitazone decreases expression ISO RGD:1613016 E RGD:6480464 20180220 CTD MESH:C057693 troglitazone results in decreased expression of PARTICL mRNA PMID:28973697 10003000 LINC01602 long intergenic non-protein coding RNA 1602 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01602 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01602 mRNA PMID:35811015 10003000 LINC01602 long intergenic non-protein coding RNA 1602 gene CHEBI:46195 paracetamol decreases expression EXP E RGD:6480464 20150505 CTD MESH:D000082 Acetaminophen results in decreased expression of LINC01602 mRNA PMID:22230336 10003000 LINC01602 long intergenic non-protein coding RNA 1602 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of LINC01602 mRNA PMID:35811015 10003000 LINC01602 long intergenic non-protein coding RNA 1602 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01602 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01602 mRNA PMID:35811015 10003008 RDH10-AS1 RDH10 antisense RNA 1 gene CHEBI:75455 2-palmitoylglycerol increases expression EXP E RGD:6480464 20240109 CTD MESH:C114956 2-palmitoylglycerol results in increased expression of RDH10-AS1 mRNA PMID:37199045 10040878 CROCC2 ciliary rootlet coiled-coil, rootletin family member 2 gene CHEBI:25812 ozone multiple interactions ISO RGD:1621187 E RGD:6480464 20220809 CTD MESH:D010126 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of CROCC2 mRNA; [Air Pollutants results in increased abundance of Ozone] which results in increased expression of CROCC2 mRNA PMID:34911549 10040878 CROCC2 ciliary rootlet coiled-coil, rootletin family member 2 gene CHEBI:28088 genistein decreases expression ISO RGD:1621187 E RGD:6480464 20200804 CTD MESH:D019833 Genistein results in decreased expression of CROCC2 mRNA PMID:32186404 10040878 CROCC2 ciliary rootlet coiled-coil, rootletin family member 2 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of CROCC2 intron PMID:30157460 10040878 CROCC2 ciliary rootlet coiled-coil, rootletin family member 2 gene CHEBI:29865 benzo[a]pyrene increases expression EXP E RGD:6480464 20241105 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of CROCC2 mRNA PMID:38036013 10040878 CROCC2 ciliary rootlet coiled-coil, rootletin family member 2 gene CHEBI:34372 4,4'-sulfonyldiphenol increases expression ISO RGD:1621187 E RGD:6480464 20191112 CTD MESH:C543008 bisphenol S results in increased expression of CROCC2 mRNA PMID:30951980 10040878 CROCC2 ciliary rootlet coiled-coil, rootletin family member 2 gene CHEBI:34575 bisphenol F increases expression ISO RGD:1621187 E RGD:6480464 20191112 CTD MESH:C008745 bisphenol F results in increased expression of CROCC2 mRNA PMID:30951980 10040878 CROCC2 ciliary rootlet coiled-coil, rootletin family member 2 gene CHEBI:50594 carbon nanotube increases expression ISO RGD:1621187 E RGD:6480464 20161228 CTD MESH:D037742 Nanotubes, Carbon results in increased expression of CROCC2 mRNA PMID:27106021 10043458 GTF2IP20 general transcription factor IIi pseudogene 20 gene CHEBI:10429 beta-lapachone increases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in increased expression of GTF2IP20 mRNA PMID:38218311 10043458 GTF2IP20 general transcription factor IIi pseudogene 20 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of GTF2IP20 mRNA PMID:35811015 10043458 GTF2IP20 general transcription factor IIi pseudogene 20 gene CHEBI:16598 DDE decreases expression EXP E RGD:6480464 20240702 CTD MESH:D003633 Dichlorodiphenyl Dichloroethylene results in decreased expression of GTF2IP20 mRNA PMID:38568856 10043458 GTF2IP20 general transcription factor IIi pseudogene 20 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of GTF2IP20 mRNA PMID:33212167 10043458 GTF2IP20 general transcription factor IIi pseudogene 20 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20160119 CTD MESH:D019256 Cadmium Chloride results in increased expression of GTF2IP20 mRNA PMID:26472689 10043458 GTF2IP20 general transcription factor IIi pseudogene 20 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of GTF2IP20 mRNA PMID:35811015 10043509 TUBB8B tubulin beta 8B gene CHEBI:4806 (-)-epigallocatechin 3-gallate increases expression EXP E RGD:6480464 20191008 CTD MESH:C045651 epigallocatechin gallate results in increased expression of TUBB8B protein PMID:31195006 10043521 LRP1-AS LRP1 antisense RNA gene CHEBI:16412 lipopolysaccharide decreases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in decreased expression of LRP1-AS mRNA PMID:35811015 10043521 LRP1-AS LRP1 antisense RNA gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LRP1-AS mRNA PMID:35811015 10043521 LRP1-AS LRP1 antisense RNA gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LRP1-AS mRNA PMID:35811015 10043559 GTF2IP4 general transcription factor IIi pseudogene 4 gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of GTF2IP4 mRNA PMID:38218311 10043559 GTF2IP4 general transcription factor IIi pseudogene 4 gene CHEBI:28748 doxorubicin decreases expression EXP E RGD:6480464 20181113 CTD MESH:D004317 Doxorubicin results in decreased expression of GTF2IP4 mRNA PMID:29803840 10043559 GTF2IP4 general transcription factor IIi pseudogene 4 gene CHEBI:35456 cadmium dichloride decreases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in decreased expression of GTF2IP4 mRNA PMID:38568856 10043559 GTF2IP4 general transcription factor IIi pseudogene 4 gene CHEBI:38940 sunitinib decreases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in decreased expression of GTF2IP4 mRNA PMID:31533062 10043559 GTF2IP4 general transcription factor IIi pseudogene 4 gene CHEBI:5063 fipronil increases expression EXP E RGD:6480464 20190219 CTD MESH:C082360 fipronil results in increased expression of GTF2IP4 mRNA PMID:28991164 10043559 GTF2IP4 general transcription factor IIi pseudogene 4 gene CHEBI:5063 fipronil multiple interactions EXP E RGD:6480464 20190219 CTD MESH:C082360 [fipronil co-treated with DEET] results in increased expression of GTF2IP4 mRNA PMID:28991164 10043559 GTF2IP4 general transcription factor IIi pseudogene 4 gene CHEBI:7071 N,N-diethyl-m-toluamide multiple interactions EXP E RGD:6480464 20190219 CTD MESH:D003671 [fipronil co-treated with DEET] results in increased expression of GTF2IP4 mRNA PMID:28991164 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:174733 Licochalcone B increases expression EXP E RGD:6480464 20210706 CTD MESH:C541528 licochalcone B results in increased expression of UQCRHL mRNA PMID:33647349 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:22977 cadmium atom multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D002104 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of UQCRHL mRNA PMID:35301059 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:27899 cisplatin decreases expression EXP E RGD:6480464 20170516 CTD MESH:D002945 Cisplatin results in decreased expression of UQCRHL mRNA PMID:27392435 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:28201 rotenone decreases expression EXP E RGD:6480464 20210907 CTD MESH:D012402 Rotenone results in decreased expression of UQCRHL mRNA PMID:32368861 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:28201 rotenone multiple interactions EXP E RGD:6480464 20210907 CTD MESH:D012402 PSME4 protein promotes the reaction [Rotenone results in decreased expression of UQCRHL protein] PMID:32368861 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:28358 rac-lactic acid decreases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in decreased expression of UQCRHL mRNA PMID:30851411 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:28619 acrylamide increases expression EXP E RGD:6480464 20210406 CTD MESH:D020106 Acrylamide results in increased expression of UQCRHL mRNA PMID:32763439 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:31575 ethylparaben decreases expression EXP E RGD:6480464 20240109 CTD MESH:C012313 ethyl-p-hydroxybenzoate results in decreased expression of UQCRHL mRNA PMID:37690743 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:35033 triphenyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C005445 triphenyl phosphate affects the expression of UQCRHL mRNA PMID:37042841 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:35456 cadmium dichloride multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D019256 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of UQCRHL mRNA PMID:35301059 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:38940 sunitinib decreases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in decreased expression of UQCRHL mRNA PMID:31533062 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:39285 chloropicrin affects expression EXP E RGD:6480464 20151215 CTD MESH:C100187 chloropicrin affects the expression of UQCRHL mRNA PMID:26352163 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:46195 paracetamol increases expression EXP E RGD:6480464 20180515 CTD MESH:D000082 Acetaminophen results in increased expression of UQCRHL mRNA PMID:29067470 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:78320 2-hydroxypropanoic acid decreases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in decreased expression of UQCRHL mRNA PMID:30851411 10045718 UQCRHL ubiquinol-cytochrome c reductase hinge protein like gene CHEBI:94688 5-methyl-4-oxido-2-pyrazin-4-iumcarboxylic acid increases expression EXP E RGD:6480464 20170307 CTD MESH:C027696 acipimox results in increased expression of UQCRHL mRNA PMID:25352640 10045909 KLF18 KLF transcription factor 18 gene CHEBI:132267 triptonide increases expression ISO RGD:1320802 E RGD:6480464 20210406 CTD MESH:C084079 triptonide results in increased expression of ZFP352 mRNA PMID:33045310 10045909 KLF18 KLF transcription factor 18 gene CHEBI:15930 atrazine affects methylation ISO RGD:1310095 E RGD:6480464 20230905 CTD MESH:D001280 Atrazine affects the methylation of ZFP352 gene PMID:35440735 10045909 KLF18 KLF transcription factor 18 gene CHEBI:16602 trichloroethene increases expression ISO RGD:1310095 E RGD:6480464 20211207 CTD MESH:D014241 Trichloroethylene results in increased expression of ZFP352 mRNA PMID:33387578 10045909 KLF18 KLF transcription factor 18 gene CHEBI:25812 ozone multiple interactions ISO RGD:1320802 E RGD:6480464 20230704 CTD MESH:D010126 [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of ZFP352 mRNA PMID:27106289 10045909 KLF18 KLF transcription factor 18 gene CHEBI:27470 folic acid decreases expression ISO RGD:1320802 E RGD:6480464 20190219 CTD MESH:D005492 Folic Acid results in decreased expression of ZFP353 mRNA PMID:25006883 10045909 KLF18 KLF transcription factor 18 gene CHEBI:27470 folic acid increases expression ISO RGD:1320802 E RGD:6480464 20200804 CTD MESH:D005492 Folic Acid results in increased expression of ZFP352 mRNA PMID:25629700 10045909 KLF18 KLF transcription factor 18 gene CHEBI:28619 acrylamide increases expression ISO RGD:1310095 E RGD:6480464 20190219 CTD MESH:D020106 Acrylamide results in increased expression of ZFP352 mRNA PMID:28959563 10045909 KLF18 KLF transcription factor 18 gene CHEBI:31767 lead diacetate increases expression ISO RGD:1320802 E RGD:6480464 20170613 CTD MESH:C008261 lead acetate results in increased expression of ZFP352 mRNA PMID:22609695 10045909 KLF18 KLF transcription factor 18 gene CHEBI:33216 bisphenol A decreases expression ISO RGD:1310095 E RGD:6480464 20190219 CTD MESH:C006780 bisphenol A results in decreased expression of ZFP353 mRNA PMID:25181051 10045909 KLF18 KLF transcription factor 18 gene CHEBI:34237 2,4-diaminotoluene decreases expression ISO RGD:1320802 E RGD:6480464 20170613 CTD MESH:C010914 2,4-diaminotoluene results in decreased expression of ZFP352 mRNA PMID:20713471 10045909 KLF18 KLF transcription factor 18 gene CHEBI:34565 benzo[b]fluoranthene decreases expression ISO RGD:1320802 E RGD:6480464 20170613 CTD MESH:C006703 benzo(b)fluoranthene results in decreased expression of ZFP352 mRNA PMID:26377693 10045909 KLF18 KLF transcription factor 18 gene CHEBI:40036 amitrole decreases expression ISO RGD:1310095 E RGD:6480464 20230606 CTD MESH:D000640 Amitrole results in decreased expression of ZFP352 mRNA PMID:30047161 10045909 KLF18 KLF transcription factor 18 gene CHEBI:50594 carbon nanotube decreases expression ISO RGD:1320802 E RGD:6480464 20170613 CTD MESH:D037742 Nanotubes, Carbon analog results in decreased expression of ZFP352 mRNA; Nanotubes, Carbon results in decreased expression of ZFP352 mRNA PMID:25554681 10045909 KLF18 KLF transcription factor 18 gene CHEBI:50673 methimazole decreases expression ISO RGD:1310095 E RGD:6480464 20230606 CTD MESH:D008713 Methimazole results in decreased expression of ZFP352 mRNA PMID:30047161 10045909 KLF18 KLF transcription factor 18 gene CHEBI:8502 6-propyl-2-thiouracil decreases expression ISO RGD:1310095 E RGD:6480464 20230606 CTD MESH:D011441 Propylthiouracil results in decreased expression of ZFP352 mRNA PMID:30047161 10045919 SNHG25 small nucleolar RNA host gene 25 gene CHEBI:28216 methylmercury chloride increases expression EXP E RGD:6480464 20220308 CTD MESH:C004925 methylmercuric chloride results in increased expression of SNHG25 mRNA PMID:34089799 10053574 GSG1L2 GSG1 like 2 gene CHEBI:30512 silver atom increases expression ISO RGD:2293965 E RGD:6480464 20161115 CTD MESH:D012834 Silver results in increased expression of GSG1L2 mRNA PMID:27131904 10053574 GSG1L2 GSG1 like 2 gene CHEBI:9141 silver(0) increases expression ISO RGD:2293965 E RGD:6480464 20161115 CTD MESH:D012834 Silver results in increased expression of GSG1L2 mRNA PMID:27131904 10053891 FRG1JP FSHD region gene 1 family member J, pseudogene gene CHEBI:38940 sunitinib increases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in increased expression of FRG1JP mRNA PMID:31533062 10053891 FRG1JP FSHD region gene 1 family member J, pseudogene gene CHEBI:5063 fipronil decreases expression EXP E RGD:6480464 20190219 CTD MESH:C082360 fipronil results in decreased expression of FRG1JP mRNA PMID:28991164 10053891 FRG1JP FSHD region gene 1 family member J, pseudogene gene CHEBI:5063 fipronil multiple interactions EXP E RGD:6480464 20190219 CTD MESH:C082360 [fipronil co-treated with DEET] results in decreased expression of FRG1JP mRNA PMID:28991164 10053891 FRG1JP FSHD region gene 1 family member J, pseudogene gene CHEBI:7071 N,N-diethyl-m-toluamide multiple interactions EXP E RGD:6480464 20190219 CTD MESH:D003671 [fipronil co-treated with DEET] results in decreased expression of FRG1JP mRNA PMID:28991164 10053911 FRG1HP FSHD region gene 1 family member H, pseudogene gene CHEBI:16469 17beta-estradiol decreases expression EXP E RGD:6480464 20220308 CTD MESH:D004958 Estradiol results in decreased expression of FRG1HP mRNA PMID:31614463 10053911 FRG1HP FSHD region gene 1 family member H, pseudogene gene CHEBI:28358 rac-lactic acid decreases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in decreased expression of FRG1HP mRNA PMID:30851411 10053911 FRG1HP FSHD region gene 1 family member H, pseudogene gene CHEBI:38940 sunitinib increases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in increased expression of FRG1HP mRNA PMID:31533062 10053911 FRG1HP FSHD region gene 1 family member H, pseudogene gene CHEBI:5063 fipronil multiple interactions EXP E RGD:6480464 20190219 CTD MESH:C082360 [fipronil co-treated with DEET] results in decreased expression of FRG1HP mRNA PMID:28991164 10053911 FRG1HP FSHD region gene 1 family member H, pseudogene gene CHEBI:7071 N,N-diethyl-m-toluamide multiple interactions EXP E RGD:6480464 20190219 CTD MESH:D003671 [fipronil co-treated with DEET] results in decreased expression of FRG1HP mRNA PMID:28991164 10053911 FRG1HP FSHD region gene 1 family member H, pseudogene gene CHEBI:78320 2-hydroxypropanoic acid decreases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in decreased expression of FRG1HP mRNA PMID:30851411 10053938 FRG1CP FSHD region gene 1 family member C, pseudogene gene CHEBI:27470 folic acid decreases expression EXP E RGD:6480464 20200804 CTD MESH:D005492 Folic Acid results in decreased expression of FRG1CP mRNA PMID:21867686 10053938 FRG1CP FSHD region gene 1 family member C, pseudogene gene CHEBI:2825 aristolochic acid A decreases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in decreased expression of FRG1CP mRNA PMID:33212167 10053938 FRG1CP FSHD region gene 1 family member C, pseudogene gene CHEBI:28619 acrylamide decreases expression EXP E RGD:6480464 20210406 CTD MESH:D020106 Acrylamide results in decreased expression of FRG1CP mRNA PMID:32763439 10053938 FRG1CP FSHD region gene 1 family member C, pseudogene gene CHEBI:35456 cadmium dichloride decreases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in decreased expression of FRG1CP mRNA PMID:38568856 10054344 DANT2 DXZ4 associated non-coding transcript 2, distal gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in decreased expression of DANT2 mRNA PMID:29301061 10054362 LCAL1 lung cancer associated lncRNA 1 gene CHEBI:16598 DDE decreases expression EXP E RGD:6480464 20240702 CTD MESH:D003633 Dichlorodiphenyl Dichloroethylene results in decreased expression of LCAL1 mRNA PMID:38568856 10054362 LCAL1 lung cancer associated lncRNA 1 gene CHEBI:28201 rotenone increases expression EXP E RGD:6480464 20181016 CTD MESH:D012402 Rotenone results in increased expression of LCAL1 mRNA PMID:29955902 10054362 LCAL1 lung cancer associated lncRNA 1 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LCAL1 mRNA PMID:38568856 10054362 LCAL1 lung cancer associated lncRNA 1 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LCAL1 mRNA PMID:38568856 10054362 LCAL1 lung cancer associated lncRNA 1 gene CHEBI:44185 methotrexate increases expression EXP E RGD:6480464 20151110 CTD MESH:D008727 Methotrexate results in increased expression of LCAL1 mRNA PMID:24449571 10059032 LINC01456 long intergenic non-protein coding RNA 1456 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC01456 intron PMID:30157460 10059032 LINC01456 long intergenic non-protein coding RNA 1456 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of LINC01456 polyA tail PMID:30157460 10059032 LINC01456 long intergenic non-protein coding RNA 1456 gene CHEBI:34567 benzo[e]pyrene decreases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in decreased methylation of LINC01456 polyA tail PMID:30157460 10059032 LINC01456 long intergenic non-protein coding RNA 1456 gene CHEBI:6820 methapyrilene decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in decreased methylation of LINC01456 polyA tail PMID:30157460 10059043 KCNK15-AS1 KCNK15 and WISP2 antisense RNA 1 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of KCNK15-AS1 intron PMID:30157460 10059043 KCNK15-AS1 KCNK15 and WISP2 antisense RNA 1 gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of KCNK15-AS1 intron PMID:30157460 10059043 KCNK15-AS1 KCNK15 and WISP2 antisense RNA 1 gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of KCNK15-AS1 intron PMID:30157460 10059045 PCSK6-AS1 PCSK6 antisense RNA 1 gene CHEBI:28358 rac-lactic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of PCSK6-AS1 mRNA PMID:30851411 10059045 PCSK6-AS1 PCSK6 antisense RNA 1 gene CHEBI:78320 2-hydroxypropanoic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of PCSK6-AS1 mRNA PMID:30851411 10059050 FAM30C family with sequence similarity 30 member C gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of FAM30C intron PMID:30157460 10059080 LINC01173 long intergenic non-protein coding RNA 1173 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of LINC01173 intron PMID:30157460 10059083 GRPEL2-AS1 GRPEL2 antisense RNA 1 gene CHEBI:28358 rac-lactic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of GRPEL2-AS1 mRNA PMID:30851411 10059083 GRPEL2-AS1 GRPEL2 antisense RNA 1 gene CHEBI:6402 leflunomide increases expression EXP E RGD:6480464 20180410 CTD MESH:C045463 leflunomide results in increased expression of GRPEL2-AS1 mRNA PMID:28988120 10059083 GRPEL2-AS1 GRPEL2 antisense RNA 1 gene CHEBI:78320 2-hydroxypropanoic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of GRPEL2-AS1 mRNA PMID:30851411 10059095 TBC1D3E TBC1 domain family member 3E gene CHEBI:166473 Dibutyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C065087 di-n-butylphosphoric acid affects the expression of TBC1D3E mRNA PMID:37042841 10059095 TBC1D3E TBC1 domain family member 3E gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of TBC1D3E promoter PMID:30157460 10059095 TBC1D3E TBC1 domain family member 3E gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of TBC1D3E promoter PMID:30157460 10059095 TBC1D3E TBC1 domain family member 3E gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of TBC1D3E promoter PMID:30157460 10059095 TBC1D3E TBC1 domain family member 3E gene CHEBI:34372 4,4'-sulfonyldiphenol increases expression EXP E RGD:6480464 20230307 CTD MESH:C543008 bisphenol S results in increased expression of TBC1D3E mRNA PMID:34979203 10059095 TBC1D3E TBC1 domain family member 3E gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of TBC1D3E promoter PMID:30157460 10059095 TBC1D3E TBC1 domain family member 3E gene CHEBI:35033 triphenyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C005445 triphenyl phosphate affects the expression of TBC1D3E mRNA PMID:37042841 10059095 TBC1D3E TBC1 domain family member 3E gene CHEBI:53620 methylisothiazolinone decreases expression EXP E RGD:6480464 20200714 CTD MESH:C011506 2-methyl-4-isothiazolin-3-one results in decreased expression of TBC1D3E mRNA PMID:31629900 10059095 TBC1D3E TBC1 domain family member 3E gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of TBC1D3E promoter PMID:30157460 10059154 LINC01037 long intergenic non-protein coding RNA 1037 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC01037 intron PMID:30157460 10059226 ARF4-AS1 ARF4 antisense RNA 1 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of ARF4-AS1 mRNA PMID:33212167 10059226 ARF4-AS1 ARF4 antisense RNA 1 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of ARF4-AS1 mRNA PMID:38568856 10059240 DIRC3-AS1 DIRC3 antisense RNA 1 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of DIRC3-AS1 mRNA PMID:38568856 10059434 FARSA-AS1 FARSA antisense RNA 1 gene CHEBI:22977 cadmium atom multiple interactions EXP E RGD:6480464 20230801 CTD MESH:D002104 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of FARSA-AS1 mRNA PMID:36602393 10059434 FARSA-AS1 FARSA antisense RNA 1 gene CHEBI:35456 cadmium dichloride multiple interactions EXP E RGD:6480464 20230801 CTD MESH:D019256 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of FARSA-AS1 mRNA PMID:36602393 10059440 LINC00604 long intergenic non-protein coding RNA 604 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC00604 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC00604 mRNA PMID:35811015 10059440 LINC00604 long intergenic non-protein coding RNA 604 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC00604 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC00604 mRNA PMID:35811015 10059442 LINC01035 long intergenic non-protein coding RNA 1035 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01035 mRNA PMID:35811015 10059442 LINC01035 long intergenic non-protein coding RNA 1035 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01035 mRNA PMID:35811015 10059556 LINC01381 long intergenic non-protein coding RNA 1381 gene CHEBI:6402 leflunomide decreases expression EXP E RGD:6480464 20180410 CTD MESH:C045463 leflunomide results in decreased expression of LINC01381 mRNA PMID:28988120 10065 ACLY ATP citrate lyase gene CHEBI:10607 n-propyl gallate affects expression ISO RGD:2018 E RGD:6480464 20141111 CTD MESH:D011435 Propyl Gallate affects the expression of ACLY mRNA PMID:18539377 10065 ACLY ATP citrate lyase gene CHEBI:116509 diuron decreases expression EXP E RGD:6480464 20230905 CTD MESH:D004237 Diuron results in decreased expression of ACLY mRNA PMID:35967413 10065 ACLY ATP citrate lyase gene CHEBI:132824 spathulenol multiple interactions EXP E RGD:6480464 20240806 CTD MESH:C013258 [beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA PMID:38000518 10065 ACLY ATP citrate lyase gene CHEBI:134716 brexpiprazole decreases expression EXP E RGD:6480464 20240109 CTD MESH:C000591922 brexpiprazole results in decreased expression of ACLY mRNA; brexpiprazole results in decreased expression of ACLY protein PMID:37347510 10065 ACLY ATP citrate lyase gene CHEBI:134751 avobenzone increases expression EXP E RGD:6480464 20190910 CTD MESH:C049935 avobenzone results in increased expression of ACLY mRNA PMID:31016361 10065 ACLY ATP citrate lyase gene CHEBI:135338 guggulsterone multiple interactions ISO RGD:10064 E RGD:6480464 20191210 CTD MESH:C023617 pregna-4,17-diene-3,16-dione inhibits the reaction [Palmitic Acid results in increased expression of ACLY mRNA] PMID:31421115 10065 ACLY ATP citrate lyase gene CHEBI:139523 Rosavin increases expression EXP E RGD:6480464 20190219 CTD MESH:C529148 rosavin results in increased expression of ACLY mRNA PMID:20706672 10065 ACLY ATP citrate lyase gene CHEBI:15351 acetyl-CoA affects abundance ISO RGD:10064 E RGD:6480464 20240604 CTD MESH:D000105 ACLY protein affects the abundance of Acetyl Coenzyme A PMID:36933457 10065 ACLY ATP citrate lyase gene CHEBI:15351 acetyl-CoA increases abundance ISO RGD:10064 E RGD:6480464 20170613 CTD MESH:D000105 ACLY protein results in increased abundance of Acetyl Coenzyme A PMID:28077572 10065 ACLY ATP citrate lyase gene CHEBI:15354 choline multiple interactions ISO RGD:10064 E RGD:6480464 20121113 CTD MESH:D002794 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ACLY gene PMID:20938992 10065 ACLY ATP citrate lyase gene CHEBI:15368 acrolein multiple interactions EXP E RGD:6480464 20231205 CTD MESH:D000171 [Acrolein co-treated with methacrylaldehyde co-treated with Ozone] results in increased oxidation of ACLY mRNA PMID:32845096 10065 ACLY ATP citrate lyase gene CHEBI:15379 dioxygen increases phosphorylation EXP E RGD:6480464 20190910 CTD MESH:D010100 Oxygen deficiency results in increased phosphorylation of ACLY protein PMID:26087400 10065 ACLY ATP citrate lyase gene CHEBI:15379 dioxygen multiple interactions ISO RGD:10064 E RGD:6480464 20190312 CTD MESH:D010100 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of ACLY mRNA PMID:30529165 10065 ACLY ATP citrate lyase gene CHEBI:15396 (R)-camphor multiple interactions EXP E RGD:6480464 20240806 CTD MESH:D002164 [beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA PMID:38000518 10065 ACLY ATP citrate lyase gene CHEBI:15443 inulin multiple interactions ISO RGD:10064 E RGD:6480464 20230502 CTD MESH:D007444 [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of ACLY mRNA PMID:36331819 10065 ACLY ATP citrate lyase gene CHEBI:15756 hexadecanoic acid increases expression ISO RGD:10064 E RGD:6480464 20191210 CTD MESH:D019308 Palmitic Acid results in increased expression of ACLY mRNA PMID:31421115 10065 ACLY ATP citrate lyase gene CHEBI:15756 hexadecanoic acid multiple interactions ISO RGD:10064 E RGD:6480464 20191210 CTD MESH:D019308 acanthoic acid inhibits the reaction [Palmitic Acid results in increased expression of ACLY mRNA]; GW 3965 inhibits the reaction [Palmitic Acid results in increased expression of ACLY mRNA]; pregna-4,17-diene-3,16-dione inhibits the reaction [Palmitic Acid results in increased expression of ACLY mRNA] PMID:31421115 10065 ACLY ATP citrate lyase gene CHEBI:15930 atrazine multiple interactions ISO RGD:10064 E RGD:6480464 20140513 CTD MESH:D001280 [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of ACLY mRNA PMID:24440342 10065 ACLY ATP citrate lyase gene CHEBI:16112 chlorogenic acid increases expression EXP E RGD:6480464 20121218 CTD MESH:D002726 Chlorogenic Acid results in increased expression of ACLY mRNA PMID:20706672 10065 ACLY ATP citrate lyase gene CHEBI:16113 cholesterol multiple interactions ISO RGD:10064 E RGD:6480464 20140513 CTD MESH:D002784 [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of ACLY mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of ACLY mRNA PMID:24440342 10065 ACLY ATP citrate lyase gene CHEBI:16196 oleic acid decreases expression EXP E RGD:6480464 20200310 CTD MESH:D019301 Oleic Acid results in decreased expression of ACLY mRNA PMID:31340670 10065 ACLY ATP citrate lyase gene CHEBI:16196 oleic acid multiple interactions EXP E RGD:6480464 20190312 CTD MESH:D019301 [[Vehicle Emissions results in increased abundance of Particulate Matter] which co-treated with Oleic Acid] results in decreased expression of ACLY mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACLY mRNA PMID:30611723|PMID:31340670 10065 ACLY ATP citrate lyase gene CHEBI:16236 ethanol affects splicing ISO RGD:10064 E RGD:6480464 20190507 CTD MESH:D000431 Ethanol affects the splicing of ACLY mRNA PMID:30319688 10065 ACLY ATP citrate lyase gene CHEBI:16236 ethanol increases expression ISO RGD:10064 E RGD:6480464 20160510 CTD MESH:D000431 Ethanol results in increased expression of ACLY mRNA PMID:12036955|PMID:19167417 10065 ACLY ATP citrate lyase gene CHEBI:16236 ethanol increases expression ISO RGD:2018 E RGD:6480464 20120918 CTD MESH:D000431 Ethanol results in increased expression of ACLY mRNA PMID:16946407|PMID:19371623 10065 ACLY ATP citrate lyase gene CHEBI:16236 ethanol multiple interactions ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D000431 [Fish Oils co-treated with Ethanol] results in increased expression of ACLY mRNA PMID:17347304 10065 ACLY ATP citrate lyase gene CHEBI:16243 quercetin decreases activity ISO RGD:10064 E RGD:6480464 20120412 CTD MESH:D011794 Quercetin results in decreased activity of ACLY protein PMID:17032037 10065 ACLY ATP citrate lyase gene CHEBI:16243 quercetin decreases expression EXP E RGD:6480464 20161213 CTD MESH:D011794 Quercetin results in decreased expression of ACLY mRNA PMID:20596804 10065 ACLY ATP citrate lyase gene CHEBI:16243 quercetin decreases expression ISO RGD:10064 E RGD:6480464 20120412 CTD MESH:D011794 Quercetin results in decreased expression of ACLY mRNA PMID:17032037 10065 ACLY ATP citrate lyase gene CHEBI:16433 trans-caffeic acid multiple interactions EXP E RGD:6480464 20180116 CTD MESH:C040048 [Metformin co-treated with caffeic acid] results in decreased expression of ACLY protein PMID:28576465 10065 ACLY ATP citrate lyase gene CHEBI:16469 17beta-estradiol decreases expression ISO RGD:10064 E RGD:6480464 20130723 CTD MESH:D004958 Estradiol results in decreased expression of ACLY mRNA PMID:19484750 10065 ACLY ATP citrate lyase gene CHEBI:16469 17beta-estradiol decreases expression ISO RGD:2018 E RGD:6480464 20230606 CTD MESH:D004958 Estradiol results in decreased expression of ACLY mRNA PMID:32145629 10065 ACLY ATP citrate lyase gene CHEBI:16469 17beta-estradiol increases expression EXP E RGD:6480464 20220308 CTD MESH:D004958 Estradiol results in increased expression of ACLY mRNA PMID:31614463 10065 ACLY ATP citrate lyase gene CHEBI:165219 PCB138 decreases expression ISO RGD:2018 E RGD:6480464 20201208 CTD MESH:C029790 2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ACLY protein PMID:21673325 10065 ACLY ATP citrate lyase gene CHEBI:16643 L-methionine multiple interactions ISO RGD:10064 E RGD:6480464 20121113 CTD MESH:D008715 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ACLY gene PMID:20938992 10065 ACLY ATP citrate lyase gene CHEBI:16716 benzene affects expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D001554 Benzene affects the expression of ACLY mRNA PMID:15878777 10065 ACLY ATP citrate lyase gene CHEBI:16742 orotic acid increases expression ISO RGD:2018 E RGD:6480464 20240806 CTD MESH:D009963 Orotic Acid results in increased expression of ACLY mRNA PMID:17203948 10065 ACLY ATP citrate lyase gene CHEBI:168262 Ganoderic acid A decreases expression EXP E RGD:6480464 20210504 CTD MESH:C515005 ganoderic acid A results in decreased expression of ACLY mRNA PMID:29852127 10065 ACLY ATP citrate lyase gene CHEBI:168262 Ganoderic acid A multiple interactions ISO RGD:10064 E RGD:6480464 20210504 CTD MESH:C515005 [Dietary Fats co-treated with ganoderic acid A] affects the expression of ACLY mRNA PMID:29852127 10065 ACLY ATP citrate lyase gene CHEBI:16827 corticosterone multiple interactions ISO RGD:2018 E RGD:6480464 20120501 CTD MESH:D003345 [Corticosterone co-treated with oleoyl-estrone] affects the expression of ACLY mRNA PMID:19545626 10065 ACLY ATP citrate lyase gene CHEBI:16842 formaldehyde decreases expression EXP E RGD:6480464 20140408 CTD MESH:D005557 Formaldehyde results in decreased expression of ACLY mRNA PMID:23649840 10065 ACLY ATP citrate lyase gene CHEBI:16899 D-mannitol increases expression ISO RGD:10064 E RGD:6480464 20150127 CTD MESH:D008353 Mannitol results in increased expression of ACLY mRNA PMID:25270620 10065 ACLY ATP citrate lyase gene CHEBI:16971 benzene-1,2,4-triol increases expression EXP E RGD:6480464 20120412 CTD MESH:C013038 hydroxyhydroquinone results in increased expression of ACLY mRNA PMID:17572062 10065 ACLY ATP citrate lyase gene CHEBI:17234 glucose increases expression EXP E RGD:6480464 20180313 CTD MESH:D005947 Glucose deficiency results in increased expression of ACLY mRNA; Glucose deficiency results in increased expression of ACLY protein PMID:26811028 10065 ACLY ATP citrate lyase gene CHEBI:17234 glucose increases expression ISO RGD:2018 E RGD:6480464 20140513 CTD MESH:D005947 Glucose results in increased expression of ACLY mRNA PMID:24349266 10065 ACLY ATP citrate lyase gene CHEBI:173086 ferrostatin-1 multiple interactions EXP E RGD:6480464 20250114 CTD MESH:C573944 ferrostatin-1 inhibits the reaction [darolutamide results in decreased expression of ACLY mRNA] PMID:39309439 10065 ACLY ATP citrate lyase gene CHEBI:17347 testosterone increases expression ISO RGD:10064 E RGD:6480464 20120412 CTD MESH:D013739 Testosterone results in increased expression of ACLY mRNA PMID:16579987 10065 ACLY ATP citrate lyase gene CHEBI:17351 linoleic acid decreases expression ISO RGD:2018 E RGD:6480464 20170303 CTD MESH:D019787 Linoleic Acid results in decreased expression of ACLY mRNA PMID:14563831 10065 ACLY ATP citrate lyase gene CHEBI:17395 cis-caffeic acid multiple interactions EXP E RGD:6480464 20180116 CTD MESH:C040048 [Metformin co-treated with caffeic acid] results in decreased expression of ACLY protein PMID:28576465 10065 ACLY ATP citrate lyase gene CHEBI:175090 Oleacein decreases activity EXP E RGD:6480464 20210706 CTD MESH:C578055 oleacein results in decreased activity of ACLY protein PMID:31150784 10065 ACLY ATP citrate lyase gene CHEBI:17578 toluene decreases expression EXP E RGD:6480464 20200609 CTD MESH:D014050 Toluene results in decreased expression of ACLY mRNA PMID:26717081 10065 ACLY ATP citrate lyase gene CHEBI:17578 toluene increases methylation EXP E RGD:6480464 20200609 CTD MESH:D014050 Toluene results in increased methylation of ACLY gene PMID:26717081 10065 ACLY ATP citrate lyase gene CHEBI:17580 linalool multiple interactions EXP E RGD:6480464 20240806 CTD MESH:C018584 [beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA PMID:38000518 10065 ACLY ATP citrate lyase gene CHEBI:17634 D-glucose increases expression EXP E RGD:6480464 20180313 CTD MESH:D005947 Glucose deficiency results in increased expression of ACLY mRNA; Glucose deficiency results in increased expression of ACLY protein PMID:26811028 10065 ACLY ATP citrate lyase gene CHEBI:17634 D-glucose increases expression ISO RGD:2018 E RGD:6480464 20140513 CTD MESH:D005947 Glucose results in increased expression of ACLY mRNA PMID:24349266 10065 ACLY ATP citrate lyase gene CHEBI:17650 cortisol increases expression EXP E RGD:6480464 20190702 CTD MESH:D006854 Hydrocortisone results in increased expression of ACLY mRNA PMID:30776459 10065 ACLY ATP citrate lyase gene CHEBI:17747 bis(2-ethylhexyl) phthalate increases expression ISO RGD:10064 E RGD:6480464 20120412 CTD MESH:D004051 Diethylhexyl Phthalate results in increased expression of ACLY mRNA PMID:19850644|PMID:35550907 10065 ACLY ATP citrate lyase gene CHEBI:17747 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:10064 E RGD:6480464 20120412 CTD MESH:D004051 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ACLY mRNA; [Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in decreased expression of ACLY mRNA; PPARA protein promotes the reaction [Diethylhexyl Phthalate results in increased expression of ACLY mRNA] PMID:19850644|PMID:28433925|PMID:35739755 10065 ACLY ATP citrate lyase gene CHEBI:178012 FR900359 affects phosphorylation EXP E RGD:6480464 20240305 CTD MESH:C000607068 FR900359 affects the phosphorylation of ACLY protein PMID:37730182 10065 ACLY ATP citrate lyase gene CHEBI:17967 urethane increases expression EXP E RGD:6480464 20171114 CTD MESH:D014520 Urethane results in increased expression of ACLY mRNA PMID:28818685 10065 ACLY ATP citrate lyase gene CHEBI:17992 sucrose multiple interactions ISO RGD:10064 E RGD:6480464 20140513 CTD MESH:D013395 [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of ACLY mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of ACLY mRNA PMID:24440342 10065 ACLY ATP citrate lyase gene CHEBI:181914 Aflatoxin B2 alpha decreases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in decreased methylation of ACLY exon; aflatoxin B2 results in decreased methylation of ACLY intron PMID:30157460 10065 ACLY ATP citrate lyase gene CHEBI:18208 benzylpenicillin increases expression ISO RGD:10064 E RGD:6480464 20161213 CTD MESH:D010400 Penicillin G results in increased expression of ACLY mRNA PMID:27503388 10065 ACLY ATP citrate lyase gene CHEBI:18208 benzylpenicillin multiple interactions ISO RGD:10064 E RGD:6480464 20161213 CTD MESH:D010400 [Penicillin G co-treated with Erythromycin] results in increased expression of ACLY mRNA PMID:27503388 10065 ACLY ATP citrate lyase gene CHEBI:18246 (1->4)-beta-D-glucan multiple interactions ISO RGD:10064 E RGD:6480464 20230502 CTD MESH:D002482 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of ACLY mRNA PMID:36331819 10065 ACLY ATP citrate lyase gene CHEBI:18407 hydrogen cyanide decreases expression ISO RGD:10064 E RGD:6480464 20211109 CTD MESH:D006856 Hydrogen Cyanide results in decreased expression of ACLY mRNA PMID:33914522 10065 ACLY ATP citrate lyase gene CHEBI:192461 toosendanin decreases expression EXP E RGD:6480464 20240903 CTD MESH:C036454 toosendanin results in decreased expression of ACLY mRNA PMID:38570025 10065 ACLY ATP citrate lyase gene CHEBI:195250 corn oil affects expression ISO RGD:2018 E RGD:6480464 20230704 CTD MESH:D003314 Corn Oil affects the expression of ACLY mRNA PMID:16360708 10065 ACLY ATP citrate lyase gene CHEBI:23924 enzyme inhibitor multiple interactions EXP E RGD:6480464 20161228 CTD MESH:D004791 [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of ACLY protein PMID:23301498 10065 ACLY ATP citrate lyase gene CHEBI:23994 ethyl methanesulfonate decreases expression EXP E RGD:6480464 20140708 CTD MESH:D005020 Ethyl Methanesulfonate results in decreased expression of ACLY mRNA PMID:23649840 10065 ACLY ATP citrate lyase gene CHEBI:2504 aflatoxin B1 decreases expression ISO RGD:10064 E RGD:6480464 20120501 CTD MESH:D016604 Aflatoxin B1 results in decreased expression of ACLY mRNA PMID:19770486 10065 ACLY ATP citrate lyase gene CHEBI:2504 aflatoxin B1 decreases expression ISO RGD:2018 E RGD:6480464 20140311 CTD MESH:D016604 Aflatoxin B1 results in decreased expression of ACLY mRNA PMID:23385219 10065 ACLY ATP citrate lyase gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of ACLY intron PMID:30157460 10065 ACLY ATP citrate lyase gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of ACLY exon PMID:30157460 10065 ACLY ATP citrate lyase gene CHEBI:2504 aflatoxin B1 multiple interactions ISO RGD:2018 E RGD:6480464 20150414 CTD MESH:D016604 [sulforaphane co-treated with Aflatoxin B1] affects the expression of ACLY mRNA PMID:25450479 10065 ACLY ATP citrate lyase gene CHEBI:25255 methyl methanesulfonate decreases expression EXP E RGD:6480464 20140408 CTD MESH:D008741 Methyl Methanesulfonate results in decreased expression of ACLY mRNA PMID:23649840 10065 ACLY ATP citrate lyase gene CHEBI:2564 aldrin increases expression ISO RGD:10064 E RGD:6480464 20140107 CTD MESH:D000452 Aldrin results in increased expression of ACLY mRNA PMID:18579281 10065 ACLY ATP citrate lyase gene CHEBI:25812 ozone decreases expression ISO RGD:10064 E RGD:6480464 20120412 CTD MESH:D010126 Ozone results in decreased expression of ACLY mRNA PMID:16183385 10065 ACLY ATP citrate lyase gene CHEBI:25812 ozone decreases expression ISO RGD:2018 E RGD:6480464 20150714 CTD MESH:D010126 Ozone results in decreased expression of ACLY mRNA PMID:25838073 10065 ACLY ATP citrate lyase gene CHEBI:25812 ozone multiple interactions EXP E RGD:6480464 20231205 CTD MESH:D010126 [Acrolein co-treated with methacrylaldehyde co-treated with Ozone] results in increased oxidation of ACLY mRNA PMID:32845096 10065 ACLY ATP citrate lyase gene CHEBI:25812 ozone multiple interactions ISO RGD:10064 E RGD:6480464 20220809 CTD MESH:D010126 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of ACLY mRNA PMID:34911549 10065 ACLY ATP citrate lyase gene CHEBI:2663 amiodarone increases expression EXP E RGD:6480464 20210706 CTD MESH:D000638 Amiodarone results in increased expression of ACLY mRNA PMID:32535746 10065 ACLY ATP citrate lyase gene CHEBI:2663 amiodarone increases expression ISO RGD:2018 E RGD:6480464 20230801 CTD MESH:D000638 Amiodarone results in increased expression of ACLY mRNA PMID:32084307 10065 ACLY ATP citrate lyase gene CHEBI:26710 sodium chloride multiple interactions EXP E RGD:6480464 20250114 CTD MESH:D012965 [Sodium Chloride co-treated with Furaldehyde] results in increased expression of and affects the localization of ACLY protein; [Sodium Chloride co-treated with pyrogallol 1,3-dimethyl ether] results in decreased expression of and affects the localization of ACLY protein PMID:38598786 10065 ACLY ATP citrate lyase gene CHEBI:27363 zinc atom increases expression ISO RGD:2018 E RGD:6480464 20130122 CTD MESH:D015032 Zinc deficiency results in increased expression of ACLY mRNA PMID:15671213 10065 ACLY ATP citrate lyase gene CHEBI:27385 tetrachloromethane affects expression ISO RGD:10064 E RGD:6480464 20200804 CTD MESH:D002251 Carbon Tetrachloride affects the expression of ACLY mRNA PMID:31919559 10065 ACLY ATP citrate lyase gene CHEBI:27385 tetrachloromethane decreases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D002251 Carbon Tetrachloride results in decreased expression of ACLY mRNA PMID:17522070 10065 ACLY ATP citrate lyase gene CHEBI:27432 alpha-linolenic acid decreases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D017962 alpha-Linolenic Acid results in decreased expression of ACLY mRNA PMID:14563831 10065 ACLY ATP citrate lyase gene CHEBI:27470 folic acid multiple interactions ISO RGD:10064 E RGD:6480464 20121113 CTD MESH:D005492 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ACLY gene; Folic Acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of ACLY mRNA] PMID:20938992|PMID:22206623 10065 ACLY ATP citrate lyase gene CHEBI:27563 arsenic atom multiple interactions ISO RGD:10064 E RGD:6480464 20220208 CTD MESH:D001151 [sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of ACLY mRNA PMID:32045263 10065 ACLY ATP citrate lyase gene CHEBI:27732 caffeine decreases phosphorylation EXP E RGD:6480464 20221004 CTD MESH:D002110 Caffeine results in decreased phosphorylation of ACLY protein PMID:35688186 10065 ACLY ATP citrate lyase gene CHEBI:27732 caffeine increases expression ISO RGD:2018 E RGD:6480464 20190702 CTD MESH:D002110 Caffeine results in increased expression of ACLY mRNA PMID:30776459 10065 ACLY ATP citrate lyase gene CHEBI:27744 glyphosate decreases expression ISO RGD:10064 E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in decreased expression of ACLY protein PMID:37208198 10065 ACLY ATP citrate lyase gene CHEBI:27856 acetamide decreases expression ISO RGD:2018 E RGD:6480464 20200519 CTD MESH:C030686 acetamide results in decreased expression of ACLY mRNA PMID:31881176 10065 ACLY ATP citrate lyase gene CHEBI:27881 resveratrol increases expression EXP E RGD:6480464 20121218 CTD MESH:C059514 resveratrol results in increased expression of ACLY mRNA PMID:20706672 10065 ACLY ATP citrate lyase gene CHEBI:27881 resveratrol multiple interactions ISO RGD:2018 E RGD:6480464 20160822 CTD MESH:C059514 [Dietary Fats co-treated with resveratrol] affects the expression of ACLY mRNA; resveratrol inhibits the reaction [Dietary Fats results in increased expression of ACLY protein] PMID:26055348 10065 ACLY ATP citrate lyase gene CHEBI:27902 tetracycline decreases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D013752 Tetracycline results in decreased expression of ACLY mRNA PMID:17522070 10065 ACLY ATP citrate lyase gene CHEBI:27961 1,8-cineole multiple interactions EXP E RGD:6480464 20240806 CTD MESH:D000077591 [beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA PMID:38000518 10065 ACLY ATP citrate lyase gene CHEBI:28088 genistein decreases expression EXP E RGD:6480464 20121113 CTD MESH:D019833 Genistein results in decreased expression of ACLY protein PMID:20884965 10065 ACLY ATP citrate lyase gene CHEBI:28088 genistein increases expression EXP E RGD:6480464 20121218 CTD MESH:D019833 Genistein results in increased expression of ACLY mRNA PMID:20706672 10065 ACLY ATP citrate lyase gene CHEBI:28088 genistein multiple interactions EXP E RGD:6480464 20121113 CTD MESH:D019833 ESR2 promotes the reaction [Genistein results in decreased expression of ACLY protein] PMID:20884965 10065 ACLY ATP citrate lyase gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:10064 E RGD:6480464 20160210 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of ACLY mRNA PMID:21570461|PMID:26377647 10065 ACLY ATP citrate lyase gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:10064 E RGD:6480464 20160119 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of ACLY mRNA PMID:18295293|PMID:26290441|PMID:28213091 10065 ACLY ATP citrate lyase gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:2018 E RGD:6480464 20130122 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of ACLY mRNA PMID:16054898|PMID:20959002|PMID:21215274|PMID:21724226 10065 ACLY ATP citrate lyase gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:10064 E RGD:6480464 20120918 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of ACLY mRNA PMID:21846477 10065 ACLY ATP citrate lyase gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:2018 E RGD:6480464 20220111 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of ACLY mRNA PMID:34747641 10065 ACLY ATP citrate lyase gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:10064 E RGD:6480464 20120918 CTD MESH:D013749 [Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in decreased expression of ACLY mRNA; Tetrachlorodibenzodioxin inhibits the reaction [NFE2L2 gene mutant form results in increased expression of ACLY mRNA] PMID:21846477|PMID:28433925 10065 ACLY ATP citrate lyase gene CHEBI:28200 2-chloroethanol increases expression ISO RGD:10064 E RGD:6480464 20160822 CTD MESH:D005023 Ethylene Chlorohydrin results in increased expression of ACLY mRNA PMID:26962056 10065 ACLY ATP citrate lyase gene CHEBI:28201 rotenone decreases expression ISO RGD:2018 E RGD:6480464 20191112 CTD MESH:D012402 Rotenone results in decreased expression of ACLY mRNA PMID:28374803 10065 ACLY ATP citrate lyase gene CHEBI:28201 rotenone increases expression EXP E RGD:6480464 20210810 CTD MESH:D012402 Rotenone results in increased expression of ACLY mRNA PMID:33512557 10065 ACLY ATP citrate lyase gene CHEBI:28201 rotenone increases oxidation ISO RGD:2018 E RGD:6480464 20190910 CTD MESH:D012402 Rotenone results in increased oxidation of ACLY protein PMID:30951809 10065 ACLY ATP citrate lyase gene CHEBI:28509 chloroethene increases expression ISO RGD:10064 E RGD:6480464 20130514 CTD MESH:D014752 Vinyl Chloride metabolite results in increased expression of ACLY mRNA; Vinyl Chloride results in increased expression of ACLY mRNA PMID:18579281|PMID:26962056 10065 ACLY ATP citrate lyase gene CHEBI:28527 rutin decreases activity ISO RGD:10064 E RGD:6480464 20120412 CTD MESH:D012431 Rutin results in decreased activity of ACLY protein PMID:17032037 10065 ACLY ATP citrate lyase gene CHEBI:28694 copper atom decreases expression ISO RGD:10064 E RGD:6480464 20120814 CTD MESH:D003300 Copper results in decreased expression of ACLY mRNA PMID:17205981 10065 ACLY ATP citrate lyase gene CHEBI:28694 copper atom multiple interactions ISO RGD:2018 E RGD:6480464 20151013 CTD MESH:D003300 [Copper co-treated with Dietary Sucrose] results in increased expression of ACLY mRNA PMID:26033743 10065 ACLY ATP citrate lyase gene CHEBI:28748 doxorubicin increases expression EXP E RGD:6480464 20181113 CTD MESH:D004317 Doxorubicin results in increased expression of ACLY mRNA PMID:29803840 10065 ACLY ATP citrate lyase gene CHEBI:28757 fructose increases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D005632 Fructose results in increased expression of ACLY mRNA PMID:1396700 10065 ACLY ATP citrate lyase gene CHEBI:28794 coumarin affects expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:C030123 coumarin affects the expression of ACLY mRNA PMID:16963487 10065 ACLY ATP citrate lyase gene CHEBI:28984 aluminium atom multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D000535 Aluminum results in increased expression of and results in increased activity of ACLY protein PMID:17762189 10065 ACLY ATP citrate lyase gene CHEBI:29678 sodium arsenite affects expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite affects the expression of ACLY mRNA PMID:34032870 10065 ACLY ATP citrate lyase gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in decreased expression of ACLY mRNA PMID:38568856 10065 ACLY ATP citrate lyase gene CHEBI:29678 sodium arsenite decreases expression ISO RGD:10064 E RGD:6480464 20161228 CTD MESH:C017947 sodium arsenite results in decreased expression of ACLY mRNA PMID:19822182 10065 ACLY ATP citrate lyase gene CHEBI:29678 sodium arsenite multiple interactions ISO RGD:10064 E RGD:6480464 20220208 CTD MESH:C017947 [sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of ACLY mRNA PMID:32045263 10065 ACLY ATP citrate lyase gene CHEBI:29699 tunicamycin decreases expression EXP E RGD:6480464 20190312 CTD MESH:D014415 Tunicamycin results in decreased expression of ACLY mRNA PMID:29453283 10065 ACLY ATP citrate lyase gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of ACLY exon PMID:30157460 10065 ACLY ATP citrate lyase gene CHEBI:29865 benzo[a]pyrene decreases expression ISO RGD:10064 E RGD:6480464 20120918 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of ACLY mRNA PMID:22228805 10065 ACLY ATP citrate lyase gene CHEBI:29865 benzo[a]pyrene increases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in increased methylation of ACLY 5' UTR PMID:27901495 10065 ACLY ATP citrate lyase gene CHEBI:29865 benzo[a]pyrene multiple interactions ISO RGD:10064 E RGD:6480464 20120918 CTD MESH:D001564 AHR protein affects the reaction [Benzo(a)pyrene affects the expression of ACLY mRNA] PMID:22228805 10065 ACLY ATP citrate lyase gene CHEBI:29866 arsenite(3-) decreases expression ISO RGD:10064 E RGD:6480464 20210504 CTD MESH:C015001 arsenite results in decreased expression of ACLY mRNA PMID:33053406 10065 ACLY ATP citrate lyase gene CHEBI:30052 copper(0) decreases expression ISO RGD:10064 E RGD:6480464 20120814 CTD MESH:D003300 Copper results in decreased expression of ACLY mRNA PMID:17205981 10065 ACLY ATP citrate lyase gene CHEBI:30052 copper(0) multiple interactions ISO RGD:2018 E RGD:6480464 20151013 CTD MESH:D003300 [Copper co-treated with Dietary Sucrose] results in increased expression of ACLY mRNA PMID:26033743 10065 ACLY ATP citrate lyase gene CHEBI:30185 zinc(0) increases expression ISO RGD:2018 E RGD:6480464 20130122 CTD MESH:D015032 Zinc deficiency results in increased expression of ACLY mRNA PMID:15671213 10065 ACLY ATP citrate lyase gene CHEBI:30563 silicon dioxide affects secretion EXP E RGD:6480464 20160315 CTD MESH:D012822 Silicon Dioxide analog affects the secretion of ACLY protein PMID:25895662 10065 ACLY ATP citrate lyase gene CHEBI:30563 silicon dioxide decreases expression ISO RGD:10064 E RGD:6480464 20140715 CTD MESH:D012822 Silicon Dioxide results in decreased expression of ACLY mRNA PMID:23221170 10065 ACLY ATP citrate lyase gene CHEBI:30563 silicon dioxide increases activity ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D012822 Silicon Dioxide results in increased activity of ACLY protein PMID:1647683 10065 ACLY ATP citrate lyase gene CHEBI:30614 benzo[a]pyrene diol epoxide I decreases expression EXP E RGD:6480464 20220308 CTD MESH:D015123 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of ACLY mRNA PMID:34454013 10065 ACLY ATP citrate lyase gene CHEBI:31206 ammonium chloride affects expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D000643 Ammonium Chloride affects the expression of ACLY mRNA PMID:16483693 10065 ACLY ATP citrate lyase gene CHEBI:31739 josamycin affects response to substance EXP E RGD:6480464 20200609 CTD MESH:D015570 ACLY protein affects the susceptibility to Josamycin PMID:31915244 10065 ACLY ATP citrate lyase gene CHEBI:3179 bromobenzene decreases expression ISO RGD:2018 E RGD:6480464 20200915 CTD MESH:C032036 bromobenzene results in decreased expression of ACLY mRNA PMID:32479839 10065 ACLY ATP citrate lyase gene CHEBI:32161 sulfadimethoxine increases expression ISO RGD:2018 E RGD:6480464 20230606 CTD MESH:D013412 Sulfadimethoxine results in increased expression of ACLY mRNA PMID:30047161 10065 ACLY ATP citrate lyase gene CHEBI:3223 buspirone decreases expression ISO RGD:2018 E RGD:6480464 20160412 CTD MESH:D002065 Buspirone results in decreased expression of ACLY mRNA PMID:24136188 10065 ACLY ATP citrate lyase gene CHEBI:32234 titanium dioxide decreases expression ISO RGD:10064 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in decreased expression of ACLY mRNA PMID:35295148 10065 ACLY ATP citrate lyase gene CHEBI:32234 titanium dioxide decreases methylation ISO RGD:10064 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in decreased methylation of ACLY gene PMID:35295148 10065 ACLY ATP citrate lyase gene CHEBI:32234 titanium dioxide increases expression ISO RGD:10064 E RGD:6480464 20140211 CTD MESH:C009495 titanium dioxide results in increased expression of ACLY mRNA PMID:23557971 10065 ACLY ATP citrate lyase gene CHEBI:32497 thioacetamide affects expression ISO RGD:2018 E RGD:6480464 20220405 CTD MESH:D013853 Thioacetamide affects the expression of ACLY mRNA PMID:34492290 10065 ACLY ATP citrate lyase gene CHEBI:32509 pirinixic acid decreases expression ISO RGD:10064 E RGD:6480464 20140610 CTD MESH:C006253 pirinixic acid results in decreased expression of ACLY mRNA PMID:18445702|PMID:23811191 10065 ACLY ATP citrate lyase gene CHEBI:32509 pirinixic acid decreases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:C006253 pirinixic acid results in decreased expression of ACLY mRNA PMID:19162173 10065 ACLY ATP citrate lyase gene CHEBI:32888 gamma-hexachlorocyclohexane affects activity ISO RGD:2018 E RGD:6480464 20130122 CTD MESH:D001556 Hexachlorocyclohexane affects the activity of ACLY protein PMID:7535533 10065 ACLY ATP citrate lyase gene CHEBI:32888 gamma-hexachlorocyclohexane decreases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D001556 Hexachlorocyclohexane results in decreased expression of ACLY mRNA PMID:17785943 10065 ACLY ATP citrate lyase gene CHEBI:33007 chromium(6+) increases expression EXP E RGD:6480464 20201006 CTD MESH:C074702 chromium hexavalent ion results in increased expression of ACLY protein PMID:32525551 10065 ACLY ATP citrate lyase gene CHEBI:33191 potassium cyanide increases expression ISO RGD:10064 E RGD:6480464 20211109 CTD MESH:D011190 Potassium Cyanide results in increased expression of ACLY mRNA PMID:33914522 10065 ACLY ATP citrate lyase gene CHEBI:33216 bisphenol A affects expression EXP E RGD:6480464 20191112 CTD MESH:C006780 bisphenol A affects the expression of ACLY mRNA PMID:30903817 10065 ACLY ATP citrate lyase gene CHEBI:33216 bisphenol A affects expression ISO RGD:2018 E RGD:6480464 20230606 CTD MESH:C006780 bisphenol A affects the expression of ACLY mRNA PMID:32145629 10065 ACLY ATP citrate lyase gene CHEBI:33216 bisphenol A affects methylation ISO RGD:10064 E RGD:6480464 20180116 CTD MESH:C006780 bisphenol A affects the methylation of ACLY promoter PMID:27334623 10065 ACLY ATP citrate lyase gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20240206 CTD MESH:C006780 bisphenol A results in decreased expression of ACLY protein PMID:37567409 10065 ACLY ATP citrate lyase gene CHEBI:33216 bisphenol A decreases expression ISO RGD:2018 E RGD:6480464 20191210 CTD MESH:C006780 bisphenol A results in decreased expression of ACLY mRNA; bisphenol A results in decreased expression of ACLY protein PMID:30816183|PMID:32145629|PMID:32528016|PMID:34947998 10065 ACLY ATP citrate lyase gene CHEBI:33216 bisphenol A increases expression ISO RGD:10064 E RGD:6480464 20120515 CTD MESH:C006780 bisphenol A results in increased expression of ACLY mRNA; bisphenol A results in increased expression of ACLY protein; bisphenol A results in increased expression of ACLY protein modified form PMID:21932408|PMID:37105096 10065 ACLY ATP citrate lyase gene CHEBI:33216 bisphenol A increases expression ISO RGD:2018 E RGD:6480464 20150310 CTD MESH:C006780 bisphenol A results in increased expression of ACLY mRNA PMID:25181051|PMID:27178563 10065 ACLY ATP citrate lyase gene CHEBI:33216 bisphenol A multiple interactions ISO RGD:10064 E RGD:6480464 20180116 CTD MESH:C006780 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ACLY mRNA; [Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in decreased expression of ACLY mRNA PMID:28433925|PMID:35739755 10065 ACLY ATP citrate lyase gene CHEBI:33217 3,3',5,5'-tetrabromobisphenol A increases expression ISO RGD:2018 E RGD:6480464 20170516 CTD MESH:C020806 tetrabromobisphenol A results in increased expression of ACLY mRNA PMID:27914987 10065 ACLY ATP citrate lyase gene CHEBI:33629 aluminium(0) multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D000535 Aluminum results in increased expression of and results in increased activity of ACLY protein PMID:17762189 10065 ACLY ATP citrate lyase gene CHEBI:34202 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions ISO RGD:10064 E RGD:6480464 20180116 CTD MESH:C014024 [Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in decreased expression of ACLY mRNA PMID:28433925 10065 ACLY ATP citrate lyase gene CHEBI:34372 4,4'-sulfonyldiphenol increases expression EXP E RGD:6480464 20191112 CTD MESH:C543008 bisphenol S results in increased expression of ACLY mRNA; bisphenol S results in increased expression of ACLY protein PMID:31121516|PMID:34186270 10065 ACLY ATP citrate lyase gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of ACLY exon PMID:30157460 10065 ACLY ATP citrate lyase gene CHEBI:34575 bisphenol F increases expression EXP E RGD:6480464 20230307 CTD MESH:C008745 bisphenol F results in increased expression of ACLY protein PMID:34186270 10065 ACLY ATP citrate lyase gene CHEBI:34575 bisphenol F increases expression ISO RGD:10064 E RGD:6480464 20241105 CTD MESH:C008745 bisphenol F results in increased expression of ACLY mRNA PMID:38685157 10065 ACLY ATP citrate lyase gene CHEBI:34581 Bisphenol B increases expression EXP E RGD:6480464 20230307 CTD MESH:C492482 bisphenol B results in increased expression of ACLY protein PMID:34186270 10065 ACLY ATP citrate lyase gene CHEBI:34595 Butylbenzyl phthalate multiple interactions ISO RGD:10064 E RGD:6480464 20240402 CTD MESH:C027561 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ACLY mRNA PMID:35739755 10065 ACLY ATP citrate lyase gene CHEBI:34631 chlorpyrifos decreases expression ISO RGD:10064 E RGD:6480464 20230606 CTD MESH:D004390 Chlorpyrifos results in decreased expression of ACLY mRNA PMID:37019170 10065 ACLY ATP citrate lyase gene CHEBI:34679 Di-n-octyl phthalate multiple interactions ISO RGD:10064 E RGD:6480464 20240402 CTD MESH:C010715 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ACLY mRNA PMID:35739755 10065 ACLY ATP citrate lyase gene CHEBI:34682 diazinon affects expression ISO RGD:2018 E RGD:6480464 20141014 CTD MESH:D003976 Diazinon affects the expression of ACLY mRNA PMID:22546817 10065 ACLY ATP citrate lyase gene CHEBI:34687 dibutyl phthalate decreases expression ISO RGD:2018 E RGD:6480464 20121113 CTD MESH:D003993 Dibutyl Phthalate results in decreased expression of ACLY mRNA PMID:17379624 10065 ACLY ATP citrate lyase gene CHEBI:34687 dibutyl phthalate multiple interactions ISO RGD:10064 E RGD:6480464 20240402 CTD MESH:D003993 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ACLY mRNA PMID:35739755 10065 ACLY ATP citrate lyase gene CHEBI:34696 dieldrin affects expression ISO RGD:2018 E RGD:6480464 20141014 CTD MESH:D004026 Dieldrin affects the expression of ACLY mRNA PMID:22546817 10065 ACLY ATP citrate lyase gene CHEBI:34698 diethyl phthalate multiple interactions ISO RGD:10064 E RGD:6480464 20240402 CTD MESH:C007379 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ACLY mRNA PMID:35739755 10065 ACLY ATP citrate lyase gene CHEBI:34709 Diisodecyl phthalate multiple interactions ISO RGD:10064 E RGD:6480464 20240402 CTD MESH:C042080 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ACLY mRNA PMID:35739755 10065 ACLY ATP citrate lyase gene CHEBI:34718 1-chloro-2,4-dinitrobenzene affects binding EXP E RGD:6480464 20210406 CTD MESH:D004137 Dinitrochlorobenzene binds to ACLY protein PMID:32991956 10065 ACLY ATP citrate lyase gene CHEBI:34768 furfural multiple interactions EXP E RGD:6480464 20250114 CTD MESH:D005662 [Sodium Chloride co-treated with Furaldehyde] results in increased expression of and affects the localization of ACLY protein PMID:38598786 10065 ACLY ATP citrate lyase gene CHEBI:34887 nickel dichloride affects expression ISO RGD:2018 E RGD:6480464 20141014 CTD MESH:C022838 nickel chloride affects the expression of ACLY mRNA PMID:22546817 10065 ACLY ATP citrate lyase gene CHEBI:35033 triphenyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C005445 triphenyl phosphate affects the expression of ACLY mRNA PMID:37042841 10065 ACLY ATP citrate lyase gene CHEBI:35033 triphenyl phosphate affects expression ISO RGD:2018 E RGD:6480464 20200331 CTD MESH:C005445 triphenyl phosphate affects the expression of ACLY mRNA PMID:30589522 10065 ACLY ATP citrate lyase gene CHEBI:35455 1-naphthyl isothiocyanate decreases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D015058 1-Naphthylisothiocyanate results in decreased expression of ACLY mRNA PMID:17522070 10065 ACLY ATP citrate lyase gene CHEBI:35455 1-naphthyl isothiocyanate increases expression ISO RGD:2018 E RGD:6480464 20190507 CTD MESH:D015058 1-Naphthylisothiocyanate results in increased expression of ACLY mRNA PMID:30723492 10065 ACLY ATP citrate lyase gene CHEBI:35456 cadmium dichloride decreases expression ISO RGD:2018 E RGD:6480464 20150825 CTD MESH:D019256 Cadmium Chloride results in decreased expression of ACLY mRNA PMID:25993096 10065 ACLY ATP citrate lyase gene CHEBI:35459 diisononyl phthalate multiple interactions ISO RGD:10064 E RGD:6480464 20240402 CTD MESH:C012125 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ACLY mRNA PMID:35739755 10065 ACLY ATP citrate lyase gene CHEBI:35549 perfluorooctanoic acid decreases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:C023036 perfluorooctanoic acid results in decreased expression of ACLY mRNA PMID:19162173 10065 ACLY ATP citrate lyase gene CHEBI:35549 perfluorooctanoic acid multiple interactions ISO RGD:10064 E RGD:6480464 20140311 CTD MESH:C023036 Dietary Fats, Unsaturated promotes the reaction [perfluorooctanoic acid results in increased expression of ACLY mRNA] PMID:23626681 10065 ACLY ATP citrate lyase gene CHEBI:35559 furan decreases expression ISO RGD:2018 E RGD:6480464 20160119 CTD MESH:C039281 furan results in decreased expression of ACLY mRNA PMID:26194646 10065 ACLY ATP citrate lyase gene CHEBI:35591 pregnenolone 16alpha-carbonitrile decreases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D011285 Pregnenolone Carbonitrile results in decreased expression of ACLY mRNA PMID:19162173 10065 ACLY ATP citrate lyase gene CHEBI:35591 pregnenolone 16alpha-carbonitrile increases expression ISO RGD:2018 E RGD:6480464 20230606 CTD MESH:D011285 Pregnenolone Carbonitrile results in increased expression of ACLY mRNA PMID:30047161 10065 ACLY ATP citrate lyase gene CHEBI:35696 cobalt dichloride decreases expression EXP E RGD:6480464 20120814 CTD MESH:C018021 cobaltous chloride results in decreased expression of ACLY mRNA PMID:19320972|PMID:19376846 10065 ACLY ATP citrate lyase gene CHEBI:3639 chlorothalonil decreases expression ISO RGD:10064 E RGD:6480464 20210810 CTD MESH:C005806 tetrachloroisophthalonitrile results in decreased expression of ACLY mRNA PMID:33246813 10065 ACLY ATP citrate lyase gene CHEBI:3639 chlorothalonil multiple interactions ISO RGD:10064 E RGD:6480464 20210810 CTD MESH:C005806 [procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of ACLY mRNA PMID:33246813 10065 ACLY ATP citrate lyase gene CHEBI:36773 camphor multiple interactions EXP E RGD:6480464 20240806 CTD MESH:D002164 [beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA PMID:38000518 10065 ACLY ATP citrate lyase gene CHEBI:3750 clofibrate decreases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D002994 Clofibrate results in decreased expression of ACLY mRNA; Clofibrate results in decreased expression of ACLY protein PMID:16470657|PMID:17522070|PMID:8240402 10065 ACLY ATP citrate lyase gene CHEBI:38658 dicrotophos increases expression EXP E RGD:6480464 20170725 CTD MESH:C000944 dicrotophos results in increased expression of ACLY mRNA PMID:28302478 10065 ACLY ATP citrate lyase gene CHEBI:38940 sunitinib increases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in increased expression of ACLY mRNA PMID:31533062 10065 ACLY ATP citrate lyase gene CHEBI:3908 coumestrol increases expression EXP E RGD:6480464 20130409 CTD MESH:D003375 Coumestrol results in increased expression of ACLY mRNA PMID:19167446 10065 ACLY ATP citrate lyase gene CHEBI:3908 coumestrol multiple interactions EXP E RGD:6480464 20130409 CTD MESH:D003375 [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACLY mRNA PMID:19167446 10065 ACLY ATP citrate lyase gene CHEBI:39285 chloropicrin decreases expression EXP E RGD:6480464 20151215 CTD MESH:C100187 chloropicrin results in decreased expression of ACLY mRNA PMID:26352163 10065 ACLY ATP citrate lyase gene CHEBI:39421 perfluorooctane-1-sulfonic acid decreases expression ISO RGD:10064 E RGD:6480464 20120412 CTD MESH:C076994 perfluorooctane sulfonic acid results in decreased expression of ACLY mRNA PMID:21705711 10065 ACLY ATP citrate lyase gene CHEBI:39421 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:10064 E RGD:6480464 20230502 CTD MESH:C076994 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of ACLY mRNA; [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of ACLY mRNA PMID:36331819 10065 ACLY ATP citrate lyase gene CHEBI:39483 sodium dichromate decreases expression ISO RGD:2018 E RGD:6480464 20150825 CTD MESH:C016104 sodium bichromate results in decreased expression of ACLY mRNA PMID:25993096 10065 ACLY ATP citrate lyase gene CHEBI:3962 curcumin affects expression ISO RGD:10064 E RGD:6480464 20161025 CTD MESH:D003474 Curcumin affects the expression of ACLY mRNA PMID:27208389 10065 ACLY ATP citrate lyase gene CHEBI:3962 curcumin decreases expression ISO RGD:2018 E RGD:6480464 20161025 CTD MESH:D003474 Curcumin results in decreased expression of ACLY mRNA PMID:27208389 10065 ACLY ATP citrate lyase gene CHEBI:39867 valproic acid affects expression EXP E RGD:6480464 20151013 CTD MESH:D014635 Valproic Acid affects the expression of ACLY mRNA PMID:25979313 10065 ACLY ATP citrate lyase gene CHEBI:39867 valproic acid affects expression ISO RGD:10064 E RGD:6480464 20120412 CTD MESH:D014635 Valproic Acid affects the expression of ACLY mRNA PMID:17292431 10065 ACLY ATP citrate lyase gene CHEBI:39867 valproic acid increases expression EXP E RGD:6480464 20181016 CTD MESH:D014635 Valproic Acid results in increased expression of ACLY mRNA; Valproic Acid results in increased expression of ACLY protein PMID:30003287 10065 ACLY ATP citrate lyase gene CHEBI:39867 valproic acid increases expression ISO RGD:10064 E RGD:6480464 20150127 CTD MESH:D014635 Valproic Acid results in increased expression of ACLY mRNA PMID:24489787 10065 ACLY ATP citrate lyase gene CHEBI:39867 valproic acid multiple interactions EXP E RGD:6480464 20181016 CTD MESH:D014635 NR1H3 protein affects the reaction [Valproic Acid results in increased expression of ACLY mRNA] PMID:30003287 10065 ACLY ATP citrate lyase gene CHEBI:40036 amitrole increases expression ISO RGD:2018 E RGD:6480464 20230606 CTD MESH:D000640 Amitrole results in increased expression of ACLY mRNA PMID:30047161 10065 ACLY ATP citrate lyase gene CHEBI:4031 cyclosporin A decreases expression EXP E RGD:6480464 20120412 CTD MESH:D016572 Cyclosporine results in decreased expression of ACLY mRNA PMID:20106945 10065 ACLY ATP citrate lyase gene CHEBI:41774 tamoxifen affects expression ISO RGD:10064 E RGD:6480464 20120412 CTD MESH:D013629 Tamoxifen affects the expression of ACLY mRNA PMID:20937368 10065 ACLY ATP citrate lyase gene CHEBI:41791 calyculin a increases expression ISO RGD:10064 E RGD:6480464 20150127 CTD MESH:C059041 calyculin A results in increased expression of ACLY mRNA PMID:25270620 10065 ACLY ATP citrate lyase gene CHEBI:41879 dexamethasone decreases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D003907 Dexamethasone results in decreased expression of ACLY mRNA PMID:17522070 10065 ACLY ATP citrate lyase gene CHEBI:42355 erythromycin A increases expression ISO RGD:10064 E RGD:6480464 20161213 CTD MESH:D004917 Erythromycin results in increased expression of ACLY mRNA PMID:27503388 10065 ACLY ATP citrate lyase gene CHEBI:42355 erythromycin A multiple interactions ISO RGD:10064 E RGD:6480464 20161213 CTD MESH:D004917 [Penicillin G co-treated with Erythromycin] results in increased expression of ACLY mRNA PMID:27503388 10065 ACLY ATP citrate lyase gene CHEBI:42758 aldehydo-D-glucose increases expression EXP E RGD:6480464 20180313 CTD MESH:D005947 Glucose deficiency results in increased expression of ACLY mRNA; Glucose deficiency results in increased expression of ACLY protein PMID:26811028 10065 ACLY ATP citrate lyase gene CHEBI:42758 aldehydo-D-glucose increases expression ISO RGD:2018 E RGD:6480464 20140513 CTD MESH:D005947 Glucose results in increased expression of ACLY mRNA PMID:24349266 10065 ACLY ATP citrate lyase gene CHEBI:44185 methotrexate decreases expression ISO RGD:2018 E RGD:6480464 20160412 CTD MESH:D008727 Methotrexate results in decreased expression of ACLY mRNA PMID:24136188 10065 ACLY ATP citrate lyase gene CHEBI:44445 nimesulide decreases expression ISO RGD:2018 E RGD:6480464 20160412 CTD MESH:C012655 nimesulide results in decreased expression of ACLY mRNA PMID:24136188 10065 ACLY ATP citrate lyase gene CHEBI:46195 paracetamol affects expression ISO RGD:10064 E RGD:6480464 20120412 CTD MESH:D000082 Acetaminophen affects the expression of ACLY mRNA PMID:17562736 10065 ACLY ATP citrate lyase gene CHEBI:46195 paracetamol decreases expression ISO RGD:2018 E RGD:6480464 20120501 CTD MESH:D000082 Acetaminophen results in decreased expression of ACLY mRNA PMID:15084756|PMID:17522070 10065 ACLY ATP citrate lyase gene CHEBI:46195 paracetamol increases expression ISO RGD:10064 E RGD:6480464 20190910 CTD MESH:D000082 Acetaminophen results in increased expression of ACLY mRNA PMID:29246445 10065 ACLY ATP citrate lyase gene CHEBI:46195 paracetamol multiple interactions ISO RGD:10064 E RGD:6480464 20150414 CTD MESH:D000082 [CTH gene mutant form results in increased susceptibility to Acetaminophen] which results in increased expression of ACLY protein; PANX1 gene mutant form inhibits the reaction [Acetaminophen results in increased expression of ACLY mRNA] PMID:25499718|PMID:29246445 10065 ACLY ATP citrate lyase gene CHEBI:47217 arsane multiple interactions ISO RGD:10064 E RGD:6480464 20220208 CTD MESH:D001151 [sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of ACLY mRNA PMID:32045263 10065 ACLY ATP citrate lyase gene CHEBI:47807 sulforaphane multiple interactions ISO RGD:2018 E RGD:6480464 20150414 CTD MESH:C016766 [sulforaphane co-treated with Aflatoxin B1] affects the expression of ACLY mRNA PMID:25450479 10065 ACLY ATP citrate lyase gene CHEBI:4791 endosulfan decreases expression ISO RGD:2018 E RGD:6480464 20180828 CTD MESH:D004726 Endosulfan results in decreased expression of ACLY mRNA PMID:29391264 10065 ACLY ATP citrate lyase gene CHEBI:4806 (-)-epigallocatechin 3-gallate increases expression EXP E RGD:6480464 20121218 CTD MESH:C045651 epigallocatechin gallate results in increased expression of ACLY mRNA PMID:20706672 10065 ACLY ATP citrate lyase gene CHEBI:4811 epoxiconazole decreases expression ISO RGD:10064 E RGD:6480464 20220906 CTD MESH:C109476 epoxiconazole results in decreased expression of ACLY mRNA PMID:35436446 10065 ACLY ATP citrate lyase gene CHEBI:4811 epoxiconazole increases expression ISO RGD:2018 E RGD:6480464 20180515 CTD MESH:C109476 epoxiconazole results in increased expression of ACLY mRNA PMID:29038839 10065 ACLY ATP citrate lyase gene CHEBI:4846 erythromycin estolate decreases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D004918 Erythromycin Estolate results in decreased expression of ACLY mRNA PMID:17522070 10065 ACLY ATP citrate lyase gene CHEBI:4903 17alpha-ethynylestradiol decreases expression ISO RGD:2018 E RGD:6480464 20120613 CTD MESH:D004997 Ethinyl Estradiol results in decreased expression of ACLY mRNA PMID:15953391|PMID:17108234 10065 ACLY ATP citrate lyase gene CHEBI:4903 17alpha-ethynylestradiol multiple interactions ISO RGD:10064 E RGD:6480464 20140513 CTD MESH:D004997 [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of ACLY mRNA PMID:24440342 10065 ACLY ATP citrate lyase gene CHEBI:49662 indometacin affects expression ISO RGD:10064 E RGD:6480464 20120412 CTD MESH:D007213 Indomethacin affects the expression of ACLY mRNA PMID:17546600 10065 ACLY ATP citrate lyase gene CHEBI:49662 indometacin increases expression EXP E RGD:6480464 20210706 CTD MESH:D007213 Indomethacin results in increased expression of ACLY mRNA PMID:32535746 10065 ACLY ATP citrate lyase gene CHEBI:5001 fenofibrate increases expression ISO RGD:10064 E RGD:6480464 20140715 CTD MESH:D011345 Fenofibrate results in increased expression of ACLY mRNA PMID:23063693 10065 ACLY ATP citrate lyase gene CHEBI:5001 fenofibrate multiple interactions ISO RGD:10064 E RGD:6480464 20140715 CTD MESH:D011345 PPARA gene mutant form inhibits the reaction [Fenofibrate results in increased expression of ACLY mRNA] PMID:23063693 10065 ACLY ATP citrate lyase gene CHEBI:50027 sabinene multiple interactions EXP E RGD:6480464 20240806 CTD MESH:C035127 [beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA PMID:38000518 10065 ACLY ATP citrate lyase gene CHEBI:50045 (+)-beta-thujone multiple interactions EXP E RGD:6480464 20240806 CTD MESH:C005790 [beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA PMID:38000518 10065 ACLY ATP citrate lyase gene CHEBI:50102 N-methyl-N-nitrosourea increases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D008770 Methylnitrosourea results in increased expression of ACLY mRNA PMID:16525678 10065 ACLY ATP citrate lyase gene CHEBI:50594 carbon nanotube decreases expression ISO RGD:10064 E RGD:6480464 20161228 CTD MESH:D037742 Nanotubes, Carbon analog results in decreased expression of ACLY mRNA; Nanotubes, Carbon results in decreased expression of ACLY mRNA PMID:25554681|PMID:25620056 10065 ACLY ATP citrate lyase gene CHEBI:50692 mifepristone increases expression EXP E RGD:6480464 20120412 CTD MESH:D015735 Mifepristone results in increased expression of ACLY mRNA PMID:17584828 10065 ACLY ATP citrate lyase gene CHEBI:50866 3H-1,2-dithiole-3-thione increases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:C049325 1,2-dithiol-3-thione results in increased expression of ACLY mRNA PMID:19162173 10065 ACLY ATP citrate lyase gene CHEBI:5132 flutamide increases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D005485 Flutamide results in increased expression of ACLY mRNA PMID:21525395 10065 ACLY ATP citrate lyase gene CHEBI:5759 Honokiol decreases expression ISO RGD:2018 E RGD:6480464 20170228 CTD MESH:C005499 honokiol results in decreased expression of ACLY mRNA PMID:19371623 10065 ACLY ATP citrate lyase gene CHEBI:6067 isotretinoin decreases expression EXP E RGD:6480464 20120412 CTD MESH:D015474 Isotretinoin results in decreased expression of ACLY mRNA PMID:20436886 10065 ACLY ATP citrate lyase gene CHEBI:6078 ivermectin decreases expression EXP E RGD:6480464 20210907 CTD MESH:D007559 Ivermectin results in decreased expression of ACLY protein PMID:32959892 10065 ACLY ATP citrate lyase gene CHEBI:63634 valdecoxib decreases expression ISO RGD:2018 E RGD:6480464 20170303 CTD MESH:C406224 valdecoxib results in decreased expression of ACLY mRNA PMID:24136188 10065 ACLY ATP citrate lyase gene CHEBI:63637 vemurafenib multiple interactions EXP E RGD:6480464 20190910 CTD MESH:C551177 [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA] PMID:29950559 10065 ACLY ATP citrate lyase gene CHEBI:63933 Aroclor 1254 decreases expression ISO RGD:10064 E RGD:6480464 20131210 CTD MESH:D020111 Chlorodiphenyl (54% Chlorine) results in decreased expression of ACLY mRNA PMID:23650126 10065 ACLY ATP citrate lyase gene CHEBI:64243 monosodium L-glutamate multiple interactions ISO RGD:10064 E RGD:6480464 20200331 CTD MESH:D012970 [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ACLY mRNA PMID:19001666 10065 ACLY ATP citrate lyase gene CHEBI:6469 linalyl acetate multiple interactions EXP E RGD:6480464 20240806 CTD MESH:C074463 [beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA PMID:38000518 10065 ACLY ATP citrate lyase gene CHEBI:65585 carnosic acid increases expression ISO RGD:10064 E RGD:6480464 20230404 CTD MESH:C018381 salvin results in increased expression of ACLY protein PMID:35926579 10065 ACLY ATP citrate lyase gene CHEBI:6801 metformin affects expression ISO RGD:2018 E RGD:6480464 20200114 CTD MESH:D008687 Metformin affects the expression of ACLY mRNA PMID:31324951 10065 ACLY ATP citrate lyase gene CHEBI:6801 metformin multiple interactions EXP E RGD:6480464 20180116 CTD MESH:D008687 [Metformin co-treated with caffeic acid] results in decreased expression of ACLY protein PMID:28576465 10065 ACLY ATP citrate lyase gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of ACLY exon PMID:30157460 10065 ACLY ATP citrate lyase gene CHEBI:6923 miconazole increases expression ISO RGD:10064 E RGD:6480464 20190910 CTD MESH:D008825 Miconazole results in increased expression of ACLY mRNA PMID:27462272 10065 ACLY ATP citrate lyase gene CHEBI:72544 flavonoids increases expression ISO RGD:2018 E RGD:6480464 20170303 CTD MESH:D005419 Flavonoids results in increased expression of ACLY mRNA PMID:18035473 10065 ACLY ATP citrate lyase gene CHEBI:72754 bisphenol AF increases expression EXP E RGD:6480464 20250114 CTD MESH:C583074 bisphenol AF results in increased expression of ACLY protein PMID:34186270 10065 ACLY ATP citrate lyase gene CHEBI:73755 1,2-dimethylhydrazine increases expression ISO RGD:10064 E RGD:6480464 20200804 CTD MESH:D019813 1,2-Dimethylhydrazine results in increased expression of ACLY mRNA PMID:22206623 10065 ACLY ATP citrate lyase gene CHEBI:73755 1,2-dimethylhydrazine multiple interactions ISO RGD:10064 E RGD:6480464 20200804 CTD MESH:D019813 Folic Acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of ACLY mRNA] PMID:22206623 10065 ACLY ATP citrate lyase gene CHEBI:7459 naloxone decreases expression ISO RGD:2018 E RGD:6480464 20120412 CTD MESH:D009270 Naloxone results in decreased expression of ACLY mRNA PMID:17522070 10065 ACLY ATP citrate lyase gene CHEBI:7494 nefazodone decreases expression ISO RGD:2018 E RGD:6480464 20160412 CTD MESH:C051752 nefazodone results in decreased expression of ACLY mRNA PMID:24136188 10065 ACLY ATP citrate lyase gene CHEBI:75170 zaragozic acid A decreases expression ISO RGD:2018 E RGD:6480464 20180220 CTD MESH:C075117 squalestatin 1 results in decreased expression of ACLY mRNA PMID:27225895 10065 ACLY ATP citrate lyase gene CHEBI:75170 zaragozic acid A increases expression ISO RGD:10064 E RGD:6480464 20180220 CTD MESH:C075117 squalestatin 1 results in increased expression of ACLY mRNA PMID:27225895 10065 ACLY ATP citrate lyase gene CHEBI:75701 sarin decreases expression EXP E RGD:6480464 20131112 CTD MESH:D012524 Sarin results in decreased expression of ACLY mRNA PMID:19522546 10065 ACLY ATP citrate lyase gene CHEBI:75998 trametinib multiple interactions EXP E RGD:6480464 20190910 CTD MESH:C560077 trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA] PMID:29950559 10065 ACLY ATP citrate lyase gene CHEBI:7797 Osajin increases expression EXP E RGD:6480464 20170110 CTD MESH:C485800 osajin results in increased expression of ACLY mRNA PMID:20706672 10065 ACLY ATP citrate lyase gene CHEBI:78334 (R)-linalyl acetate multiple interactions EXP E RGD:6480464 20240806 CTD MESH:C074463 [beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA PMID:38000518 10065 ACLY ATP citrate lyase gene CHEBI:79995 GW 3965 multiple interactions ISO RGD:10064 E RGD:6480464 20191210 CTD MESH:C473027 GW 3965 inhibits the reaction [Palmitic Acid results in increased expression of ACLY mRNA] PMID:31421115 10065 ACLY ATP citrate lyase gene CHEBI:79997 GW 4064 multiple interactions EXP E RGD:6480464 20190312 CTD MESH:C412815 [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACLY mRNA PMID:30611723 10065 ACLY ATP citrate lyase gene CHEBI:8064 phenformin decreases expression ISO RGD:2018 E RGD:6480464 20200114 CTD MESH:D010629 Phenformin results in decreased expression of ACLY mRNA PMID:31324951 10065 ACLY ATP citrate lyase gene CHEBI:8069 phenobarbital affects expression ISO RGD:10064 E RGD:6480464 20130514 CTD MESH:D010634 Phenobarbital affects the expression of ACLY mRNA PMID:23091169 10065 ACLY ATP citrate lyase gene CHEBI:80774 tauroursodeoxycholic acid decreases expression ISO RGD:2018 E RGD:6480464 20141111 CTD MESH:C031655 ursodoxicoltaurine results in decreased expression of ACLY mRNA PMID:15885361 10065 ACLY ATP citrate lyase gene CHEBI:81506 2,3,7,8-Tetrachlorodibenzofuran decreases expression ISO RGD:2018 E RGD:6480464 20141111 CTD MESH:C014211 2,3,7,8-tetrachlorodibenzofuran results in decreased expression of ACLY mRNA PMID:21724226|PMID:32109520 10065 ACLY ATP citrate lyase gene CHEBI:81508 2,3,4,7,8-Pentachlorodibenzofuran decreases expression ISO RGD:2018 E RGD:6480464 20141111 CTD MESH:C038890 2,3,4,7,8-pentachlorodibenzofuran results in decreased expression of ACLY mRNA PMID:21724226 10065 ACLY ATP citrate lyase gene CHEBI:81543 Tributyltin oxide decreases phosphorylation ISO RGD:10064 E RGD:6480464 20161213 CTD MESH:C005961 bis(tri-n-butyltin)oxide results in decreased phosphorylation of ACLY protein PMID:22174045 10065 ACLY ATP citrate lyase gene CHEBI:81555 Enterolactone multiple interactions EXP E RGD:6480464 20151103 CTD MESH:C029497 [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACLY mRNA PMID:19167446 10065 ACLY ATP citrate lyase gene CHEBI:81584 2,2',4,4'-Tetrabromodiphenyl ether decreases expression ISO RGD:2018 E RGD:6480464 20170303 CTD MESH:C511295 2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of ACLY mRNA PMID:20056577 10065 ACLY ATP citrate lyase gene CHEBI:81758 cyproconazole increases expression ISO RGD:2018 E RGD:6480464 20180515 CTD MESH:C093628 cyproconazole results in increased expression of ACLY mRNA PMID:29038839 10065 ACLY ATP citrate lyase gene CHEBI:81892 Brodifacoum increases expression ISO RGD:2018 E RGD:6480464 20171114 CTD MESH:C013418 bromfenacoum results in increased expression of ACLY protein PMID:28903499 10065 ACLY ATP citrate lyase gene CHEBI:82033 propamocarb decreases expression ISO RGD:10064 E RGD:6480464 20190219 CTD MESH:C033205 propamocarb results in decreased expression of ACLY mRNA PMID:29137890 10065 ACLY ATP citrate lyase gene CHEBI:83197 picoxystrobin increases expression EXP E RGD:6480464 20210810 CTD MESH:C556557 picoxystrobin results in increased expression of ACLY mRNA PMID:33512557 10065 ACLY ATP citrate lyase gene CHEBI:8329 Pomiferin increases expression EXP E RGD:6480464 20170110 CTD MESH:C474837 pomiferin results in increased expression of ACLY mRNA PMID:20706672 10065 ACLY ATP citrate lyase gene CHEBI:8450 procymidone decreases expression ISO RGD:10064 E RGD:6480464 20210810 CTD MESH:C035988 procymidone results in decreased expression of ACLY mRNA PMID:33246813 10065 ACLY ATP citrate lyase gene CHEBI:8450 procymidone increases expression ISO RGD:10064 E RGD:6480464 20230606 CTD MESH:C035988 procymidone results in increased expression of ACLY mRNA PMID:36764477 10065 ACLY ATP citrate lyase gene CHEBI:8450 procymidone multiple interactions ISO RGD:10064 E RGD:6480464 20210810 CTD MESH:C035988 [procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of ACLY mRNA PMID:33246813 10065 ACLY ATP citrate lyase gene CHEBI:8489 propiconazole increases expression ISO RGD:2018 E RGD:6480464 20230606 CTD MESH:C045950 propiconazole results in increased expression of ACLY mRNA PMID:30047161 10065 ACLY ATP citrate lyase gene CHEBI:8493 Propiverine affects binding ISO RGD:2018 E RGD:6480464 20180410 CTD MESH:C015586 propiverine binds to ACLY protein PMID:29273565 10065 ACLY ATP citrate lyase gene CHEBI:8502 6-propyl-2-thiouracil increases expression ISO RGD:2018 E RGD:6480464 20230606 CTD MESH:D011441 Propylthiouracil results in increased expression of ACLY mRNA PMID:30047161 10065 ACLY ATP citrate lyase gene CHEBI:8633 puerarin increases expression EXP E RGD:6480464 20141111 CTD MESH:C033607 puerarin results in increased expression of ACLY mRNA PMID:20706672 10065 ACLY ATP citrate lyase gene CHEBI:88046 cylindrospermopsin decreases expression EXP E RGD:6480464 20250114 CTD MESH:C089595 cylindrospermopsin results in decreased expression of ACLY mRNA PMID:38735451 10065 ACLY ATP citrate lyase gene CHEBI:91108 SB 431542 multiple interactions EXP E RGD:6480464 20240206 CTD MESH:C459179 [LDN 193189 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in decreased expression of ACLY protein PMID:37664457 10065 ACLY ATP citrate lyase gene CHEBI:9144 silibinin decreases phosphorylation EXP E RGD:6480464 20191114 CTD MESH:C440975 Silybin results in decreased phosphorylation of ACLY protein PMID:25294820 10065 ACLY ATP citrate lyase gene CHEBI:93310 N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide multiple interactions ISO RGD:10064 E RGD:6480464 20181016 CTD MESH:C492919 N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Particulate Matter results in increased expression of ACLY protein] PMID:29635361 10065 ACLY ATP citrate lyase gene CHEBI:9352 sulindac increases expression EXP E RGD:6480464 20210706 CTD MESH:D013467 Sulindac results in increased expression of ACLY mRNA PMID:32535746 10065 ACLY ATP citrate lyase gene CHEBI:9381 T-2 toxin decreases expression ISO RGD:2018 E RGD:6480464 20151110 CTD MESH:D013605 T-2 Toxin results in decreased expression of ACLY mRNA PMID:26141394 10065 ACLY ATP citrate lyase gene CHEBI:9495 thiram decreases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in decreased expression of ACLY mRNA PMID:38568856 10065 ACLY ATP citrate lyase gene CHEBI:9516 thapsigargin increases expression ISO RGD:10064 E RGD:6480464 20160412 CTD MESH:D019284 Thapsigargin results in increased expression of ACLY protein PMID:24648495 10065 ACLY ATP citrate lyase gene CHEBI:9516 thapsigargin increases expression ISO RGD:2018 E RGD:6480464 20221101 CTD MESH:D019284 Thapsigargin results in increased expression of ACLY protein PMID:35544339 10065 ACLY ATP citrate lyase gene CHEBI:955 2,6-dimethoxyphenol multiple interactions EXP E RGD:6480464 20250114 CTD MESH:C010120 [Sodium Chloride co-treated with pyrogallol 1,3-dimethyl ether] results in decreased expression of and affects the localization of ACLY protein PMID:38598786 10065 ACLY ATP citrate lyase gene CHEBI:9747 Triptolide decreases expression ISO RGD:10064 E RGD:6480464 20210706 CTD MESH:C001899 triptolide results in decreased expression of ACLY mRNA PMID:32835833 10065 ACLY ATP citrate lyase gene CHEBI:9753 troglitazone decreases expression EXP E RGD:6480464 20150825 CTD MESH:C057693 troglitazone results in decreased expression of ACLY mRNA PMID:25572481 10067 ACO1 aconitase 1 gene CHEBI:10106 zearalenone decreases expression ISO RGD:10066 E RGD:6480464 20230404 CTD MESH:D015025 Zearalenone results in decreased expression of ACO1 protein PMID:36252740 10067 ACO1 aconitase 1 gene CHEBI:1224 2-nitrofluorene increases expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:C019499 2-nitrofluorene results in increased expression of ACO1 mRNA PMID:15890375 10067 ACO1 aconitase 1 gene CHEBI:132267 triptonide decreases expression ISO RGD:10066 E RGD:6480464 20210406 CTD MESH:C084079 triptonide results in decreased expression of ACO1 mRNA PMID:33045310 10067 ACO1 aconitase 1 gene CHEBI:132471 (+)-schisandrin B multiple interactions ISO RGD:2019 E RGD:6480464 20190910 CTD MESH:C015499 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of ACO1 mRNA] PMID:31150632 10067 ACO1 aconitase 1 gene CHEBI:15367 all-trans-retinoic acid decreases expression EXP E RGD:6480464 20220208 CTD MESH:D014212 Tretinoin results in decreased expression of ACO1 mRNA PMID:33167477 10067 ACO1 aconitase 1 gene CHEBI:15367 all-trans-retinoic acid increases expression EXP E RGD:6480464 20140408 CTD MESH:D014212 Tretinoin results in increased expression of ACO1 mRNA PMID:23724009 10067 ACO1 aconitase 1 gene CHEBI:15368 acrolein multiple interactions EXP E RGD:6480464 20210112 CTD MESH:D000171 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased expression of ACO1 mRNA; [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased expression of ACO1 mRNA PMID:32699268 10067 ACO1 aconitase 1 gene CHEBI:15379 dioxygen multiple interactions ISO RGD:2019 E RGD:6480464 20181016 CTD MESH:D010100 [Oxygen deficiency co-treated with Glucose deficiency] affects the activity of ACO1 protein; Oxygen inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the activity of ACO1 protein] PMID:16135072 10067 ACO1 aconitase 1 gene CHEBI:16240 hydrogen peroxide affects expression EXP E RGD:6480464 20120412 CTD MESH:D006861 Hydrogen Peroxide affects the expression of ACO1 mRNA PMID:20044591 10067 ACO1 aconitase 1 gene CHEBI:16240 hydrogen peroxide increases activity ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:D006861 Hydrogen Peroxide results in increased activity of ACO1 protein PMID:15664434 10067 ACO1 aconitase 1 gene CHEBI:16243 quercetin increases expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D011794 Quercetin results in increased expression of ACO1 mRNA PMID:17103110 10067 ACO1 aconitase 1 gene CHEBI:16412 lipopolysaccharide increases activity ISO RGD:10066 E RGD:6480464 20161228 CTD MESH:D008070 Lipopolysaccharides results in increased activity of ACO1 protein PMID:11054110 10067 ACO1 aconitase 1 gene CHEBI:16412 lipopolysaccharide multiple interactions ISO RGD:10066 E RGD:6480464 20161228 CTD MESH:D008070 [Lipopolysaccharides co-treated with IFNG protein] results in increased activity of ACO1 protein PMID:11054110 10067 ACO1 aconitase 1 gene CHEBI:16469 17beta-estradiol affects expression ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:D004958 Estradiol affects the expression of ACO1 mRNA PMID:16684588 10067 ACO1 aconitase 1 gene CHEBI:16469 17beta-estradiol decreases expression EXP E RGD:6480464 20121113 CTD MESH:D004958 Estradiol results in decreased expression of ACO1 mRNA PMID:21185374 10067 ACO1 aconitase 1 gene CHEBI:16469 17beta-estradiol multiple interactions ISO RGD:2019 E RGD:6480464 20160705 CTD MESH:D004958 [bisphenol A co-treated with Estradiol] results in decreased expression of ACO1 mRNA PMID:26496021 10067 ACO1 aconitase 1 gene CHEBI:16480 nitric oxide decreases expression ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:D009569 Nitric Oxide results in decreased expression of ACO1 mRNA PMID:16886906 10067 ACO1 aconitase 1 gene CHEBI:16480 nitric oxide multiple interactions ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:D009569 STAT5A protein affects the reaction [Nitric Oxide results in decreased expression of ACO1 mRNA]; STAT5B protein affects the reaction [Nitric Oxide results in decreased expression of ACO1 mRNA] PMID:16886906 10067 ACO1 aconitase 1 gene CHEBI:16602 trichloroethene decreases expression ISO RGD:2019 E RGD:6480464 20211207 CTD MESH:D014241 Trichloroethylene results in decreased expression of ACO1 mRNA PMID:33387578 10067 ACO1 aconitase 1 gene CHEBI:17234 glucose increases expression EXP E RGD:6480464 20240806 CTD MESH:D005947 Glucose results in increased expression of ACO1 protein PMID:38483099 10067 ACO1 aconitase 1 gene CHEBI:17234 glucose increases expression ISO RGD:2019 E RGD:6480464 20240806 CTD MESH:D005947 Glucose results in increased expression of ACO1 protein PMID:38483099 10067 ACO1 aconitase 1 gene CHEBI:17234 glucose multiple interactions ISO RGD:2019 E RGD:6480464 20181016 CTD MESH:D005947 [Oxygen deficiency co-treated with Glucose deficiency] affects the activity of ACO1 protein; Oxygen inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the activity of ACO1 protein] PMID:16135072 10067 ACO1 aconitase 1 gene CHEBI:174045 Fluorocitric acid decreases activity ISO RGD:2019 E RGD:6480464 20210706 CTD MESH:C007744 fluorocitrate results in decreased activity of ACO1 protein PMID:17469137 10067 ACO1 aconitase 1 gene CHEBI:17580 linalool increases expression EXP E RGD:6480464 20190219 CTD MESH:C018584 linalool results in increased expression of ACO1 mRNA PMID:24752549 10067 ACO1 aconitase 1 gene CHEBI:17634 D-glucose increases expression EXP E RGD:6480464 20240806 CTD MESH:D005947 Glucose results in increased expression of ACO1 protein PMID:38483099 10067 ACO1 aconitase 1 gene CHEBI:17634 D-glucose increases expression ISO RGD:2019 E RGD:6480464 20240806 CTD MESH:D005947 Glucose results in increased expression of ACO1 protein PMID:38483099 10067 ACO1 aconitase 1 gene CHEBI:17634 D-glucose multiple interactions ISO RGD:2019 E RGD:6480464 20181016 CTD MESH:D005947 [Oxygen deficiency co-treated with Glucose deficiency] affects the activity of ACO1 protein; Oxygen inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the activity of ACO1 protein] PMID:16135072 10067 ACO1 aconitase 1 gene CHEBI:18246 (1->4)-beta-D-glucan multiple interactions ISO RGD:10066 E RGD:6480464 20230502 CTD MESH:D002482 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of ACO1 mRNA PMID:36331819 10067 ACO1 aconitase 1 gene CHEBI:18248 iron atom affects metabolic processing ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:D007501 ACO1 protein affects the metabolism of Iron PMID:17194590 10067 ACO1 aconitase 1 gene CHEBI:18248 iron atom multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D007501 Iron inhibits the reaction [nickel chloride results in increased activity of ACO1 protein]; Iron inhibits the reaction [Nickel results in increased activity of ACO1 protein] PMID:16039939|PMID:16877034 10067 ACO1 aconitase 1 gene CHEBI:18248 iron atom multiple interactions ISO RGD:2019 E RGD:6480464 20120814 CTD MESH:D007501 [Deferoxamine results in decreased abundance of Iron] which results in increased activity of ACO1 protein PMID:15893546 10067 ACO1 aconitase 1 gene CHEBI:18291 manganese atom decreases activity ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D008345 Manganese results in decreased activity of ACO1 protein PMID:17469137 10067 ACO1 aconitase 1 gene CHEBI:18291 manganese atom increases activity EXP E RGD:6480464 20120412 CTD MESH:D008345 Manganese results in increased activity of ACO1 protein PMID:16386771 10067 ACO1 aconitase 1 gene CHEBI:18291 manganese atom increases activity ISO RGD:2019 E RGD:6480464 20120501 CTD MESH:D008345 Manganese results in increased activity of ACO1 protein PMID:16545456|PMID:16568477 10067 ACO1 aconitase 1 gene CHEBI:18291 manganese atom multiple interactions ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D008345 Manganese results in increased stability of [ACO1 protein binds to SLC11A2 mRNA] PMID:16729984 10067 ACO1 aconitase 1 gene CHEBI:18421 superoxide decreases activity ISO RGD:10066 E RGD:6480464 20190219 CTD MESH:D013481 Superoxides results in decreased activity of ACO1 protein PMID:28542246 10067 ACO1 aconitase 1 gene CHEBI:18421 superoxide multiple interactions ISO RGD:10066 E RGD:6480464 20190219 CTD MESH:D013481 [SOD1 protein results in decreased abundance of Superoxides] which results in increased expression of ACO1 protein PMID:28542246 10067 ACO1 aconitase 1 gene CHEBI:18721 3-chloropropane-1,2-diol affects expression ISO RGD:2019 E RGD:6480464 20170516 CTD MESH:D000517 alpha-Chlorohydrin affects the expression of ACO1 protein PMID:26597043 10067 ACO1 aconitase 1 gene CHEBI:18721 3-chloropropane-1,2-diol decreases expression ISO RGD:2019 E RGD:6480464 20170516 CTD MESH:D000517 alpha-Chlorohydrin analog results in decreased expression of ACO1 protein PMID:26597043 10067 ACO1 aconitase 1 gene CHEBI:18721 3-chloropropane-1,2-diol increases expression ISO RGD:2019 E RGD:6480464 20171010 CTD MESH:D000517 alpha-Chlorohydrin results in increased expression of ACO1 mRNA PMID:28522335 10067 ACO1 aconitase 1 gene CHEBI:188851 Muraglitazar increases expression ISO RGD:2019 E RGD:6480464 20220104 CTD MESH:C500085 muraglitazar results in increased expression of ACO1 mRNA PMID:21515302 10067 ACO1 aconitase 1 gene CHEBI:22977 cadmium atom multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D002104 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of ACO1 mRNA PMID:35301059 10067 ACO1 aconitase 1 gene CHEBI:231505 gallium nitrate increases expression EXP E RGD:6480464 20240702 CTD MESH:C027235 gallium nitrate results in increased expression of ACO1 mRNA PMID:18586083 10067 ACO1 aconitase 1 gene CHEBI:2504 aflatoxin B1 increases expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D016604 Aflatoxin B1 results in increased expression of ACO1 mRNA PMID:15890375 10067 ACO1 aconitase 1 gene CHEBI:25812 ozone multiple interactions EXP E RGD:6480464 20210112 CTD MESH:D010126 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased expression of ACO1 mRNA; [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased expression of ACO1 mRNA; [Air Pollutants results in increased abundance of Ozone] which affects the expression of ACO1 mRNA; [Volatile Organic Compounds co-treated with Ozone] results in increased expression of ACO1 mRNA PMID:32699268|PMID:35430440 10067 ACO1 aconitase 1 gene CHEBI:25812 ozone multiple interactions ISO RGD:10066 E RGD:6480464 20220809 CTD MESH:D010126 [Air Pollutants results in increased abundance of Ozone] which results in increased expression of ACO1 mRNA PMID:34911549 10067 ACO1 aconitase 1 gene CHEBI:2663 amiodarone affects expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D000638 Amiodarone affects the expression of ACO1 mRNA PMID:19483382 10067 ACO1 aconitase 1 gene CHEBI:27363 zinc atom decreases activity ISO RGD:10066 E RGD:6480464 20130122 CTD MESH:D015032 Zinc deficiency results in decreased activity of ACO1 protein PMID:18073202 10067 ACO1 aconitase 1 gene CHEBI:27385 tetrachloromethane decreases expression ISO RGD:10066 E RGD:6480464 20200804 CTD MESH:D002251 Carbon Tetrachloride results in decreased expression of ACO1 mRNA PMID:31919559 10067 ACO1 aconitase 1 gene CHEBI:27385 tetrachloromethane decreases expression ISO RGD:2019 E RGD:6480464 20190910 CTD MESH:D002251 Carbon Tetrachloride results in decreased expression of ACO1 mRNA PMID:31150632 10067 ACO1 aconitase 1 gene CHEBI:27385 tetrachloromethane multiple interactions ISO RGD:2019 E RGD:6480464 20190910 CTD MESH:D002251 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of ACO1 mRNA] PMID:31150632 10067 ACO1 aconitase 1 gene CHEBI:27470 folic acid decreases expression ISO RGD:10066 E RGD:6480464 20200804 CTD MESH:D005492 Folic Acid results in decreased expression of ACO1 mRNA PMID:25629700 10067 ACO1 aconitase 1 gene CHEBI:27504 mitomycin C affects response to substance EXP E RGD:6480464 20120412 CTD MESH:D016685 ACO1 protein affects the susceptibility to Mitomycin PMID:16217747 10067 ACO1 aconitase 1 gene CHEBI:27563 arsenic atom increases activity EXP E RGD:6480464 20120412 CTD MESH:D001151 Arsenic results in increased activity of ACO1 protein PMID:16386771 10067 ACO1 aconitase 1 gene CHEBI:27638 cobalt atom increases activity EXP E RGD:6480464 20120717 CTD MESH:D003035 Cobalt results in increased activity of ACO1 protein PMID:16386771|PMID:16877034 10067 ACO1 aconitase 1 gene CHEBI:27666 actinomycin D multiple interactions EXP E RGD:6480464 20240806 CTD MESH:D003609 [Dactinomycin co-treated with nutlin 3] results in increased secretion of ACO1 protein PMID:38460933 10067 ACO1 aconitase 1 gene CHEBI:27698 vanadium atom increases activity EXP E RGD:6480464 20120412 CTD MESH:D014639 Vanadium results in increased activity of ACO1 protein PMID:16386771 10067 ACO1 aconitase 1 gene CHEBI:28112 nickel atom decreases expression EXP E RGD:6480464 20151110 CTD MESH:D009532 Nickel results in decreased expression of ACO1 mRNA PMID:25583101 10067 ACO1 aconitase 1 gene CHEBI:28112 nickel atom increases activity EXP E RGD:6480464 20120412 CTD MESH:D009532 Nickel results in increased activity of ACO1 protein PMID:16386771|PMID:16877034 10067 ACO1 aconitase 1 gene CHEBI:28112 nickel atom multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D009532 ferric sulfate inhibits the reaction [Nickel results in increased activity of ACO1 protein]; Iron inhibits the reaction [Nickel results in increased activity of ACO1 protein] PMID:16877034 10067 ACO1 aconitase 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:10066 E RGD:6480464 20121009 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of ACO1 mRNA PMID:21570461 10067 ACO1 aconitase 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases activity ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased activity of ACO1 protein PMID:9443932 10067 ACO1 aconitase 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of ACO1 mRNA; Tetrachlorodibenzodioxin results in decreased expression of ACO1 protein PMID:18163543|PMID:28213091 10067 ACO1 aconitase 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:D013749 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ACO1 mRNA; Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ACO1 gene] PMID:17942748|PMID:28213091 10067 ACO1 aconitase 1 gene CHEBI:28201 rotenone decreases activity EXP E RGD:6480464 20130416 CTD MESH:D012402 Rotenone results in decreased activity of ACO1 protein PMID:21570952 10067 ACO1 aconitase 1 gene CHEBI:28201 rotenone increases activity EXP E RGD:6480464 20130416 CTD MESH:D012402 Rotenone results in increased activity of ACO1 protein PMID:21570952 10067 ACO1 aconitase 1 gene CHEBI:28694 copper atom decreases expression ISO RGD:2019 E RGD:6480464 20120717 CTD MESH:D003300 Copper results in decreased expression of ACO1 mRNA PMID:22465980 10067 ACO1 aconitase 1 gene CHEBI:28694 copper atom increases activity EXP E RGD:6480464 20120412 CTD MESH:D003300 Copper results in increased activity of ACO1 protein PMID:16386771 10067 ACO1 aconitase 1 gene CHEBI:28748 doxorubicin affects activity ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D004317 Doxorubicin affects the activity of ACO1 protein PMID:11731422 10067 ACO1 aconitase 1 gene CHEBI:28748 doxorubicin affects response to substance EXP E RGD:6480464 20120412 CTD MESH:D004317 ACO1 protein affects the susceptibility to Doxorubicin PMID:16217747 10067 ACO1 aconitase 1 gene CHEBI:28748 doxorubicin decreases expression EXP E RGD:6480464 20181113 CTD MESH:D004317 Doxorubicin results in decreased expression of ACO1 mRNA PMID:29803840 10067 ACO1 aconitase 1 gene CHEBI:2877 aspartame multiple interactions ISO RGD:10066 E RGD:6480464 20200317 CTD MESH:D001218 [Fats, Unsaturated co-treated with Aspartame] affects the expression of ACO1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACO1 mRNA PMID:23783067 10067 ACO1 aconitase 1 gene CHEBI:28794 coumarin affects expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:C030123 coumarin affects the expression of ACO1 mRNA PMID:16963487 10067 ACO1 aconitase 1 gene CHEBI:28869 menadione affects activity ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:D024483 Vitamin K 3 affects the activity of ACO1 protein PMID:10037708 10067 ACO1 aconitase 1 gene CHEBI:28984 aluminium atom decreases activity ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D000535 Aluminum results in decreased activity of ACO1 protein PMID:10806405 10067 ACO1 aconitase 1 gene CHEBI:29287 gold atom multiple interactions EXP E RGD:6480464 20171010 CTD MESH:D006046 [Polyethyleneimine binds to Gold] which results in increased expression of ACO1 mRNA PMID:28433809 10067 ACO1 aconitase 1 gene CHEBI:29678 sodium arsenite increases expression ISO RGD:2019 E RGD:6480464 20190507 CTD MESH:C017947 sodium arsenite results in increased expression of ACO1 protein PMID:29459688 10067 ACO1 aconitase 1 gene CHEBI:29865 benzo[a]pyrene decreases methylation ISO RGD:10066 E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in decreased methylation of ACO1 exon; Benzo(a)pyrene results in decreased methylation of ACO1 intron PMID:27901495 10067 ACO1 aconitase 1 gene CHEBI:29865 benzo[a]pyrene increases expression ISO RGD:10066 E RGD:6480464 20120918 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of ACO1 mRNA PMID:22228805 10067 ACO1 aconitase 1 gene CHEBI:29865 benzo[a]pyrene multiple interactions EXP E RGD:6480464 20140812 CTD MESH:D001564 [Soot co-treated with Benzo(a)pyrene] results in increased expression of ACO1 protein PMID:24464499 10067 ACO1 aconitase 1 gene CHEBI:30050 gold(0) multiple interactions EXP E RGD:6480464 20171010 CTD MESH:D006046 [Polyethyleneimine binds to Gold] which results in increased expression of ACO1 mRNA PMID:28433809 10067 ACO1 aconitase 1 gene CHEBI:30052 copper(0) decreases expression ISO RGD:2019 E RGD:6480464 20120717 CTD MESH:D003300 Copper results in decreased expression of ACO1 mRNA PMID:22465980 10067 ACO1 aconitase 1 gene CHEBI:30052 copper(0) increases activity EXP E RGD:6480464 20120412 CTD MESH:D003300 Copper results in increased activity of ACO1 protein PMID:16386771 10067 ACO1 aconitase 1 gene CHEBI:30185 zinc(0) decreases activity ISO RGD:10066 E RGD:6480464 20130122 CTD MESH:D015032 Zinc deficiency results in decreased activity of ACO1 protein PMID:18073202 10067 ACO1 aconitase 1 gene CHEBI:3023 benzbromarone affects expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D001553 Benzbromarone affects the expression of ACO1 mRNA PMID:19483382 10067 ACO1 aconitase 1 gene CHEBI:30621 diarsenic trioxide decreases expression EXP E RGD:6480464 20191114 CTD MESH:C006632 Arsenic Trioxide results in decreased expression of ACO1 protein PMID:19364129 10067 ACO1 aconitase 1 gene CHEBI:30621 diarsenic trioxide increases expression EXP E RGD:6480464 20191114 CTD MESH:C006632 Arsenic Trioxide results in increased expression of ACO1 mRNA PMID:20458559 10067 ACO1 aconitase 1 gene CHEBI:31206 ammonium chloride affects expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D000643 Ammonium Chloride affects the expression of ACO1 mRNA PMID:16483693 10067 ACO1 aconitase 1 gene CHEBI:31604 ferric ammonium citrate decreases activity ISO RGD:10066 E RGD:6480464 20130122 CTD MESH:C013531 ferric ammonium citrate results in decreased activity of ACO1 protein PMID:18073202 10067 ACO1 aconitase 1 gene CHEBI:31604 ferric ammonium citrate increases activity ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:C013531 ferric ammonium citrate results in increased activity of ACO1 protein PMID:11054110 10067 ACO1 aconitase 1 gene CHEBI:31638 fulvestrant increases methylation EXP E RGD:6480464 20220308 CTD MESH:C070081 Fulvestrant results in increased methylation of ACO1 gene PMID:31601247 10067 ACO1 aconitase 1 gene CHEBI:32161 sulfadimethoxine increases expression ISO RGD:2019 E RGD:6480464 20230606 CTD MESH:D013412 Sulfadimethoxine results in increased expression of ACO1 mRNA PMID:30047161 10067 ACO1 aconitase 1 gene CHEBI:32195 Tesaglitazar increases expression ISO RGD:2019 E RGD:6480464 20170303 CTD MESH:C501413 tesaglitazar results in increased expression of ACO1 mRNA PMID:21515302 10067 ACO1 aconitase 1 gene CHEBI:32234 titanium dioxide increases expression ISO RGD:10066 E RGD:6480464 20191112 CTD MESH:C009495 titanium dioxide results in increased expression of ACO1 mRNA PMID:29264374 10067 ACO1 aconitase 1 gene CHEBI:32497 thioacetamide affects expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D013853 Thioacetamide affects the expression of ACO1 mRNA PMID:19483382 10067 ACO1 aconitase 1 gene CHEBI:32497 thioacetamide decreases expression ISO RGD:2019 E RGD:6480464 20220405 CTD MESH:D013853 Thioacetamide results in decreased expression of ACO1 mRNA PMID:34492290 10067 ACO1 aconitase 1 gene CHEBI:32506 4,4'-diaminodiphenylmethane increases expression ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:C009505 4,4'-diaminodiphenylmethane results in increased expression of ACO1 mRNA PMID:18648102 10067 ACO1 aconitase 1 gene CHEBI:32509 pirinixic acid affects expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:C006253 pirinixic acid affects the expression of ACO1 mRNA PMID:19483382 10067 ACO1 aconitase 1 gene CHEBI:32509 pirinixic acid increases expression ISO RGD:2019 E RGD:6480464 20121113 CTD MESH:C006253 pirinixic acid results in increased expression of ACO1 mRNA PMID:15890375|PMID:16940010|PMID:19162173|PMID:22484513 10067 ACO1 aconitase 1 gene CHEBI:32687 piperonyl butoxide increases expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D010882 Piperonyl Butoxide results in increased expression of ACO1 mRNA PMID:15890375 10067 ACO1 aconitase 1 gene CHEBI:32692 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one increases expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:C016583 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of ACO1 mRNA PMID:15890375 10067 ACO1 aconitase 1 gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20230307 CTD MESH:C006780 bisphenol A results in decreased expression of ACO1 protein PMID:34186270 10067 ACO1 aconitase 1 gene CHEBI:33216 bisphenol A decreases methylation EXP E RGD:6480464 20220308 CTD MESH:C006780 bisphenol A results in decreased methylation of ACO1 gene PMID:31601247 10067 ACO1 aconitase 1 gene CHEBI:33216 bisphenol A increases expression ISO RGD:2019 E RGD:6480464 20150310 CTD MESH:C006780 bisphenol A results in increased expression of ACO1 mRNA PMID:25181051 10067 ACO1 aconitase 1 gene CHEBI:33216 bisphenol A multiple interactions ISO RGD:2019 E RGD:6480464 20160705 CTD MESH:C006780 [bisphenol A co-treated with Estradiol] results in decreased expression of ACO1 mRNA PMID:26496021 10067 ACO1 aconitase 1 gene CHEBI:33217 3,3',5,5'-tetrabromobisphenol A decreases expression EXP E RGD:6480464 20220308 CTD MESH:C020806 tetrabromobisphenol A results in decreased expression of ACO1 protein PMID:31675489 10067 ACO1 aconitase 1 gene CHEBI:33629 aluminium(0) decreases activity ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D000535 Aluminum results in decreased activity of ACO1 protein PMID:10806405 10067 ACO1 aconitase 1 gene CHEBI:34031 1,1-dichloroethene decreases expression ISO RGD:10066 E RGD:6480464 20170725 CTD MESH:C029297 vinylidene chloride results in decreased expression of ACO1 mRNA PMID:26682919 10067 ACO1 aconitase 1 gene CHEBI:34575 bisphenol F increases expression EXP E RGD:6480464 20230307 CTD MESH:C008745 bisphenol F results in increased expression of ACO1 protein PMID:34186270 10067 ACO1 aconitase 1 gene CHEBI:34581 Bisphenol B increases expression EXP E RGD:6480464 20230307 CTD MESH:C492482 bisphenol B results in increased expression of ACO1 protein PMID:34186270 10067 ACO1 aconitase 1 gene CHEBI:34631 chlorpyrifos increases expression ISO RGD:10066 E RGD:6480464 20230606 CTD MESH:D004390 Chlorpyrifos results in increased expression of ACO1 mRNA PMID:37019170 10067 ACO1 aconitase 1 gene CHEBI:34648 clofibric acid affects expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D002995 Clofibric Acid affects the expression of ACO1 mRNA PMID:17602206 10067 ACO1 aconitase 1 gene CHEBI:34682 diazinon increases methylation EXP E RGD:6480464 20141014 CTD MESH:D003976 Diazinon results in increased methylation of ACO1 gene PMID:22964155 10067 ACO1 aconitase 1 gene CHEBI:34887 nickel dichloride decreases activity EXP E RGD:6480464 20120412 CTD MESH:C022838 nickel chloride results in decreased activity of ACO1 protein PMID:17018869 10067 ACO1 aconitase 1 gene CHEBI:34887 nickel dichloride increases activity EXP E RGD:6480464 20120814 CTD MESH:C022838 nickel chloride results in increased activity of ACO1 protein PMID:16039939|PMID:16649251 10067 ACO1 aconitase 1 gene CHEBI:34887 nickel dichloride multiple interactions EXP E RGD:6480464 20120717 CTD MESH:C022838 [nickel chloride results in increased activity of ACO1 protein] inhibits the reaction [ferrous sulfate results in increased expression of FTL protein]; [nickel chloride results in increased activity of ACO1 protein] which results in increased expression of and results in increased stability of TFRC mRNA; Iron inhibits the reaction [nickel chloride results in increased activity of ACO1 protein] PMID:16039939 10067 ACO1 aconitase 1 gene CHEBI:34905 paraquat decreases activity ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D010269 Paraquat results in decreased activity of ACO1 protein PMID:11520895|PMID:17324120 10067 ACO1 aconitase 1 gene CHEBI:34905 paraquat decreases expression ISO RGD:10066 E RGD:6480464 20190219 CTD MESH:D010269 Paraquat results in decreased expression of ACO1 protein PMID:28542246 10067 ACO1 aconitase 1 gene CHEBI:34905 paraquat increases activity ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:D010269 Paraquat results in increased activity of ACO1 protein PMID:15664434 10067 ACO1 aconitase 1 gene CHEBI:35033 triphenyl phosphate increases expression ISO RGD:2019 E RGD:6480464 20200331 CTD MESH:C005445 triphenyl phosphate results in increased expression of ACO1 mRNA PMID:30589522 10067 ACO1 aconitase 1 gene CHEBI:35154 manganese(0) decreases activity ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D008345 Manganese results in decreased activity of ACO1 protein PMID:17469137 10067 ACO1 aconitase 1 gene CHEBI:35154 manganese(0) increases activity EXP E RGD:6480464 20120412 CTD MESH:D008345 Manganese results in increased activity of ACO1 protein PMID:16386771 10067 ACO1 aconitase 1 gene CHEBI:35154 manganese(0) increases activity ISO RGD:2019 E RGD:6480464 20120501 CTD MESH:D008345 Manganese results in increased activity of ACO1 protein PMID:16545456|PMID:16568477 10067 ACO1 aconitase 1 gene CHEBI:35154 manganese(0) multiple interactions ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D008345 Manganese results in increased stability of [ACO1 protein binds to SLC11A2 mRNA] PMID:16729984 10067 ACO1 aconitase 1 gene CHEBI:35170 vanadium(0) increases activity EXP E RGD:6480464 20120412 CTD MESH:D014639 Vanadium results in increased activity of ACO1 protein PMID:16386771 10067 ACO1 aconitase 1 gene CHEBI:35456 cadmium dichloride affects localization ISO RGD:2019 E RGD:6480464 20141223 CTD MESH:D019256 Cadmium Chloride affects the localization of ACO1 protein PMID:25106854 10067 ACO1 aconitase 1 gene CHEBI:35456 cadmium dichloride decreases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in decreased expression of ACO1 mRNA PMID:38568856 10067 ACO1 aconitase 1 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20160119 CTD MESH:D019256 Cadmium Chloride results in increased expression of ACO1 mRNA PMID:26472689 10067 ACO1 aconitase 1 gene CHEBI:35456 cadmium dichloride multiple interactions EXP E RGD:6480464 20141223 CTD MESH:D019256 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of ACO1 mRNA; Cadmium Chloride results in decreased activity of and affects the folding of ACO1 protein PMID:25106854|PMID:35301059 10067 ACO1 aconitase 1 gene CHEBI:35456 cadmium dichloride multiple interactions ISO RGD:2019 E RGD:6480464 20141223 CTD MESH:D019256 Butylated Hydroxyanisole inhibits the reaction [Cadmium Chloride affects the localization of ACO1 protein]; Cadmium Chloride promotes the reaction [ACO1 protein binds to ACO1 protein]; Cadmium Chloride results in decreased expression of and results in decreased activity of ACO1 protein; KN 93 inhibits the reaction [Cadmium Chloride affects the localization of ACO1 protein] PMID:25106854 10067 ACO1 aconitase 1 gene CHEBI:35549 perfluorooctanoic acid increases expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:C023036 perfluorooctanoic acid results in increased expression of ACO1 mRNA PMID:19162173|PMID:28511854 10067 ACO1 aconitase 1 gene CHEBI:35559 furan increases methylation ISO RGD:2019 E RGD:6480464 20120918 CTD MESH:C039281 furan results in increased methylation of ACO1 gene PMID:22079235 10067 ACO1 aconitase 1 gene CHEBI:35696 cobalt dichloride decreases expression ISO RGD:2019 E RGD:6480464 20151215 CTD MESH:C018021 cobaltous chloride results in decreased expression of ACO1 mRNA PMID:24386269 10067 ACO1 aconitase 1 gene CHEBI:35807 N-nitrosodimethylamine decreases expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D004128 Dimethylnitrosamine results in decreased expression of ACO1 mRNA PMID:15890375 10067 ACO1 aconitase 1 gene CHEBI:36740 alpha-pinene multiple interactions EXP E RGD:6480464 20210112 CTD MESH:C005451 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased expression of ACO1 mRNA; [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased expression of ACO1 mRNA PMID:32699268 10067 ACO1 aconitase 1 gene CHEBI:37187 lead nitrate decreases expression EXP E RGD:6480464 20170303 CTD MESH:C017461 lead nitrate results in decreased expression of ACO1 protein PMID:22502979 10067 ACO1 aconitase 1 gene CHEBI:37187 lead nitrate multiple interactions EXP E RGD:6480464 20170303 CTD MESH:C017461 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lead nitrate results in decreased expression of ACO1 protein] PMID:22502979 10067 ACO1 aconitase 1 gene CHEBI:3750 clofibrate affects expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D002994 Clofibrate affects the expression of ACO1 mRNA PMID:19483382 10067 ACO1 aconitase 1 gene CHEBI:3750 clofibrate increases activity ISO RGD:2019 E RGD:6480464 20120613 CTD MESH:D002994 Clofibrate results in increased activity of ACO1 protein PMID:11969379 10067 ACO1 aconitase 1 gene CHEBI:37537 phorbol 13-acetate 12-myristate increases activity ISO RGD:10066 E RGD:6480464 20181016 CTD MESH:D013755 Tetradecanoylphorbol Acetate results in increased activity of ACO1 protein PMID:10889193 10067 ACO1 aconitase 1 gene CHEBI:37537 phorbol 13-acetate 12-myristate increases activity ISO RGD:2019 E RGD:6480464 20181016 CTD MESH:D013755 Tetradecanoylphorbol Acetate results in increased activity of ACO1 protein PMID:10889193 10067 ACO1 aconitase 1 gene CHEBI:37537 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:10066 E RGD:6480464 20181016 CTD MESH:D013755 Tetradecanoylphorbol Acetate inhibits the reaction [TRH protein results in increased activity of ACO1 protein] PMID:10889193 10067 ACO1 aconitase 1 gene CHEBI:37537 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:2019 E RGD:6480464 20181016 CTD MESH:D013755 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of ACO1 protein]; Okadaic Acid promotes the reaction [Tetradecanoylphorbol Acetate results in increased activity of ACO1 protein]; pervanadate promotes the reaction [Tetradecanoylphorbol Acetate results in increased activity of ACO1 protein] PMID:10889193 10067 ACO1 aconitase 1 gene CHEBI:37699 protein kinase inhibitor multiple interactions ISO RGD:10066 E RGD:6480464 20181016 CTD MESH:D047428 Protein Kinase Inhibitors inhibits the reaction [TRH protein results in increased activity of ACO1 protein] PMID:10889193 10067 ACO1 aconitase 1 gene CHEBI:37825 p-toluidine increases expression ISO RGD:2019 E RGD:6480464 20170516 CTD MESH:C029370 4-toluidine results in increased expression of ACO1 mRNA PMID:27638505 10067 ACO1 aconitase 1 gene CHEBI:39421 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:10066 E RGD:6480464 20230502 CTD MESH:C076994 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of ACO1 mRNA PMID:36331819 10067 ACO1 aconitase 1 gene CHEBI:39867 valproic acid affects expression EXP E RGD:6480464 20151013 CTD MESH:D014635 Valproic Acid affects the expression of ACO1 mRNA PMID:25979313 10067 ACO1 aconitase 1 gene CHEBI:40036 amitrole increases expression ISO RGD:2019 E RGD:6480464 20230606 CTD MESH:D000640 Amitrole results in increased expression of ACO1 mRNA PMID:30047161 10067 ACO1 aconitase 1 gene CHEBI:4031 cyclosporin A decreases expression EXP E RGD:6480464 20120412 CTD MESH:D016572 Cyclosporine results in decreased expression of ACO1 mRNA PMID:20106945 10067 ACO1 aconitase 1 gene CHEBI:41879 dexamethasone increases expression EXP E RGD:6480464 20160705 CTD MESH:D003907 Dexamethasone results in increased expression of ACO1 mRNA PMID:25047013 10067 ACO1 aconitase 1 gene CHEBI:41922 diethylstilbestrol increases expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D004054 Diethylstilbestrol results in increased expression of ACO1 mRNA PMID:15890375 10067 ACO1 aconitase 1 gene CHEBI:42588 4-hydroxyphenyl retinamide decreases expression ISO RGD:10066 E RGD:6480464 20180220 CTD MESH:D017313 Fenretinide results in decreased expression of ACO1 mRNA PMID:28973697 10067 ACO1 aconitase 1 gene CHEBI:42758 aldehydo-D-glucose increases expression EXP E RGD:6480464 20240806 CTD MESH:D005947 Glucose results in increased expression of ACO1 protein PMID:38483099 10067 ACO1 aconitase 1 gene CHEBI:42758 aldehydo-D-glucose increases expression ISO RGD:2019 E RGD:6480464 20240806 CTD MESH:D005947 Glucose results in increased expression of ACO1 protein PMID:38483099 10067 ACO1 aconitase 1 gene CHEBI:42758 aldehydo-D-glucose multiple interactions ISO RGD:2019 E RGD:6480464 20181016 CTD MESH:D005947 [Oxygen deficiency co-treated with Glucose deficiency] affects the activity of ACO1 protein; Oxygen inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the activity of ACO1 protein] PMID:16135072 10067 ACO1 aconitase 1 gene CHEBI:4356 desferrioxamine B increases activity EXP E RGD:6480464 20190611 CTD MESH:D003676 Deferoxamine results in increased activity of ACO1 protein PMID:10397746 10067 ACO1 aconitase 1 gene CHEBI:4356 desferrioxamine B increases activity ISO RGD:10066 E RGD:6480464 20130122 CTD MESH:D003676 Deferoxamine results in increased activity of ACO1 protein PMID:11054110|PMID:18073202 10067 ACO1 aconitase 1 gene CHEBI:4356 desferrioxamine B increases activity ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D003676 Deferoxamine results in increased activity of ACO1 protein PMID:16568477 10067 ACO1 aconitase 1 gene CHEBI:4356 desferrioxamine B increases expression ISO RGD:2019 E RGD:6480464 20141223 CTD MESH:D003676 Deferoxamine results in increased expression of ACO1 protein PMID:25106854 10067 ACO1 aconitase 1 gene CHEBI:4356 desferrioxamine B multiple interactions ISO RGD:2019 E RGD:6480464 20120814 CTD MESH:D003676 [Deferoxamine results in decreased abundance of Iron] which results in increased activity of ACO1 protein PMID:15893546 10067 ACO1 aconitase 1 gene CHEBI:44445 nimesulide increases expression ISO RGD:2019 E RGD:6480464 20160412 CTD MESH:C012655 nimesulide results in increased expression of ACO1 mRNA PMID:24136188 10067 ACO1 aconitase 1 gene CHEBI:44658 okadaic acid multiple interactions ISO RGD:2019 E RGD:6480464 20181016 CTD MESH:D019319 Okadaic Acid inhibits the reaction [EGF protein results in decreased activity of ACO1 protein]; Okadaic Acid inhibits the reaction [TRH protein results in decreased activity of ACO1 protein]; Okadaic Acid promotes the reaction [Tetradecanoylphorbol Acetate results in increased activity of ACO1 protein] PMID:10889193 10067 ACO1 aconitase 1 gene CHEBI:46024 trichostatin A affects expression EXP E RGD:6480464 20170613 CTD MESH:C012589 trichostatin A affects the expression of ACO1 mRNA PMID:28542535 10067 ACO1 aconitase 1 gene CHEBI:46195 paracetamol affects expression ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:D000082 Acetaminophen affects the expression of ACO1 mRNA PMID:17562736 10067 ACO1 aconitase 1 gene CHEBI:46195 paracetamol decreases expression EXP E RGD:6480464 20180515 CTD MESH:D000082 Acetaminophen results in decreased expression of ACO1 mRNA PMID:29067470 10067 ACO1 aconitase 1 gene CHEBI:46742 Nutlin-3 multiple interactions EXP E RGD:6480464 20240806 CTD MESH:C482205 [Dactinomycin co-treated with nutlin 3] results in increased secretion of ACO1 protein PMID:38460933 10067 ACO1 aconitase 1 gene CHEBI:47217 arsane increases activity EXP E RGD:6480464 20140805 CTD MESH:D001151 Arsenic results in increased activity of ACO1 protein PMID:16386771 10067 ACO1 aconitase 1 gene CHEBI:4791 endosulfan decreases expression ISO RGD:2019 E RGD:6480464 20180828 CTD MESH:D004726 Endosulfan results in decreased expression of ACO1 mRNA PMID:29391264 10067 ACO1 aconitase 1 gene CHEBI:4811 epoxiconazole multiple interactions ISO RGD:2019 E RGD:6480464 20180515 CTD MESH:C109476 [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACO1 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of ACO1 mRNA PMID:29038839 10067 ACO1 aconitase 1 gene CHEBI:4886 L-ethionine affects expression ISO RGD:2019 E RGD:6480464 20121106 CTD MESH:D005001 Ethionine affects the expression of ACO1 mRNA PMID:19483382 10067 ACO1 aconitase 1 gene CHEBI:4903 17alpha-ethynylestradiol multiple interactions ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:D004997 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ACO1 mRNA PMID:17942748 10067 ACO1 aconitase 1 gene CHEBI:4911 etoposide increases expression ISO RGD:10066 E RGD:6480464 20150127 CTD MESH:D005047 Etoposide results in increased expression of ACO1 mRNA PMID:25270620 10067 ACO1 aconitase 1 gene CHEBI:49553 copper(II) chloride decreases expression ISO RGD:10066 E RGD:6480464 20181016 CTD MESH:C029892 cupric chloride results in decreased expression of ACO1 protein PMID:29617964 10067 ACO1 aconitase 1 gene CHEBI:49662 indometacin decreases expression ISO RGD:2019 E RGD:6480464 20230704 CTD MESH:D007213 Indomethacin results in decreased expression of ACO1 mRNA PMID:36868495 10067 ACO1 aconitase 1 gene CHEBI:49900 arsenous acid decreases expression EXP E RGD:6480464 20191114 CTD MESH:C032793 Arsenic Trioxide results in decreased expression of ACO1 protein PMID:19364129 10067 ACO1 aconitase 1 gene CHEBI:49900 arsenous acid increases expression EXP E RGD:6480464 20191114 CTD MESH:C032793 Arsenic Trioxide results in increased expression of ACO1 mRNA PMID:20458559 10067 ACO1 aconitase 1 gene CHEBI:5001 fenofibrate increases expression ISO RGD:2019 E RGD:6480464 20121113 CTD MESH:D011345 Fenofibrate results in increased expression of ACO1 mRNA PMID:17264098 10067 ACO1 aconitase 1 gene CHEBI:50385 hemin decreases activity ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D006427 Hemin results in decreased activity of ACO1 protein PMID:16568477 10067 ACO1 aconitase 1 gene CHEBI:50594 carbon nanotube decreases expression ISO RGD:10066 E RGD:6480464 20161228 CTD MESH:D037742 Nanotubes, Carbon analog results in decreased expression of ACO1 mRNA; Nanotubes, Carbon results in decreased expression of ACO1 mRNA PMID:25620056 10067 ACO1 aconitase 1 gene CHEBI:50673 methimazole increases expression ISO RGD:2019 E RGD:6480464 20230606 CTD MESH:D008713 Methimazole results in increased expression of ACO1 mRNA PMID:30047161 10067 ACO1 aconitase 1 gene CHEBI:5132 flutamide decreases expression ISO RGD:2019 E RGD:6480464 20140909 CTD MESH:D005485 Flutamide results in decreased expression of ACO1 mRNA PMID:24793618 10067 ACO1 aconitase 1 gene CHEBI:53001 nickel sulfate decreases expression EXP E RGD:6480464 20120412 CTD MESH:C029938 nickel sulfate results in decreased expression of ACO1 mRNA PMID:16780908 10067 ACO1 aconitase 1 gene CHEBI:53438 iron(3+) sulfate multiple interactions EXP E RGD:6480464 20120412 CTD MESH:C024823 ferric sulfate inhibits the reaction [Nickel results in increased activity of ACO1 protein] PMID:16877034 10067 ACO1 aconitase 1 gene CHEBI:6067 isotretinoin decreases expression EXP E RGD:6480464 20120412 CTD MESH:D015474 Isotretinoin results in decreased expression of ACO1 mRNA PMID:20436886 10067 ACO1 aconitase 1 gene CHEBI:6078 ivermectin decreases expression EXP E RGD:6480464 20210907 CTD MESH:D007559 Ivermectin results in decreased expression of ACO1 protein PMID:32959892 10067 ACO1 aconitase 1 gene CHEBI:63041 manganese(II) chloride increases activity ISO RGD:2019 E RGD:6480464 20120814 CTD MESH:C025340 manganese chloride results in increased activity of ACO1 protein PMID:15893546|PMID:16545456|PMID:16568477 10067 ACO1 aconitase 1 gene CHEBI:63634 valdecoxib increases expression ISO RGD:2019 E RGD:6480464 20170303 CTD MESH:C406224 valdecoxib results in increased expression of ACO1 mRNA PMID:24136188 10067 ACO1 aconitase 1 gene CHEBI:63921 2-butoxyethanol increases expression ISO RGD:10066 E RGD:6480464 20120412 CTD MESH:C017096 n-butoxyethanol results in increased expression of ACO1 mRNA PMID:19812364 10067 ACO1 aconitase 1 gene CHEBI:6402 leflunomide increases expression ISO RGD:2019 E RGD:6480464 20161213 CTD MESH:C045463 leflunomide results in increased expression of ACO1 mRNA PMID:24136188 10067 ACO1 aconitase 1 gene CHEBI:64090 tert-butyl hydroperoxide increases expression EXP E RGD:6480464 20120412 CTD MESH:D020122 tert-Butylhydroperoxide results in increased expression of ACO1 mRNA PMID:15336504 10067 ACO1 aconitase 1 gene CHEBI:64243 monosodium L-glutamate multiple interactions ISO RGD:10066 E RGD:6480464 20200317 CTD MESH:D012970 [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACO1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of ACO1 mRNA PMID:23783067 10067 ACO1 aconitase 1 gene CHEBI:6773 Mesaconitine increases expression ISO RGD:2019 E RGD:6480464 20231031 CTD MESH:C019470 mesaconitine results in increased expression of ACO1 protein PMID:37182599 10067 ACO1 aconitase 1 gene CHEBI:6809 methamphetamine increases expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D008694 Methamphetamine results in increased expression of ACO1 protein PMID:19826936 10067 ACO1 aconitase 1 gene CHEBI:6820 methapyrilene decreases expression ISO RGD:2019 E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in decreased expression of ACO1 mRNA PMID:30467583 10067 ACO1 aconitase 1 gene CHEBI:6820 methapyrilene increases expression EXP E RGD:6480464 20180116 CTD MESH:D008701 Methapyrilene results in increased expression of ACO1 mRNA PMID:28935588 10067 ACO1 aconitase 1 gene CHEBI:6820 methapyrilene increases expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D008701 Methapyrilene results in increased expression of ACO1 mRNA PMID:15890375 10067 ACO1 aconitase 1 gene CHEBI:6923 miconazole increases expression ISO RGD:10066 E RGD:6480464 20190910 CTD MESH:D008825 Miconazole results in increased expression of ACO1 mRNA PMID:27462272 10067 ACO1 aconitase 1 gene CHEBI:72564 temozolomide decreases expression EXP E RGD:6480464 20210706 CTD MESH:C047246 Temozolomide results in decreased expression of ACO1 mRNA PMID:31758290 10067 ACO1 aconitase 1 gene CHEBI:72754 bisphenol AF increases expression EXP E RGD:6480464 20250114 CTD MESH:C583074 bisphenol AF results in increased expression of ACO1 protein PMID:34186270 10067 ACO1 aconitase 1 gene CHEBI:73755 1,2-dimethylhydrazine decreases expression ISO RGD:10066 E RGD:6480464 20200804 CTD MESH:D019813 1,2-Dimethylhydrazine results in decreased expression of ACO1 mRNA PMID:22206623 10067 ACO1 aconitase 1 gene CHEBI:7494 nefazodone increases expression ISO RGD:2019 E RGD:6480464 20160412 CTD MESH:C051752 nefazodone results in increased expression of ACO1 mRNA PMID:24136188 10067 ACO1 aconitase 1 gene CHEBI:75832 iron(2+) sulfate (anhydrous) multiple interactions EXP E RGD:6480464 20161213 CTD MESH:C020748 [nickel chloride results in increased activity of ACO1 protein] inhibits the reaction [ferrous sulfate results in increased expression of FTL protein] PMID:16039939 10067 ACO1 aconitase 1 gene CHEBI:76359 butylated hydroxyanisole multiple interactions ISO RGD:2019 E RGD:6480464 20141223 CTD MESH:D002083 Butylated Hydroxyanisole inhibits the reaction [Cadmium Chloride affects the localization of ACO1 protein] PMID:25106854 10067 ACO1 aconitase 1 gene CHEBI:77260 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole affects expression ISO RGD:2019 E RGD:6480464 20140805 CTD MESH:D009853 Omeprazole affects the expression of ACO1 mRNA PMID:19483382 10067 ACO1 aconitase 1 gene CHEBI:7772 omeprazole affects expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D009853 Omeprazole affects the expression of ACO1 mRNA PMID:19483382 10067 ACO1 aconitase 1 gene CHEBI:78741 oxidopamine affects response to substance ISO RGD:10066 E RGD:6480464 20181016 CTD MESH:D016627 ACO1 protein affects the susceptibility to Oxidopamine PMID:19913091 10067 ACO1 aconitase 1 gene CHEBI:78741 oxidopamine increases expression ISO RGD:10066 E RGD:6480464 20181016 CTD MESH:D016627 Oxidopamine results in increased expression of ACO1 mRNA PMID:19913091 10067 ACO1 aconitase 1 gene CHEBI:78741 oxidopamine multiple interactions ISO RGD:10066 E RGD:6480464 20181016 CTD MESH:D016627 [ACO1 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA; Oxidopamine promotes the reaction [ACO1 protein results in decreased expression of SLC40A1 mRNA] PMID:19913091 10067 ACO1 aconitase 1 gene CHEBI:79994 CGP 52608 multiple interactions EXP E RGD:6480464 20220607 CTD MESH:C092451 CGP 52608 promotes the reaction [RORA protein binds to ACO1 gene] PMID:28238834 10067 ACO1 aconitase 1 gene CHEBI:8069 phenobarbital affects expression EXP E RGD:6480464 20121009 CTD MESH:D010634 Phenobarbital affects the expression of ACO1 mRNA PMID:19159669 10067 ACO1 aconitase 1 gene CHEBI:8113 phlorizin decreases expression ISO RGD:10066 E RGD:6480464 20121009 CTD MESH:D010695 Phlorhizin results in decreased expression of ACO1 mRNA PMID:22538082 10067 ACO1 aconitase 1 gene CHEBI:81758 cyproconazole multiple interactions ISO RGD:2019 E RGD:6480464 20180515 CTD MESH:C093628 [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACO1 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of ACO1 mRNA PMID:29038839 10067 ACO1 aconitase 1 gene CHEBI:82436 decabromodiphenyl ether decreases expression EXP E RGD:6480464 20220308 CTD MESH:C010902 decabromobiphenyl ether results in decreased expression of ACO1 protein PMID:31675489 10067 ACO1 aconitase 1 gene CHEBI:82664 iron(0) affects metabolic processing ISO RGD:10066 E RGD:6480464 20140902 CTD MESH:D007501 ACO1 protein affects the metabolism of Iron PMID:17194590 10067 ACO1 aconitase 1 gene CHEBI:82664 iron(0) multiple interactions EXP E RGD:6480464 20140902 CTD MESH:D007501 Iron inhibits the reaction [nickel chloride results in increased activity of ACO1 protein]; Iron inhibits the reaction [Nickel results in increased activity of ACO1 protein] PMID:16039939|PMID:16877034 10067 ACO1 aconitase 1 gene CHEBI:82664 iron(0) multiple interactions ISO RGD:2019 E RGD:6480464 20140902 CTD MESH:D007501 [Deferoxamine results in decreased abundance of Iron] which results in increased activity of ACO1 protein PMID:15893546 10067 ACO1 aconitase 1 gene CHEBI:84050 trabectedin increases expression EXP E RGD:6480464 20230404 CTD MESH:C099150 Trabectedin results in increased expression of ACO1 mRNA; Trabectedin results in increased expression of ACO1 protein PMID:36396105 10067 ACO1 aconitase 1 gene CHEBI:8434 prochloraz multiple interactions ISO RGD:2019 E RGD:6480464 20180515 CTD MESH:C045362 [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACO1 mRNA PMID:29038839 10067 ACO1 aconitase 1 gene CHEBI:8489 propiconazole increases expression ISO RGD:2019 E RGD:6480464 20230606 CTD MESH:C045950 propiconazole results in increased expression of ACO1 mRNA PMID:30047161 10067 ACO1 aconitase 1 gene CHEBI:8502 6-propyl-2-thiouracil affects expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:D011441 Propylthiouracil affects the expression of ACO1 mRNA PMID:19483382 10067 ACO1 aconitase 1 gene CHEBI:8502 6-propyl-2-thiouracil increases expression ISO RGD:2019 E RGD:6480464 20230606 CTD MESH:D011441 Propylthiouracil results in increased expression of ACO1 mRNA PMID:30047161 10067 ACO1 aconitase 1 gene CHEBI:91460 KN-93 multiple interactions ISO RGD:2019 E RGD:6480464 20160503 CTD MESH:C072105 KN 93 inhibits the reaction [Cadmium Chloride affects the localization of ACO1 protein] PMID:25106854 10067 ACO1 aconitase 1 gene CHEBI:9195 Soman decreases expression ISO RGD:2019 E RGD:6480464 20141111 CTD MESH:D012999 Soman results in decreased expression of ACO1 mRNA PMID:19281266 10067 ACO1 aconitase 1 gene CHEBI:920 2,4-dinitrotoluene affects expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:C016403 2,4-dinitrotoluene affects the expression of ACO1 mRNA PMID:21346803 10067 ACO1 aconitase 1 gene CHEBI:9495 thiram decreases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in decreased expression of ACO1 mRNA PMID:38568856 10067 ACO1 aconitase 1 gene CHEBI:9516 thapsigargin increases expression ISO RGD:2019 E RGD:6480464 20221101 CTD MESH:D019284 Thapsigargin results in increased expression of ACO1 protein PMID:35544339 10067 ACO1 aconitase 1 gene CHEBI:957 2,6-dinitrotoluene affects expression ISO RGD:2019 E RGD:6480464 20120412 CTD MESH:C023514 2,6-dinitrotoluene affects the expression of ACO1 mRNA PMID:21346803 10067 ACO1 aconitase 1 gene CHEBI:9753 troglitazone increases expression ISO RGD:2019 E RGD:6480464 20120918 CTD MESH:C057693 troglitazone results in increased expression of ACO1 mRNA PMID:21515302 10067 ACO1 aconitase 1 gene CHEBI:9986 vinclozolin increases methylation ISO RGD:2019 E RGD:6480464 20201215 CTD MESH:C025643 vinclozolin results in increased methylation of ACO1 gene PMID:31079544 10069 ACP1 acid phosphatase 1 gene CHEBI:132448 perfluorohexanesulfonic acid decreases expression EXP E RGD:6480464 20211207 CTD MESH:C471071 perfluorohexanesulfonic acid results in decreased expression of ACP1 mRNA PMID:25812627 10069 ACP1 acid phosphatase 1 gene CHEBI:15367 all-trans-retinoic acid decreases expression EXP E RGD:6480464 20120501 CTD MESH:D014212 Tretinoin results in decreased expression of ACP1 mRNA PMID:21934132|PMID:33167477 10069 ACP1 acid phosphatase 1 gene CHEBI:15743 butanal decreases expression EXP E RGD:6480464 20150825 CTD MESH:C018475 butyraldehyde results in decreased expression of ACP1 mRNA PMID:26079696 10069 ACP1 acid phosphatase 1 gene CHEBI:16602 trichloroethene increases expression ISO RGD:10068 E RGD:6480464 20120412 CTD MESH:D014241 Trichloroethylene results in increased expression of ACP1 mRNA PMID:19448997 10069 ACP1 acid phosphatase 1 gene CHEBI:17440 4-nitrophenyl phosphate increases hydrolysis EXP E RGD:6480464 20161115 CTD MESH:C008644 ACP1 protein results in increased hydrolysis of nitrophenylphosphate PMID:24287560 10069 ACP1 acid phosphatase 1 gene CHEBI:17440 4-nitrophenyl phosphate multiple interactions EXP E RGD:6480464 20161115 CTD MESH:C008644 Benzoic Acid analog inhibits the reaction [ACP1 protein results in increased hydrolysis of nitrophenylphosphate]; Thiazolidines analog inhibits the reaction [ACP1 protein results in increased hydrolysis of nitrophenylphosphate] PMID:24287560 10069 ACP1 acid phosphatase 1 gene CHEBI:17688 (S)-nicotine decreases expression ISO RGD:10068 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in decreased expression of ACP1 mRNA PMID:17997037 10069 ACP1 acid phosphatase 1 gene CHEBI:178012 FR900359 increases phosphorylation EXP E RGD:6480464 20240305 CTD MESH:C000607068 FR900359 results in increased phosphorylation of ACP1 protein PMID:37730182 10069 ACP1 acid phosphatase 1 gene CHEBI:18723 nicotine decreases expression ISO RGD:10068 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in decreased expression of ACP1 mRNA PMID:17997037 10069 ACP1 acid phosphatase 1 gene CHEBI:22977 cadmium atom increases expression ISO RGD:2020 E RGD:6480464 20130618 CTD MESH:D002104 Cadmium results in increased expression of ACP1 mRNA PMID:17327700 10069 ACP1 acid phosphatase 1 gene CHEBI:2504 aflatoxin B1 increases expression EXP E RGD:6480464 20161025 CTD MESH:D016604 Aflatoxin B1 results in increased expression of ACP1 mRNA PMID:27153756 10069 ACP1 acid phosphatase 1 gene CHEBI:25812 ozone multiple interactions EXP E RGD:6480464 20231031 CTD MESH:D010126 [Air Pollutants results in increased abundance of Ozone] which affects the expression of ACP1 mRNA PMID:35430440 10069 ACP1 acid phosphatase 1 gene CHEBI:2654 aminoglutethimide decreases expression EXP E RGD:6480464 20150825 CTD MESH:D000616 Aminoglutethimide results in decreased expression of ACP1 protein PMID:26102013 10069 ACP1 acid phosphatase 1 gene CHEBI:26710 sodium chloride multiple interactions EXP E RGD:6480464 20250114 CTD MESH:D012965 [Sodium Chloride co-treated with Furaldehyde] results in increased expression of and affects the localization of ACP1 protein; [Sodium Chloride co-treated with pyrogallol 1,3-dimethyl ether] results in decreased expression of and affects the localization of ACP1 protein PMID:38598786 10069 ACP1 acid phosphatase 1 gene CHEBI:27375 vincaleukoblastine affects response to substance EXP E RGD:6480464 20120412 CTD MESH:D014747 ACP1 protein affects the susceptibility to Vinblastine PMID:16217747 10069 ACP1 acid phosphatase 1 gene CHEBI:27470 folic acid decreases expression ISO RGD:10068 E RGD:6480464 20200804 CTD MESH:D005492 Folic Acid results in decreased expression of ACP1 mRNA PMID:25629700 10069 ACP1 acid phosphatase 1 gene CHEBI:27568 selenium atom decreases expression EXP E RGD:6480464 20120412 CTD MESH:D012643 Selenium results in decreased expression of ACP1 mRNA PMID:19244175 10069 ACP1 acid phosphatase 1 gene CHEBI:27666 actinomycin D multiple interactions EXP E RGD:6480464 20240806 CTD MESH:D003609 [Dactinomycin co-treated with nutlin 3] results in increased secretion of ACP1 protein PMID:38460933 10069 ACP1 acid phosphatase 1 gene CHEBI:27881 resveratrol increases expression ISO RGD:10068 E RGD:6480464 20160822 CTD MESH:C059514 resveratrol results in increased expression of ACP1 protein PMID:25505154 10069 ACP1 acid phosphatase 1 gene CHEBI:27889 lead(0) affects splicing EXP E RGD:6480464 20171114 CTD MESH:D007854 Lead affects the splicing of ACP1 mRNA PMID:28903495 10069 ACP1 acid phosphatase 1 gene CHEBI:28112 nickel atom increases expression EXP E RGD:6480464 20151110 CTD MESH:D009532 Nickel results in increased expression of ACP1 mRNA PMID:24768652|PMID:25583101 10069 ACP1 acid phosphatase 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:2020 E RGD:6480464 20200609 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of ACP1 mRNA PMID:32109520 10069 ACP1 acid phosphatase 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:2020 E RGD:6480464 20220111 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of ACP1 mRNA PMID:34747641 10069 ACP1 acid phosphatase 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:10068 E RGD:6480464 20120412 CTD MESH:D013749 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ACP1 mRNA PMID:17942748 10069 ACP1 acid phosphatase 1 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of ACP1 protein PMID:33212167 10069 ACP1 acid phosphatase 1 gene CHEBI:28358 rac-lactic acid decreases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in decreased expression of ACP1 mRNA PMID:30851411 10069 ACP1 acid phosphatase 1 gene CHEBI:28741 sodium fluoride decreases expression ISO RGD:10068 E RGD:6480464 20180116 CTD MESH:D012969 Sodium Fluoride results in decreased expression of ACP1 protein PMID:28918527 10069 ACP1 acid phosphatase 1 gene CHEBI:28748 doxorubicin affects response to substance EXP E RGD:6480464 20120412 CTD MESH:D004317 ACP1 protein affects the susceptibility to Doxorubicin PMID:16217747 10069 ACP1 acid phosphatase 1 gene CHEBI:29287 gold atom decreases expression EXP E RGD:6480464 20150414 CTD MESH:D006046 Gold results in decreased expression of ACP1 mRNA PMID:25523186 10069 ACP1 acid phosphatase 1 gene CHEBI:29865 benzo[a]pyrene decreases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in decreased methylation of ACP1 promoter PMID:27901495 10069 ACP1 acid phosphatase 1 gene CHEBI:29865 benzo[a]pyrene multiple interactions ISO RGD:10068 E RGD:6480464 20120515 CTD MESH:D001564 Benzo(a)pyrene promotes the reaction [AHR protein binds to ACP1 promoter] PMID:19654925 10069 ACP1 acid phosphatase 1 gene CHEBI:29866 arsenite(3-) multiple interactions EXP E RGD:6480464 20220405 CTD MESH:C015001 arsenite promotes the reaction [G3BP1 protein binds to ACP1 mRNA]; arsenite promotes the reaction [G3BP1 protein binds to ACP1 protein] PMID:32406909 10069 ACP1 acid phosphatase 1 gene CHEBI:30050 gold(0) decreases expression EXP E RGD:6480464 20150414 CTD MESH:D006046 Gold results in decreased expression of ACP1 mRNA PMID:25523186 10069 ACP1 acid phosphatase 1 gene CHEBI:301 (-)-alpha-phellandrene decreases expression EXP E RGD:6480464 20220208 CTD MESH:C005403 alpha phellandrene results in decreased expression of ACP1 mRNA PMID:25075043 10069 ACP1 acid phosphatase 1 gene CHEBI:30746 benzoic acid decreases activity EXP E RGD:6480464 20161213 CTD MESH:D019817 Benzoic Acid analog results in decreased activity of ACP1 protein PMID:24287560 10069 ACP1 acid phosphatase 1 gene CHEBI:30746 benzoic acid multiple interactions EXP E RGD:6480464 20161213 CTD MESH:D019817 Benzoic Acid analog inhibits the reaction [ACP1 protein results in increased hydrolysis of nitrophenylphosphate] PMID:24287560 10069 ACP1 acid phosphatase 1 gene CHEBI:31206 ammonium chloride affects expression ISO RGD:2020 E RGD:6480464 20130618 CTD MESH:D000643 Ammonium Chloride affects the expression of ACP1 mRNA PMID:16483693 10069 ACP1 acid phosphatase 1 gene CHEBI:31746 kainic acid decreases expression ISO RGD:10068 E RGD:6480464 20120412 CTD MESH:D007608 Kainic Acid results in decreased expression of ACP1 mRNA PMID:17997037 10069 ACP1 acid phosphatase 1 gene CHEBI:31941 oxaliplatin decreases expression ISO RGD:2020 E RGD:6480464 20161213 CTD MESH:C030110 oxaliplatin results in decreased expression of ACP1 mRNA PMID:25729387 10069 ACP1 acid phosphatase 1 gene CHEBI:31941 oxaliplatin multiple interactions ISO RGD:2020 E RGD:6480464 20161213 CTD MESH:C030110 [oxaliplatin co-treated with Topotecan] results in decreased expression of ACP1 mRNA PMID:25729387 10069 ACP1 acid phosphatase 1 gene CHEBI:32234 titanium dioxide increases methylation ISO RGD:10068 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in increased methylation of ACP1 promoter alternative form PMID:35295148 10069 ACP1 acid phosphatase 1 gene CHEBI:32506 4,4'-diaminodiphenylmethane increases expression ISO RGD:10068 E RGD:6480464 20120412 CTD MESH:C009505 4,4'-diaminodiphenylmethane results in increased expression of ACP1 mRNA PMID:18648102 10069 ACP1 acid phosphatase 1 gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20220308 CTD MESH:C006780 bisphenol A results in decreased expression of ACP1 protein PMID:31675489 10069 ACP1 acid phosphatase 1 gene CHEBI:33216 bisphenol A increases expression EXP E RGD:6480464 20230307 CTD MESH:C006780 bisphenol A results in increased expression of ACP1 protein PMID:34186270|PMID:37567409 10069 ACP1 acid phosphatase 1 gene CHEBI:33216 bisphenol A increases expression ISO RGD:10068 E RGD:6480464 20220208 CTD MESH:C006780 bisphenol A results in increased expression of ACP1 mRNA PMID:33221593 10069 ACP1 acid phosphatase 1 gene CHEBI:33216 bisphenol A increases expression ISO RGD:2020 E RGD:6480464 20150310 CTD MESH:C006780 bisphenol A results in increased expression of ACP1 mRNA PMID:25181051|PMID:32145629|PMID:34947998 10069 ACP1 acid phosphatase 1 gene CHEBI:33216 bisphenol A increases methylation EXP E RGD:6480464 20220308 CTD MESH:C006780 bisphenol A results in increased methylation of ACP1 gene PMID:31601247 10069 ACP1 acid phosphatase 1 gene CHEBI:33217 3,3',5,5'-tetrabromobisphenol A increases expression EXP E RGD:6480464 20220308 CTD MESH:C020806 tetrabromobisphenol A results in increased expression of ACP1 protein PMID:31675489 10069 ACP1 acid phosphatase 1 gene CHEBI:33234 vitamin E decreases expression EXP E RGD:6480464 20161228 CTD MESH:D024502 Vitamin E results in decreased expression of ACP1 mRNA PMID:19244175 10069 ACP1 acid phosphatase 1 gene CHEBI:34687 dibutyl phthalate decreases expression ISO RGD:10068 E RGD:6480464 20121113 CTD MESH:D003993 Dibutyl Phthalate results in decreased expression of ACP1 mRNA PMID:17361019|PMID:21266533 10069 ACP1 acid phosphatase 1 gene CHEBI:34718 1-chloro-2,4-dinitrobenzene affects binding EXP E RGD:6480464 20210406 CTD MESH:D004137 Dinitrochlorobenzene binds to ACP1 protein PMID:32991956 10069 ACP1 acid phosphatase 1 gene CHEBI:34761 fenthion increases expression ISO RGD:10068 E RGD:6480464 20220607 CTD MESH:D005284 Fenthion results in increased expression of ACP1 mRNA PMID:34813904 10069 ACP1 acid phosphatase 1 gene CHEBI:34768 furfural multiple interactions EXP E RGD:6480464 20250114 CTD MESH:D005662 [Sodium Chloride co-treated with Furaldehyde] results in increased expression of and affects the localization of ACP1 protein PMID:38598786 10069 ACP1 acid phosphatase 1 gene CHEBI:35456 cadmium dichloride increases expression ISO RGD:2020 E RGD:6480464 20130618 CTD MESH:D019256 Cadmium Chloride results in increased expression of ACP1 mRNA PMID:17327700 10069 ACP1 acid phosphatase 1 gene CHEBI:35549 perfluorooctanoic acid decreases expression EXP E RGD:6480464 20121009 CTD MESH:C023036 perfluorooctanoic acid results in decreased expression of ACP1 protein PMID:22609092 10069 ACP1 acid phosphatase 1 gene CHEBI:35549 perfluorooctanoic acid increases expression EXP E RGD:6480464 20211207 CTD MESH:C023036 perfluorooctanoic acid results in increased expression of ACP1 mRNA PMID:25812627 10069 ACP1 acid phosphatase 1 gene CHEBI:35549 perfluorooctanoic acid increases expression ISO RGD:10068 E RGD:6480464 20240206 CTD MESH:C023036 perfluorooctanoic acid results in increased expression of ACP1 protein PMID:37422089 10069 ACP1 acid phosphatase 1 gene CHEBI:35622 thiazolidines decreases activity EXP E RGD:6480464 20170303 CTD MESH:D053778 Thiazolidines analog results in decreased activity of ACP1 protein PMID:24287560 10069 ACP1 acid phosphatase 1 gene CHEBI:35622 thiazolidines multiple interactions EXP E RGD:6480464 20170303 CTD MESH:D053778 Thiazolidines analog inhibits the reaction [ACP1 protein results in increased hydrolysis of nitrophenylphosphate] PMID:24287560 10069 ACP1 acid phosphatase 1 gene CHEBI:35842 antirheumatic drug increases expression EXP E RGD:6480464 20161228 CTD MESH:D018501 Antirheumatic Agents results in increased expression of ACP1 mRNA PMID:24449571 10069 ACP1 acid phosphatase 1 gene CHEBI:36904 elemental selenium decreases expression EXP E RGD:6480464 20120412 CTD MESH:D012643 Selenium results in decreased expression of ACP1 mRNA PMID:19244175 10069 ACP1 acid phosphatase 1 gene CHEBI:3750 clofibrate decreases expression ISO RGD:10068 E RGD:6480464 20120515 CTD MESH:D002994 Clofibrate results in decreased expression of ACP1 mRNA PMID:17585979 10069 ACP1 acid phosphatase 1 gene CHEBI:3750 clofibrate multiple interactions ISO RGD:10068 E RGD:6480464 20120515 CTD MESH:D002994 [Clofibrate co-treated with Acetaminophen] affects the expression of ACP1 mRNA; PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of ACP1 mRNA] PMID:17585979 10069 ACP1 acid phosphatase 1 gene CHEBI:38658 dicrotophos decreases expression EXP E RGD:6480464 20170725 CTD MESH:C000944 dicrotophos results in decreased expression of ACP1 mRNA PMID:28302478 10069 ACP1 acid phosphatase 1 gene CHEBI:38940 sunitinib increases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in increased expression of ACP1 mRNA PMID:31533062 10069 ACP1 acid phosphatase 1 gene CHEBI:39285 chloropicrin decreases expression EXP E RGD:6480464 20151215 CTD MESH:C100187 chloropicrin results in decreased expression of ACP1 mRNA PMID:26352163|PMID:28476498 10069 ACP1 acid phosphatase 1 gene CHEBI:39421 perfluorooctane-1-sulfonic acid increases expression EXP E RGD:6480464 20211207 CTD MESH:C076994 perfluorooctane sulfonic acid results in increased expression of ACP1 mRNA PMID:25812627 10069 ACP1 acid phosphatase 1 gene CHEBI:39867 valproic acid affects expression EXP E RGD:6480464 20151013 CTD MESH:D014635 Valproic Acid affects the expression of ACP1 mRNA PMID:25979313 10069 ACP1 acid phosphatase 1 gene CHEBI:39867 valproic acid affects expression ISO RGD:10068 E RGD:6480464 20120412 CTD MESH:D014635 Valproic Acid affects the expression of ACP1 mRNA PMID:17963808 10069 ACP1 acid phosphatase 1 gene CHEBI:39867 valproic acid decreases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in decreased methylation of ACP1 gene PMID:29154799 10069 ACP1 acid phosphatase 1 gene CHEBI:41774 tamoxifen affects expression ISO RGD:10068 E RGD:6480464 20120412 CTD MESH:D013629 Tamoxifen affects the expression of ACP1 mRNA PMID:17555576 10069 ACP1 acid phosphatase 1 gene CHEBI:42588 4-hydroxyphenyl retinamide decreases expression ISO RGD:10068 E RGD:6480464 20180220 CTD MESH:D017313 Fenretinide results in decreased expression of ACP1 mRNA PMID:28973697 10069 ACP1 acid phosphatase 1 gene CHEBI:45716 vorinostat increases expression EXP E RGD:6480464 20161213 CTD MESH:C111237 vorinostat results in increased expression of ACP1 protein PMID:20543569 10069 ACP1 acid phosphatase 1 gene CHEBI:46195 paracetamol multiple interactions ISO RGD:10068 E RGD:6480464 20120515 CTD MESH:D000082 [Clofibrate co-treated with Acetaminophen] affects the expression of ACP1 mRNA; PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of ACP1 mRNA] PMID:17585979 10069 ACP1 acid phosphatase 1 gene CHEBI:46742 Nutlin-3 multiple interactions EXP E RGD:6480464 20240806 CTD MESH:C482205 [Dactinomycin co-treated with nutlin 3] results in increased secretion of ACP1 protein PMID:38460933 10069 ACP1 acid phosphatase 1 gene CHEBI:4903 17alpha-ethynylestradiol increases expression ISO RGD:10068 E RGD:6480464 20120412 CTD MESH:D004997 Ethinyl Estradiol results in increased expression of ACP1 mRNA PMID:17555576 10069 ACP1 acid phosphatase 1 gene CHEBI:4903 17alpha-ethynylestradiol multiple interactions ISO RGD:10068 E RGD:6480464 20120412 CTD MESH:D004997 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ACP1 mRNA PMID:17942748 10069 ACP1 acid phosphatase 1 gene CHEBI:50035 alpha-phellandrene decreases expression EXP E RGD:6480464 20220208 CTD MESH:C005403 alpha phellandrene results in decreased expression of ACP1 mRNA PMID:25075043 10069 ACP1 acid phosphatase 1 gene CHEBI:50594 carbon nanotube decreases expression ISO RGD:10068 E RGD:6480464 20200714 CTD MESH:D037742 Nanotubes, Carbon results in decreased expression of ACP1 mRNA PMID:31978390 10069 ACP1 acid phosphatase 1 gene CHEBI:50594 carbon nanotube increases expression ISO RGD:10068 E RGD:6480464 20161228 CTD MESH:D037742 Nanotubes, Carbon analog results in increased expression of ACP1 mRNA; Nanotubes, Carbon results in increased expression of ACP1 mRNA PMID:25554681 10069 ACP1 acid phosphatase 1 gene CHEBI:5063 fipronil increases expression ISO RGD:2020 E RGD:6480464 20140408 CTD MESH:C082360 fipronil results in increased expression of ACP1 mRNA PMID:23962444 10069 ACP1 acid phosphatase 1 gene CHEBI:5132 flutamide increases expression ISO RGD:2020 E RGD:6480464 20160412 CTD MESH:D005485 Flutamide results in increased expression of ACP1 mRNA PMID:24136188 10069 ACP1 acid phosphatase 1 gene CHEBI:6078 ivermectin decreases expression EXP E RGD:6480464 20210907 CTD MESH:D007559 Ivermectin results in decreased expression of ACP1 protein PMID:32959892 10069 ACP1 acid phosphatase 1 gene CHEBI:63632 topotecan decreases expression ISO RGD:2020 E RGD:6480464 20160315 CTD MESH:D019772 Topotecan results in decreased expression of ACP1 mRNA PMID:25729387 10069 ACP1 acid phosphatase 1 gene CHEBI:63632 topotecan multiple interactions ISO RGD:2020 E RGD:6480464 20160315 CTD MESH:D019772 [oxaliplatin co-treated with Topotecan] results in decreased expression of ACP1 mRNA PMID:25729387 10069 ACP1 acid phosphatase 1 gene CHEBI:63921 2-butoxyethanol increases expression ISO RGD:10068 E RGD:6480464 20120412 CTD MESH:C017096 n-butoxyethanol results in increased expression of ACP1 mRNA PMID:19812364 10069 ACP1 acid phosphatase 1 gene CHEBI:63933 Aroclor 1254 decreases expression ISO RGD:10068 E RGD:6480464 20131210 CTD MESH:D020111 Chlorodiphenyl (54% Chlorine) results in decreased expression of ACP1 mRNA PMID:23650126 10069 ACP1 acid phosphatase 1 gene CHEBI:73755 1,2-dimethylhydrazine decreases expression ISO RGD:10068 E RGD:6480464 20200804 CTD MESH:D019813 1,2-Dimethylhydrazine results in decreased expression of ACP1 mRNA PMID:22206623 10069 ACP1 acid phosphatase 1 gene CHEBI:7494 nefazodone increases expression ISO RGD:2020 E RGD:6480464 20160412 CTD MESH:C051752 nefazodone results in increased expression of ACP1 mRNA PMID:24136188 10069 ACP1 acid phosphatase 1 gene CHEBI:78320 2-hydroxypropanoic acid decreases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in decreased expression of ACP1 mRNA PMID:30851411 10069 ACP1 acid phosphatase 1 gene CHEBI:78870 sodium nitrite increases activity EXP E RGD:6480464 20151215 CTD MESH:D012977 Sodium Nitrite results in increased activity of ACP1 protein PMID:26231821 10069 ACP1 acid phosphatase 1 gene CHEBI:81506 2,3,7,8-Tetrachlorodibenzofuran decreases expression ISO RGD:2020 E RGD:6480464 20200609 CTD MESH:C014211 2,3,7,8-tetrachlorodibenzofuran results in decreased expression of ACP1 mRNA PMID:32109520 10069 ACP1 acid phosphatase 1 gene CHEBI:81584 2,2',4,4'-Tetrabromodiphenyl ether increases expression EXP E RGD:6480464 20220308 CTD MESH:C511295 2,2',4,4'-tetrabromodiphenyl ether results in increased expression of ACP1 protein PMID:31675489 10069 ACP1 acid phosphatase 1 gene CHEBI:82436 decabromodiphenyl ether increases expression EXP E RGD:6480464 20220308 CTD MESH:C010902 decabromobiphenyl ether results in increased expression of ACP1 protein PMID:31675489 10069 ACP1 acid phosphatase 1 gene CHEBI:84069 pentanal decreases expression EXP E RGD:6480464 20150825 CTD MESH:C046012 pentanal results in decreased expression of ACP1 mRNA PMID:26079696 10069 ACP1 acid phosphatase 1 gene CHEBI:90633 perfluorododecanoic acid increases expression ISO RGD:2020 E RGD:6480464 20170303 CTD MESH:C522391 perfluorododecanoic acid results in increased expression of ACP1 protein PMID:19854247 10069 ACP1 acid phosphatase 1 gene CHEBI:91108 SB 431542 multiple interactions EXP E RGD:6480464 20240206 CTD MESH:C459179 [LDN 193189 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in increased expression of ACP1 protein PMID:37664457 10069 ACP1 acid phosphatase 1 gene CHEBI:920 2,4-dinitrotoluene affects expression ISO RGD:2020 E RGD:6480464 20130618 CTD MESH:C016403 2,4-dinitrotoluene affects the expression of ACP1 mRNA PMID:21346803 10069 ACP1 acid phosphatase 1 gene CHEBI:9422 tebufenpyrad decreases expression EXP E RGD:6480464 20210810 CTD MESH:C429623 4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide results in decreased expression of ACP1 mRNA PMID:33512557 10069 ACP1 acid phosphatase 1 gene CHEBI:955 2,6-dimethoxyphenol multiple interactions EXP E RGD:6480464 20250114 CTD MESH:C010120 [Sodium Chloride co-treated with pyrogallol 1,3-dimethyl ether] results in decreased expression of and affects the localization of ACP1 protein PMID:38598786 10069 ACP1 acid phosphatase 1 gene CHEBI:957 2,6-dinitrotoluene affects expression ISO RGD:2020 E RGD:6480464 20130618 CTD MESH:C023514 2,6-dinitrotoluene affects the expression of ACP1 mRNA PMID:21346803 10069 ACP1 acid phosphatase 1 gene CHEBI:9986 vinclozolin increases expression ISO RGD:2020 E RGD:6480464 20150825 CTD MESH:C025643 vinclozolin results in increased expression of ACP1 mRNA PMID:23034163 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:133152 2-bromohexadecanoic acid multiple interactions EXP E RGD:6480464 20240702 CTD MESH:C022776 2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of ACP2 protein] PMID:38195004 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:1391 3,4-methylenedioxymethamphetamine increases expression ISO RGD:10070 E RGD:6480464 20120918 CTD MESH:D018817 N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of ACP2 mRNA PMID:20188158 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:15367 all-trans-retinoic acid increases expression EXP E RGD:6480464 20220208 CTD MESH:D014212 Tretinoin results in increased expression of ACP2 mRNA PMID:33167477 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:15443 inulin multiple interactions ISO RGD:10070 E RGD:6480464 20230502 CTD MESH:D007444 [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of ACP2 mRNA PMID:36331819 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:16170 mercury(0) decreases expression EXP E RGD:6480464 20120412 CTD MESH:D008628 Mercury results in decreased expression of ACP2 mRNA PMID:17547211 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:16236 ethanol affects splicing ISO RGD:10070 E RGD:6480464 20190507 CTD MESH:D000431 Ethanol affects the splicing of ACP2 mRNA PMID:30319688 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:16482 naphthalene affects expression EXP E RGD:6480464 20180515 CTD MESH:C031721 naphthalene affects the expression of ACP2 protein PMID:28803881 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:16482 naphthalene multiple interactions EXP E RGD:6480464 20180515 CTD MESH:C031721 [naphthalene co-treated with anthracene co-treated with phenanthrene co-treated with pyrene] affects the expression of ACP2 protein PMID:28803881 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:166473 Dibutyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C065087 di-n-butylphosphoric acid affects the expression of ACP2 mRNA PMID:37042841 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:17642 pentachlorophenol decreases expression ISO RGD:10070 E RGD:6480464 20140311 CTD MESH:D010416 Pentachlorophenol results in decreased expression of ACP2 mRNA PMID:23892564 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:17833 gentamycin decreases expression ISO RGD:2021 E RGD:6480464 20211207 CTD MESH:D005839 Gentamicins results in decreased expression of ACP2 mRNA PMID:33387578 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:22977 cadmium atom multiple interactions EXP E RGD:6480464 20240702 CTD MESH:D002104 2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of ACP2 protein]; [Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of ACP2 protein PMID:38195004 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:2504 aflatoxin B1 decreases expression EXP E RGD:6480464 20161025 CTD MESH:D016604 Aflatoxin B1 results in decreased expression of ACP2 mRNA PMID:27153756 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:25195 mercury atom decreases expression EXP E RGD:6480464 20120412 CTD MESH:D008628 Mercury results in decreased expression of ACP2 mRNA PMID:17547211 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:27470 folic acid multiple interactions ISO RGD:10070 E RGD:6480464 20200804 CTD MESH:D005492 Folic Acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of ACP2 mRNA] PMID:22206623 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:2761 dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate decreases expression EXP E RGD:6480464 20120412 CTD MESH:D000966 Antimony Potassium Tartrate results in decreased expression of ACP2 mRNA PMID:17547211 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:28073 chromium atom decreases expression EXP E RGD:6480464 20120412 CTD MESH:D002857 Chromium results in decreased expression of ACP2 mRNA PMID:17547211 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:10070 E RGD:6480464 20121009 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of ACP2 mRNA PMID:21570461 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:10070 E RGD:6480464 20120501 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of ACP2 mRNA PMID:19770486 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:2021 E RGD:6480464 20130122 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of ACP2 mRNA PMID:16054898|PMID:18178546|PMID:18796159|PMID:20959002|PMID:22342509|PMID:32109520 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:28619 acrylamide decreases expression ISO RGD:2021 E RGD:6480464 20180410 CTD MESH:D020106 Acrylamide results in decreased expression of ACP2 mRNA PMID:28959563 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:28748 doxorubicin decreases expression EXP E RGD:6480464 20181113 CTD MESH:D004317 Doxorubicin results in decreased expression of ACP2 mRNA PMID:29803840 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:28851 phenanthrene affects expression EXP E RGD:6480464 20180515 CTD MESH:C031181 phenanthrene affects the expression of ACP2 protein PMID:28803881 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:28851 phenanthrene multiple interactions EXP E RGD:6480464 20180515 CTD MESH:C031181 [naphthalene co-treated with anthracene co-treated with phenanthrene co-treated with pyrene] affects the expression of ACP2 protein PMID:28803881 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:29865 benzo[a]pyrene increases expression ISO RGD:10070 E RGD:6480464 20120918 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of ACP2 mRNA PMID:22228805 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:30304 antimony(0) decreases expression EXP E RGD:6480464 20120412 CTD MESH:D000965 Antimony results in decreased expression of ACP2 mRNA PMID:17547211 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:30812 iron dichloride decreases expression EXP E RGD:6480464 20231003 CTD MESH:C029451 ferrous chloride results in decreased expression of ACP2 mRNA PMID:35984750 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:31206 ammonium chloride affects expression ISO RGD:2021 E RGD:6480464 20120412 CTD MESH:D000643 Ammonium Chloride affects the expression of ACP2 mRNA PMID:16483693 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:32161 sulfadimethoxine increases expression ISO RGD:2021 E RGD:6480464 20230606 CTD MESH:D013412 Sulfadimethoxine results in increased expression of ACP2 mRNA PMID:30047161 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:32234 titanium dioxide decreases methylation ISO RGD:10070 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in decreased methylation of ACP2 promoter alternative form PMID:35295148 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:32497 thioacetamide decreases expression ISO RGD:2021 E RGD:6480464 20220405 CTD MESH:D013853 Thioacetamide results in decreased expression of ACP2 mRNA PMID:34492290 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:32506 4,4'-diaminodiphenylmethane increases expression ISO RGD:10070 E RGD:6480464 20120412 CTD MESH:C009505 4,4'-diaminodiphenylmethane results in increased expression of ACP2 mRNA PMID:18648102 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:32509 pirinixic acid increases expression ISO RGD:10070 E RGD:6480464 20120412 CTD MESH:C006253 pirinixic acid results in increased expression of ACP2 mRNA PMID:18301758 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:33216 bisphenol A affects expression EXP E RGD:6480464 20191112 CTD MESH:C006780 bisphenol A affects the expression of ACP2 mRNA PMID:30903817 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:33216 bisphenol A affects expression ISO RGD:2021 E RGD:6480464 20150310 CTD MESH:C006780 bisphenol A affects the expression of ACP2 mRNA PMID:25181051 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:33216 bisphenol A decreases expression ISO RGD:2021 E RGD:6480464 20191210 CTD MESH:C006780 bisphenol A results in decreased expression of ACP2 mRNA PMID:30816183|PMID:32528016|PMID:34947998 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:33216 bisphenol A increases expression EXP E RGD:6480464 20230307 CTD MESH:C006780 bisphenol A results in increased expression of ACP2 protein PMID:34186270|PMID:37567409 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:3387 carbamazepine affects expression EXP E RGD:6480464 20151013 CTD MESH:D002220 Carbamazepine affects the expression of ACP2 mRNA PMID:25979313 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:34317 3,3',4,4',5-pentachlorobiphenyl increases expression ISO RGD:2021 E RGD:6480464 20130122 CTD MESH:C023035 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of ACP2 mRNA PMID:20959002 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:34372 4,4'-sulfonyldiphenol increases expression EXP E RGD:6480464 20230307 CTD MESH:C543008 bisphenol S results in increased expression of ACP2 protein PMID:34186270 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:34581 Bisphenol B increases expression EXP E RGD:6480464 20230307 CTD MESH:C492482 bisphenol B results in increased expression of ACP2 protein PMID:34186270 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:34631 chlorpyrifos increases expression ISO RGD:10070 E RGD:6480464 20230606 CTD MESH:D004390 Chlorpyrifos results in increased expression of ACP2 mRNA PMID:37019170 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:35033 triphenyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C005445 triphenyl phosphate affects the expression of ACP2 mRNA PMID:37042841 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:35298 anthracene affects expression EXP E RGD:6480464 20180515 CTD MESH:C034020 anthracene affects the expression of ACP2 protein PMID:28803881 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:35298 anthracene multiple interactions EXP E RGD:6480464 20180515 CTD MESH:C034020 [naphthalene co-treated with anthracene co-treated with phenanthrene co-treated with pyrene] affects the expression of ACP2 protein PMID:28803881 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:35456 cadmium dichloride multiple interactions EXP E RGD:6480464 20240702 CTD MESH:D019256 2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of ACP2 protein]; [Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of ACP2 protein PMID:38195004 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:35696 cobalt dichloride decreases expression ISO RGD:2021 E RGD:6480464 20151215 CTD MESH:C018021 cobaltous chloride results in decreased expression of ACP2 mRNA PMID:24386269 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:35807 N-nitrosodimethylamine decreases expression EXP E RGD:6480464 20120412 CTD MESH:D004128 Dimethylnitrosamine results in decreased expression of ACP2 mRNA PMID:17547211 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:35842 antirheumatic drug decreases expression EXP E RGD:6480464 20161228 CTD MESH:D018501 Antirheumatic Agents results in decreased expression of ACP2 mRNA PMID:24449571 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:3764 clotrimazole increases expression ISO RGD:2021 E RGD:6480464 20230606 CTD MESH:D003022 Clotrimazole results in increased expression of ACP2 mRNA PMID:30047161 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:37825 p-toluidine decreases expression ISO RGD:2021 E RGD:6480464 20170516 CTD MESH:C029370 4-toluidine results in decreased expression of ACP2 mRNA PMID:27638505 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:38922 dibenzofurans increases expression ISO RGD:10070 E RGD:6480464 20230704 CTD MESH:D000072318 Dibenzofurans results in increased expression of ACP2 mRNA PMID:34254344 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:39106 pyrene affects expression EXP E RGD:6480464 20180515 CTD MESH:C030984 pyrene affects the expression of ACP2 protein PMID:28803881 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:39106 pyrene multiple interactions EXP E RGD:6480464 20180515 CTD MESH:C030984 [naphthalene co-treated with anthracene co-treated with phenanthrene co-treated with pyrene] affects the expression of ACP2 protein PMID:28803881 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:39421 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:10070 E RGD:6480464 20230502 CTD MESH:C076994 [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of ACP2 mRNA PMID:36331819 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:40036 amitrole increases expression ISO RGD:2021 E RGD:6480464 20230606 CTD MESH:D000640 Amitrole results in increased expression of ACP2 mRNA PMID:30047161 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:4031 cyclosporin A decreases expression EXP E RGD:6480464 20150825 CTD MESH:D016572 Cyclosporine results in decreased expression of ACP2 mRNA PMID:20106945|PMID:25562108 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:46195 paracetamol affects expression ISO RGD:10070 E RGD:6480464 20120412 CTD MESH:D000082 Acetaminophen affects the expression of ACP2 mRNA PMID:17562736 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:46195 paracetamol decreases expression ISO RGD:2021 E RGD:6480464 20211207 CTD MESH:D000082 Acetaminophen results in decreased expression of ACP2 mRNA PMID:33387578 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:4811 epoxiconazole decreases expression ISO RGD:10070 E RGD:6480464 20220906 CTD MESH:C109476 epoxiconazole results in decreased expression of ACP2 mRNA PMID:35436446 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:4811 epoxiconazole increases expression ISO RGD:10070 E RGD:6480464 20141111 CTD MESH:C109476 epoxiconazole results in increased expression of ACP2 mRNA PMID:22334560 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:50594 carbon nanotube increases expression ISO RGD:10070 E RGD:6480464 20161228 CTD MESH:D037742 Nanotubes, Carbon analog results in increased expression of ACP2 mRNA; Nanotubes, Carbon results in increased expression of ACP2 mRNA PMID:25554681 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:5063 fipronil increases expression ISO RGD:2021 E RGD:6480464 20211109 CTD MESH:C082360 fipronil results in increased expression of ACP2 mRNA PMID:34044035 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:5132 flutamide decreases expression ISO RGD:2021 E RGD:6480464 20140909 CTD MESH:D005485 Flutamide results in decreased expression of ACP2 mRNA PMID:24793618 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:53444 potassium dichromate decreases expression EXP E RGD:6480464 20120412 CTD MESH:D011192 Potassium Dichromate results in decreased expression of ACP2 mRNA PMID:17547211 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:6078 ivermectin decreases expression EXP E RGD:6480464 20210907 CTD MESH:D007559 Ivermectin results in decreased expression of ACP2 protein PMID:32959892 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:63933 Aroclor 1254 increases expression ISO RGD:2021 E RGD:6480464 20120412 CTD MESH:D020111 Chlorodiphenyl (54% Chlorine) results in increased expression of ACP2 mRNA PMID:18178546 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:6402 leflunomide increases expression ISO RGD:2021 E RGD:6480464 20161213 CTD MESH:C045463 leflunomide results in increased expression of ACP2 mRNA PMID:24136188 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:641 N-methyl-4-phenylpyridinium affects expression EXP E RGD:6480464 20130611 CTD MESH:D015655 1-Methyl-4-phenylpyridinium affects the expression of ACP2 mRNA PMID:12710931 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:64215 2,3-dimethoxynaphthalene-1,4-dione decreases expression EXP E RGD:6480464 20120412 CTD MESH:C063002 2,3-dimethoxy-1,4-naphthoquinone results in decreased expression of ACP2 mRNA PMID:17547211 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:69808 14-Deoxy-11,12-didehydroandrographolide decreases expression EXP E RGD:6480464 20170303 CTD MESH:C495626 14-deoxy-11,12-didehydroandrographolide results in decreased expression of ACP2 mRNA PMID:22101062 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:72564 temozolomide increases expression EXP E RGD:6480464 20210706 CTD MESH:C047246 Temozolomide results in increased expression of ACP2 mRNA PMID:31758290 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:72754 bisphenol AF increases expression EXP E RGD:6480464 20250114 CTD MESH:C583074 bisphenol AF results in increased expression of ACP2 protein PMID:34186270 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:73755 1,2-dimethylhydrazine increases expression ISO RGD:10070 E RGD:6480464 20200804 CTD MESH:D019813 1,2-Dimethylhydrazine results in increased expression of ACP2 mRNA PMID:22206623 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:73755 1,2-dimethylhydrazine multiple interactions ISO RGD:10070 E RGD:6480464 20200804 CTD MESH:D019813 Folic Acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of ACP2 mRNA] PMID:22206623 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:7494 nefazodone decreases expression ISO RGD:2021 E RGD:6480464 20160412 CTD MESH:C051752 nefazodone results in decreased expression of ACP2 mRNA PMID:24136188 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:8069 phenobarbital affects expression ISO RGD:10070 E RGD:6480464 20130514 CTD MESH:D010634 Phenobarbital affects the expression of ACP2 mRNA PMID:23091169 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:81758 cyproconazole increases expression ISO RGD:10070 E RGD:6480464 20141111 CTD MESH:C093628 cyproconazole results in increased expression of ACP2 mRNA PMID:22334560 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:8489 propiconazole increases expression ISO RGD:10070 E RGD:6480464 20120918 CTD MESH:C045950 propiconazole results in increased expression of ACP2 mRNA PMID:21278054|PMID:22334560 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:8502 6-propyl-2-thiouracil increases expression ISO RGD:2021 E RGD:6480464 20230606 CTD MESH:D011441 Propylthiouracil results in increased expression of ACP2 mRNA PMID:30047161 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:91108 SB 431542 multiple interactions EXP E RGD:6480464 20240206 CTD MESH:C459179 [LDN 193189 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in increased expression of ACP2 protein PMID:37664457 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:9195 Soman decreases expression ISO RGD:2021 E RGD:6480464 20141111 CTD MESH:D012999 Soman results in decreased expression of ACP2 mRNA PMID:19281266 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:9352 sulindac increases expression EXP E RGD:6480464 20120412 CTD MESH:D013467 Sulindac results in increased expression of ACP2 mRNA PMID:11906190 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:9495 thiram decreases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in decreased expression of ACP2 mRNA PMID:38568856 10071 ACP2 acid phosphatase 2, lysosomal gene CHEBI:957 2,6-dinitrotoluene affects expression ISO RGD:2021 E RGD:6480464 20120412 CTD MESH:C023514 2,6-dinitrotoluene affects the expression of ACP2 mRNA PMID:21346803 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of ACP5 mRNA PMID:38218311 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:116509 diuron increases expression ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D004237 Diuron results in increased expression of ACP5 mRNA PMID:21551480 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:132082 entinostat increases expression EXP E RGD:6480464 20161228 CTD MESH:C118739 entinostat results in increased expression of ACP5 mRNA PMID:26272509 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:132082 entinostat multiple interactions EXP E RGD:6480464 20161228 CTD MESH:C118739 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP5 mRNA PMID:27188386 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:133663 thymol sulfate(1-) multiple interactions ISO RGD:10072 E RGD:6480464 20181016 CTD MESH:D013943 Thymol inhibits the reaction [Lipopolysaccharides results in increased expression of ACP5 mRNA]; Thymol inhibits the reaction [Lipopolysaccharides results in increased expression of ACP5 protein]; Thymol inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] PMID:30048646 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:136004 linsidomine increases oxidation ISO RGD:2022 E RGD:6480464 20180220 CTD MESH:C002385 linsidomine results in increased oxidation of ACP5 protein PMID:28086193 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:1391 3,4-methylenedioxymethamphetamine increases expression ISO RGD:10072 E RGD:6480464 20160210 CTD MESH:D018817 N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of ACP5 mRNA PMID:26251327 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:1391 3,4-methylenedioxymethamphetamine increases methylation ISO RGD:10072 E RGD:6480464 20160210 CTD MESH:D018817 N-Methyl-3,4-methylenedioxyamphetamine results in increased methylation of ACP5 promoter PMID:26251327 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:15367 all-trans-retinoic acid increases expression ISO RGD:10072 E RGD:6480464 20120412 CTD MESH:D014212 Tretinoin results in increased expression of ACP5 mRNA PMID:16604517 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:15367 all-trans-retinoic acid multiple interactions ISO RGD:10072 E RGD:6480464 20240402 CTD MESH:D014212 [mono-(2-ethylhexyl)phthalate co-treated with Tretinoin] results in increased expression of ACP5 mRNA PMID:36189433 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:15379 dioxygen multiple interactions ISO RGD:2022 E RGD:6480464 20220510 CTD MESH:D010100 [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in increased expression of ACP5 mRNA PMID:33729688 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:16171 NMN zwitterion multiple interactions ISO RGD:2022 E RGD:6480464 20190219 CTD MESH:D009537 Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of ACP5 protein] PMID:30292833 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:16236 ethanol increases expression ISO RGD:10072 E RGD:6480464 20140408 CTD MESH:D000431 Ethanol results in increased expression of ACP5 mRNA PMID:22892342 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:16236 ethanol multiple interactions ISO RGD:10072 E RGD:6480464 20140408 CTD MESH:D000431 Vitamin D inhibits the reaction [Ethanol results in increased expression of ACP5 mRNA] PMID:22892342 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:16412 lipopolysaccharide increases expression ISO RGD:10072 E RGD:6480464 20161228 CTD MESH:D008070 Lipopolysaccharides results in increased expression of ACP5 mRNA; Lipopolysaccharides results in increased expression of ACP5 protein PMID:22067001|PMID:30048646|PMID:39111524 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:16412 lipopolysaccharide increases expression ISO RGD:2022 E RGD:6480464 20241203 CTD MESH:D008070 Lipopolysaccharides results in increased expression of ACP5 protein PMID:39111524 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:16412 lipopolysaccharide multiple interactions ISO RGD:10072 E RGD:6480464 20161228 CTD MESH:D008070 CSF1R affects the reaction [Lipopolysaccharides results in increased expression of ACP5 mRNA]; ganoderic acid A inhibits the reaction [Lipopolysaccharides results in increased expression of ACP5 protein]; Thymol inhibits the reaction [Lipopolysaccharides results in increased expression of ACP5 mRNA]; Thymol inhibits the reaction [Lipopolysaccharides results in increased expression of ACP5 protein] PMID:22067001|PMID:30048646|PMID:39111524 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:16412 lipopolysaccharide multiple interactions ISO RGD:2022 E RGD:6480464 20241203 CTD MESH:D008070 ganoderic acid A inhibits the reaction [Lipopolysaccharides results in increased expression of ACP5 protein] PMID:39111524 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:16469 17beta-estradiol decreases expression ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D004958 Estradiol results in decreased expression of ACP5 protein PMID:15917159 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:16469 17beta-estradiol multiple interactions EXP E RGD:6480464 20190611 CTD MESH:D004958 [Estradiol co-treated with TGFB1 protein] results in decreased expression of ACP5 mRNA PMID:30165855 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:166473 Dibutyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C065087 di-n-butylphosphoric acid affects the expression of ACP5 mRNA PMID:37042841 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:168262 Ganoderic acid A multiple interactions ISO RGD:10072 E RGD:6480464 20241203 CTD MESH:C515005 ganoderic acid A inhibits the reaction [Lipopolysaccharides results in increased expression of ACP5 protein] PMID:39111524 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:168262 Ganoderic acid A multiple interactions ISO RGD:2022 E RGD:6480464 20241203 CTD MESH:C515005 ganoderic acid A inhibits the reaction [Lipopolysaccharides results in increased expression of ACP5 protein] PMID:39111524 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:17158 methylglyoxal increases expression ISO RGD:10072 E RGD:6480464 20190910 CTD MESH:D011765 Pyruvaldehyde results in increased expression of ACP5 mRNA PMID:31103701 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:17158 methylglyoxal increases expression ISO RGD:2022 E RGD:6480464 20190910 CTD MESH:D011765 Pyruvaldehyde results in increased expression of ACP5 mRNA; Pyruvaldehyde results in increased expression of ACP5 protein PMID:31103701 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:17158 methylglyoxal multiple interactions ISO RGD:10072 E RGD:6480464 20190219 CTD MESH:D011765 [TNFSF11 protein co-treated with Pyruvaldehyde] affects the activity of ACP5 protein; [TNFSF11 protein co-treated with Pyruvaldehyde] results in decreased activity of ACP5 protein; bergenin inhibits the reaction [[TNFSF11 protein co-treated with Pyruvaldehyde] results in decreased activity of ACP5 protein]; MAPK8 protein affects the reaction [Pyruvaldehyde results in increased expression of ACP5 mRNA] PMID:30217477|PMID:31103701|PMID:31369791 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:17243 mono(2-ethylhexyl) phthalate multiple interactions ISO RGD:10072 E RGD:6480464 20240402 CTD MESH:C016599 [mono-(2-ethylhexyl)phthalate co-treated with Tretinoin] results in increased expression of ACP5 mRNA PMID:36189433 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:17347 testosterone increases expression ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D013739 Testosterone results in increased expression of ACP5 mRNA PMID:15917159 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:17823 calcitriol decreases expression EXP E RGD:6480464 20120814 CTD MESH:D002117 Calcitriol results in decreased expression of ACP5 protein PMID:21985997 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:17833 gentamycin increases expression ISO RGD:2022 E RGD:6480464 20161228 CTD MESH:D005839 Gentamicins results in increased expression of ACP5 mRNA PMID:22061828 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:17963 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine increases expression ISO RGD:10072 E RGD:6480464 20190312 CTD MESH:D015632 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACP5 mRNA PMID:30529163 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:18088 formononetin multiple interactions ISO RGD:10072 E RGD:6480464 20221206 CTD MESH:C007768 formononetin inhibits the reaction [Streptozocin results in increased activity of ACP5 protein]; formononetin inhibits the reaction [Streptozocin results in increased expression of ACP5 mRNA] PMID:35315182 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:201431 Cyclosporin H multiple interactions ISO RGD:10072 E RGD:6480464 20231219 CTD MESH:C050025 cyclosporin H inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] PMID:15207740 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:22977 cadmium atom increases expression ISO RGD:2022 E RGD:6480464 20140211 CTD MESH:D002104 Cadmium results in increased expression of ACP5 protein alternative form PMID:23954550 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:22977 cadmium atom multiple interactions ISO RGD:10072 E RGD:6480464 20200609 CTD MESH:D002104 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester affects the reaction [[Cadmium co-treated with TNFSF11 protein co-treated with CSF1R protein] affects the expression of ACP5 protein]; 2-aminoethoxydiphenyl borate affects the reaction [[Cadmium co-treated with TNFSF11 protein co-treated with CSF1R protein] affects the expression of ACP5 protein]; [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of ACP5 mRNA; [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of ACP5 protein; [Cadmium co-treated with TNFSF11 protein co-treated with CSF1R protein] affects the expression of ACP5 mRNA; [Cadmium co-treated with TNFSF11 protein co-treated with CSF1R protein] affects the expression of ACP5 protein; KN 93 affects the reaction [[Cadmium co-treated with TNFSF11 protein co-treated with CSF1R protein] affects the expression of ACP5 protein]; STO 609 affects the reaction [[Cadmium co-treated with TNFSF11 protein co-treated with CSF1R protein] affects the expression of ACP5 protein]; W 7 affects the reaction [[Cadmium co-treated with TNFSF11 protein co-treated with CSF1R protein] affects the expression of ACP5 protein] PMID:31793751|PMID:32522522|PMID:37325564 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:23414 copper(II) sulfate decreases expression EXP E RGD:6480464 20120814 CTD MESH:D019327 Copper Sulfate results in decreased expression of ACP5 mRNA PMID:19549813 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:2504 aflatoxin B1 decreases expression EXP E RGD:6480464 20161025 CTD MESH:D016604 Aflatoxin B1 results in decreased expression of ACP5 mRNA PMID:27153756 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:2504 aflatoxin B1 increases expression EXP E RGD:6480464 20120918 CTD MESH:D016604 Aflatoxin B1 results in increased expression of ACP5 mRNA PMID:21641981 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:2567 alendronic acid multiple interactions ISO RGD:2022 E RGD:6480464 20170207 CTD MESH:D019386 Alendronate inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein]; Alendronate inhibits the reaction [modafinil results in increased expression of ACP5 mRNA] PMID:27387537|PMID:29649498 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:25812 ozone multiple interactions ISO RGD:10072 E RGD:6480464 20220809 CTD MESH:D010126 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of ACP5 mRNA PMID:34911549 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27214 uranium atom increases expression ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D014501 Uranium results in increased expression of ACP5 protein PMID:16436523 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27214 uranium atom increases secretion ISO RGD:2022 E RGD:6480464 20180828 CTD MESH:D014501 Uranium results in increased secretion of ACP5 protein PMID:29477364 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27214 uranium atom multiple interactions ISO RGD:2022 E RGD:6480464 20180828 CTD MESH:D014501 GHRL protein inhibits the reaction [Uranium results in increased secretion of ACP5 protein] PMID:29477364 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27300 vitamin D multiple interactions ISO RGD:10072 E RGD:6480464 20170303 CTD MESH:D014807 Vitamin D inhibits the reaction [Ethanol results in increased expression of ACP5 mRNA] PMID:22892342 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27363 zinc atom decreases activity ISO RGD:2022 E RGD:6480464 20130212 CTD MESH:D015032 Zinc deficiency results in decreased activity of ACP5 protein PMID:21893222 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27363 zinc atom decreases expression ISO RGD:2022 E RGD:6480464 20130212 CTD MESH:D015032 Zinc deficiency results in decreased expression of ACP5 mRNA PMID:21893222 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27385 tetrachloromethane decreases expression ISO RGD:10072 E RGD:6480464 20200804 CTD MESH:D002251 Carbon Tetrachloride results in decreased expression of ACP5 mRNA PMID:31919559 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27607 thymol multiple interactions ISO RGD:10072 E RGD:6480464 20181016 CTD MESH:D013943 Thymol inhibits the reaction [Lipopolysaccharides results in increased expression of ACP5 mRNA]; Thymol inhibits the reaction [Lipopolysaccharides results in increased expression of ACP5 protein]; Thymol inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] PMID:30048646 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27666 actinomycin D multiple interactions EXP E RGD:6480464 20240806 CTD MESH:D003609 [Dactinomycin co-treated with nutlin 3] results in increased expression of ACP5 mRNA; [Dactinomycin co-treated with nutlin 3] results in increased secretion of ACP5 protein PMID:38460933 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27856 acetamide increases expression ISO RGD:2022 E RGD:6480464 20200519 CTD MESH:C030686 acetamide results in increased expression of ACP5 mRNA PMID:31881176 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27881 resveratrol multiple interactions EXP E RGD:6480464 20120412 CTD MESH:C059514 resveratrol inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased activity of ACP5 protein] PMID:16267019 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27899 cisplatin increases expression EXP E RGD:6480464 20180220 CTD MESH:D002945 Cisplatin results in increased expression of ACP5 mRNA PMID:27594783 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27899 cisplatin multiple interactions EXP E RGD:6480464 20170516 CTD MESH:D002945 [Cisplatin co-treated with jinfukang] results in increased expression of ACP5 mRNA PMID:27392435 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:27998 tungsten multiple interactions ISO RGD:10072 E RGD:6480464 20210209 CTD MESH:D014414 Tungsten promotes the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] PMID:33146397 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28073 chromium atom decreases activity ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D002857 Chromium results in decreased activity of ACP5 protein PMID:16866188 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28088 genistein decreases expression ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D019833 Genistein results in decreased expression of ACP5 mRNA PMID:12075121 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28088 genistein multiple interactions ISO RGD:10072 E RGD:6480464 20130122 CTD MESH:D019833 [Zinc Sulfate co-treated with Genistein co-treated with CSF1 protein co-treated with TNFSF11 protein] results in decreased expression of ACP5 mRNA PMID:17295206 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:2022 E RGD:6480464 20220111 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of ACP5 mRNA PMID:34747641 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:2022 E RGD:6480464 20200609 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of ACP5 mRNA PMID:32109520 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:10072 E RGD:6480464 20120515 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of ACP5 mRNA PMID:17035482|PMID:21041162 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:2022 E RGD:6480464 20211207 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of ACP5 mRNA PMID:33387578 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:10072 E RGD:6480464 20120412 CTD MESH:D013749 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ACP5 mRNA; Tetrachlorodibenzodioxin results in increased expression of and results in increased secretion of ACP5 protein PMID:17942748|PMID:29673856 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28177 theophylline increases expression ISO RGD:2022 E RGD:6480464 20160607 CTD MESH:D013806 Theophylline results in increased expression of ACP5 mRNA; Theophylline results in increased expression of ACP5 protein PMID:26851681 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28179 benzamide multiple interactions ISO RGD:10072 E RGD:6480464 20181113 CTD MESH:C037689 benzamide analog inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ACP5 mRNA] PMID:29935282 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28201 rotenone increases expression ISO RGD:2022 E RGD:6480464 20191112 CTD MESH:D012402 Rotenone results in increased expression of ACP5 mRNA PMID:28374803 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28201 rotenone multiple interactions EXP E RGD:6480464 20130416 CTD MESH:D012402 Rotenone inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] PMID:19900598 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of ACP5 mRNA PMID:33212167 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28358 rac-lactic acid decreases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in decreased expression of ACP5 mRNA PMID:30851411 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28618 1,4-dichlorobenzene increases expression ISO RGD:10072 E RGD:6480464 20171114 CTD MESH:C018511 4-dichlorobenzene results in increased expression of ACP5 mRNA PMID:26975756 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28741 sodium fluoride decreases expression ISO RGD:10072 E RGD:6480464 20180410 CTD MESH:D012969 Sodium Fluoride results in decreased expression of ACP5 protein PMID:29127033 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28741 sodium fluoride increases expression ISO RGD:10072 E RGD:6480464 20180410 CTD MESH:D012969 Sodium Fluoride results in increased expression of ACP5 mRNA PMID:29127033|PMID:32156525 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28741 sodium fluoride multiple interactions ISO RGD:10072 E RGD:6480464 20180410 CTD MESH:D012969 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Sodium Fluoride results in increased expression of ACP5 mRNA]; [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Sodium Fluoride] affects the expression of ACP5 protein; Sodium Fluoride promotes the reaction [TNFSF11 protein results in increased expression of ACP5 protein] PMID:29127033|PMID:32156525 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28748 doxorubicin decreases expression EXP E RGD:6480464 20181113 CTD MESH:D004317 Doxorubicin results in decreased expression of ACP5 mRNA PMID:29803840 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28819 naringin decreases expression ISO RGD:10072 E RGD:6480464 20150512 CTD MESH:C005274 naringin results in decreased expression of ACP5 mRNA PMID:24376342 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:28819 naringin multiple interactions ISO RGD:10072 E RGD:6480464 20150512 CTD MESH:C005274 naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ACP5 mRNA]; naringin inhibits the reaction [Polymethyl Methacrylate analog results in increased expression of and results in increased activity of ACP5 protein] PMID:21835177|PMID:24376342 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:2942 azadirachtin A decreases expression ISO RGD:10072 E RGD:6480464 20201215 CTD MESH:C010329 azadirachtin results in decreased expression of ACP5 mRNA PMID:31225646 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:2942 azadirachtin A multiple interactions ISO RGD:10072 E RGD:6480464 20201215 CTD MESH:C010329 azadirachtin inhibits the reaction [Estrogens deficiency results in increased expression of ACP5 mRNA] PMID:31225646 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:29678 sodium arsenite multiple interactions ISO RGD:10072 E RGD:6480464 20190409 CTD MESH:C017947 [NFE2L2 protein affects the susceptibility to sodium arsenite] which affects the expression of ACP5 protein PMID:30742845 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of ACP5 5' UTR; Benzo(a)pyrene affects the methylation of ACP5 promoter PMID:27901495 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:29865 benzo[a]pyrene decreases expression ISO RGD:2022 E RGD:6480464 20120613 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of ACP5 mRNA PMID:21839799 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:29865 benzo[a]pyrene increases activity ISO RGD:10072 E RGD:6480464 20221004 CTD MESH:D001564 Benzo(a)pyrene results in increased activity of ACP5 protein PMID:35777681 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:29865 benzo[a]pyrene increases expression EXP E RGD:6480464 20120918 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of ACP5 mRNA PMID:20064835|PMID:22316170 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:3001 beclomethasone decreases activity EXP E RGD:6480464 20131210 CTD MESH:D001507 Beclomethasone results in decreased activity of ACP5 protein PMID:8429434 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:30185 zinc(0) decreases activity ISO RGD:2022 E RGD:6480464 20130212 CTD MESH:D015032 Zinc deficiency results in decreased activity of ACP5 protein PMID:21893222 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:30185 zinc(0) decreases expression ISO RGD:2022 E RGD:6480464 20130212 CTD MESH:D015032 Zinc deficiency results in decreased expression of ACP5 mRNA PMID:21893222 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:30187 aluminium oxide decreases expression EXP E RGD:6480464 20120412 CTD MESH:D000537 Aluminum Oxide results in decreased expression of ACP5 mRNA PMID:15585240 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:30563 silicon dioxide increases expression EXP E RGD:6480464 20160315 CTD MESH:D012822 Silicon Dioxide analog results in increased expression of ACP5 mRNA PMID:23806026|PMID:25895662 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:30563 silicon dioxide increases expression ISO RGD:10072 E RGD:6480464 20200310 CTD MESH:D012822 Silicon Dioxide results in increased expression of ACP5 mRNA PMID:29341224 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:30812 iron dichloride decreases expression EXP E RGD:6480464 20231003 CTD MESH:C029451 ferrous chloride results in decreased expression of ACP5 mRNA PMID:35984750 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:30812 iron dichloride multiple interactions ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:C029451 ferrous chloride inhibits the reaction [Dithionite results in decreased activity of ACP5 protein] PMID:6886379 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:31604 ferric ammonium citrate increases expression ISO RGD:2022 E RGD:6480464 20230404 CTD MESH:C013531 ferric ammonium citrate results in increased expression of ACP5 protein PMID:36087815 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:31604 ferric ammonium citrate multiple interactions ISO RGD:2022 E RGD:6480464 20230404 CTD MESH:C013531 Silybin inhibits the reaction [ferric ammonium citrate results in increased expression of ACP5 protein] PMID:36087815 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:31801 Maxacalcitol decreases expression EXP E RGD:6480464 20141111 CTD MESH:C051883 maxacalcitol results in decreased expression of ACP5; maxacalcitol results in decreased expression of ACP5 protein PMID:11576942|PMID:8840326 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:31859 modafinil increases expression ISO RGD:2022 E RGD:6480464 20180828 CTD MESH:C048833 modafinil results in increased expression of ACP5 mRNA; modafinil results in increased expression of ACP5 protein PMID:29649498 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:31859 modafinil multiple interactions ISO RGD:2022 E RGD:6480464 20180828 CTD MESH:C048833 Alendronate inhibits the reaction [modafinil results in increased expression of ACP5 mRNA] PMID:29649498 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:31941 oxaliplatin increases expression ISO RGD:2022 E RGD:6480464 20161213 CTD MESH:C030110 oxaliplatin results in increased expression of ACP5 mRNA PMID:25729387 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:31941 oxaliplatin multiple interactions ISO RGD:2022 E RGD:6480464 20161213 CTD MESH:C030110 [oxaliplatin co-treated with Topotecan] results in increased expression of ACP5 mRNA PMID:25729387 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:32161 sulfadimethoxine increases expression ISO RGD:2022 E RGD:6480464 20230606 CTD MESH:D013412 Sulfadimethoxine results in increased expression of ACP5 mRNA PMID:30047161 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:32234 titanium dioxide decreases expression ISO RGD:10072 E RGD:6480464 20140211 CTD MESH:C009495 titanium dioxide results in decreased expression of ACP5 mRNA PMID:23557971|PMID:35295148 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:32497 thioacetamide increases expression ISO RGD:2022 E RGD:6480464 20140408 CTD MESH:D013853 Thioacetamide results in increased expression of ACP5 mRNA PMID:23411599 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:32497 thioacetamide multiple interactions ISO RGD:2022 E RGD:6480464 20180116 CTD MESH:D013853 [Diethylnitrosamine co-treated with Thioacetamide] results in increased expression of ACP5 mRNA PMID:28943392 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:32506 4,4'-diaminodiphenylmethane increases expression ISO RGD:2022 E RGD:6480464 20160315 CTD MESH:C009505 4,4'-diaminodiphenylmethane results in increased expression of ACP5 mRNA PMID:25380136 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:33216 bisphenol A decreases expression ISO RGD:2022 E RGD:6480464 20230606 CTD MESH:C006780 bisphenol A results in decreased expression of ACP5 mRNA PMID:32145629 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:33216 bisphenol A increases expression ISO RGD:10072 E RGD:6480464 20220208 CTD MESH:C006780 bisphenol A results in increased expression of ACP5 mRNA PMID:32156529|PMID:33221593|PMID:34585602|PMID:38701888 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:33216 bisphenol A increases expression ISO RGD:2022 E RGD:6480464 20150310 CTD MESH:C006780 bisphenol A results in increased expression of ACP5 mRNA PMID:25181051 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:33216 bisphenol A increases methylation ISO RGD:2022 E RGD:6480464 20180116 CTD MESH:C006780 bisphenol A results in increased methylation of ACP5 gene PMID:28505145 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:34039 1,2,4-trimethylbenzene decreases expression ISO RGD:2022 E RGD:6480464 20120918 CTD MESH:C010313 pseudocumene results in decreased expression of ACP5 protein PMID:17337753 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:34372 4,4'-sulfonyldiphenol decreases methylation ISO RGD:10072 E RGD:6480464 20220208 CTD MESH:C543008 bisphenol S results in decreased methylation of ACP5 promoter PMID:33297965 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:34631 chlorpyrifos increases expression ISO RGD:10072 E RGD:6480464 20210706 CTD MESH:D004390 Chlorpyrifos results in increased expression of ACP5 mRNA PMID:32715474 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:34786 Heptachlor epoxide increases expression ISO RGD:10072 E RGD:6480464 20150127 CTD MESH:D006534 Heptachlor Epoxide results in increased expression of ACP5 mRNA PMID:25270620 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:34873 N-nitrosodiethylamine increases expression ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D004052 Diethylnitrosamine results in increased expression of ACP5 mRNA PMID:19638242 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:34873 N-nitrosodiethylamine multiple interactions ISO RGD:2022 E RGD:6480464 20180116 CTD MESH:D004052 [Diethylnitrosamine co-treated with Thioacetamide] results in increased expression of ACP5 mRNA PMID:28943392 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:35064 alpha-Zearalanol increases expression ISO RGD:2022 E RGD:6480464 20240430 CTD MESH:D015029 Zeranol results in increased expression of ACP5 mRNA PMID:35163327 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:35176 zinc sulfate multiple interactions ISO RGD:10072 E RGD:6480464 20130122 CTD MESH:D019287 [Cryptoxanthins co-treated with Zinc Sulfate] results in decreased expression of ACP5 mRNA; [CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins co-treated with Zinc Sulfate] results in decreased expression of ACP5 mRNA; [Zinc Sulfate co-treated with Genistein co-treated with CSF1 protein co-treated with TNFSF11 protein] results in decreased expression of ACP5 mRNA PMID:17295206|PMID:18636177 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:35455 1-naphthyl isothiocyanate increases expression ISO RGD:2022 E RGD:6480464 20160315 CTD MESH:D015058 1-Naphthylisothiocyanate results in increased expression of ACP5 mRNA PMID:25380136 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:35456 cadmium dichloride decreases expression EXP E RGD:6480464 20241001 CTD MESH:D019256 Cadmium Chloride results in decreased expression of ACP5 mRNA PMID:38382870 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:35456 cadmium dichloride decreases expression ISO RGD:2022 E RGD:6480464 20150825 CTD MESH:D019256 Cadmium Chloride results in decreased expression of ACP5 mRNA PMID:25993096 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:35456 cadmium dichloride multiple interactions ISO RGD:10072 E RGD:6480464 20120717 CTD MESH:D019256 [Cadmium Chloride co-treated with TNFSF11] results in increased activity of ACP5 protein; [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of ACP5 mRNA; [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of ACP5 protein PMID:21723911|PMID:31793751|PMID:37325564 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:35559 furan increases expression ISO RGD:2022 E RGD:6480464 20150414 CTD MESH:C039281 furan results in increased expression of ACP5 mRNA PMID:25539665 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:35807 N-nitrosodimethylamine increases expression ISO RGD:2022 E RGD:6480464 20160315 CTD MESH:D004128 Dimethylnitrosamine results in increased expression of ACP5 mRNA PMID:25380136 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:3647 chlorpromazine multiple interactions ISO RGD:10072 E RGD:6480464 20120412 CTD MESH:D002746 Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] PMID:21869564 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:3720 cisapride multiple interactions ISO RGD:10072 E RGD:6480464 20190910 CTD MESH:D020117 Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] PMID:31150804 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:3750 clofibrate decreases expression ISO RGD:10072 E RGD:6480464 20120515 CTD MESH:D002994 Clofibrate results in decreased expression of ACP5 mRNA PMID:17585979 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:38397 perfluorononanoic acid affects expression EXP E RGD:6480464 20241203 CTD MESH:C101816 perfluoro-n-nonanoic acid affects the expression of ACP5 protein PMID:38537583 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:39481 chloroprene decreases expression ISO RGD:2022 E RGD:6480464 20130514 CTD MESH:D002737 Chloroprene results in decreased expression of ACP5 mRNA PMID:23125180 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:39483 sodium dichromate increases expression ISO RGD:2022 E RGD:6480464 20121009 CTD MESH:C016104 sodium bichromate results in increased expression of ACP5 mRNA PMID:22561333 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:39867 valproic acid affects expression ISO RGD:10072 E RGD:6480464 20120412 CTD MESH:D014635 Valproic Acid affects the expression of ACP5 mRNA PMID:17292431 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:39867 valproic acid decreases expression EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in decreased expression of ACP5 mRNA PMID:29154799 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:39867 valproic acid increases expression EXP E RGD:6480464 20160119 CTD MESH:D014635 Valproic Acid results in increased expression of ACP5 mRNA PMID:23179753|PMID:26272509 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:39867 valproic acid multiple interactions EXP E RGD:6480464 20161025 CTD MESH:D014635 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP5 mRNA PMID:27188386 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:40036 amitrole increases expression ISO RGD:2022 E RGD:6480464 20230606 CTD MESH:D000640 Amitrole results in increased expression of ACP5 mRNA PMID:30047161 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:4031 cyclosporin A decreases expression EXP E RGD:6480464 20170516 CTD MESH:D016572 Cyclosporine results in decreased expression of ACP5 mRNA PMID:27989131 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:4031 cyclosporin A multiple interactions ISO RGD:10072 E RGD:6480464 20120412 CTD MESH:D016572 Cyclosporine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] PMID:15207740 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:41879 dexamethasone increases activity ISO RGD:2022 E RGD:6480464 20170207 CTD MESH:D003907 Dexamethasone results in increased activity of ACP5 protein PMID:27387537|PMID:28363435 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:41879 dexamethasone increases expression ISO RGD:10072 E RGD:6480464 20120515 CTD MESH:D003907 Dexamethasone results in increased expression of ACP5 mRNA PMID:21041162 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:41879 dexamethasone multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D003907 [Thalidomide co-treated with Dexamethasone] results in decreased expression of ACP5 protein PMID:16079895 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:41879 dexamethasone multiple interactions ISO RGD:2022 E RGD:6480464 20170207 CTD MESH:D003907 Alendronate inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein]; caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein] PMID:27387537|PMID:28363435 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:41922 diethylstilbestrol increases expression ISO RGD:10072 E RGD:6480464 20120515 CTD MESH:D004054 Diethylstilbestrol results in increased expression of ACP5 mRNA PMID:21041162 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:42160 dithionite(2-) decreases activity ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D004227 Dithionite results in decreased activity of ACP5 protein PMID:6886379 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:42160 dithionite(2-) multiple interactions ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D004227 ferrous chloride inhibits the reaction [Dithionite results in decreased activity of ACP5 protein] PMID:6886379 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:42588 4-hydroxyphenyl retinamide decreases expression ISO RGD:10072 E RGD:6480464 20180220 CTD MESH:D017313 Fenretinide results in decreased expression of ACP5 mRNA PMID:28973697 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:42588 4-hydroxyphenyl retinamide multiple interactions ISO RGD:10072 E RGD:6480464 20120412 CTD MESH:D017313 Fenretinide inhibits the reaction [TNF protein results in increased expression of ACP5 protein] PMID:16230421 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:4356 desferrioxamine B decreases activity ISO RGD:10072 E RGD:6480464 20191008 CTD MESH:D003676 Deferoxamine results in decreased activity of ACP5 protein PMID:31238089 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:4356 desferrioxamine B multiple interactions ISO RGD:10072 E RGD:6480464 20191008 CTD MESH:D003676 Deferoxamine inhibits the reaction [TF protein results in increased activity of ACP5 protein]; TF protein inhibits the reaction [Deferoxamine results in decreased activity of ACP5 protein] PMID:31238089 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:46195 paracetamol affects expression ISO RGD:10072 E RGD:6480464 20120412 CTD MESH:D000082 Acetaminophen affects the expression of ACP5 mRNA PMID:17562736 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:4629 diosgenin multiple interactions ISO RGD:10072 E RGD:6480464 20130702 CTD MESH:D004144 Diosgenin inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] PMID:16331273 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:4630 diosmetin multiple interactions ISO RGD:10072 E RGD:6480464 20230404 CTD MESH:C039602 diosmetin inhibits the reaction [RANK Ligand affects the expression of ACP5 mRNA] PMID:36563736 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:46742 Nutlin-3 multiple interactions EXP E RGD:6480464 20240806 CTD MESH:C482205 [Dactinomycin co-treated with nutlin 3] results in increased expression of ACP5 mRNA; [Dactinomycin co-treated with nutlin 3] results in increased secretion of ACP5 protein PMID:38460933 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:4775 ellagic acid multiple interactions ISO RGD:10072 E RGD:6480464 20210309 CTD MESH:D004610 Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] PMID:32971123 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:47807 sulforaphane increases expression ISO RGD:10072 E RGD:6480464 20190312 CTD MESH:C016766 sulforaphane results in increased expression of ACP5 mRNA PMID:30529165 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:479072 2-aminopurine multiple interactions ISO RGD:10072 E RGD:6480464 20190702 CTD MESH:D015075 2-Aminopurine inhibits the reaction [[TNF protein co-treated with TNFSF11 protein] results in increased expression of ACP5 protein] PMID:25739386 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:48107 nitric acid increases expression ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D017942 Nitric Acid results in increased expression of ACP5 protein PMID:16436523 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:4903 17alpha-ethynylestradiol affects expression ISO RGD:10072 E RGD:6480464 20120412 CTD MESH:D004997 Ethinyl Estradiol affects the expression of ACP5 mRNA PMID:17555576 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:4903 17alpha-ethynylestradiol increases expression ISO RGD:10072 E RGD:6480464 20120412 CTD MESH:D004997 Ethinyl Estradiol results in increased expression of ACP5 mRNA PMID:17942748 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:4903 17alpha-ethynylestradiol multiple interactions ISO RGD:10072 E RGD:6480464 20120412 CTD MESH:D004997 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ACP5 mRNA PMID:17942748 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:49662 indometacin decreases expression ISO RGD:2022 E RGD:6480464 20150825 CTD MESH:D007213 Indomethacin results in decreased expression of ACP5 mRNA PMID:25972201 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:50131 5-aza-2'-deoxycytidine affects expression EXP E RGD:6480464 20191114 CTD MESH:C014347 Decitabine affects the expression of ACP5 mRNA PMID:17145863 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:50594 carbon nanotube decreases expression ISO RGD:10072 E RGD:6480464 20161228 CTD MESH:D037742 Nanotubes, Carbon analog results in decreased expression of ACP5 mRNA; Nanotubes, Carbon results in decreased expression of ACP5 mRNA PMID:25620056 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:50594 carbon nanotube increases expression ISO RGD:10072 E RGD:6480464 20161228 CTD MESH:D037742 Nanotubes, Carbon analog results in increased expression of ACP5 mRNA; Nanotubes, Carbon results in increased expression of ACP5 mRNA PMID:25554681 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:50673 methimazole increases expression ISO RGD:2022 E RGD:6480464 20230606 CTD MESH:D008713 Methimazole results in increased expression of ACP5 mRNA PMID:30047161 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:5118 fluoxetine multiple interactions ISO RGD:10072 E RGD:6480464 20120613 CTD MESH:D005473 Fluoxetine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] PMID:15312242 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:53205 poly(methyl methacrylate) macromolecule multiple interactions ISO RGD:10072 E RGD:6480464 20150512 CTD MESH:D019904 naringin inhibits the reaction [Polymethyl Methacrylate analog results in increased expression of and results in increased activity of ACP5 protein]; Polymethyl Methacrylate analog results in increased expression of and results in increased activity of ACP5 protein PMID:24376342 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:53227 poly(ethylene) decreases expression EXP E RGD:6480464 20120412 CTD MESH:D020959 Polyethylene results in decreased expression of ACP5 mRNA PMID:15585240 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:53444 potassium dichromate decreases activity ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D011192 Potassium Dichromate results in decreased activity of ACP5 protein PMID:16866188 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:5557 guanethidine affects expression ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D006145 Guanethidine affects the expression of ACP5 protein PMID:14527964 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:5557 guanethidine increases expression ISO RGD:2022 E RGD:6480464 20120412 CTD MESH:D006145 Guanethidine results in increased expression of ACP5 mRNA PMID:14527964 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:6078 ivermectin decreases expression EXP E RGD:6480464 20210907 CTD MESH:D007559 Ivermectin results in decreased expression of ACP5 protein PMID:32959892 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:61057 tacrolimus hydrate multiple interactions ISO RGD:10072 E RGD:6480464 20120412 CTD MESH:D016559 Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] PMID:15207740 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:61076 belinostat decreases expression EXP E RGD:6480464 20170303 CTD MESH:C487081 belinostat results in decreased expression of ACP5 mRNA PMID:27188386 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:63041 manganese(II) chloride increases expression ISO RGD:2022 E RGD:6480464 20120717 CTD MESH:C025340 manganese chloride results in increased expression of ACP5 mRNA PMID:22281203|PMID:28801915 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:63041 manganese(II) chloride increases methylation ISO RGD:2022 E RGD:6480464 20190219 CTD MESH:C025340 manganese chloride results in increased methylation of ACP5 gene PMID:28801915 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:63623 succimer multiple interactions ISO RGD:10072 E RGD:6480464 20120918 CTD MESH:D004113 [Succimer binds to Magnetite Nanoparticles] which results in increased expression of ACP5 mRNA; [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of ACP5 mRNA PMID:21641980|PMID:26378955 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:63632 topotecan increases expression ISO RGD:2022 E RGD:6480464 20160315 CTD MESH:D019772 Topotecan results in increased expression of ACP5 mRNA PMID:25729387 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:63632 topotecan multiple interactions ISO RGD:2022 E RGD:6480464 20160315 CTD MESH:D019772 [oxaliplatin co-treated with Topotecan] results in increased expression of ACP5 mRNA PMID:25729387 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:641 N-methyl-4-phenylpyridinium decreases expression ISO RGD:2022 E RGD:6480464 20130611 CTD MESH:D015655 1-Methyl-4-phenylpyridinium results in decreased expression of ACP5 mRNA PMID:16026605 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:6682 mangiferin multiple interactions ISO RGD:10072 E RGD:6480464 20120412 CTD MESH:C013592 mangiferin inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] PMID:20683903 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:6698 (-)-matairesinol decreases activity ISO RGD:10072 E RGD:6480464 20230404 CTD MESH:C068935 matairesinol results in decreased activity of ACP5 protein PMID:24444335 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:67991 (20S)-ginsenoside Rg3 multiple interactions ISO RGD:2022 E RGD:6480464 20170207 CTD MESH:C097367 ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein] PMID:27387537 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:6925 microcystin-LR increases expression ISO RGD:2022 E RGD:6480464 20231031 CTD MESH:C057862 cyanoginosin LR results in increased expression of ACP5 protein PMID:37467923 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:69499 Bergenin multiple interactions ISO RGD:10072 E RGD:6480464 20191210 CTD MESH:C006741 bergenin inhibits the reaction [[TNFSF11 protein co-treated with Pyruvaldehyde] results in decreased activity of ACP5 protein] PMID:31369791 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:7005 morusin decreases expression ISO RGD:10072 E RGD:6480464 20240702 CTD MESH:C057451 morusin results in decreased expression of ACP5 mRNA PMID:38522564 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:7553 niclosamide multiple interactions EXP E RGD:6480464 20191114 CTD MESH:D009534 Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] PMID:26792726 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:7553 niclosamide multiple interactions ISO RGD:10072 E RGD:6480464 20191114 CTD MESH:D009534 Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ACP5 mRNA] PMID:28824321 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:7590 nitrofen increases expression ISO RGD:2022 E RGD:6480464 20210810 CTD MESH:C007350 nitrofen results in increased expression of ACP5 mRNA PMID:33484710 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:78320 2-hydroxypropanoic acid decreases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in decreased expression of ACP5 mRNA PMID:30851411 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:78510 dorsomorphin multiple interactions EXP E RGD:6480464 20161228 CTD MESH:C516138 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP5 mRNA; [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP5 mRNA PMID:27188386 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:79068 crocin-1 multiple interactions ISO RGD:10072 E RGD:6480464 20190312 CTD MESH:C029036 crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]] PMID:30580027 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:79516 Nonylphenol decreases expression ISO RGD:2022 E RGD:6480464 20240903 CTD MESH:C025256 nonylphenol results in decreased expression of ACP5 protein PMID:34219512 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:8062 phenethyl caffeate multiple interactions ISO RGD:2022 E RGD:6480464 20170613 CTD MESH:C055494 caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein] PMID:28363435 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:80852 Morroniside decreases expression ISO RGD:10072 E RGD:6480464 20221004 CTD MESH:C488401 morroniside results in decreased expression of ACP5 mRNA PMID:34638983 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:81582 2,4-dibromophenyl 2,4,5-tribromophenyl ether affects expression ISO RGD:10072 E RGD:6480464 20240903 CTD MESH:C477694 2,2',4,4',5-brominated diphenyl ether affects the expression of ACP5 mRNA PMID:38648751 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:8489 propiconazole increases expression ISO RGD:2022 E RGD:6480464 20230606 CTD MESH:C045950 propiconazole results in increased expression of ACP5 mRNA PMID:30047161 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:8502 6-propyl-2-thiouracil increases expression ISO RGD:2022 E RGD:6480464 20230606 CTD MESH:D011441 Propylthiouracil results in increased expression of ACP5 mRNA PMID:30047161 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:9053 sclareol decreases expression ISO RGD:10072 E RGD:6480464 20210706 CTD MESH:C070760 sclareol results in decreased expression of ACP5 mRNA; sclareol results in decreased expression of ACP5 protein PMID:33423118 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:9053 sclareol multiple interactions ISO RGD:10072 E RGD:6480464 20210706 CTD MESH:C070760 sclareol inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; sclareol inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] PMID:33423118 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:90695 anthra[1,9-cd]pyrazol-6(2H)-one multiple interactions ISO RGD:10072 E RGD:6480464 20190312 CTD MESH:C432165 crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]]; pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein] PMID:30580027 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:91108 SB 431542 multiple interactions EXP E RGD:6480464 20161220 CTD MESH:C459179 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP5 mRNA; [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP5 mRNA PMID:27188386 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:91108 SB 431542 multiple interactions ISO RGD:10072 E RGD:6480464 20180410 CTD MESH:C459179 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Sodium Fluoride results in increased expression of ACP5 mRNA]; [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Sodium Fluoride] affects the expression of ACP5 protein PMID:29127033 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:9144 silibinin multiple interactions ISO RGD:2022 E RGD:6480464 20230404 CTD MESH:C440975 Silybin inhibits the reaction [ferric ammonium citrate results in increased expression of ACP5 protein] PMID:36087815 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:91460 KN-93 multiple interactions ISO RGD:10072 E RGD:6480464 20200915 CTD MESH:C072105 KN 93 affects the reaction [[Cadmium co-treated with TNFSF11 protein co-treated with CSF1R protein] affects the expression of ACP5 protein] PMID:32522522 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:9195 Soman increases expression ISO RGD:2022 E RGD:6480464 20141111 CTD MESH:D012999 Soman results in increased expression of ACP5 mRNA PMID:19281266 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:9271 stevioside decreases secretion ISO RGD:2022 E RGD:6480464 20180703 CTD MESH:C012043 stevioside results in decreased secretion of ACP5 protein PMID:21089163 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:9288 streptozocin increases activity ISO RGD:10072 E RGD:6480464 20221206 CTD MESH:D013311 Streptozocin results in increased activity of ACP5 protein PMID:35315182 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:9288 streptozocin increases expression ISO RGD:10072 E RGD:6480464 20221206 CTD MESH:D013311 Streptozocin results in increased expression of ACP5 mRNA PMID:35315182 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:9288 streptozocin multiple interactions ISO RGD:10072 E RGD:6480464 20221206 CTD MESH:D013311 formononetin inhibits the reaction [Streptozocin results in increased activity of ACP5 protein]; formononetin inhibits the reaction [Streptozocin results in increased expression of ACP5 mRNA] PMID:35315182 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:9434 telmisartan decreases activity ISO RGD:2022 E RGD:329956421|PMID:33364953 20230720 RGD MESH:C084178 telmisartan decreases enzyme activity of Trap, Acp5 in serum of rats with periodontal disease 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:95129 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxybenzamide multiple interactions ISO RGD:10072 E RGD:6480464 20190910 CTD MESH:D020117 Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] PMID:31150804 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:9513 thalidomide multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D013792 [Thalidomide co-treated with Dexamethasone] results in decreased expression of ACP5 protein PMID:16079895 10073 ACP5 acid phosphatase 5, tartrate resistant gene CHEBI:9944 venlafaxine hydrochloride decreases expression EXP E RGD:6480464 20170303 CTD MESH:D000069470 Venlafaxine Hydrochloride results in decreased expression of ACP5 mRNA PMID:16341940 10216 ATP7A ATPase copper transporting alpha gene CHEBI:132082 entinostat decreases expression EXP E RGD:6480464 20161228 CTD MESH:C118739 entinostat results in decreased expression of ATP7A mRNA PMID:26272509 10216 ATP7A ATPase copper transporting alpha gene CHEBI:132082 entinostat multiple interactions EXP E RGD:6480464 20161228 CTD MESH:C118739 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP7A mRNA PMID:27188386 10216 ATP7A ATPase copper transporting alpha gene CHEBI:1391 3,4-methylenedioxymethamphetamine decreases expression ISO RGD:10215 E RGD:6480464 20160210 CTD MESH:D018817 N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of ATP7A mRNA PMID:20188158|PMID:26251327 10216 ATP7A ATPase copper transporting alpha gene CHEBI:15355 acetylcholine multiple interactions ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D000109 ATP7A mutant form inhibits the reaction [AGT protein results in increased susceptibility to Acetylcholine]; tempol inhibits the reaction [ATP7A mutant form inhibits the reaction [AGT protein results in increased susceptibility to Acetylcholine]] PMID:18768397 10216 ATP7A ATPase copper transporting alpha gene CHEBI:15367 all-trans-retinoic acid increases expression EXP E RGD:6480464 20120501 CTD MESH:D014212 Tretinoin results in increased expression of ATP7A mRNA PMID:16012519|PMID:21934132 10216 ATP7A ATPase copper transporting alpha gene CHEBI:15379 dioxygen affects localization ISO RGD:10215 E RGD:6480464 20120814 CTD MESH:D010100 Oxygen deficiency affects the localization of ATP7A protein PMID:19351718 10216 ATP7A ATPase copper transporting alpha gene CHEBI:15379 dioxygen increases expression EXP E RGD:6480464 20151013 CTD MESH:D010100 Oxygen deficiency results in increased expression of ATP7A mRNA PMID:24614111 10216 ATP7A ATPase copper transporting alpha gene CHEBI:15379 dioxygen increases expression ISO RGD:10215 E RGD:6480464 20120814 CTD MESH:D010100 Oxygen deficiency results in increased expression of ATP7A mRNA; Oxygen deficiency results in increased expression of ATP7A protein PMID:19351718|PMID:24614111 10216 ATP7A ATPase copper transporting alpha gene CHEBI:15379 dioxygen multiple interactions ISO RGD:10215 E RGD:6480464 20120814 CTD MESH:D010100 tetrathiomolybdate inhibits the reaction [Oxygen deficiency affects the localization of ATP7A protein] PMID:19351718 10216 ATP7A ATPase copper transporting alpha gene CHEBI:15422 ATP multiple interactions EXP E RGD:6480464 20120717 CTD MESH:D000255 [Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7A protein PMID:20964302 10216 ATP7A ATPase copper transporting alpha gene CHEBI:15743 butanal decreases expression EXP E RGD:6480464 20150825 CTD MESH:C018475 butyraldehyde results in decreased expression of ATP7A mRNA PMID:26079696 10216 ATP7A ATPase copper transporting alpha gene CHEBI:15756 hexadecanoic acid increases phosphorylation EXP E RGD:6480464 20190702 CTD MESH:D019308 Palmitic Acid results in increased phosphorylation of ATP7A protein PMID:28073184 10216 ATP7A ATPase copper transporting alpha gene CHEBI:15930 atrazine decreases expression EXP E RGD:6480464 20141014 CTD MESH:D001280 Atrazine results in decreased expression of ATP7A mRNA PMID:22378314 10216 ATP7A ATPase copper transporting alpha gene CHEBI:16240 hydrogen peroxide multiple interactions EXP E RGD:6480464 20120717 CTD MESH:D006861 ATP7A protein promotes the reaction [Paraquat results in increased chemical synthesis of Hydrogen Peroxide]; Hydrogen Peroxide promotes the reaction [CLU protein binds to ATP7A protein] PMID:21242307|PMID:29058724 10216 ATP7A ATPase copper transporting alpha gene CHEBI:16243 quercetin decreases expression EXP E RGD:6480464 20121009 CTD MESH:D011794 Quercetin results in decreased expression of ATP7A mRNA PMID:21632981 10216 ATP7A ATPase copper transporting alpha gene CHEBI:16412 lipopolysaccharide increases expression ISO RGD:10215 E RGD:6480464 20161228 CTD MESH:D008070 Lipopolysaccharides results in increased expression of ATP7A mRNA PMID:22369063 10216 ATP7A ATPase copper transporting alpha gene CHEBI:166473 Dibutyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C065087 di-n-butylphosphoric acid affects the expression of ATP7A mRNA PMID:37042841 10216 ATP7A ATPase copper transporting alpha gene CHEBI:178012 FR900359 affects phosphorylation EXP E RGD:6480464 20240305 CTD MESH:C000607068 FR900359 affects the phosphorylation of ATP7A protein PMID:37730182 10216 ATP7A ATPase copper transporting alpha gene CHEBI:180664 4-hydroxy-TEMPO multiple interactions ISO RGD:10215 E RGD:6480464 20211109 CTD MESH:C001803 tempol inhibits the reaction [ATP7A mutant form inhibits the reaction [AGT protein results in increased susceptibility to Acetylcholine]]; tempol inhibits the reaction [ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]] PMID:18768397 10216 ATP7A ATPase copper transporting alpha gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of ATP7A intron PMID:30157460 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18248 iron atom affects metabolic processing ISO RGD:10215 E RGD:6480464 20150512 CTD MESH:D007501 ATP7A protein mutant form affects the metabolism of Iron PMID:25247420 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18248 iron atom affects transport ISO RGD:2179 E RGD:6480464 20150609 CTD MESH:D007501 ATP7A mutant form affects the transport of Iron PMID:24174620 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18248 iron atom decreases oxidation ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:D007501 ATP7A gene mutant form results in decreased oxidation of Iron PMID:23776592 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18248 iron atom increases expression ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:D007501 Iron deficiency results in increased expression of ATP7A mRNA PMID:23776592|PMID:24089420 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18248 iron atom increases expression ISO RGD:2179 E RGD:6480464 20151013 CTD MESH:D007501 Iron deficiency results in increased expression of ATP7A; Iron deficiency results in increased expression of ATP7A mRNA; Iron deficiency results in increased expression of ATP7A protein PMID:16629162|PMID:21852364|PMID:23174565|PMID:23814049|PMID:24089420|PMID:24174620 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18248 iron atom increases response to substance ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:D007501 ATP7A gene mutant form results in increased susceptibility to Iron deficiency PMID:23776592 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18248 iron atom multiple interactions ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:D007501 [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Copper; [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Iron; ATP7A gene mutant form promotes the reaction [Iron deficiency results in increased expression of MT1 mRNA]; Iron deficiency inhibits the reaction [ATP7A gene mutant form results in decreased oxidation of Iron] PMID:23776592 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18248 iron atom multiple interactions ISO RGD:2179 E RGD:6480464 20150609 CTD MESH:D007501 [Iron deficiency results in increased expression of ATP7A] which results in increased abundance of Copper PMID:24174620 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18291 manganese atom affects localization ISO RGD:2179 E RGD:6480464 20140715 CTD MESH:D008345 Manganese affects the localization of ATP7A protein PMID:24614235 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18291 manganese atom decreases expression ISO RGD:2179 E RGD:6480464 20140715 CTD MESH:D008345 Manganese results in decreased expression of ATP7A mRNA; Manganese results in decreased expression of ATP7A protein PMID:24614235 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18320 1,4-dithiothreitol multiple interactions EXP E RGD:6480464 20151013 CTD MESH:D004229 Dithiothreitol inhibits the reaction [Ethylmaleimide results in increased glutathionylation of ATP7A protein] PMID:20566629 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18421 superoxide increases abundance ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D013481 ATP7A mutant form results in increased abundance of Superoxides PMID:18768397 10216 ATP7A ATPase copper transporting alpha gene CHEBI:18421 superoxide multiple interactions ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D013481 [ATP7A protein results in increased activity of SOD3 protein] which results in decreased chemical synthesis of Superoxides; ATP7A gene mutant form promotes the reaction [Streptozocin results in increased chemical synthesis of Superoxides]; ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]; ATP7A protein inhibits the reaction [Streptozocin results in increased chemical synthesis of Superoxides]; tempol inhibits the reaction [ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]] PMID:18768397|PMID:23884884 10216 ATP7A ATPase copper transporting alpha gene CHEBI:22977 cadmium atom decreases expression EXP E RGD:6480464 20140513 CTD MESH:D002104 Cadmium results in decreased expression of ATP7A mRNA PMID:24376830 10216 ATP7A ATPase copper transporting alpha gene CHEBI:22977 cadmium atom increases expression ISO RGD:2179 E RGD:6480464 20210406 CTD MESH:D002104 Cadmium results in increased expression of ATP7A mRNA; Cadmium results in increased expression of ATP7A protein PMID:32879253 10216 ATP7A ATPase copper transporting alpha gene CHEBI:232612 Azoxymethane multiple interactions ISO RGD:10215 E RGD:6480464 20241203 CTD MESH:D001397 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA PMID:29950665 10216 ATP7A ATPase copper transporting alpha gene CHEBI:23414 copper(II) sulfate increases expression EXP E RGD:6480464 20151110 CTD MESH:D019327 Copper Sulfate results in increased expression of ATP7A protein PMID:24815816 10216 ATP7A ATPase copper transporting alpha gene CHEBI:23994 ethyl methanesulfonate increases expression EXP E RGD:6480464 20140708 CTD MESH:D005020 Ethyl Methanesulfonate results in increased expression of ATP7A mRNA PMID:23649840 10216 ATP7A ATPase copper transporting alpha gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20161025 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of ATP7A gene PMID:27153756 10216 ATP7A ATPase copper transporting alpha gene CHEBI:25179 melanins multiple interactions EXP E RGD:6480464 20170303 CTD MESH:D008543 [TYR protein co-treated with ATP7A protein] results in increased abundance of Melanins PMID:11092760 10216 ATP7A ATPase copper transporting alpha gene CHEBI:25255 methyl methanesulfonate increases expression EXP E RGD:6480464 20140408 CTD MESH:D008741 Methyl Methanesulfonate results in increased expression of ATP7A mRNA PMID:23649840 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27385 tetrachloromethane increases expression ISO RGD:10215 E RGD:6480464 20160822 CTD MESH:D002251 Carbon Tetrachloride results in increased expression of ATP7A mRNA PMID:27339419 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27470 folic acid multiple interactions ISO RGD:10215 E RGD:6480464 20200804 CTD MESH:D005492 [1,2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of ATP7A mRNA PMID:22206623 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27617 monensin A multiple interactions EXP E RGD:6480464 20120814 CTD MESH:D008985 Monensin inhibits the reaction [ATP7A protein affects the localization of Doxorubicin] PMID:17510416 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27641 cycloheximide decreases expression ISO RGD:2179 E RGD:6480464 20151013 CTD MESH:D003513 Cycloheximide results in decreased expression of ATP7A protein PMID:23174565 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27641 cycloheximide multiple interactions ISO RGD:2179 E RGD:6480464 20151013 CTD MESH:D003513 cupric chloride inhibits the reaction [Cycloheximide results in decreased expression of ATP7A protein] PMID:23174565 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27856 acetamide increases expression ISO RGD:2179 E RGD:6480464 20200519 CTD MESH:C030686 acetamide results in increased expression of ATP7A mRNA PMID:31881176 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27881 resveratrol multiple interactions EXP E RGD:6480464 20220510 CTD MESH:C059514 [Plant Extracts co-treated with Resveratrol] results in increased expression of ATP7A mRNA PMID:23557933 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27899 cisplatin affects localization EXP E RGD:6480464 20150512 CTD MESH:D002945 Cisplatin affects the localization of ATP7A protein PMID:24150977 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27899 cisplatin affects response to substance EXP E RGD:6480464 20140311 CTD MESH:D002945 ATP7A protein affects the susceptibility to Cisplatin PMID:17609664 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27899 cisplatin decreases expression EXP E RGD:6480464 20240806 CTD MESH:D002945 Cisplatin results in decreased expression of ATP7A mRNA PMID:38462020 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27899 cisplatin decreases expression ISO RGD:10215 E RGD:6480464 20240806 CTD MESH:D002945 Cisplatin results in decreased expression of ATP7A PMID:38462020 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27899 cisplatin decreases response to substance EXP E RGD:6480464 20151013 CTD MESH:D002945 ATP7A protein results in decreased susceptibility to Cisplatin PMID:17510416|PMID:25801007 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27899 cisplatin decreases response to substance ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D002945 ATP7A protein results in decreased susceptibility to Cisplatin PMID:16170571 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27899 cisplatin increases expression ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D002945 Cisplatin results in increased expression of ATP7A mRNA PMID:21151649 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27899 cisplatin increases response to substance EXP E RGD:6480464 20151013 CTD MESH:D002945 ATP7A mutant form results in increased susceptibility to Cisplatin PMID:22304828 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27899 cisplatin multiple interactions EXP E RGD:6480464 20150512 CTD MESH:D002945 [ATOX1 protein binds to Cisplatin] promotes the reaction [ATP7A protein binds to and results in increased metabolism of Cisplatin]; [MIR495 mRNA results in decreased expression of ATP7A protein] which results in increased susceptibility to Cisplatin; ATP7A protein inhibits the reaction [MIR495 mRNA results in increased uptake of and results in increased susceptibility to Cisplatin]; ATP7A protein promotes the reaction [ANXA4 protein results in decreased susceptibility to Cisplatin] PMID:23751120|PMID:24038379|PMID:24150977 10216 ATP7A ATPase copper transporting alpha gene CHEBI:27998 tungsten increases expression ISO RGD:10215 E RGD:6480464 20190910 CTD MESH:D014414 Tungsten results in increased expression of ATP7A mRNA PMID:30912803 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:10215 E RGD:6480464 20121009 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of ATP7A mRNA PMID:21570461 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:10215 E RGD:6480464 20120501 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of ATP7A mRNA PMID:19770486|PMID:33956508 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:2179 E RGD:6480464 20200609 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of ATP7A mRNA PMID:32109520 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D013749 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ATP7A mRNA PMID:17942748 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28216 methylmercury chloride decreases expression EXP E RGD:6480464 20170516 CTD MESH:C004925 methylmercuric chloride results in decreased expression of ATP7A mRNA PMID:28001369 10216 ATP7A ATPase copper transporting alpha gene CHEBI:2825 aristolochic acid A decreases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in decreased expression of ATP7A mRNA PMID:33212167 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28358 rac-lactic acid decreases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in decreased expression of ATP7A mRNA PMID:30851411 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28445 vincristine decreases response to substance EXP E RGD:6480464 20161213 CTD MESH:D014750 ATP7A protein results in decreased susceptibility to Vincristine PMID:17510416 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom affects binding EXP E RGD:6480464 20120412 CTD MESH:D003300 ATP7A protein binds to Copper; Copper binds to ATP7A protein PMID:16873374|PMID:22577880 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom affects export ISO RGD:10215 E RGD:6480464 20121113 CTD MESH:D003300 ATP7A protein affects the export of Copper PMID:21409224 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom affects localization EXP E RGD:6480464 20150512 CTD MESH:D003300 Copper affects the localization of ATP7A protein PMID:20964302|PMID:23423674 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom affects localization ISO RGD:10215 E RGD:6480464 20120814 CTD MESH:D003300 ATP7A gene mutant form affects the localization of Copper; Copper affects the localization of ATP7A protein PMID:17483305|PMID:20671235|PMID:22089129|PMID:25337692 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom affects localization ISO RGD:2179 E RGD:6480464 20140715 CTD MESH:D003300 Copper affects the localization of ATP7A protein PMID:20671235|PMID:24614235 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom affects metabolic processing EXP E RGD:6480464 20120412 CTD MESH:D003300 ATP7A protein affects the metabolism of Copper PMID:16890543 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom affects transport EXP E RGD:6480464 20120412 CTD MESH:D003300 ATP7A protein affects the transport of Copper PMID:17109627 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom decreases abundance EXP E RGD:6480464 20120814 CTD MESH:D003300 ATP7A gene mutant form results in decreased abundance of Copper; ATP7A protein mutant form results in decreased abundance of Copper; ATP7A protein results in decreased abundance of Copper PMID:11350187|PMID:14985339|PMID:15923132|PMID:24522273 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom decreases abundance ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:D003300 ATP7A gene mutant form results in decreased abundance of Copper; ATP7A protein mutant form results in decreased abundance of Copper; ATP7A protein results in decreased abundance of Copper PMID:21336677|PMID:23776592|PMID:25247420 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom decreases export ISO RGD:2179 E RGD:6480464 20140610 CTD MESH:D003300 ATP7A mutant form results in decreased export of Copper PMID:24316150 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom increases abundance EXP E RGD:6480464 20120814 CTD MESH:D003300 ATP7A gene mutant form results in increased abundance of Copper PMID:15923132 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom increases abundance ISO RGD:10215 E RGD:6480464 20120814 CTD MESH:D003300 ATP7A gene mutant form results in increased abundance of Copper PMID:15467011 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom increases export EXP E RGD:6480464 20120918 CTD MESH:D003300 ATP7A protein results in increased export of Copper PMID:16397091|PMID:17975309|PMID:18779306 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom increases expression ISO RGD:2179 E RGD:6480464 20120412 CTD MESH:D003300 Copper results in increased expression of ATP7A mRNA PMID:15591161 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom increases secretion ISO RGD:2179 E RGD:6480464 20120412 CTD MESH:D003300 ATP7A protein results in increased secretion of Copper PMID:16741141 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom increases transport EXP E RGD:6480464 20120717 CTD MESH:D003300 ATP7A protein results in increased transport of Copper PMID:21667063 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom increases transport ISO RGD:2179 E RGD:6480464 20140715 CTD MESH:D003300 ATP7A protein results in increased transport of Copper PMID:24614235 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D003300 [ATP7A protein affects the oxidation of SCO1 protein] which affects the abundance of Copper; [COMMD1 protein results in increased activity of ATP7A protein mutant form] which results in increased transport of Copper; [Copper binds to ATP7A protein] which results in decreased oxidation of Copper; [Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7A protein; [NSC 689534 binds to Copper] which results in increased expression of ATP7A mRNA; [Tetradecanoylphorbol Acetate results in increased expression of ATP7A protein] which results in increased export of Copper; AP1S1 gene mutant form inhibits the reaction [Copper affects the localization of ATP7A protein]; ARF1 mutant form inhibits the reaction [ATP7A gene mutant form results in decreased export of and results in increased abundance of Copper]; ATP7A gene mutant form affects the reaction [STX5 mutant form results in decreased uptake of Copper]; ATP7A gene mutant form results in decreased export of and results in increased abundance of Copper; ATP7A protein results in decreased susceptibility to [cupric chloride results in increased abundance of Copper]; ATP7A protein results in decreased uptake of [cupric chloride results in increased abundance of Copper]; Copper binds to and affects the folding of ATP7A protein; Copper results in increased phosphorylation of and affects the localization of ATP7A protein; Copper results in increased phosphorylation of and results in increased activity of ATP7A protein; Estrogens promotes the reaction [ATP7A protein affects the transport of Copper] PMID:10841766|PMID:17009961|PMID:17109627|PMID:19205902|PMID:19576997|PMID:20964302|PMID:20971185|PMID:21034850|PMID:21188142|PMID:21646353|PMID:21667063|PMID:23345593|PMID:23423674|PMID:32278528 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom multiple interactions ISO RGD:10215 E RGD:6480464 20120814 CTD MESH:D003300 [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Copper; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ACTR2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ADRA1B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of AFMID mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of APCS mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of APRT mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ARL10 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of BNIP3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of BZW2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CCND1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CCNG1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CCT2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CCT5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CD9 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CDK1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CHRNB1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CKS1B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CLCA2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CLDN3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CLDN6 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CST6 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CYP2B9 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of DDX49 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of DHCR24 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of DUSP18 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of DUSP6 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of EEF1B2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of EIF1AX mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of EIF6 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of FABP5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of FXYD5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of GART mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of GDF15 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of GLUL mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of GTF2H4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of HILPDA mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of HMGA1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of HMGCS1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of HSPA9 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ID2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of IDH3B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of IDI1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of IFITM3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of IL33 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ISYNA1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ITSN1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of KIF5B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of KRT13 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of KRT19 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of KRT4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of KRT7 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of L1CAM mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of LY6A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of LY6C2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of MAL mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of MAST2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of MGST3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of MIA2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of MYBBP1A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of NOLC1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of NOP14 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of NT5DC2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PA2G4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PAK2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PAQR7 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PBK mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PEA15A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PES1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PEX3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PGLYRP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PHF24 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PIP5K1B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PLAA mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PRKAG1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PRKG2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PSMB3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of RNF126 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of RRAD mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SCGB3A2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SFN mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SLC38A1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SMC2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SPAST mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SPRR1A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of TK1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of TMCO1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of TPRKB mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of TUBA4A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of VAC14 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of VEGFC mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of WDR75 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of WFDC2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of YBX3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ZDHHC13 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ZFP518B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ABCC5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ABI1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ACTA2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ADD3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ADGRE5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ADGRL2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of AIF1L mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ALDH1A1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ALKBH5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ANKRD44 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ANXA6 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of APLP2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of APP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of AQP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ARID1B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ARL4C mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ARRDC3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ARXES1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ATL2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ATP11A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ATP1B1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ATP6V0D1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of B2M mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of BMP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of BST1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CALD1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CARTPT mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CBX5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CCDC80 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CCN4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CDC42 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CDH11 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CDH13 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CDH2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CDON mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CKAP4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CLEC4A1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CLIC4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CLU mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of COL4A1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of COLGALT1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CPD mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CPE mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CPT1A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CRTAP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CSRP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CST3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CTSA mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CTSL mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CXADR mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CYB5R4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of DAG1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of DDAH1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of DHRS3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of DKK3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of DUSP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of DUSP16 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of EGR1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ENAH mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ENPP5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of EXTL3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FADS3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FAM98A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FARP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FHL1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FNDC3B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FOLR1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FSCN1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FSTL1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FYN mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GABARAPL1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GAS1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GNAI2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GRB10 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GRCC10 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GSTM1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GSTM2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GSTM7 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of H6PD mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of HEXA mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of HEY1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of HS6ST2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of HSPG2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of IFI27L1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of IL12B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of IL1R1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of INA mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ITGB5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of JAK1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of LAMC1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of LAMP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of LARGE1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of LOX mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of LOXL1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of LPP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MACF1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MAP1LC3B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MAP4K3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MBD1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MFGE8 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MFSD1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MKRN2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MORF4L1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MSTO1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MT1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MYL12A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MYL12B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of NEDD4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of NFAT5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of NREP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of NRP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of NRXN2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of OAT mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of OSBPL9 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PALLD mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PARM1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PCOLCE mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PDIA4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PFKP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PFN2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PICALM mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PKD2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PLSCR2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of POSTN mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PRNP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of RASL11A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of RASL11B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of RBPMS mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of RETREG1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of RMND5A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SDC2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SELENOP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SENP6 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SEPTIN4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SERINC3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SERPINH1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SHC1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SLC25A13 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SLC25A36 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SPARC mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SPART mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SPG21 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SPP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SSH1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ST3GAL2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of STX12 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TAGLN3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TCEAL8 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TGFBR2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of THBS1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of THBS2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TIMP2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TIMP3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TMEM176B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TMEM18 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TMEM30A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TMEM33 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TMT1A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TNC mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TNS1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TNS2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TPM4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TPP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TRP53INP2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TSC22D1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TSHZ1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TSPAN3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TSPAN5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TTC3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TXLNG mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of UBE2D2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of UBE2J1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of VCL mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of VIM mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of VWA5A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of WWTR1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of XPC mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of YBX1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ZBED3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ZFP91 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ZMYND8 mRNA; ATP7A protein binds to and results in increased transport of Copper; ATP7A protein mutant form inhibits the reaction [Copper affects the localization of ATP7A protein]; ATP7A protein mutant form results in decreased export of and results in increased abundance of Copper; ATP7A protein promotes the reaction [Copper binds to CP protein]; Copper binds to and affects the localization of ATP7A protein; Omeprazole inhibits the reaction [Copper affects the localization of ATP7A protein] PMID:15467011|PMID:19351718|PMID:22089129|PMID:23776592|PMID:25337692 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28694 copper atom multiple interactions ISO RGD:2179 E RGD:6480464 20120412 CTD MESH:D003300 [Iron deficiency results in increased expression of ATP7A] which results in increased abundance of Copper; PRL protein promotes the reaction [ATP7A protein results in increased secretion of Copper] PMID:16741141|PMID:24174620 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28748 doxorubicin affects localization EXP E RGD:6480464 20120814 CTD MESH:D004317 ATP7A protein affects the localization of Doxorubicin PMID:17510416 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28748 doxorubicin decreases response to substance EXP E RGD:6480464 20120814 CTD MESH:D004317 ATP7A protein results in decreased susceptibility to Doxorubicin PMID:17510416 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28748 doxorubicin increases export EXP E RGD:6480464 20120814 CTD MESH:D004317 ATP7A protein results in increased export of Doxorubicin PMID:17510416 10216 ATP7A ATPase copper transporting alpha gene CHEBI:28748 doxorubicin multiple interactions EXP E RGD:6480464 20120814 CTD MESH:D004317 Brefeldin A inhibits the reaction [ATP7A protein affects the localization of Doxorubicin]; Monensin inhibits the reaction [ATP7A protein affects the localization of Doxorubicin] PMID:17510416 10216 ATP7A ATPase copper transporting alpha gene CHEBI:29678 sodium arsenite decreases expression ISO RGD:10215 E RGD:6480464 20240206 CTD MESH:C017947 sodium arsenite results in decreased expression of ATP7A mRNA PMID:37682722 10216 ATP7A ATPase copper transporting alpha gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of ATP7A mRNA PMID:38568856 10216 ATP7A ATPase copper transporting alpha gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of ATP7A promoter PMID:27901495 10216 ATP7A ATPase copper transporting alpha gene CHEBI:29865 benzo[a]pyrene increases expression ISO RGD:10215 E RGD:6480464 20120918 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of ATP7A mRNA PMID:20504355|PMID:22228805 10216 ATP7A ATPase copper transporting alpha gene CHEBI:29865 benzo[a]pyrene increases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in increased methylation of ATP7A exon PMID:27901495 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) affects binding EXP E RGD:6480464 20120412 CTD MESH:D003300 ATP7A protein binds to Copper; Copper binds to ATP7A protein PMID:16873374|PMID:22577880 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) affects export ISO RGD:10215 E RGD:6480464 20121113 CTD MESH:D003300 ATP7A protein affects the export of Copper PMID:21409224 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) affects localization EXP E RGD:6480464 20150512 CTD MESH:D003300 Copper affects the localization of ATP7A protein PMID:20964302|PMID:23423674 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) affects localization ISO RGD:10215 E RGD:6480464 20120814 CTD MESH:D003300 ATP7A gene mutant form affects the localization of Copper; Copper affects the localization of ATP7A protein PMID:17483305|PMID:20671235|PMID:22089129|PMID:25337692 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) affects localization ISO RGD:2179 E RGD:6480464 20140715 CTD MESH:D003300 Copper affects the localization of ATP7A protein PMID:20671235|PMID:24614235 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) affects metabolic processing EXP E RGD:6480464 20120412 CTD MESH:D003300 ATP7A protein affects the metabolism of Copper PMID:16890543 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) affects transport EXP E RGD:6480464 20120412 CTD MESH:D003300 ATP7A protein affects the transport of Copper PMID:17109627 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) decreases abundance EXP E RGD:6480464 20120814 CTD MESH:D003300 ATP7A gene mutant form results in decreased abundance of Copper; ATP7A protein mutant form results in decreased abundance of Copper; ATP7A protein results in decreased abundance of Copper PMID:11350187|PMID:14985339|PMID:15923132|PMID:24522273 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) decreases abundance ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:D003300 ATP7A gene mutant form results in decreased abundance of Copper; ATP7A protein mutant form results in decreased abundance of Copper; ATP7A protein results in decreased abundance of Copper PMID:21336677|PMID:23776592|PMID:25247420 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) decreases export ISO RGD:2179 E RGD:6480464 20140610 CTD MESH:D003300 ATP7A mutant form results in decreased export of Copper PMID:24316150 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) increases abundance EXP E RGD:6480464 20120814 CTD MESH:D003300 ATP7A gene mutant form results in increased abundance of Copper PMID:15923132 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) increases abundance ISO RGD:10215 E RGD:6480464 20120814 CTD MESH:D003300 ATP7A gene mutant form results in increased abundance of Copper PMID:15467011 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) increases export EXP E RGD:6480464 20120918 CTD MESH:D003300 ATP7A protein results in increased export of Copper PMID:16397091|PMID:17975309|PMID:18779306 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) increases expression ISO RGD:2179 E RGD:6480464 20120412 CTD MESH:D003300 Copper results in increased expression of ATP7A mRNA PMID:15591161 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) increases secretion ISO RGD:2179 E RGD:6480464 20120412 CTD MESH:D003300 ATP7A protein results in increased secretion of Copper PMID:16741141 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) increases transport EXP E RGD:6480464 20120717 CTD MESH:D003300 ATP7A protein results in increased transport of Copper PMID:21667063 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) increases transport ISO RGD:2179 E RGD:6480464 20140715 CTD MESH:D003300 ATP7A protein results in increased transport of Copper PMID:24614235 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D003300 [ATP7A protein affects the oxidation of SCO1 protein] which affects the abundance of Copper; [COMMD1 protein results in increased activity of ATP7A protein mutant form] which results in increased transport of Copper; [Copper binds to ATP7A protein] which results in decreased oxidation of Copper; [Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7A protein; [NSC 689534 binds to Copper] which results in increased expression of ATP7A mRNA; [Tetradecanoylphorbol Acetate results in increased expression of ATP7A protein] which results in increased export of Copper; AP1S1 gene mutant form inhibits the reaction [Copper affects the localization of ATP7A protein]; ARF1 mutant form inhibits the reaction [ATP7A gene mutant form results in decreased export of and results in increased abundance of Copper]; ATP7A gene mutant form affects the reaction [STX5 mutant form results in decreased uptake of Copper]; ATP7A gene mutant form results in decreased export of and results in increased abundance of Copper; ATP7A protein results in decreased susceptibility to [cupric chloride results in increased abundance of Copper]; ATP7A protein results in decreased uptake of [cupric chloride results in increased abundance of Copper]; Copper binds to and affects the folding of ATP7A protein; Copper results in increased phosphorylation of and affects the localization of ATP7A protein; Copper results in increased phosphorylation of and results in increased activity of ATP7A protein; Estrogens promotes the reaction [ATP7A protein affects the transport of Copper] PMID:10841766|PMID:17009961|PMID:17109627|PMID:19205902|PMID:19576997|PMID:20964302|PMID:20971185|PMID:21034850|PMID:21188142|PMID:21646353|PMID:21667063|PMID:23345593|PMID:23423674|PMID:32278528 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) multiple interactions ISO RGD:10215 E RGD:6480464 20120814 CTD MESH:D003300 [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Copper; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ACTR2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ADRA1B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of AFMID mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of APCS mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of APRT mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ARL10 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of BNIP3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of BZW2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CCND1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CCNG1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CCT2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CCT5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CD9 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CDK1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CHRNB1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CKS1B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CLCA2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CLDN3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CLDN6 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CST6 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of CYP2B9 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of DDX49 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of DHCR24 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of DUSP18 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of DUSP6 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of EEF1B2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of EIF1AX mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of EIF6 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of FABP5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of FXYD5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of GART mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of GDF15 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of GLUL mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of GTF2H4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of HILPDA mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of HMGA1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of HMGCS1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of HSPA9 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ID2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of IDH3B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of IDI1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of IFITM3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of IL33 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ISYNA1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ITSN1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of KIF5B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of KRT13 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of KRT19 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of KRT4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of KRT7 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of L1CAM mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of LY6A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of LY6C2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of MAL mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of MAST2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of MGST3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of MIA2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of MYBBP1A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of NOLC1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of NOP14 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of NT5DC2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PA2G4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PAK2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PAQR7 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PBK mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PEA15A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PES1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PEX3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PGLYRP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PHF24 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PIP5K1B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PLAA mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PRKAG1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PRKG2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of PSMB3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of RNF126 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of RRAD mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SCGB3A2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SFN mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SLC38A1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SMC2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SPAST mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SPRR1A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of TK1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of TMCO1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of TPRKB mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of TUBA4A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of VAC14 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of VEGFC mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of WDR75 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of WFDC2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of YBX3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ZDHHC13 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of ZFP518B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ABCC5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ABI1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ACTA2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ADD3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ADGRE5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ADGRL2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of AIF1L mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ALDH1A1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ALKBH5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ANKRD44 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ANXA6 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of APLP2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of APP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of AQP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ARID1B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ARL4C mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ARRDC3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ARXES1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ATL2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ATP11A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ATP1B1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ATP6V0D1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of B2M mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of BMP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of BST1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CALD1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CARTPT mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CBX5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CCDC80 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CCN4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CDC42 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CDH11 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CDH13 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CDH2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CDON mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CKAP4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CLEC4A1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CLIC4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CLU mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of COL4A1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of COLGALT1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CPD mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CPE mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CPT1A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CRTAP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CSRP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CST3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CTSA mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CTSL mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CXADR mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of CYB5R4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of DAG1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of DDAH1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of DHRS3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of DKK3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of DUSP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of DUSP16 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of EGR1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ENAH mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ENPP5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of EXTL3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FADS3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FAM98A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FARP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FHL1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FNDC3B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FOLR1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FSCN1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FSTL1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FYN mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GABARAPL1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GAS1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GNAI2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GRB10 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GRCC10 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GSTM1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GSTM2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GSTM7 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of H6PD mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of HEXA mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of HEY1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of HS6ST2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of HSPG2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of IFI27L1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of IL12B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of IL1R1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of INA mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ITGB5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of JAK1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of LAMC1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of LAMP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of LARGE1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of LOX mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of LOXL1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of LPP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MACF1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MAP1LC3B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MAP4K3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MBD1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MFGE8 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MFSD1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MKRN2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MORF4L1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MSTO1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MT1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MYL12A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MYL12B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of NEDD4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of NFAT5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of NREP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of NRP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of NRXN2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of OAT mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of OSBPL9 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PALLD mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PARM1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PCOLCE mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PDIA4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PFKP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PFN2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PICALM mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PKD2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PLSCR2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of POSTN mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of PRNP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of RASL11A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of RASL11B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of RBPMS mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of RETREG1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of RMND5A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SDC2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SELENOP mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SENP6 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SEPTIN4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SERINC3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SERPINH1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SHC1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SLC25A13 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SLC25A36 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SPARC mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SPART mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SPG21 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SPP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SSH1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ST3GAL2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of STX12 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TAGLN3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TCEAL8 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TGFBR2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of THBS1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of THBS2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TIMP2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TIMP3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TMEM176B mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TMEM18 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TMEM30A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TMEM33 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TMT1A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TNC mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TNS1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TNS2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TPM4 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TPP1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TRP53INP2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TSC22D1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TSHZ1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TSPAN3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TSPAN5 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TTC3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of TXLNG mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of UBE2D2 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of UBE2J1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of VCL mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of VIM mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of VWA5A mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of WWTR1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of XPC mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of YBX1 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ZBED3 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ZFP91 mRNA; [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ZMYND8 mRNA; ATP7A protein binds to and results in increased transport of Copper; ATP7A protein mutant form inhibits the reaction [Copper affects the localization of ATP7A protein]; ATP7A protein mutant form results in decreased export of and results in increased abundance of Copper; ATP7A protein promotes the reaction [Copper binds to CP protein]; Copper binds to and affects the localization of ATP7A protein; Omeprazole inhibits the reaction [Copper affects the localization of ATP7A protein] PMID:15467011|PMID:19351718|PMID:22089129|PMID:23776592|PMID:25337692 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30052 copper(0) multiple interactions ISO RGD:2179 E RGD:6480464 20120412 CTD MESH:D003300 [Iron deficiency results in increased expression of ATP7A] which results in increased abundance of Copper; PRL protein promotes the reaction [ATP7A protein results in increased secretion of Copper] PMID:16741141|PMID:24174620 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30341 silver monochloride affects localization ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:C037548 silver chloride affects the localization of ATP7A protein PMID:16317117 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30512 silver atom affects binding EXP E RGD:6480464 20120717 CTD MESH:D012834 Silver binds to ATP7A protein PMID:10841766|PMID:21646353 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30512 silver atom affects localization ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D012834 Silver affects the localization of ATP7A protein PMID:16317117 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30512 silver atom decreases expression ISO RGD:10215 E RGD:6480464 20161115 CTD MESH:D012834 Silver results in decreased expression of ATP7A mRNA PMID:27131904 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30563 silicon dioxide decreases expression EXP E RGD:6480464 20160315 CTD MESH:D012822 Silicon Dioxide analog results in decreased expression of ATP7A mRNA PMID:25895662 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30563 silicon dioxide increases expression ISO RGD:10215 E RGD:6480464 20241105 CTD MESH:D012822 Silicon Dioxide results in increased expression of ATP7A mRNA PMID:38403151 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30621 diarsenic trioxide decreases expression ISO RGD:10215 E RGD:6480464 20240402 CTD MESH:C006632 Arsenic Trioxide results in decreased expression of ATP7A mRNA PMID:35676786 10216 ATP7A ATPase copper transporting alpha gene CHEBI:30703 tetrathiomolybdate(2-) multiple interactions ISO RGD:10215 E RGD:6480464 20120814 CTD MESH:C020809 tetrathiomolybdate inhibits the reaction [Oxygen deficiency affects the localization of ATP7A protein] PMID:19351718 10216 ATP7A ATPase copper transporting alpha gene CHEBI:31206 ammonium chloride affects expression ISO RGD:2179 E RGD:6480464 20120412 CTD MESH:D000643 Ammonium Chloride affects the expression of ATP7A mRNA PMID:16483693 10216 ATP7A ATPase copper transporting alpha gene CHEBI:31355 carboplatin affects localization EXP E RGD:6480464 20150512 CTD MESH:D016190 Carboplatin affects the localization of ATP7A protein PMID:24150977 10216 ATP7A ATPase copper transporting alpha gene CHEBI:31355 carboplatin multiple interactions EXP E RGD:6480464 20150512 CTD MESH:D016190 [MIR495 mRNA results in decreased expression of ATP7A protein] which results in increased susceptibility to Carboplatin; ATP7A protein promotes the reaction [ANXA4 protein results in decreased susceptibility to Carboplatin] PMID:24038379|PMID:24150977 10216 ATP7A ATPase copper transporting alpha gene CHEBI:31767 lead diacetate decreases expression ISO RGD:2179 E RGD:6480464 20140610 CTD MESH:C008261 lead acetate results in decreased expression of ATP7A mRNA; lead acetate results in decreased expression of ATP7A protein PMID:24316150 10216 ATP7A ATPase copper transporting alpha gene CHEBI:31767 lead diacetate increases expression ISO RGD:2179 E RGD:6480464 20151013 CTD MESH:C008261 lead acetate results in increased expression of ATP7A mRNA PMID:25579025 10216 ATP7A ATPase copper transporting alpha gene CHEBI:31767 lead diacetate multiple interactions ISO RGD:2179 E RGD:6480464 20120814 CTD MESH:C008261 ATP7A protein modified form inhibits the reaction [lead acetate binds to HSPA5 protein] PMID:10702365 10216 ATP7A ATPase copper transporting alpha gene CHEBI:31856 mithramycin decreases expression ISO RGD:2179 E RGD:6480464 20150512 CTD MESH:D008926 Plicamycin results in decreased expression of ATP7A mRNA PMID:23814049 10216 ATP7A ATPase copper transporting alpha gene CHEBI:31856 mithramycin multiple interactions ISO RGD:2179 E RGD:6480464 20150512 CTD MESH:D008926 Plicamycin inhibits the reaction [cobaltous chloride results in increased expression of ATP7A mRNA] PMID:23814049 10216 ATP7A ATPase copper transporting alpha gene CHEBI:31941 oxaliplatin affects response to substance EXP E RGD:6480464 20161213 CTD MESH:C030110 ATP7A protein affects the susceptibility to oxaliplatin PMID:16773204|PMID:17609664 10216 ATP7A ATPase copper transporting alpha gene CHEBI:31941 oxaliplatin decreases response to substance EXP E RGD:6480464 20161213 CTD MESH:C030110 ATP7A protein results in decreased susceptibility to oxaliplatin PMID:25801007 10216 ATP7A ATPase copper transporting alpha gene CHEBI:31941 oxaliplatin increases expression EXP E RGD:6480464 20161213 CTD MESH:C030110 oxaliplatin results in increased expression of ATP7A mRNA PMID:16773204 10216 ATP7A ATPase copper transporting alpha gene CHEBI:31941 oxaliplatin multiple interactions EXP E RGD:6480464 20161213 CTD MESH:C030110 [MIR495 mRNA results in decreased expression of ATP7A protein] which results in increased susceptibility to oxaliplatin PMID:24038379 10216 ATP7A ATPase copper transporting alpha gene CHEBI:32234 titanium dioxide decreases expression ISO RGD:10215 E RGD:6480464 20191112 CTD MESH:C009495 titanium dioxide results in decreased expression of ATP7A mRNA PMID:29264374 10216 ATP7A ATPase copper transporting alpha gene CHEBI:32234 titanium dioxide multiple interactions ISO RGD:10215 E RGD:6480464 20190702 CTD MESH:C009495 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA PMID:29950665 10216 ATP7A ATPase copper transporting alpha gene CHEBI:32497 thioacetamide increases expression ISO RGD:2179 E RGD:6480464 20140408 CTD MESH:D013853 Thioacetamide results in increased expression of ATP7A mRNA PMID:23411599 10216 ATP7A ATPase copper transporting alpha gene CHEBI:32509 pirinixic acid decreases expression ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:C006253 pirinixic acid results in decreased expression of ATP7A mRNA PMID:20813756 10216 ATP7A ATPase copper transporting alpha gene CHEBI:32509 pirinixic acid multiple interactions ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:C006253 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of ATP7A mRNA PMID:19710929 10216 ATP7A ATPase copper transporting alpha gene CHEBI:33007 chromium(6+) decreases expression EXP E RGD:6480464 20190507 CTD MESH:C074702 chromium hexavalent ion results in decreased expression of ATP7A mRNA PMID:30690063 10216 ATP7A ATPase copper transporting alpha gene CHEBI:33216 bisphenol A affects expression ISO RGD:2179 E RGD:6480464 20150310 CTD MESH:C006780 bisphenol A affects the expression of ATP7A mRNA PMID:25181051 10216 ATP7A ATPase copper transporting alpha gene CHEBI:33216 bisphenol A decreases expression ISO RGD:10215 E RGD:6480464 20180116 CTD MESH:C006780 bisphenol A results in decreased expression of ATP7A mRNA; bisphenol A results in decreased expression of ATP7A protein PMID:27690074 10216 ATP7A ATPase copper transporting alpha gene CHEBI:33216 bisphenol A increases expression EXP E RGD:6480464 20180515 CTD MESH:C006780 bisphenol A results in increased expression of ATP7A mRNA PMID:29275510 10216 ATP7A ATPase copper transporting alpha gene CHEBI:33216 bisphenol A increases expression ISO RGD:2179 E RGD:6480464 20191210 CTD MESH:C006780 bisphenol A results in increased expression of ATP7A mRNA PMID:30816183|PMID:34947998 10216 ATP7A ATPase copper transporting alpha gene CHEBI:33364 platinum increases uptake ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D010984 ATP7A protein results in increased uptake of Platinum PMID:16170571 10216 ATP7A ATPase copper transporting alpha gene CHEBI:33400 platinum(0) increases uptake ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D010984 ATP7A protein results in increased uptake of Platinum PMID:16170571 10216 ATP7A ATPase copper transporting alpha gene CHEBI:34031 1,1-dichloroethene increases expression ISO RGD:10215 E RGD:6480464 20170725 CTD MESH:C029297 vinylidene chloride results in increased expression of ATP7A mRNA PMID:26682919 10216 ATP7A ATPase copper transporting alpha gene CHEBI:34372 4,4'-sulfonyldiphenol decreases methylation ISO RGD:10215 E RGD:6480464 20220208 CTD MESH:C543008 bisphenol S results in decreased methylation of ATP7A exon PMID:33297965 10216 ATP7A ATPase copper transporting alpha gene CHEBI:34567 benzo[e]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene affects the methylation of ATP7A intron PMID:30157460 10216 ATP7A ATPase copper transporting alpha gene CHEBI:34674 dextran sulfate multiple interactions ISO RGD:10215 E RGD:6480464 20190702 CTD MESH:D016264 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA PMID:29950665 10216 ATP7A ATPase copper transporting alpha gene CHEBI:34687 dibutyl phthalate increases expression ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D003993 Dibutyl Phthalate results in increased expression of ATP7A mRNA PMID:21266533 10216 ATP7A ATPase copper transporting alpha gene CHEBI:34905 paraquat increases expression EXP E RGD:6480464 20220111 CTD MESH:D010269 Paraquat results in increased expression of ATP7A mRNA PMID:34097952 10216 ATP7A ATPase copper transporting alpha gene CHEBI:34905 paraquat increases response to substance EXP E RGD:6480464 20190219 CTD MESH:D010269 ATP7A protein results in increased susceptibility to Paraquat PMID:29058724 10216 ATP7A ATPase copper transporting alpha gene CHEBI:34905 paraquat multiple interactions EXP E RGD:6480464 20190219 CTD MESH:D010269 ATP7A protein promotes the reaction [Paraquat results in increased chemical synthesis of Hydrogen Peroxide] PMID:29058724 10216 ATP7A ATPase copper transporting alpha gene CHEBI:35154 manganese(0) affects localization ISO RGD:2179 E RGD:6480464 20140715 CTD MESH:D008345 Manganese affects the localization of ATP7A protein PMID:24614235 10216 ATP7A ATPase copper transporting alpha gene CHEBI:35154 manganese(0) decreases expression ISO RGD:2179 E RGD:6480464 20140715 CTD MESH:D008345 Manganese results in decreased expression of ATP7A mRNA; Manganese results in decreased expression of ATP7A protein PMID:24614235 10216 ATP7A ATPase copper transporting alpha gene CHEBI:35456 cadmium dichloride decreases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in decreased expression of ATP7A mRNA PMID:38568856 10216 ATP7A ATPase copper transporting alpha gene CHEBI:35456 cadmium dichloride decreases expression ISO RGD:10215 E RGD:6480464 20150310 CTD MESH:D019256 Cadmium Chloride results in decreased expression of ATP7A mRNA PMID:24982889 10216 ATP7A ATPase copper transporting alpha gene CHEBI:35696 cobalt dichloride increases expression EXP E RGD:6480464 20151013 CTD MESH:C018021 cobaltous chloride results in increased expression of ATP7A mRNA PMID:24614111 10216 ATP7A ATPase copper transporting alpha gene CHEBI:35696 cobalt dichloride increases expression ISO RGD:2179 E RGD:6480464 20150512 CTD MESH:C018021 cobaltous chloride results in increased expression of ATP7A mRNA PMID:23814049 10216 ATP7A ATPase copper transporting alpha gene CHEBI:35696 cobalt dichloride multiple interactions ISO RGD:2179 E RGD:6480464 20150512 CTD MESH:C018021 Plicamycin inhibits the reaction [cobaltous chloride results in increased expression of ATP7A mRNA] PMID:23814049 10216 ATP7A ATPase copper transporting alpha gene CHEBI:37537 phorbol 13-acetate 12-myristate increases expression EXP E RGD:6480464 20120814 CTD MESH:D013755 Tetradecanoylphorbol Acetate results in increased expression of ATP7A protein PMID:19205902 10216 ATP7A ATPase copper transporting alpha gene CHEBI:37537 phorbol 13-acetate 12-myristate multiple interactions EXP E RGD:6480464 20120814 CTD MESH:D013755 [Tetradecanoylphorbol Acetate results in increased expression of ATP7A protein] which results in increased export of Copper; ATP7A protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of FLT1 mRNA] PMID:19205902 10216 ATP7A ATPase copper transporting alpha gene CHEBI:39481 chloroprene increases expression ISO RGD:2179 E RGD:6480464 20130514 CTD MESH:D002737 Chloroprene results in increased expression of ATP7A mRNA PMID:23125180 10216 ATP7A ATPase copper transporting alpha gene CHEBI:39501 2,2,2-tetramine increases expression ISO RGD:2179 E RGD:6480464 20150512 CTD MESH:D014266 Trientine results in increased expression of ATP7A mRNA; Trientine results in increased expression of ATP7A protein PMID:24927960 10216 ATP7A ATPase copper transporting alpha gene CHEBI:39867 valproic acid affects splicing ISO RGD:2179 E RGD:6480464 20180828 CTD MESH:D014635 Valproic Acid affects the splicing of ATP7A mRNA PMID:29427782 10216 ATP7A ATPase copper transporting alpha gene CHEBI:39867 valproic acid decreases expression ISO RGD:10215 E RGD:6480464 20120814 CTD MESH:D014635 Valproic Acid results in decreased expression of ATP7A mRNA PMID:20546886 10216 ATP7A ATPase copper transporting alpha gene CHEBI:39867 valproic acid increases expression EXP E RGD:6480464 20120412 CTD MESH:D014635 Valproic Acid results in increased expression of ATP7A mRNA PMID:19101580|PMID:29154799 10216 ATP7A ATPase copper transporting alpha gene CHEBI:39867 valproic acid increases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in increased methylation of ATP7A gene PMID:29154799 10216 ATP7A ATPase copper transporting alpha gene CHEBI:4031 cyclosporin A decreases expression EXP E RGD:6480464 20150825 CTD MESH:D016572 Cyclosporine results in decreased expression of ATP7A mRNA PMID:25562108 10216 ATP7A ATPase copper transporting alpha gene CHEBI:4031 cyclosporin A decreases expression ISO RGD:10215 E RGD:6480464 20120501 CTD MESH:D016572 Cyclosporine results in decreased expression of ATP7A mRNA PMID:19770486 10216 ATP7A ATPase copper transporting alpha gene CHEBI:42106 L-1,4-dithiothreitol multiple interactions EXP E RGD:6480464 20151013 CTD MESH:D004229 Dithiothreitol inhibits the reaction [Ethylmaleimide results in increased glutathionylation of ATP7A protein] PMID:20566629 10216 ATP7A ATPase copper transporting alpha gene CHEBI:4356 desferrioxamine B increases expression ISO RGD:2179 E RGD:6480464 20151013 CTD MESH:D003676 Deferoxamine results in increased expression of ATP7A mRNA PMID:23174565 10216 ATP7A ATPase copper transporting alpha gene CHEBI:4356 desferrioxamine B multiple interactions ISO RGD:2179 E RGD:6480464 20151013 CTD MESH:D003676 cupric chloride promotes the reaction [Deferoxamine results in increased expression of ATP7A mRNA]; Deferoxamine promotes the reaction [cupric chloride results in increased expression of ATP7A protein] PMID:23174565 10216 ATP7A ATPase copper transporting alpha gene CHEBI:44485 N-ethylmaleimide increases glutathionylation EXP E RGD:6480464 20151013 CTD MESH:D005033 Ethylmaleimide results in increased glutathionylation of ATP7A protein PMID:20566629 10216 ATP7A ATPase copper transporting alpha gene CHEBI:44485 N-ethylmaleimide multiple interactions EXP E RGD:6480464 20151013 CTD MESH:D005033 Dithiothreitol inhibits the reaction [Ethylmaleimide results in increased glutathionylation of ATP7A protein] PMID:20566629 10216 ATP7A ATPase copper transporting alpha gene CHEBI:45863 paclitaxel decreases response to substance EXP E RGD:6480464 20161213 CTD MESH:D017239 ATP7A protein results in decreased susceptibility to Paclitaxel PMID:17510416 10216 ATP7A ATPase copper transporting alpha gene CHEBI:45863 paclitaxel increases expression EXP E RGD:6480464 20161213 CTD MESH:D017239 Paclitaxel results in increased expression of ATP7A mRNA PMID:20737486 10216 ATP7A ATPase copper transporting alpha gene CHEBI:46024 trichostatin A increases expression EXP E RGD:6480464 20170613 CTD MESH:C012589 trichostatin A results in increased expression of ATP7A mRNA PMID:28542535 10216 ATP7A ATPase copper transporting alpha gene CHEBI:46195 paracetamol affects expression ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D000082 Acetaminophen affects the expression of ATP7A mRNA PMID:17562736 10216 ATP7A ATPase copper transporting alpha gene CHEBI:47286 CU-O LINKAGE increases expression EXP E RGD:6480464 20170307 CTD MESH:C030973 cupric oxide analog results in increased expression of ATP7A mRNA; cupric oxide analog results in increased expression of ATP7A protein PMID:24815816 10216 ATP7A ATPase copper transporting alpha gene CHEBI:48080 brefeldin A multiple interactions EXP E RGD:6480464 20120814 CTD MESH:D020126 Brefeldin A inhibits the reaction [ATP7A protein affects the localization of Doxorubicin] PMID:17510416 10216 ATP7A ATPase copper transporting alpha gene CHEBI:48958 1,1'-azobis(N,N-dimethylformamide) multiple interactions EXP E RGD:6480464 20120717 CTD MESH:D003958 Diamide promotes the reaction [CLU protein binds to ATP7A protein] PMID:21242307 10216 ATP7A ATPase copper transporting alpha gene CHEBI:4903 17alpha-ethynylestradiol decreases expression ISO RGD:10215 E RGD:6480464 20180116 CTD MESH:D004997 Ethinyl Estradiol results in decreased expression of ATP7A mRNA; Ethinyl Estradiol results in decreased expression of ATP7A protein PMID:27690074 10216 ATP7A ATPase copper transporting alpha gene CHEBI:4903 17alpha-ethynylestradiol increases expression ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D004997 Ethinyl Estradiol results in increased expression of ATP7A mRNA PMID:17942748 10216 ATP7A ATPase copper transporting alpha gene CHEBI:4903 17alpha-ethynylestradiol multiple interactions ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D004997 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ATP7A mRNA PMID:17942748 10216 ATP7A ATPase copper transporting alpha gene CHEBI:4911 etoposide decreases response to substance EXP E RGD:6480464 20120814 CTD MESH:D005047 ATP7A protein results in decreased susceptibility to Etoposide PMID:17510416 10216 ATP7A ATPase copper transporting alpha gene CHEBI:49553 copper(II) chloride affects localization ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:C029892 cupric chloride affects the localization of ATP7A protein PMID:16317117|PMID:25337692 10216 ATP7A ATPase copper transporting alpha gene CHEBI:49553 copper(II) chloride decreases glutathionylation EXP E RGD:6480464 20151013 CTD MESH:C029892 cupric chloride results in decreased glutathionylation of ATP7A protein PMID:20566629 10216 ATP7A ATPase copper transporting alpha gene CHEBI:49553 copper(II) chloride increases expression ISO RGD:2179 E RGD:6480464 20151013 CTD MESH:C029892 cupric chloride results in increased expression of ATP7A protein PMID:23174565 10216 ATP7A ATPase copper transporting alpha gene CHEBI:49553 copper(II) chloride increases transport EXP E RGD:6480464 20120412 CTD MESH:C029892 ATP7A protein results in increased transport of cupric chloride PMID:17009961 10216 ATP7A ATPase copper transporting alpha gene CHEBI:49553 copper(II) chloride multiple interactions EXP E RGD:6480464 20120717 CTD MESH:C029892 ATP7A protein results in decreased susceptibility to [cupric chloride results in increased abundance of Copper]; ATP7A protein results in decreased uptake of [cupric chloride results in increased abundance of Copper]; cupric chloride inhibits the reaction [bathocuproine sulfonate inhibits the reaction [ATP7A protein results in increased activity of TYR protein]]; cupric chloride promotes the reaction [CLU protein binds to ATP7A protein] PMID:11092760|PMID:21242307|PMID:32278528 10216 ATP7A ATPase copper transporting alpha gene CHEBI:49553 copper(II) chloride multiple interactions ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:C029892 Omeprazole inhibits the reaction [cupric chloride affects the localization of ATP7A protein] PMID:25337692 10216 ATP7A ATPase copper transporting alpha gene CHEBI:49553 copper(II) chloride multiple interactions ISO RGD:2179 E RGD:6480464 20151013 CTD MESH:C029892 cupric chloride inhibits the reaction [Cycloheximide results in decreased expression of ATP7A protein]; cupric chloride promotes the reaction [Deferoxamine results in increased expression of ATP7A mRNA]; Deferoxamine promotes the reaction [cupric chloride results in increased expression of ATP7A protein] PMID:23174565 10216 ATP7A ATPase copper transporting alpha gene CHEBI:49900 arsenous acid decreases expression ISO RGD:10215 E RGD:6480464 20240402 CTD MESH:C032793 Arsenic Trioxide results in decreased expression of ATP7A mRNA PMID:35676786 10216 ATP7A ATPase copper transporting alpha gene CHEBI:50673 methimazole increases expression ISO RGD:2179 E RGD:6480464 20121009 CTD MESH:D008713 Methimazole results in increased expression of ATP7A mRNA PMID:22504374 10216 ATP7A ATPase copper transporting alpha gene CHEBI:50729 mitoxantrone decreases response to substance EXP E RGD:6480464 20120814 CTD MESH:D008942 ATP7A protein results in decreased susceptibility to Mitoxantrone PMID:17510416 10216 ATP7A ATPase copper transporting alpha gene CHEBI:6121 ketamine decreases expression ISO RGD:2179 E RGD:6480464 20121218 CTD MESH:D007649 Ketamine results in decreased expression of ATP7A mRNA PMID:20080153 10216 ATP7A ATPase copper transporting alpha gene CHEBI:63041 manganese(II) chloride affects localization ISO RGD:2179 E RGD:6480464 20140715 CTD MESH:C025340 manganese chloride affects the localization of ATP7A protein PMID:24614235 10216 ATP7A ATPase copper transporting alpha gene CHEBI:63041 manganese(II) chloride decreases expression ISO RGD:2179 E RGD:6480464 20140715 CTD MESH:C025340 manganese chloride results in decreased expression of ATP7A mRNA; manganese chloride results in decreased expression of ATP7A protein PMID:24614235 10216 ATP7A ATPase copper transporting alpha gene CHEBI:63623 succimer multiple interactions ISO RGD:10215 E RGD:6480464 20151215 CTD MESH:D004113 [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of ATP7A mRNA PMID:26378955 10216 ATP7A ATPase copper transporting alpha gene CHEBI:63934 bathocuproine disulfonic acid multiple interactions EXP E RGD:6480464 20120814 CTD MESH:C028559 [Penicillamine co-treated with bathocuproine sulfonate] promotes the reaction [CLU protein binds to ATP7A protein]; bathocuproine sulfonate inhibits the reaction [ATP7A protein results in increased activity of TYR protein]; cupric chloride inhibits the reaction [bathocuproine sulfonate inhibits the reaction [ATP7A protein results in increased activity of TYR protein]] PMID:11092760|PMID:21242307 10216 ATP7A ATPase copper transporting alpha gene CHEBI:6820 methapyrilene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene affects the methylation of ATP7A intron PMID:30157460 10216 ATP7A ATPase copper transporting alpha gene CHEBI:73755 1,2-dimethylhydrazine multiple interactions ISO RGD:10215 E RGD:6480464 20200804 CTD MESH:D019813 [1,2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of ATP7A mRNA PMID:22206623 10216 ATP7A ATPase copper transporting alpha gene CHEBI:73755 1,2-dimethylhydrazine multiple interactions ISO RGD:2179 E RGD:6480464 20180220 CTD MESH:D019813 [APC protein affects the susceptibility to 1,2-Dimethylhydrazine] which results in increased expression of ATP7A mRNA PMID:27840820 10216 ATP7A ATPase copper transporting alpha gene CHEBI:75249 potassium chromate decreases expression EXP E RGD:6480464 20160705 CTD MESH:C027373 potassium chromate(VI) results in decreased expression of ATP7A mRNA PMID:22714537 10216 ATP7A ATPase copper transporting alpha gene CHEBI:7590 nitrofen decreases expression ISO RGD:2179 E RGD:6480464 20151013 CTD MESH:C007350 nitrofen results in decreased expression of ATP7A mRNA; nitrofen results in decreased expression of ATP7A protein PMID:25319798 10216 ATP7A ATPase copper transporting alpha gene CHEBI:77260 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole multiple interactions EXP E RGD:6480464 20150609 CTD MESH:D009853 Omeprazole inhibits the reaction [ATP7A protein results in increased activity of TYR protein] PMID:25337692 10216 ATP7A ATPase copper transporting alpha gene CHEBI:77260 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole multiple interactions ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:D009853 Omeprazole inhibits the reaction [Copper affects the localization of ATP7A protein]; Omeprazole inhibits the reaction [cupric chloride affects the localization of ATP7A protein] PMID:25337692 10216 ATP7A ATPase copper transporting alpha gene CHEBI:7772 omeprazole multiple interactions EXP E RGD:6480464 20150609 CTD MESH:D009853 Omeprazole inhibits the reaction [ATP7A protein results in increased activity of TYR protein] PMID:25337692 10216 ATP7A ATPase copper transporting alpha gene CHEBI:7772 omeprazole multiple interactions ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:D009853 Omeprazole inhibits the reaction [Copper affects the localization of ATP7A protein]; Omeprazole inhibits the reaction [cupric chloride affects the localization of ATP7A protein] PMID:25337692 10216 ATP7A ATPase copper transporting alpha gene CHEBI:78320 2-hydroxypropanoic acid decreases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in decreased expression of ATP7A mRNA PMID:30851411 10216 ATP7A ATPase copper transporting alpha gene CHEBI:78510 dorsomorphin multiple interactions EXP E RGD:6480464 20161228 CTD MESH:C516138 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP7A mRNA PMID:27188386 10216 ATP7A ATPase copper transporting alpha gene CHEBI:78782 pyrrolidine dithiocarbamate decreases expression EXP E RGD:6480464 20151013 CTD MESH:C020972 pyrrolidine dithiocarbamic acid results in decreased expression of ATP7A PMID:25070243 10216 ATP7A ATPase copper transporting alpha gene CHEBI:7959 D-penicillamine multiple interactions EXP E RGD:6480464 20120717 CTD MESH:D010396 [Penicillamine co-treated with bathocuproine sulfonate] promotes the reaction [CLU protein binds to ATP7A protein] PMID:21242307 10216 ATP7A ATPase copper transporting alpha gene CHEBI:80630 irinotecan decreases response to substance EXP E RGD:6480464 20181113 CTD MESH:D000077146 ATP7A protein results in decreased susceptibility to Irinotecan PMID:17510416 10216 ATP7A ATPase copper transporting alpha gene CHEBI:80630 irinotecan increases export EXP E RGD:6480464 20181113 CTD MESH:D000077146 ATP7A protein results in increased export of Irinotecan PMID:17510416 10216 ATP7A ATPase copper transporting alpha gene CHEBI:82436 decabromodiphenyl ether decreases expression ISO RGD:2179 E RGD:6480464 20141111 CTD MESH:C010902 decabromobiphenyl ether results in decreased expression of ATP7A mRNA PMID:23914054 10216 ATP7A ATPase copper transporting alpha gene CHEBI:82664 iron(0) affects metabolic processing ISO RGD:10215 E RGD:6480464 20150512 CTD MESH:D007501 ATP7A protein mutant form affects the metabolism of Iron PMID:25247420 10216 ATP7A ATPase copper transporting alpha gene CHEBI:82664 iron(0) affects transport ISO RGD:2179 E RGD:6480464 20150609 CTD MESH:D007501 ATP7A mutant form affects the transport of Iron PMID:24174620 10216 ATP7A ATPase copper transporting alpha gene CHEBI:82664 iron(0) decreases oxidation ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:D007501 ATP7A gene mutant form results in decreased oxidation of Iron PMID:23776592 10216 ATP7A ATPase copper transporting alpha gene CHEBI:82664 iron(0) increases expression ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:D007501 Iron deficiency results in increased expression of ATP7A mRNA PMID:23776592|PMID:24089420 10216 ATP7A ATPase copper transporting alpha gene CHEBI:82664 iron(0) increases expression ISO RGD:2179 E RGD:6480464 20151013 CTD MESH:D007501 Iron deficiency results in increased expression of ATP7A; Iron deficiency results in increased expression of ATP7A mRNA; Iron deficiency results in increased expression of ATP7A protein PMID:16629162|PMID:21852364|PMID:23174565|PMID:23814049|PMID:24089420|PMID:24174620 10216 ATP7A ATPase copper transporting alpha gene CHEBI:82664 iron(0) increases response to substance ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:D007501 ATP7A gene mutant form results in increased susceptibility to Iron deficiency PMID:23776592 10216 ATP7A ATPase copper transporting alpha gene CHEBI:82664 iron(0) multiple interactions ISO RGD:10215 E RGD:6480464 20150609 CTD MESH:D007501 [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Copper; [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Iron; ATP7A gene mutant form promotes the reaction [Iron deficiency results in increased expression of MT1 mRNA]; Iron deficiency inhibits the reaction [ATP7A gene mutant form results in decreased oxidation of Iron] PMID:23776592 10216 ATP7A ATPase copper transporting alpha gene CHEBI:82664 iron(0) multiple interactions ISO RGD:2179 E RGD:6480464 20150609 CTD MESH:D007501 [Iron deficiency results in increased expression of ATP7A] which results in increased abundance of Copper PMID:24174620 10216 ATP7A ATPase copper transporting alpha gene CHEBI:84070 sodium arsenate increases expression ISO RGD:10215 E RGD:6480464 20170303 CTD MESH:C009277 sodium arsenate results in increased expression of ATP7A mRNA PMID:21795629 10216 ATP7A ATPase copper transporting alpha gene CHEBI:8502 6-propyl-2-thiouracil increases expression ISO RGD:2179 E RGD:6480464 20121009 CTD MESH:D011441 Propylthiouracil results in increased expression of ATP7A mRNA PMID:22504374 10216 ATP7A ATPase copper transporting alpha gene CHEBI:85609 satraplatin decreases response to substance ISO RGD:10215 E RGD:6480464 20170303 CTD MESH:C081294 ATP7A protein results in decreased susceptibility to satraplatin metabolite PMID:16170571 10216 ATP7A ATPase copper transporting alpha gene CHEBI:91108 SB 431542 multiple interactions EXP E RGD:6480464 20161220 CTD MESH:C459179 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP7A mRNA PMID:27188386 10216 ATP7A ATPase copper transporting alpha gene CHEBI:91222 neocuproine multiple interactions ISO RGD:10215 E RGD:6480464 20160315 CTD MESH:C002701 neocuproine inhibits the reaction [ATP7A protein mutant form promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL1 protein]]; neocuproine promotes the reaction [ATP7A protein mutant form inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 protein]]; neocuproine promotes the reaction [ATP7A protein mutant form inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL7 protein]]; neocuproine promotes the reaction [ATP7A protein mutant form inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNG protein]]; neocuproine promotes the reaction [ATP7A protein mutant form inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of VEGFA protein]] PMID:23604539 10216 ATP7A ATPase copper transporting alpha gene CHEBI:9141 silver(0) affects binding EXP E RGD:6480464 20120717 CTD MESH:D012834 Silver binds to ATP7A protein PMID:10841766|PMID:21646353 10216 ATP7A ATPase copper transporting alpha gene CHEBI:9141 silver(0) affects localization ISO RGD:10215 E RGD:6480464 20120412 CTD MESH:D012834 Silver affects the localization of ATP7A protein PMID:16317117 10216 ATP7A ATPase copper transporting alpha gene CHEBI:9141 silver(0) decreases expression ISO RGD:10215 E RGD:6480464 20161115 CTD MESH:D012834 Silver results in decreased expression of ATP7A mRNA PMID:27131904 10216 ATP7A ATPase copper transporting alpha gene CHEBI:9288 streptozocin decreases expression ISO RGD:10215 E RGD:6480464 20150512 CTD MESH:D013311 Streptozocin results in decreased expression of ATP7A protein PMID:23884884 10216 ATP7A ATPase copper transporting alpha gene CHEBI:9288 streptozocin multiple interactions ISO RGD:10215 E RGD:6480464 20150512 CTD MESH:D013311 ATP7A gene mutant form promotes the reaction [Streptozocin results in increased chemical synthesis of Superoxides]; ATP7A protein inhibits the reaction [Streptozocin results in increased chemical synthesis of Superoxides]; INS protein inhibits the reaction [Streptozocin results in decreased expression of ATP7A protein] PMID:23884884 10216 ATP7A ATPase copper transporting alpha gene CHEBI:9753 troglitazone decreases expression ISO RGD:10215 E RGD:6480464 20180220 CTD MESH:C057693 troglitazone results in decreased expression of ATP7A mRNA PMID:28973697 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:10429 beta-lapachone increases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in increased expression of CEACAM1 mRNA PMID:38218311 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:116509 diuron increases expression EXP E RGD:6480464 20140311 CTD MESH:D004237 Diuron metabolite results in increased expression of CEACAM1 mRNA PMID:24172598 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:132082 entinostat increases expression EXP E RGD:6480464 20161228 CTD MESH:C118739 entinostat results in increased expression of CEACAM1 mRNA PMID:27188386 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:132471 (+)-schisandrin B multiple interactions ISO RGD:67396 E RGD:6480464 20190910 CTD MESH:C015499 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of CEACAM1 mRNA] PMID:31150632 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:138858 Azaspiracid increases expression EXP E RGD:6480464 20190219 CTD MESH:C406592 azaspiracid results in increased expression of CEACAM1 mRNA PMID:21853993|PMID:28939011 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:1391 3,4-methylenedioxymethamphetamine decreases expression ISO RGD:10240 E RGD:6480464 20160210 CTD MESH:D018817 N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of CEACAM1 mRNA PMID:26251327 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:144400 dinophysistoxin 1 increases expression EXP E RGD:6480464 20190903 CTD MESH:C051904 dinophysistoxin 1 results in increased expression of CEACAM1 mRNA PMID:21853993|PMID:28939011 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:15367 all-trans-retinoic acid increases expression EXP E RGD:6480464 20160607 CTD MESH:D014212 Tretinoin results in increased expression of CEACAM1 mRNA PMID:23830798|PMID:33167477 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:15443 inulin multiple interactions ISO RGD:10240 E RGD:6480464 20230502 CTD MESH:D007444 [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of CEACAM1 mRNA PMID:36331819 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:15743 butanal decreases expression EXP E RGD:6480464 20150825 CTD MESH:C018475 butyraldehyde results in decreased expression of CEACAM1 mRNA PMID:26079696 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:16240 hydrogen peroxide affects expression EXP E RGD:6480464 20120412 CTD MESH:D006861 Hydrogen Peroxide affects the expression of CEACAM1 mRNA PMID:20044591 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:16469 17beta-estradiol affects expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D004958 Estradiol affects the expression of CEACAM1 mRNA PMID:15598610 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:16469 17beta-estradiol decreases expression ISO RGD:67396 E RGD:6480464 20230606 CTD MESH:D004958 Estradiol results in decreased expression of CEACAM1 mRNA PMID:32145629 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:16469 17beta-estradiol increases expression EXP E RGD:6480464 20120412 CTD MESH:D004958 Estradiol results in increased expression of CEACAM1 mRNA PMID:19619570 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:16469 17beta-estradiol increases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D004958 Estradiol results in increased expression of CEACAM1 mRNA PMID:15289156 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:16469 17beta-estradiol multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D004958 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of CEACAM1 mRNA PMID:19619570 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:16598 DDE decreases expression EXP E RGD:6480464 20240702 CTD MESH:D003633 Dichlorodiphenyl Dichloroethylene results in decreased expression of CEACAM1 mRNA PMID:38568856 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:16602 trichloroethene decreases expression ISO RGD:67396 E RGD:6480464 20211207 CTD MESH:D014241 Trichloroethylene results in decreased expression of CEACAM1 mRNA PMID:33387578 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:166473 Dibutyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C065087 di-n-butylphosphoric acid affects the expression of CEACAM1 mRNA PMID:37042841 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:16767 3,4-dichloroaniline increases expression EXP E RGD:6480464 20140311 CTD MESH:C014464 3,4-dichloroaniline results in increased expression of CEACAM1 mRNA PMID:24172598 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:16842 formaldehyde decreases expression EXP E RGD:6480464 20171114 CTD MESH:D005557 Formaldehyde results in decreased expression of CEACAM1 mRNA PMID:28937961 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:16842 formaldehyde increases expression EXP E RGD:6480464 20140408 CTD MESH:D005557 Formaldehyde results in increased expression of CEACAM1 mRNA PMID:23649840 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:17026 progesterone increases expression EXP E RGD:6480464 20130910 CTD MESH:D011374 Progesterone results in increased expression of CEACAM1 mRNA PMID:18692832 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:17234 glucose decreases expression EXP E RGD:6480464 20120814 CTD MESH:D005947 Glucose results in decreased expression of CEACAM1 mRNA PMID:19924377 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:17234 glucose decreases secretion EXP E RGD:6480464 20120814 CTD MESH:D005947 Glucose results in decreased secretion of CEACAM1 protein PMID:19924377 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:17234 glucose multiple interactions EXP E RGD:6480464 20120814 CTD MESH:D005947 cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of CEACAM1 mRNA]; cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased secretion of CEACAM1 protein] PMID:19924377 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of CEACAM1 mRNA PMID:33359661 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:17347 testosterone decreases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D013739 Testosterone results in decreased expression of CEACAM1 mRNA PMID:20600201|PMID:21669218 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:17634 D-glucose decreases expression EXP E RGD:6480464 20120814 CTD MESH:D005947 Glucose results in decreased expression of CEACAM1 mRNA PMID:19924377 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:17634 D-glucose decreases secretion EXP E RGD:6480464 20120814 CTD MESH:D005947 Glucose results in decreased secretion of CEACAM1 protein PMID:19924377 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:17634 D-glucose multiple interactions EXP E RGD:6480464 20120814 CTD MESH:D005947 cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of CEACAM1 mRNA]; cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased secretion of CEACAM1 protein] PMID:19924377 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:17688 (S)-nicotine increases expression ISO RGD:10240 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in increased expression of CEACAM1 mRNA PMID:17997037 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:17747 bis(2-ethylhexyl) phthalate increases expression EXP E RGD:6480464 20240402 CTD MESH:D004051 Diethylhexyl Phthalate results in increased expression of CEACAM1 mRNA PMID:36774801 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:17823 calcitriol increases expression EXP E RGD:6480464 20160412 CTD MESH:D002117 Calcitriol results in increased expression of CEACAM1 mRNA PMID:26485663 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:18246 (1->4)-beta-D-glucan multiple interactions ISO RGD:10240 E RGD:6480464 20230502 CTD MESH:D002482 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of CEACAM1 mRNA PMID:36331819 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:18305 hydroquinone O-beta-D-glucopyranoside decreases expression EXP E RGD:6480464 20120412 CTD MESH:D001104 Arbutin results in decreased expression of CEACAM1 mRNA PMID:17103032 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:18407 hydrogen cyanide increases expression ISO RGD:10240 E RGD:6480464 20211109 CTD MESH:D006856 Hydrogen Cyanide results in increased expression of CEACAM1 mRNA PMID:33914522 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:18721 3-chloropropane-1,2-diol increases expression ISO RGD:67396 E RGD:6480464 20220705 CTD MESH:D000517 alpha-Chlorohydrin results in increased expression of CEACAM1 protein PMID:34915118 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:18723 nicotine increases expression ISO RGD:10240 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in increased expression of CEACAM1 mRNA PMID:17997037 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:23994 ethyl methanesulfonate increases expression EXP E RGD:6480464 20140708 CTD MESH:D005020 Ethyl Methanesulfonate results in increased expression of CEACAM1 mRNA PMID:23649840 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:24631 hydrazines decreases expression ISO RGD:10240 E RGD:6480464 20170117 CTD MESH:D006834 Hydrazines results in decreased expression of CEACAM1 mRNA PMID:21647536 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:2504 aflatoxin B1 affects expression EXP E RGD:6480464 20120412 CTD MESH:D016604 Aflatoxin B1 affects the expression of CEACAM1 protein PMID:20106945 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:2504 aflatoxin B1 decreases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D016604 Aflatoxin B1 results in decreased expression of CEACAM1 mRNA PMID:19770486 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:2504 aflatoxin B1 increases expression EXP E RGD:6480464 20121009 CTD MESH:D016604 Aflatoxin B1 results in increased expression of CEACAM1 mRNA PMID:21641981|PMID:22100608 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:25255 methyl methanesulfonate increases expression EXP E RGD:6480464 20140408 CTD MESH:D008741 Methyl Methanesulfonate results in increased expression of CEACAM1 mRNA PMID:23649840 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:25434 bis(2-chloroethyl) sulfide increases expression EXP E RGD:6480464 20150414 CTD MESH:D009151 Mustard Gas results in increased expression of CEACAM1 mRNA PMID:25102026 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:25434 bis(2-chloroethyl) sulfide increases secretion EXP E RGD:6480464 20210608 CTD MESH:D009151 Mustard Gas results in increased secretion of CEACAM1 protein PMID:33491125 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:25812 ozone increases expression EXP E RGD:6480464 20191210 CTD MESH:D010126 Ozone results in increased expression of CEACAM1 mRNA PMID:31476115 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:25812 ozone increases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D010126 Ozone results in increased expression of CEACAM1 mRNA PMID:19555225 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:25812 ozone increases expression ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:D010126 Ozone results in increased expression of CEACAM1 mRNA PMID:16330353 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27363 zinc atom increases expression ISO RGD:67396 E RGD:6480464 20130122 CTD MESH:D015032 Zinc deficiency results in increased expression of CEACAM1 mRNA PMID:11717422 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27385 tetrachloromethane affects expression ISO RGD:10240 E RGD:6480464 20200804 CTD MESH:D002251 Carbon Tetrachloride affects the expression of CEACAM1 mRNA PMID:31919559 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27385 tetrachloromethane decreases expression ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:D002251 Carbon Tetrachloride results in decreased expression of CEACAM1 mRNA PMID:17522070|PMID:31150632 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27385 tetrachloromethane multiple interactions ISO RGD:10240 E RGD:6480464 20181016 CTD MESH:D002251 [PANX1 protein co-treated with Carbon Tetrachloride] affects the expression of CEACAM1 mRNA PMID:29987408 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27385 tetrachloromethane multiple interactions ISO RGD:67396 E RGD:6480464 20190910 CTD MESH:D002251 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of CEACAM1 mRNA] PMID:31150632 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27470 folic acid multiple interactions EXP E RGD:6480464 20151110 CTD MESH:D005492 [Folic Acid deficiency co-treated with Methotrexate] results in increased expression of CEACAM1 mRNA PMID:24657277 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27656 camptothecin increases expression EXP E RGD:6480464 20120412 CTD MESH:D002166 Camptothecin results in increased expression of CEACAM1 mRNA PMID:17374387|PMID:38460933 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27666 actinomycin D increases expression EXP E RGD:6480464 20240806 CTD MESH:D003609 Dactinomycin results in increased expression of CEACAM1 mRNA PMID:38460933 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27666 actinomycin D multiple interactions EXP E RGD:6480464 20240806 CTD MESH:D003609 [Dactinomycin co-treated with nutlin 3] results in increased expression of CEACAM1 mRNA PMID:38460933 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27732 caffeine increases phosphorylation EXP E RGD:6480464 20221004 CTD MESH:D002110 Caffeine results in increased phosphorylation of CEACAM1 protein PMID:35688186 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27881 resveratrol increases expression EXP E RGD:6480464 20150714 CTD MESH:C059514 resveratrol results in increased expression of CEACAM1 mRNA PMID:15280659|PMID:25888808 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27899 cisplatin affects expression EXP E RGD:6480464 20140513 CTD MESH:D002945 Cisplatin affects the expression of CEACAM1 mRNA PMID:23300844 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27899 cisplatin increases expression EXP E RGD:6480464 20170516 CTD MESH:D002945 Cisplatin results in increased expression of CEACAM1 mRNA PMID:27392435 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27899 cisplatin multiple interactions EXP E RGD:6480464 20151013 CTD MESH:D002945 [Cisplatin co-treated with jinfukang] results in increased expression of CEACAM1 mRNA; [Cisplatin co-treated with Paclitaxel] results in increased expression of CEACAM1 mRNA PMID:20705681|PMID:27392435 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:27998 tungsten decreases expression ISO RGD:10240 E RGD:6480464 20190910 CTD MESH:D014414 Tungsten results in decreased expression of CEACAM1 mRNA PMID:30912803 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28001 vancomycin increases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D014640 Vancomycin results in increased expression of CEACAM1 mRNA PMID:18930951 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28088 genistein decreases expression ISO RGD:10240 E RGD:6480464 20200804 CTD MESH:D019833 Genistein results in decreased expression of CEACAM1 mRNA PMID:32186404 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28088 genistein increases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D019833 Genistein results in increased expression of CEACAM1 mRNA PMID:15289156 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28088 genistein increases expression ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:D019833 Genistein results in increased expression of CEACAM1 mRNA PMID:12075121 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP E RGD:6480464 20120412 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of CEACAM1 mRNA PMID:19619570 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of CEACAM1 mRNA PMID:19770486 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:67396 E RGD:6480464 20130514 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of CEACAM1 mRNA PMID:20959002|PMID:23238561|PMID:33387578 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP E RGD:6480464 20130514 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of CEACAM1 mRNA PMID:23152189 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of CEACAM1 mRNA PMID:23238561 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of CEACAM1 mRNA PMID:16054898|PMID:18796159|PMID:32109520|PMID:34747641 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D013749 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of CEACAM1 mRNA PMID:19619570 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28177 theophylline decreases expression ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:D013806 Theophylline results in decreased expression of CEACAM1 mRNA PMID:17522070 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of CEACAM1 mRNA PMID:33212167 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28445 vincristine increases expression EXP E RGD:6480464 20161213 CTD MESH:D014750 Vincristine results in increased expression of CEACAM1 mRNA PMID:23649840 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28593 quinidine increases expression ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:D011802 Quinidine results in increased expression of CEACAM1 mRNA PMID:17522070 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28619 acrylamide decreases expression ISO RGD:67396 E RGD:6480464 20180410 CTD MESH:D020106 Acrylamide results in decreased expression of CEACAM1 mRNA PMID:28959563 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:28940 calciol increases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D002762 Cholecalciferol results in increased expression of CEACAM1 mRNA PMID:17170073 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of CEACAM1 mRNA PMID:38568856 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:29865 benzo[a]pyrene decreases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of CEACAM1 mRNA PMID:19770486 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:29865 benzo[a]pyrene increases expression EXP E RGD:6480464 20160119 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of CEACAM1 mRNA PMID:21632981|PMID:26238291|PMID:32234424 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:29865 benzo[a]pyrene increases expression ISO RGD:10240 E RGD:6480464 20230606 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of CEACAM1 protein PMID:35920545 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:29865 benzo[a]pyrene increases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in increased methylation of CEACAM1 3' UTR; Benzo(a)pyrene results in increased methylation of CEACAM1 5' UTR; Benzo(a)pyrene results in increased methylation of CEACAM1 promoter PMID:27901495 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:29865 benzo[a]pyrene multiple interactions ISO RGD:10240 E RGD:6480464 20230606 CTD MESH:D001564 Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of CEACAM1 protein] PMID:35920545 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:30185 zinc(0) increases expression ISO RGD:67396 E RGD:6480464 20130122 CTD MESH:D015032 Zinc deficiency results in increased expression of CEACAM1 mRNA PMID:11717422 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:30563 silicon dioxide decreases expression EXP E RGD:6480464 20160315 CTD MESH:D012822 Silicon Dioxide analog results in decreased expression of CEACAM1 mRNA PMID:25895662 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:30563 silicon dioxide increases expression EXP E RGD:6480464 20161025 CTD MESH:D012822 Silicon Dioxide results in increased expression of CEACAM1 mRNA PMID:22300531 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:30614 benzo[a]pyrene diol epoxide I increases expression EXP E RGD:6480464 20160119 CTD MESH:D015123 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of CEACAM1 mRNA PMID:26238291 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:31206 ammonium chloride affects expression ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:D000643 Ammonium Chloride affects the expression of CEACAM1 mRNA PMID:16483693 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:31653 glafenine decreases expression ISO RGD:67396 E RGD:6480464 20160412 CTD MESH:D005897 Glafenine results in decreased expression of CEACAM1 mRNA PMID:24136188 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:31746 kainic acid increases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D007608 Kainic Acid results in increased expression of CEACAM1 mRNA PMID:17997037 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:31767 lead diacetate decreases expression ISO RGD:67396 E RGD:6480464 20130312 CTD MESH:C008261 lead acetate results in decreased expression of CEACAM1 mRNA PMID:22641619 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:31767 lead diacetate increases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:C008261 lead acetate results in increased expression of CEACAM1 mRNA PMID:22609695 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:31767 lead diacetate increases methylation ISO RGD:67396 E RGD:6480464 20180828 CTD MESH:C008261 lead acetate results in increased methylation of CEACAM1 gene PMID:29571894 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:31941 oxaliplatin multiple interactions ISO RGD:67396 E RGD:6480464 20161213 CTD MESH:C030110 [oxaliplatin co-treated with Topotecan] results in increased expression of CEACAM1 mRNA PMID:25729387 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:3223 buspirone decreases expression ISO RGD:67396 E RGD:6480464 20160412 CTD MESH:D002065 Buspirone results in decreased expression of CEACAM1 mRNA PMID:24136188 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:32234 titanium dioxide decreases expression ISO RGD:10240 E RGD:6480464 20140211 CTD MESH:C009495 titanium dioxide results in decreased expression of CEACAM1 mRNA PMID:23557971 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:32497 thioacetamide decreases expression ISO RGD:67396 E RGD:6480464 20220405 CTD MESH:D013853 Thioacetamide results in decreased expression of CEACAM1 mRNA PMID:34492290 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:32506 4,4'-diaminodiphenylmethane increases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:C009505 4,4'-diaminodiphenylmethane results in increased expression of CEACAM1 mRNA PMID:18648102 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:32509 pirinixic acid decreases expression ISO RGD:10240 E RGD:6480464 20140610 CTD MESH:C006253 pirinixic acid results in decreased expression of CEACAM1 mRNA PMID:16221962|PMID:17426115|PMID:20059764|PMID:23811191 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:32509 pirinixic acid multiple interactions ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:C006253 PPARA protein promotes the reaction [pirinixic acid results in decreased expression of CEACAM1 mRNA] PMID:20059764 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:33007 chromium(6+) affects expression ISO RGD:10240 E RGD:6480464 20171010 CTD MESH:C074702 chromium hexavalent ion affects the expression of CEACAM1 mRNA PMID:28472532 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:33191 potassium cyanide increases expression ISO RGD:10240 E RGD:6480464 20211109 CTD MESH:D011190 Potassium Cyanide results in increased expression of CEACAM1 mRNA PMID:33914522 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:33216 bisphenol A decreases expression ISO RGD:67396 E RGD:6480464 20150310 CTD MESH:C006780 bisphenol A results in decreased expression of CEACAM1 mRNA PMID:25181051|PMID:32145629 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:33216 bisphenol A increases expression EXP E RGD:6480464 20130122 CTD MESH:C006780 bisphenol A results in increased expression of CEACAM1 mRNA PMID:22576693 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:33216 bisphenol A increases expression ISO RGD:10240 E RGD:6480464 20220208 CTD MESH:C006780 bisphenol A results in increased expression of CEACAM1 mRNA PMID:33221593 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:33216 bisphenol A increases expression ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:C006780 bisphenol A results in increased expression of CEACAM1 mRNA PMID:12075121 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:34575 bisphenol F increases expression ISO RGD:10240 E RGD:6480464 20191112 CTD MESH:C008745 bisphenol F results in increased expression of CEACAM1 mRNA PMID:30951980 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:34648 clofibric acid affects expression ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:D002995 Clofibric Acid affects the expression of CEACAM1 mRNA PMID:17602206 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:34761 fenthion increases expression ISO RGD:10240 E RGD:6480464 20220607 CTD MESH:D005284 Fenthion results in increased expression of CEACAM1 mRNA PMID:34813904 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:34837 methidathion decreases expression ISO RGD:10240 E RGD:6480464 20220607 CTD MESH:C005828 methidathion results in decreased expression of CEACAM1 mRNA PMID:34813904 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:34873 N-nitrosodiethylamine multiple interactions ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:D004052 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CEACAM1 mRNA PMID:18164116 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:35033 triphenyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C005445 triphenyl phosphate affects the expression of CEACAM1 mRNA PMID:37042841 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:35033 triphenyl phosphate affects expression ISO RGD:67396 E RGD:6480464 20200331 CTD MESH:C005445 triphenyl phosphate affects the expression of CEACAM1 mRNA PMID:30589522 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:35842 antirheumatic drug decreases expression EXP E RGD:6480464 20161228 CTD MESH:D018501 Antirheumatic Agents results in decreased expression of CEACAM1 mRNA PMID:24449571 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:3750 clofibrate decreases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D002994 Clofibrate results in decreased expression of CEACAM1 mRNA PMID:17585979 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:3750 clofibrate multiple interactions ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D002994 [Clofibrate co-treated with Acetaminophen] affects the expression of CEACAM1 mRNA; PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of CEACAM1 mRNA] PMID:17585979 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:37825 p-toluidine decreases expression ISO RGD:67396 E RGD:6480464 20170516 CTD MESH:C029370 4-toluidine results in decreased expression of CEACAM1 mRNA PMID:27638505 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:38221 fumonisin B1 decreases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:C056933 fumonisin B1 results in decreased expression of CEACAM1 mRNA PMID:16221962 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:38658 dicrotophos increases expression EXP E RGD:6480464 20170725 CTD MESH:C000944 dicrotophos results in increased expression of CEACAM1 mRNA PMID:28302478 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:39421 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:10240 E RGD:6480464 20230502 CTD MESH:C076994 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of CEACAM1 mRNA; [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of CEACAM1 mRNA; [perfluorooctane sulfonic acid co-treated with Pectins] results in decreased expression of CEACAM1 mRNA PMID:36331819 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:39481 chloroprene increases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D002737 Chloroprene results in increased expression of CEACAM1 mRNA PMID:23125180 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:39867 valproic acid affects expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D014635 Valproic Acid affects the expression of CEACAM1 mRNA PMID:17292431 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:39867 valproic acid decreases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in decreased methylation of CEACAM1 gene PMID:29154799 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:39867 valproic acid increases expression EXP E RGD:6480464 20140408 CTD MESH:D014635 Valproic Acid results in increased expression of CEACAM1 mRNA PMID:23527032 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:4031 cyclosporin A decreases expression EXP E RGD:6480464 20150825 CTD MESH:D016572 Cyclosporine results in decreased expression of CEACAM1 mRNA PMID:20106945|PMID:25562108 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:4031 cyclosporin A decreases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D016572 Cyclosporine results in decreased expression of CEACAM1 mRNA PMID:19770486 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:40953 doramapimod decreases expression ISO RGD:67396 E RGD:6480464 20170228 CTD MESH:C452139 doramapimod results in decreased expression of CEACAM1 mRNA PMID:24303162 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:41879 dexamethasone increases expression ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:D003907 Dexamethasone results in increased expression of CEACAM1 mRNA PMID:17522070 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:41922 diethylstilbestrol increases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D004054 Diethylstilbestrol results in increased expression of CEACAM1 mRNA PMID:15289156 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:41977 daunorubicin increases expression EXP E RGD:6480464 20120412 CTD MESH:D003630 Daunorubicin results in increased expression of CEACAM1 mRNA PMID:17374387 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:42588 4-hydroxyphenyl retinamide increases expression ISO RGD:10240 E RGD:6480464 20180220 CTD MESH:D017313 Fenretinide results in increased expression of CEACAM1 mRNA PMID:28973697 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:42758 aldehydo-D-glucose decreases expression EXP E RGD:6480464 20140304 CTD MESH:D005947 Glucose results in decreased expression of CEACAM1 mRNA PMID:19924377 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:42758 aldehydo-D-glucose decreases secretion EXP E RGD:6480464 20140304 CTD MESH:D005947 Glucose results in decreased secretion of CEACAM1 protein PMID:19924377 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:42758 aldehydo-D-glucose multiple interactions EXP E RGD:6480464 20140304 CTD MESH:D005947 cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of CEACAM1 mRNA]; cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased secretion of CEACAM1 protein] PMID:19924377 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:43572 kojic acid decreases expression EXP E RGD:6480464 20120412 CTD MESH:C011890 kojic acid results in decreased expression of CEACAM1 mRNA PMID:16595896 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:4393 (-)-demecolcine increases expression EXP E RGD:6480464 20140408 CTD MESH:D003703 Demecolcine results in increased expression of CEACAM1 mRNA PMID:23649840 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:44185 methotrexate multiple interactions EXP E RGD:6480464 20151110 CTD MESH:D008727 [Folic Acid deficiency co-treated with Methotrexate] results in increased expression of CEACAM1 mRNA PMID:24657277 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:44445 nimesulide decreases expression ISO RGD:67396 E RGD:6480464 20160412 CTD MESH:C012655 nimesulide results in decreased expression of CEACAM1 mRNA PMID:24136188 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:45863 paclitaxel multiple interactions EXP E RGD:6480464 20161213 CTD MESH:D017239 [Cisplatin co-treated with Paclitaxel] results in increased expression of CEACAM1 mRNA PMID:20705681 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:46024 trichostatin A increases expression EXP E RGD:6480464 20140909 CTD MESH:C012589 trichostatin A results in increased expression of CEACAM1 mRNA PMID:24935251 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:46195 paracetamol decreases expression EXP E RGD:6480464 20120918 CTD MESH:D000082 Acetaminophen results in decreased expression of CEACAM1 mRNA PMID:21420995|PMID:29067470 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:46195 paracetamol decreases expression ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:D000082 Acetaminophen results in decreased expression of CEACAM1 mRNA PMID:17522070 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:46195 paracetamol multiple interactions ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D000082 [Clofibrate co-treated with Acetaminophen] affects the expression of CEACAM1 mRNA; PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of CEACAM1 mRNA] PMID:17585979 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:4631 diosmin multiple interactions ISO RGD:10240 E RGD:6480464 20230606 CTD MESH:D004145 Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of CEACAM1 protein] PMID:35920545 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:46666 crocidolite asbestos decreases expression ISO RGD:10240 E RGD:6480464 20200915 CTD MESH:D017638 Asbestos, Crocidolite results in decreased expression of CEACAM1 mRNA PMID:29279043 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:46666 crocidolite asbestos increases expression EXP E RGD:6480464 20161115 CTD MESH:D017638 Asbestos, Crocidolite results in increased expression of CEACAM1 mRNA PMID:25351596 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:46742 Nutlin-3 increases expression EXP E RGD:6480464 20240806 CTD MESH:C482205 nutlin 3 results in increased expression of CEACAM1 mRNA PMID:38460933 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:46742 Nutlin-3 multiple interactions EXP E RGD:6480464 20240806 CTD MESH:C482205 [Dactinomycin co-treated with nutlin 3] results in increased expression of CEACAM1 mRNA PMID:38460933 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:4846 erythromycin estolate decreases expression ISO RGD:67396 E RGD:6480464 20120412 CTD MESH:D004918 Erythromycin Estolate results in decreased expression of CEACAM1 mRNA PMID:17522070 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:4903 17alpha-ethynylestradiol increases expression ISO RGD:67396 E RGD:6480464 20120515 CTD MESH:D004997 Ethinyl Estradiol results in increased expression of CEACAM1 mRNA PMID:12075121|PMID:12655037|PMID:15834898 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:4911 etoposide increases expression EXP E RGD:6480464 20120412 CTD MESH:D005047 Etoposide results in increased expression of CEACAM1 mRNA PMID:17374387 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:4918 O-methyleugenol increases expression EXP E RGD:6480464 20200714 CTD MESH:C005223 methyleugenol results in increased expression of CEACAM1 mRNA PMID:32234424 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:50131 5-aza-2'-deoxycytidine affects expression EXP E RGD:6480464 20191114 CTD MESH:C014347 Decitabine affects the expression of CEACAM1 mRNA PMID:23300844 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:5130 flurbiprofen increases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D005480 Flurbiprofen results in increased expression of CEACAM1 mRNA PMID:16949054 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:5132 flutamide decreases expression ISO RGD:67396 E RGD:6480464 20140909 CTD MESH:D005485 Flutamide results in decreased expression of CEACAM1 mRNA PMID:24793618 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:5855 ibuprofen affects expression EXP E RGD:6480464 20120412 CTD MESH:D007052 Ibuprofen affects the expression of CEACAM1 mRNA PMID:17070997 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:6067 isotretinoin decreases expression EXP E RGD:6480464 20120412 CTD MESH:D015474 Isotretinoin results in decreased expression of CEACAM1 mRNA PMID:20436886 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:63632 topotecan increases expression ISO RGD:67396 E RGD:6480464 20160315 CTD MESH:D019772 Topotecan results in increased expression of CEACAM1 mRNA PMID:25729387 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:63632 topotecan multiple interactions ISO RGD:67396 E RGD:6480464 20160315 CTD MESH:D019772 [oxaliplatin co-treated with Topotecan] results in increased expression of CEACAM1 mRNA PMID:25729387 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:6402 leflunomide increases expression EXP E RGD:6480464 20180410 CTD MESH:C045463 leflunomide results in increased expression of CEACAM1 mRNA PMID:28988120 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:6402 leflunomide increases expression ISO RGD:67396 E RGD:6480464 20161213 CTD MESH:C045463 leflunomide results in increased expression of CEACAM1 mRNA PMID:24136188 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:6820 methapyrilene decreases expression ISO RGD:67396 E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in decreased expression of CEACAM1 mRNA PMID:30467583 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:73755 1,2-dimethylhydrazine decreases expression ISO RGD:10240 E RGD:6480464 20200804 CTD MESH:D019813 1,2-Dimethylhydrazine results in decreased expression of CEACAM1 mRNA PMID:22206623 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:7494 nefazodone decreases expression ISO RGD:67396 E RGD:6480464 20160412 CTD MESH:C051752 nefazodone results in decreased expression of CEACAM1 mRNA PMID:24136188 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:7590 nitrofen increases expression ISO RGD:67396 E RGD:6480464 20210810 CTD MESH:C007350 nitrofen results in increased expression of CEACAM1 mRNA PMID:33484710 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:77013 beta-naphthoflavone multiple interactions ISO RGD:67396 E RGD:6480464 20140204 CTD MESH:D019324 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CEACAM1 mRNA PMID:18164116 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:8069 phenobarbital decreases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:D010634 Phenobarbital results in decreased expression of CEACAM1 mRNA PMID:23091169 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:8069 phenobarbital increases expression ISO RGD:10240 E RGD:6480464 20150127 CTD MESH:D010634 Phenobarbital results in increased expression of CEACAM1 mRNA PMID:19270015|PMID:25270620 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:81506 2,3,7,8-Tetrachlorodibenzofuran increases expression ISO RGD:67396 E RGD:6480464 20200609 CTD MESH:C014211 2,3,7,8-tetrachlorodibenzofuran results in increased expression of CEACAM1 mRNA PMID:32109520 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:81582 2,4-dibromophenyl 2,4,5-tribromophenyl ether increases expression EXP E RGD:6480464 20220510 CTD MESH:C477694 2,2',4,4',5-brominated diphenyl ether results in increased expression of CEACAM1 mRNA PMID:26705709 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:82019 folpet decreases expression ISO RGD:10240 E RGD:6480464 20201103 CTD MESH:C005020 folpet results in decreased expression of CEACAM1 mRNA PMID:31558096 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:82362 N-Nitrosopyrrolidine increases expression EXP E RGD:6480464 20200714 CTD MESH:D009242 N-Nitrosopyrrolidine results in increased expression of CEACAM1 mRNA PMID:32234424 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:82436 decabromodiphenyl ether increases expression ISO RGD:67396 E RGD:6480464 20141111 CTD MESH:C010902 decabromobiphenyl ether results in increased expression of CEACAM1 mRNA PMID:23914054 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:84070 sodium arsenate increases expression ISO RGD:10240 E RGD:6480464 20170303 CTD MESH:C009277 sodium arsenate results in increased expression of CEACAM1 mRNA PMID:21795629 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:8489 propiconazole decreases expression ISO RGD:10240 E RGD:6480464 20131220 CTD MESH:C045950 propiconazole results in decreased expression of CEACAM1 mRNA PMID:21278054 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:8887 rofecoxib affects expression EXP E RGD:6480464 20170303 CTD MESH:C116926 rofecoxib affects the expression of CEACAM1 mRNA PMID:17070997 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of CEACAM1 mRNA PMID:38568856 10241 CEACAM1 CEA cell adhesion molecule 1 gene CHEBI:9753 troglitazone decreases expression ISO RGD:10240 E RGD:6480464 20180220 CTD MESH:C057693 troglitazone results in decreased expression of CEACAM1 mRNA PMID:28973697 10249 BSG basigin (Ok blood group) gene CHEBI:10429 beta-lapachone increases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in increased expression of BSG mRNA PMID:38218311 10249 BSG basigin (Ok blood group) gene CHEBI:116509 diuron decreases expression ISO RGD:2220 E RGD:6480464 20120412 CTD MESH:D004237 Diuron results in decreased expression of BSG mRNA PMID:21551480 10249 BSG basigin (Ok blood group) gene CHEBI:132471 (+)-schisandrin B multiple interactions ISO RGD:2220 E RGD:6480464 20190910 CTD MESH:C015499 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of BSG mRNA] PMID:31150632 10249 BSG basigin (Ok blood group) gene CHEBI:15368 acrolein multiple interactions EXP E RGD:6480464 20210112 CTD MESH:D000171 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of BSG mRNA; [Acrolein co-treated with methacrylaldehyde co-treated with Ozone] results in increased oxidation of BSG mRNA; [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of BSG mRNA PMID:32699268|PMID:32845096 10249 BSG basigin (Ok blood group) gene CHEBI:15930 atrazine increases expression EXP E RGD:6480464 20141014 CTD MESH:D001280 Atrazine results in increased expression of BSG mRNA PMID:22378314 10249 BSG basigin (Ok blood group) gene CHEBI:15930 atrazine multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D001280 [Atrazine co-treated with Arsenates] results in increased expression of BSG mRNA PMID:18585445 10249 BSG basigin (Ok blood group) gene CHEBI:16236 ethanol affects splicing ISO RGD:10248 E RGD:6480464 20190507 CTD MESH:D000431 Ethanol affects the splicing of BSG mRNA PMID:30319688 10249 BSG basigin (Ok blood group) gene CHEBI:16236 ethanol decreases expression ISO RGD:2220 E RGD:6480464 20120412 CTD MESH:D000431 Ethanol results in decreased expression of BSG mRNA PMID:17920746 10249 BSG basigin (Ok blood group) gene CHEBI:16236 ethanol multiple interactions ISO RGD:10248 E RGD:6480464 20190910 CTD MESH:D000431 [Carbon Tetrachloride co-treated with Ethanol] results in increased expression of BSG mRNA PMID:30517762 10249 BSG basigin (Ok blood group) gene CHEBI:16243 quercetin increases expression EXP E RGD:6480464 20121009 CTD MESH:D011794 Quercetin results in increased expression of BSG mRNA PMID:21632981 10249 BSG basigin (Ok blood group) gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20230502 CTD MESH:D008070 [NAT10 protein affects the susceptibility to Lipopolysaccharides] which affects the expression of BSG mRNA PMID:35877022 10249 BSG basigin (Ok blood group) gene CHEBI:16469 17beta-estradiol increases expression EXP E RGD:6480464 20130122 CTD MESH:D004958 Estradiol results in increased expression of BSG mRNA PMID:19167446 10249 BSG basigin (Ok blood group) gene CHEBI:16469 17beta-estradiol increases expression ISO RGD:10248 E RGD:6480464 20120412 CTD MESH:D004958 Estradiol results in increased expression of BSG mRNA PMID:15289156 10249 BSG basigin (Ok blood group) gene CHEBI:16602 trichloroethene multiple interactions ISO RGD:10248 E RGD:6480464 20120412 CTD MESH:D014241 PPARA protein inhibits the reaction [Trichloroethylene results in decreased expression of BSG mRNA] PMID:15363585 10249 BSG basigin (Ok blood group) gene CHEBI:16695 uridine 5'-monophosphate decreases expression EXP E RGD:6480464 20230704 CTD MESH:D014542 Uridine Monophosphate results in decreased expression of BSG protein PMID:36574092 10249 BSG basigin (Ok blood group) gene CHEBI:16716 benzene increases expression EXP E RGD:6480464 20160510 CTD MESH:D001554 Benzene results in increased expression of BSG mRNA PMID:24993241 10249 BSG basigin (Ok blood group) gene CHEBI:17347 testosterone multiple interactions ISO RGD:2220 E RGD:6480464 20160705 CTD MESH:D013739 [bisphenol A co-treated with Testosterone] results in increased expression of BSG mRNA PMID:26496021 10249 BSG basigin (Ok blood group) gene CHEBI:17747 bis(2-ethylhexyl) phthalate increases expression ISO RGD:10248 E RGD:6480464 20120412 CTD MESH:D004051 Diethylhexyl Phthalate results in increased expression of BSG mRNA PMID:19850644 10249 BSG basigin (Ok blood group) gene CHEBI:17747 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:10248 E RGD:6480464 20120412 CTD MESH:D004051 PPARA protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of BSG mRNA] PMID:19850644 10249 BSG basigin (Ok blood group) gene CHEBI:178012 FR900359 increases phosphorylation EXP E RGD:6480464 20240305 CTD MESH:C000607068 FR900359 results in increased phosphorylation of BSG protein PMID:37730182 10249 BSG basigin (Ok blood group) gene CHEBI:17833 gentamycin increases expression ISO RGD:2220 E RGD:6480464 20211207 CTD MESH:D005839 Gentamicins results in increased expression of BSG mRNA PMID:33387578 10249 BSG basigin (Ok blood group) gene CHEBI:17967 urethane increases expression EXP E RGD:6480464 20171114 CTD MESH:D014520 Urethane results in increased expression of BSG mRNA PMID:28818685 10249 BSG basigin (Ok blood group) gene CHEBI:18246 (1->4)-beta-D-glucan multiple interactions ISO RGD:10248 E RGD:6480464 20230502 CTD MESH:D002482 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of BSG mRNA PMID:36331819 10249 BSG basigin (Ok blood group) gene CHEBI:18721 3-chloropropane-1,2-diol increases expression ISO RGD:2220 E RGD:6480464 20220705 CTD MESH:D000517 alpha-Chlorohydrin results in increased expression of BSG protein PMID:34915118 10249 BSG basigin (Ok blood group) gene CHEBI:21759 N-methyl-N'-nitro-N-nitrosoguanidine increases expression ISO RGD:2220 E RGD:6480464 20220906 CTD MESH:D008769 Methylnitronitrosoguanidine results in increased expression of BSG mRNA PMID:35103375 10249 BSG basigin (Ok blood group) gene CHEBI:21759 N-methyl-N'-nitro-N-nitrosoguanidine multiple interactions ISO RGD:2220 E RGD:6480464 20220906 CTD MESH:D008769 corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BSG mRNA] PMID:35103375 10249 BSG basigin (Ok blood group) gene CHEBI:229272 N6-(2-Hydroxyethyl)adenosine decreases expression EXP E RGD:6480464 20240206 CTD MESH:C528186 N6-(2-hydroxyethyl)adenosine results in decreased expression of BSG protein PMID:36574092 10249 BSG basigin (Ok blood group) gene CHEBI:23924 enzyme inhibitor multiple interactions EXP E RGD:6480464 20161228 CTD MESH:D004791 [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of BSG protein PMID:23301498 10249 BSG basigin (Ok blood group) gene CHEBI:2504 aflatoxin B1 decreases expression ISO RGD:10248 E RGD:6480464 20120501 CTD MESH:D016604 Aflatoxin B1 results in decreased expression of BSG mRNA PMID:19770486 10249 BSG basigin (Ok blood group) gene CHEBI:25434 bis(2-chloroethyl) sulfide increases expression ISO RGD:10248 E RGD:6480464 20120412 CTD MESH:D009151 Mustard Gas results in increased expression of BSG mRNA PMID:18955075 10249 BSG basigin (Ok blood group) gene CHEBI:2564 aldrin decreases expression ISO RGD:10248 E RGD:6480464 20140107 CTD MESH:D000452 Aldrin results in decreased expression of BSG mRNA PMID:18579281 10249 BSG basigin (Ok blood group) gene CHEBI:25812 ozone multiple interactions EXP E RGD:6480464 20210112 CTD MESH:D010126 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of BSG mRNA; [Acrolein co-treated with methacrylaldehyde co-treated with Ozone] results in increased oxidation of BSG mRNA; [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of BSG mRNA; [Volatile Organic Compounds co-treated with Ozone] results in increased oxidation of BSG mRNA PMID:32699268|PMID:32845096 10249 BSG basigin (Ok blood group) gene CHEBI:2663 amiodarone increases expression EXP E RGD:6480464 20120412 CTD MESH:D000638 Amiodarone results in increased expression of BSG mRNA PMID:19774075 10249 BSG basigin (Ok blood group) gene CHEBI:26710 sodium chloride multiple interactions EXP E RGD:6480464 20250114 CTD MESH:D012965 [Sodium Chloride co-treated with Furaldehyde] results in decreased expression of and affects the localization of BSG protein; [Sodium Chloride co-treated with pyrogallol 1,3-dimethyl ether] results in increased expression of and affects the localization of BSG protein PMID:38598786 10249 BSG basigin (Ok blood group) gene CHEBI:27363 zinc atom multiple interactions ISO RGD:10248 E RGD:6480464 20220111 CTD MESH:D015032 [Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of BSG protein] PMID:34508822 10249 BSG basigin (Ok blood group) gene CHEBI:27385 tetrachloromethane decreases expression ISO RGD:2220 E RGD:6480464 20190910 CTD MESH:D002251 Carbon Tetrachloride results in decreased expression of BSG mRNA PMID:31150632 10249 BSG basigin (Ok blood group) gene CHEBI:27385 tetrachloromethane multiple interactions ISO RGD:10248 E RGD:6480464 20190910 CTD MESH:D002251 [Carbon Tetrachloride co-treated with Ethanol] results in increased expression of BSG mRNA PMID:30517762 10249 BSG basigin (Ok blood group) gene CHEBI:27385 tetrachloromethane multiple interactions ISO RGD:2220 E RGD:6480464 20190910 CTD MESH:D002251 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of BSG mRNA] PMID:31150632 10249 BSG basigin (Ok blood group) gene CHEBI:27470 folic acid multiple interactions ISO RGD:10248 E RGD:6480464 20200804 CTD MESH:D005492 Folic Acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of BSG mRNA] PMID:22206623 10249 BSG basigin (Ok blood group) gene CHEBI:27732 caffeine decreases phosphorylation EXP E RGD:6480464 20221004 CTD MESH:D002110 Caffeine results in decreased phosphorylation of BSG protein PMID:35688186 10249 BSG basigin (Ok blood group) gene CHEBI:27744 glyphosate decreases expression ISO RGD:10248 E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in decreased expression of BSG protein PMID:36173347 10249 BSG basigin (Ok blood group) gene CHEBI:27881 resveratrol decreases expression EXP E RGD:6480464 20130122 CTD MESH:C059514 resveratrol results in decreased expression of BSG protein PMID:17007354 10249 BSG basigin (Ok blood group) gene CHEBI:27881 resveratrol multiple interactions EXP E RGD:6480464 20130212 CTD MESH:C059514 2-chloro-5-nitrobenzanilide inhibits the reaction [resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [resveratrol results in decreased expression of BSG protein]; resveratrol inhibits the reaction [BSG protein results in increased expression of and results in increased secretion of IL18 protein]; resveratrol inhibits the reaction [BSG protein results in increased expression of IL18 mRNA]; resveratrol inhibits the reaction [IL18 protein results in increased expression of BSG mRNA]; resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein]; resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG] PMID:17007354|PMID:17055343|PMID:18647594|PMID:19561311 10249 BSG basigin (Ok blood group) gene CHEBI:27889 lead(0) multiple interactions ISO RGD:10248 E RGD:6480464 20220111 CTD MESH:D007854 [lead acetate results in increased abundance of Lead] which results in decreased expression of BSG protein; [Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of BSG protein] PMID:34508822 10249 BSG basigin (Ok blood group) gene CHEBI:27899 cisplatin decreases response to substance EXP E RGD:6480464 20120412 CTD MESH:D002945 BSG protein results in decreased susceptibility to Cisplatin PMID:21165561 10249 BSG basigin (Ok blood group) gene CHEBI:27899 cisplatin multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D002945 [[BSG binds to PPIA] which results in decreased susceptibility to Cisplatin] which results in increased expression of MMP9; [BSG binds to PPIA] which results in decreased susceptibility to Cisplatin PMID:21956400 10249 BSG basigin (Ok blood group) gene CHEBI:28088 genistein increases expression ISO RGD:10248 E RGD:6480464 20120412 CTD MESH:D019833 Genistein results in increased expression of BSG mRNA PMID:15289156 10249 BSG basigin (Ok blood group) gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:10248 E RGD:6480464 20160210 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of BSG mRNA PMID:21570461|PMID:24680724|PMID:26377647 10249 BSG basigin (Ok blood group) gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:2220 E RGD:6480464 20220111 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of BSG mRNA PMID:34747641 10249 BSG basigin (Ok blood group) gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:10248 E RGD:6480464 20210907 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of BSG mRNA PMID:33956508 10249 BSG basigin (Ok blood group) gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:2220 E RGD:6480464 20211207 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of BSG mRNA PMID:33387578 10249 BSG basigin (Ok blood group) gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of BSG mRNA PMID:33212167 10249 BSG basigin (Ok blood group) gene CHEBI:28284 N(6),N(6)-dimethyladenosine decreases expression EXP E RGD:6480464 20230704 CTD MESH:C021013 N(6),N(6)-dimethyladenosine results in decreased expression of BSG protein PMID:36574092 10249 BSG basigin (Ok blood group) gene CHEBI:28509 chloroethene decreases expression ISO RGD:10248 E RGD:6480464 20130514 CTD MESH:D014752 Vinyl Chloride results in decreased expression of BSG mRNA PMID:18579281 10249 BSG basigin (Ok blood group) gene CHEBI:28619 acrylamide increases expression ISO RGD:2220 E RGD:6480464 20180410 CTD MESH:D020106 Acrylamide results in increased expression of BSG mRNA PMID:28959563 10249 BSG basigin (Ok blood group) gene CHEBI:28748 doxorubicin increases expression EXP E RGD:6480464 20181113 CTD MESH:D004317 Doxorubicin results in increased expression of BSG mRNA PMID:29803840 10249 BSG basigin (Ok blood group) gene CHEBI:28794 coumarin increases phosphorylation EXP E RGD:6480464 20221004 CTD MESH:C030123 coumarin results in increased phosphorylation of BSG protein PMID:35688186 10249 BSG basigin (Ok blood group) gene CHEBI:28885 butan-1-ol multiple interactions EXP E RGD:6480464 20181016 CTD MESH:D020001 [[Gasoline co-treated with 1-Butanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of BSG mRNA PMID:29432896 10249 BSG basigin (Ok blood group) gene CHEBI:29014 cordycepin decreases expression EXP E RGD:6480464 20230704 CTD MESH:C058120 cordycepin results in decreased expression of BSG protein PMID:36574092 10249 BSG basigin (Ok blood group) gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20161228 CTD MESH:C017947 sodium arsenite results in increased expression of BSG mRNA PMID:24570342 10249 BSG basigin (Ok blood group) gene CHEBI:29678 sodium arsenite increases methylation EXP E RGD:6480464 20161228 CTD MESH:C017947 sodium arsenite results in increased methylation of BSG gene PMID:24570342 10249 BSG basigin (Ok blood group) gene CHEBI:29699 tunicamycin decreases expression EXP E RGD:6480464 20141014 CTD MESH:D014415 Tunicamycin results in decreased expression of BSG mRNA PMID:22378314 10249 BSG basigin (Ok blood group) gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of BSG 3' UTR PMID:27901495 10249 BSG basigin (Ok blood group) gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20121009 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of BSG mRNA PMID:20106945|PMID:21632981 10249 BSG basigin (Ok blood group) gene CHEBI:29865 benzo[a]pyrene decreases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in decreased methylation of BSG promoter PMID:27901495 10249 BSG basigin (Ok blood group) gene CHEBI:29865 benzo[a]pyrene decreases methylation ISO RGD:10248 E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in decreased methylation of BSG exon; Benzo(a)pyrene results in decreased methylation of BSG intron PMID:27901495 10249 BSG basigin (Ok blood group) gene CHEBI:30185 zinc(0) multiple interactions ISO RGD:10248 E RGD:6480464 20220111 CTD MESH:D015032 [Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of BSG protein] PMID:34508822 10249 BSG basigin (Ok blood group) gene CHEBI:3048 benzatropine decreases expression EXP E RGD:6480464 20211207 CTD MESH:D001590 Benztropine results in decreased expression of BSG protein PMID:34122009 10249 BSG basigin (Ok blood group) gene CHEBI:30512 silver atom increases expression ISO RGD:10248 E RGD:6480464 20161115 CTD MESH:D012834 Silver results in increased expression of BSG mRNA PMID:27131904 10249 BSG basigin (Ok blood group) gene CHEBI:30563 silicon dioxide decreases expression EXP E RGD:6480464 20160315 CTD MESH:D012822 Silicon Dioxide analog results in decreased expression of BSG mRNA PMID:25895662 10249 BSG basigin (Ok blood group) gene CHEBI:30621 diarsenic trioxide decreases expression EXP E RGD:6480464 20191114 CTD MESH:C006632 Arsenic Trioxide results in decreased expression of BSG mRNA; Arsenic Trioxide results in decreased expression of BSG protein PMID:23232515 10249 BSG basigin (Ok blood group) gene CHEBI:31206 ammonium chloride affects expression ISO RGD:2220 E RGD:6480464 20120412 CTD MESH:D000643 Ammonium Chloride affects the expression of BSG mRNA PMID:16483693 10249 BSG basigin (Ok blood group) gene CHEBI:31638 fulvestrant multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C070081 [bisphenol A co-treated with Fulvestrant] results in increased methylation of BSG gene PMID:31601247 10249 BSG basigin (Ok blood group) gene CHEBI:31767 lead diacetate affects expression ISO RGD:10248 E RGD:6480464 20190312 CTD MESH:C008261 lead acetate affects the expression of BSG mRNA PMID:30615929 10249 BSG basigin (Ok blood group) gene CHEBI:31767 lead diacetate multiple interactions ISO RGD:10248 E RGD:6480464 20190312 CTD MESH:C008261 [lead acetate results in increased abundance of Lead] which results in decreased expression of BSG protein; [Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of BSG protein]; lead acetate results in decreased expression of and affects the localization of BSG protein PMID:30615929|PMID:34508822 10249 BSG basigin (Ok blood group) gene CHEBI:32234 titanium dioxide decreases methylation ISO RGD:10248 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in decreased methylation of BSG gene PMID:35295148 10249 BSG basigin (Ok blood group) gene CHEBI:32234 titanium dioxide increases methylation ISO RGD:10248 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in increased methylation of BSG promoter PMID:35295148 10249 BSG basigin (Ok blood group) gene CHEBI:32509 pirinixic acid increases expression ISO RGD:10248 E RGD:6480464 20140610 CTD MESH:C006253 pirinixic acid results in increased expression of BSG mRNA PMID:18301758|PMID:20813756|PMID:23811191 10249 BSG basigin (Ok blood group) gene CHEBI:32509 pirinixic acid multiple interactions ISO RGD:10248 E RGD:6480464 20120412 CTD MESH:C006253 [pirinixic acid co-treated with PPARA] results in increased expression of BSG mRNA PMID:20813756 10249 BSG basigin (Ok blood group) gene CHEBI:33216 bisphenol A affects expression EXP E RGD:6480464 20191112 CTD MESH:C006780 bisphenol A affects the expression of BSG mRNA PMID:30903817 10249 BSG basigin (Ok blood group) gene CHEBI:33216 bisphenol A decreases expression ISO RGD:10248 E RGD:6480464 20221206 CTD MESH:C006780 bisphenol A results in decreased expression of BSG mRNA PMID:35598803 10249 BSG basigin (Ok blood group) gene CHEBI:33216 bisphenol A increases expression EXP E RGD:6480464 20230307 CTD MESH:C006780 bisphenol A results in increased expression of BSG protein PMID:34186270 10249 BSG basigin (Ok blood group) gene CHEBI:33216 bisphenol A increases expression ISO RGD:2220 E RGD:6480464 20150310 CTD MESH:C006780 bisphenol A results in increased expression of BSG mRNA; bisphenol A results in increased expression of BSG protein PMID:25181051|PMID:32145629 10249 BSG basigin (Ok blood group) gene CHEBI:33216 bisphenol A multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C006780 [bisphenol A co-treated with Fulvestrant] results in increased methylation of BSG gene PMID:31601247 10249 BSG basigin (Ok blood group) gene CHEBI:33216 bisphenol A multiple interactions ISO RGD:2220 E RGD:6480464 20160705 CTD MESH:C006780 [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BSG mRNA; [bisphenol A co-treated with Testosterone] results in increased expression of BSG mRNA PMID:26496021|PMID:36041667 10249 BSG basigin (Ok blood group) gene CHEBI:34372 4,4'-sulfonyldiphenol increases expression EXP E RGD:6480464 20230307 CTD MESH:C543008 bisphenol S results in increased expression of BSG protein PMID:34186270 10249 BSG basigin (Ok blood group) gene CHEBI:34372 4,4'-sulfonyldiphenol multiple interactions ISO RGD:2220 E RGD:6480464 20230307 CTD MESH:C543008 [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BSG mRNA PMID:36041667 10249 BSG basigin (Ok blood group) gene CHEBI:34575 bisphenol F increases expression EXP E RGD:6480464 20230307 CTD MESH:C008745 bisphenol F results in increased expression of BSG protein PMID:34186270 10249 BSG basigin (Ok blood group) gene CHEBI:34575 bisphenol F multiple interactions ISO RGD:2220 E RGD:6480464 20230307 CTD MESH:C008745 [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BSG mRNA PMID:36041667 10249 BSG basigin (Ok blood group) gene CHEBI:34581 Bisphenol B increases expression EXP E RGD:6480464 20230307 CTD MESH:C492482 bisphenol B results in increased expression of BSG protein PMID:34186270 10249 BSG basigin (Ok blood group) gene CHEBI:34631 chlorpyrifos increases expression ISO RGD:10248 E RGD:6480464 20230606 CTD MESH:D004390 Chlorpyrifos results in increased expression of BSG mRNA PMID:37019170 10249 BSG basigin (Ok blood group) gene CHEBI:34687 dibutyl phthalate decreases expression ISO RGD:2220 E RGD:6480464 20120412 CTD MESH:D003993 Dibutyl Phthalate results in decreased expression of BSG mRNA PMID:21266533 10249 BSG basigin (Ok blood group) gene CHEBI:34768 furfural multiple interactions EXP E RGD:6480464 20250114 CTD MESH:D005662 [Sodium Chloride co-treated with Furaldehyde] results in decreased expression of and affects the localization of BSG protein PMID:38598786 10249 BSG basigin (Ok blood group) gene CHEBI:34905 paraquat increases expression ISO RGD:10248 E RGD:6480464 20190219 CTD MESH:D010269 Paraquat results in increased expression of BSG protein PMID:29287252 10249 BSG basigin (Ok blood group) gene CHEBI:35033 triphenyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C005445 triphenyl phosphate affects the expression of BSG mRNA PMID:37042841 10249 BSG basigin (Ok blood group) gene CHEBI:35456 cadmium dichloride decreases expression ISO RGD:10248 E RGD:6480464 20190312 CTD MESH:D019256 Cadmium Chloride results in decreased expression of BSG mRNA PMID:30615929 10249 BSG basigin (Ok blood group) gene CHEBI:35456 cadmium dichloride multiple interactions ISO RGD:10248 E RGD:6480464 20190312 CTD MESH:D019256 Cadmium Chloride affects the expression of and affects the localization of BSG protein PMID:30615929 10249 BSG basigin (Ok blood group) gene CHEBI:35559 furan increases expression ISO RGD:2220 E RGD:6480464 20160119 CTD MESH:C039281 furan results in increased expression of BSG mRNA PMID:26194646 10249 BSG basigin (Ok blood group) gene CHEBI:35559 furan increases methylation ISO RGD:2220 E RGD:6480464 20120918 CTD MESH:C039281 furan results in increased methylation of BSG gene PMID:22079235 10249 BSG basigin (Ok blood group) gene CHEBI:35696 cobalt dichloride decreases expression EXP E RGD:6480464 20120814 CTD MESH:C018021 cobaltous chloride results in decreased expression of BSG mRNA PMID:19376846 10249 BSG basigin (Ok blood group) gene CHEBI:35842 antirheumatic drug decreases expression EXP E RGD:6480464 20161228 CTD MESH:D018501 Antirheumatic Agents results in decreased expression of BSG mRNA PMID:25339124 10249 BSG basigin (Ok blood group) gene CHEBI:35842 antirheumatic drug multiple interactions EXP E RGD:6480464 20161228 CTD MESH:D018501 [Antirheumatic Agents co-treated with Methotrexate] results in decreased expression of BSG mRNA; [Antirheumatic Agents co-treated with Methotrexate] results in decreased expression of BSG protein PMID:23146660 10249 BSG basigin (Ok blood group) gene CHEBI:36467 ciguatoxin CTX1B affects expression ISO RGD:10248 E RGD:6480464 20121009 CTD MESH:D002922 Ciguatoxins affects the expression of BSG mRNA PMID:18353800 10249 BSG basigin (Ok blood group) gene CHEBI:36740 alpha-pinene multiple interactions EXP E RGD:6480464 20210112 CTD MESH:C005451 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of BSG mRNA; [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of BSG mRNA PMID:32699268 10249 BSG basigin (Ok blood group) gene CHEBI:3750 clofibrate decreases expression ISO RGD:10248 E RGD:6480464 20120515 CTD MESH:D002994 Clofibrate results in decreased expression of BSG mRNA PMID:17585979 10249 BSG basigin (Ok blood group) gene CHEBI:3750 clofibrate multiple interactions EXP E RGD:6480464 20120717 CTD MESH:D002994 Clofibrate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG mRNA]; Clofibrate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein] PMID:16860414 10249 BSG basigin (Ok blood group) gene CHEBI:37537 phorbol 13-acetate 12-myristate increases expression EXP E RGD:6480464 20130122 CTD MESH:D013755 Tetradecanoylphorbol Acetate results in increased expression of BSG mRNA; Tetradecanoylphorbol Acetate results in increased expression of BSG protein PMID:16860414|PMID:17055343|PMID:18647594 10249 BSG basigin (Ok blood group) gene CHEBI:37537 phorbol 13-acetate 12-myristate multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D013755 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein]]; Clofibrate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG mRNA]; Clofibrate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein]; Pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG mRNA]; Pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein]; Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein]; Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG mRNA]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein] PMID:16860414|PMID:17055343|PMID:18647594 10249 BSG basigin (Ok blood group) gene CHEBI:3884 corilagin multiple interactions ISO RGD:2220 E RGD:6480464 20220906 CTD MESH:C049096 corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BSG mRNA] PMID:35103375 10249 BSG basigin (Ok blood group) gene CHEBI:3908 coumestrol multiple interactions EXP E RGD:6480464 20130409 CTD MESH:D003375 [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BSG mRNA PMID:19167446 10249 BSG basigin (Ok blood group) gene CHEBI:39285 chloropicrin increases expression EXP E RGD:6480464 20151215 CTD MESH:C100187 chloropicrin results in increased expression of BSG mRNA PMID:26352163 10249 BSG basigin (Ok blood group) gene CHEBI:39421 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:10248 E RGD:6480464 20230502 CTD MESH:C076994 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of BSG mRNA; [perfluorooctane sulfonic acid co-treated with Pectins] results in increased expression of BSG mRNA PMID:36331819 10249 BSG basigin (Ok blood group) gene CHEBI:39483 sodium dichromate increases expression ISO RGD:10248 E RGD:6480464 20201103 CTD MESH:C016104 sodium bichromate results in increased expression of BSG mRNA PMID:31558096 10249 BSG basigin (Ok blood group) gene CHEBI:3962 curcumin decreases response to substance ISO RGD:10248 E RGD:6480464 20120412 CTD MESH:D003474 BSG protein results in decreased susceptibility to Curcumin PMID:18379992 10249 BSG basigin (Ok blood group) gene CHEBI:39867 valproic acid affects expression EXP E RGD:6480464 20151013 CTD MESH:D014635 Valproic Acid affects the expression of BSG mRNA PMID:25979313 10249 BSG basigin (Ok blood group) gene CHEBI:39867 valproic acid decreases expression EXP E RGD:6480464 20140513 CTD MESH:D014635 Valproic Acid results in decreased expression of BSG mRNA PMID:23179753 10249 BSG basigin (Ok blood group) gene CHEBI:39867 valproic acid increases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in increased methylation of BSG gene PMID:29154799 10249 BSG basigin (Ok blood group) gene CHEBI:4027 cyclophosphamide decreases expression ISO RGD:10248 E RGD:6480464 20120412 CTD MESH:D003520 Cyclophosphamide results in decreased expression of BSG mRNA PMID:15331540 10249 BSG basigin (Ok blood group) gene CHEBI:41922 diethylstilbestrol increases expression ISO RGD:10248 E RGD:6480464 20120412 CTD MESH:D004054 Diethylstilbestrol results in increased expression of BSG mRNA PMID:15289156 10249 BSG basigin (Ok blood group) gene CHEBI:4357 deguelin increases expression EXP E RGD:6480464 20210810 CTD MESH:C107676 deguelin results in increased expression of BSG mRNA PMID:33512557 10249 BSG basigin (Ok blood group) gene CHEBI:44185 methotrexate decreases expression EXP E RGD:6480464 20151013 CTD MESH:D008727 Methotrexate results in decreased expression of BSG mRNA PMID:25339124 10249 BSG basigin (Ok blood group) gene CHEBI:44185 methotrexate multiple interactions EXP E RGD:6480464 20151110 CTD MESH:D008727 [Antirheumatic Agents co-treated with Methotrexate] results in decreased expression of BSG mRNA; [Antirheumatic Agents co-treated with Methotrexate] results in decreased expression of BSG protein PMID:23146660 10249 BSG basigin (Ok blood group) gene CHEBI:46024 trichostatin A affects expression EXP E RGD:6480464 20170613 CTD MESH:C012589 trichostatin A affects the expression of BSG mRNA PMID:28542535 10249 BSG basigin (Ok blood group) gene CHEBI:47286 CU-O LINKAGE decreases expression EXP E RGD:6480464 20170307 CTD MESH:C030973 cupric oxide results in decreased expression of BSG protein PMID:25470785 10249 BSG basigin (Ok blood group) gene CHEBI:4903 17alpha-ethynylestradiol increases expression ISO RGD:10248 E RGD:6480464 20120412 CTD MESH:D004997 Ethinyl Estradiol results in increased expression of BSG mRNA PMID:17942748 10249 BSG basigin (Ok blood group) gene CHEBI:4903 17alpha-ethynylestradiol increases expression ISO RGD:2220 E RGD:6480464 20120412 CTD MESH:D004997 Ethinyl Estradiol results in increased expression of BSG mRNA PMID:17108234 10249 BSG basigin (Ok blood group) gene CHEBI:49900 arsenous acid decreases expression EXP E RGD:6480464 20191114 CTD MESH:C032793 Arsenic Trioxide results in decreased expression of BSG mRNA; Arsenic Trioxide results in decreased expression of BSG protein PMID:23232515 10249 BSG basigin (Ok blood group) gene CHEBI:6067 isotretinoin decreases expression EXP E RGD:6480464 20120412 CTD MESH:D015474 Isotretinoin results in decreased expression of BSG mRNA PMID:20436886 10249 BSG basigin (Ok blood group) gene CHEBI:6078 ivermectin decreases expression EXP E RGD:6480464 20210907 CTD MESH:D007559 Ivermectin results in decreased expression of BSG protein PMID:32959892 10249 BSG basigin (Ok blood group) gene CHEBI:62984 zinc acetate multiple interactions ISO RGD:10248 E RGD:6480464 20220111 CTD MESH:D019345 [Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of BSG protein] PMID:34508822 10249 BSG basigin (Ok blood group) gene CHEBI:65347 carfilzomib decreases expression EXP E RGD:6480464 20210209 CTD MESH:C524865 carfilzomib results in decreased expression of BSG mRNA PMID:27769052 10249 BSG basigin (Ok blood group) gene CHEBI:65347 carfilzomib multiple interactions EXP E RGD:6480464 20210209 CTD MESH:C524865 carfilzomib promotes the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of BSG mRNA] PMID:27769052 10249 BSG basigin (Ok blood group) gene CHEBI:68641 (-)-cotinine multiple interactions EXP E RGD:6480464 20220906 CTD MESH:D003367 [Tobacco Smoke Pollution results in increased abundance of Cotinine] which affects the methylation of BSG gene PMID:34009014 10249 BSG basigin (Ok blood group) gene CHEBI:6925 microcystin-LR decreases expression ISO RGD:10248 E RGD:6480464 20120412 CTD MESH:C057862 cyanoginosin LR results in decreased expression of BSG mRNA PMID:17383702 10249 BSG basigin (Ok blood group) gene CHEBI:69478 cannabidiol decreases expression EXP E RGD:6480464 20210209 CTD MESH:D002185 Cannabidiol results in decreased expression of BSG mRNA PMID:27769052 10249 BSG basigin (Ok blood group) gene CHEBI:69478 cannabidiol multiple interactions EXP E RGD:6480464 20210209 CTD MESH:D002185 [Dronabinol co-treated with Cannabidiol] results in decreased expression of BSG mRNA; Cannabidiol promotes the reaction [Dronabinol results in decreased expression of BSG mRNA]; carfilzomib promotes the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of BSG mRNA]; Dronabinol promotes the reaction [Cannabidiol results in decreased expression of BSG mRNA] PMID:27769052 10249 BSG basigin (Ok blood group) gene CHEBI:72544 flavonoids increases expression EXP E RGD:6480464 20170303 CTD MESH:D005419 Flavonoids results in increased expression of BSG mRNA PMID:15465739 10249 BSG basigin (Ok blood group) gene CHEBI:72564 temozolomide decreases expression EXP E RGD:6480464 20210706 CTD MESH:C047246 Temozolomide results in decreased expression of BSG mRNA PMID:31758290 10249 BSG basigin (Ok blood group) gene CHEBI:72754 bisphenol AF increases expression EXP E RGD:6480464 20250114 CTD MESH:C583074 bisphenol AF results in increased expression of BSG protein PMID:34186270 10249 BSG basigin (Ok blood group) gene CHEBI:73755 1,2-dimethylhydrazine increases expression ISO RGD:10248 E RGD:6480464 20200804 CTD MESH:D019813 1,2-Dimethylhydrazine results in increased expression of BSG mRNA PMID:22206623 10249 BSG basigin (Ok blood group) gene CHEBI:73755 1,2-dimethylhydrazine multiple interactions ISO RGD:10248 E RGD:6480464 20200804 CTD MESH:D019813 Folic Acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of BSG mRNA] PMID:22206623 10249 BSG basigin (Ok blood group) gene CHEBI:77986 dibenziodolium multiple interactions EXP E RGD:6480464 20140415 CTD MESH:C007517 diphenyleneiodonium inhibits the reaction [IL18 protein results in increased expression of BSG mRNA] PMID:19561311 10249 BSG basigin (Ok blood group) gene CHEBI:81555 Enterolactone multiple interactions EXP E RGD:6480464 20151103 CTD MESH:C029497 [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BSG mRNA PMID:19167446 10249 BSG basigin (Ok blood group) gene CHEBI:81582 2,4-dibromophenyl 2,4,5-tribromophenyl ether affects expression ISO RGD:10248 E RGD:6480464 20240903 CTD MESH:C477694 2,2',4,4',5-brominated diphenyl ether affects the expression of BSG mRNA PMID:38648751 10249 BSG basigin (Ok blood group) gene CHEBI:81794 thifluzamide increases expression EXP E RGD:6480464 20210810 CTD MESH:C494892 thifluzamide results in increased expression of BSG mRNA PMID:33512557 10249 BSG basigin (Ok blood group) gene CHEBI:81892 Brodifacoum increases expression ISO RGD:2220 E RGD:6480464 20171114 CTD MESH:C013418 bromfenacoum results in increased expression of BSG protein PMID:28903499 10249 BSG basigin (Ok blood group) gene CHEBI:82019 folpet increases expression ISO RGD:10248 E RGD:6480464 20201103 CTD MESH:C005020 folpet results in increased expression of BSG mRNA PMID:31558096 10249 BSG basigin (Ok blood group) gene CHEBI:8228 pioglitazone decreases expression EXP E RGD:6480464 20130122 CTD MESH:C060836 pioglitazone results in decreased expression of BSG protein PMID:17007354 10249 BSG basigin (Ok blood group) gene CHEBI:8228 pioglitazone multiple interactions EXP E RGD:6480464 20120717 CTD MESH:C060836 2-chloro-5-nitrobenzanilide inhibits the reaction [pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein]]; pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG mRNA]; pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein] PMID:16860414|PMID:17055343 10249 BSG basigin (Ok blood group) gene CHEBI:90705 SB 203580 multiple interactions EXP E RGD:6480464 20170303 CTD MESH:C093642 SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG mRNA]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein] PMID:18647594 10249 BSG basigin (Ok blood group) gene CHEBI:91108 SB 431542 increases expression EXP E RGD:6480464 20161220 CTD MESH:C459179 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of BSG protein PMID:25670856 10249 BSG basigin (Ok blood group) gene CHEBI:91108 SB 431542 multiple interactions EXP E RGD:6480464 20240206 CTD MESH:C459179 [LDN 193189 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in decreased expression of BSG protein PMID:37664457 10249 BSG basigin (Ok blood group) gene CHEBI:9141 silver(0) increases expression ISO RGD:10248 E RGD:6480464 20161115 CTD MESH:D012834 Silver results in increased expression of BSG mRNA PMID:27131904 10249 BSG basigin (Ok blood group) gene CHEBI:9190 solasodine decreases expression EXP E RGD:6480464 20170516 CTD MESH:C012037 solasodine results in decreased expression of BSG mRNA PMID:28283413 10249 BSG basigin (Ok blood group) gene CHEBI:955 2,6-dimethoxyphenol multiple interactions EXP E RGD:6480464 20250114 CTD MESH:C010120 [Sodium Chloride co-treated with pyrogallol 1,3-dimethyl ether] results in increased expression of and affects the localization of BSG protein PMID:38598786 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:101278 diltiazem multiple interactions ISO RGD:1550302 E RGD:6480464 20161025 CTD MESH:D004110 Diltiazem inhibits the reaction [Iron-Dextran Complex affects the expression of CACNA1C protein] PMID:27095094 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:114786 sodium disulfite decreases expression ISO RGD:2245 E RGD:6480464 20220906 CTD MESH:C005200 sodium metabisulfite results in decreased expression of CACNA1C mRNA; sodium metabisulfite results in decreased expression of CACNA1C protein PMID:25463229|PMID:26015265 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:132267 triptonide decreases expression ISO RGD:1550302 E RGD:6480464 20210406 CTD MESH:C084079 triptonide results in decreased expression of CACNA1C mRNA PMID:33045310 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:135937 enzacamene multiple interactions ISO RGD:2245 E RGD:6480464 20170307 CTD MESH:C038939 [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA1C mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1C mRNA PMID:25607892 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:136004 linsidomine multiple interactions EXP E RGD:6480464 20170307 CTD MESH:C002385 [linsidomine co-treated with Peroxynitrous Acid] results in increased nitrosation of CACNA1C protein PMID:17551092 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:15367 all-trans-retinoic acid increases expression ISO RGD:2245 E RGD:6480464 20130416 CTD MESH:D014212 Tretinoin results in increased expression of CACNA1C mRNA PMID:23056435 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:15379 dioxygen multiple interactions ISO RGD:2245 E RGD:6480464 20220510 CTD MESH:D010100 [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in decreased expression of CACNA1C mRNA PMID:33729688 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:15743 butanal increases expression EXP E RGD:6480464 20150825 CTD MESH:C018475 butyraldehyde results in increased expression of CACNA1C mRNA PMID:26079696 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:15930 atrazine affects methylation ISO RGD:2245 E RGD:6480464 20230905 CTD MESH:D001280 Atrazine affects the methylation of CACNA1C gene PMID:35440735 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:16236 ethanol affects expression ISO RGD:1550302 E RGD:6480464 20190507 CTD MESH:D000431 Ethanol affects the expression of CACNA1C mRNA PMID:30319688 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:16236 ethanol decreases expression ISO RGD:1550302 E RGD:6480464 20220607 CTD MESH:D000431 Ethanol results in decreased expression of CACNA1C mRNA; Ethanol results in decreased expression of CACNA1C protein PMID:34864093 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:16236 ethanol increases expression ISO RGD:1550302 E RGD:6480464 20190507 CTD MESH:D000431 Ethanol results in increased expression of CACNA1C mRNA PMID:30319688 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:16236 ethanol multiple interactions ISO RGD:1550302 E RGD:6480464 20220607 CTD MESH:D000431 ferrostatin-1 inhibits the reaction [Ethanol results in decreased expression of CACNA1C mRNA] PMID:34864093 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:16598 DDE multiple interactions ISO RGD:2245 E RGD:6480464 20160705 CTD MESH:D003633 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1C mRNA PMID:25607892 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:16602 trichloroethene decreases expression EXP E RGD:6480464 20150714 CTD MESH:D014241 Trichloroethylene results in decreased expression of CACNA1C mRNA PMID:25847060 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:16602 trichloroethene increases expression ISO RGD:2245 E RGD:6480464 20211207 CTD MESH:D014241 Trichloroethylene results in increased expression of CACNA1C mRNA PMID:33387578 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:167808 Nor-9-carboxy-delta9-THC multiple interactions EXP E RGD:6480464 20210406 CTD MESH:C016780 [Cannabinoids results in increased abundance of 11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid] which affects the methylation of CACNA1C gene PMID:30521419 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:16836 4-nitrophenol decreases expression ISO RGD:1550302 E RGD:6480464 20220111 CTD MESH:C024836 4-nitrophenol results in decreased expression of CACNA1C mRNA PMID:34673133 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:16842 formaldehyde decreases expression ISO RGD:2245 E RGD:6480464 20191112 CTD MESH:D005557 Formaldehyde results in decreased expression of CACNA1C protein PMID:30974163 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:17026 progesterone increases expression ISO RGD:2245 E RGD:6480464 20130723 CTD MESH:D011374 Progesterone results in increased expression of CACNA1C mRNA PMID:20726854 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:173086 ferrostatin-1 multiple interactions ISO RGD:1550302 E RGD:6480464 20220607 CTD MESH:C573944 ferrostatin-1 inhibits the reaction [Ethanol results in decreased expression of CACNA1C mRNA] PMID:34864093 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:17688 (S)-nicotine increases expression ISO RGD:1550302 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in increased expression of CACNA1C protein PMID:11756415 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:177406 Bardoxolone methyl decreases activity EXP E RGD:6480464 20210907 CTD MESH:C445068 bardoxolone methyl results in decreased activity of CACNA1C protein PMID:28790194 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:17747 bis(2-ethylhexyl) phthalate increases expression ISO RGD:2245 E RGD:6480464 20120613 CTD MESH:D004051 Diethylhexyl Phthalate results in increased expression of CACNA1C mRNA PMID:20920545 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:17747 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:2245 E RGD:6480464 20160705 CTD MESH:D004051 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1C mRNA PMID:25607892 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of CACNA1C exon; aflatoxin B2 results in increased methylation of CACNA1C intron PMID:30157460 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:18248 iron atom multiple interactions EXP E RGD:6480464 20210504 CTD MESH:D007501 [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein] PMID:33285147 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:18422 sulfur dioxide decreases expression ISO RGD:2245 E RGD:6480464 20240604 CTD MESH:D013458 Sulfur Dioxide results in decreased expression of CACNA1C mRNA; Sulfur Dioxide results in decreased expression of CACNA1C protein PMID:26112951 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:18723 nicotine increases expression ISO RGD:1550302 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in increased expression of CACNA1C protein PMID:11756415 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:22977 cadmium atom affects expression EXP E RGD:6480464 20230502 CTD MESH:D002104 Cadmium affects the expression of CACNA1C mRNA PMID:36321828 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:22977 cadmium atom multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D002104 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of CACNA1C mRNA PMID:35301059 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:22977 cadmium atom multiple interactions ISO RGD:1550302 E RGD:6480464 20231205 CTD MESH:D002104 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of CACNA1C mRNA PMID:37325564 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:22984 calcium atom increases transport EXP E RGD:6480464 20120412 CTD MESH:D002118 CACNA1C protein results in increased transport of Calcium PMID:15299022 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:22984 calcium atom increases transport ISO RGD:2245 E RGD:6480464 20120412 CTD MESH:D002118 CACNA1C protein results in increased transport of Calcium PMID:14634047 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:22984 calcium atom multiple interactions EXP E RGD:6480464 20120515 CTD MESH:D002118 [CACNA1C protein co-treated with CACNB3 protein] results in increased transport of Calcium; [CACNA2D4 protein binds to CACNA1C protein binds to CACNB3 protein] which results in increased transport of Calcium; CACNA2D4 protein promotes the reaction [[CACNA1C protein co-treated with CACNB3 protein] results in increased transport of Calcium] PMID:12181424 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:22984 calcium atom multiple interactions ISO RGD:2245 E RGD:6480464 20120412 CTD MESH:D002118 Allethrins inhibits the reaction [CACNA1C protein results in increased transport of Calcium] PMID:14634047 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:2430 aconitine decreases expression ISO RGD:2245 E RGD:6480464 20210309 CTD MESH:D000157 Aconitine results in decreased expression of CACNA1C protein PMID:33236894 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:2504 aflatoxin B1 decreases expression EXP E RGD:6480464 20200714 CTD MESH:D016604 Aflatoxin B1 results in decreased expression of CACNA1C mRNA PMID:32234424 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20161025 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of CACNA1C gene PMID:27153756 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of CACNA1C exon; Aflatoxin B1 results in increased methylation of CACNA1C intron PMID:30157460 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:25351 mevalonic acid multiple interactions ISO RGD:2245 E RGD:6480464 20230502 CTD MESH:D008798 Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C protein]; Mevalonic Acid inhibits the reaction [Verapamil results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Verapamil results in decreased expression of CACNA1C protein] PMID:19791473 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:25942 peroxynitrous acid increases metabolic processing EXP E RGD:6480464 20121218 CTD MESH:D030421 Peroxynitrous Acid results in increased metabolism of CACNA1C protein alternative form PMID:20128810 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:25942 peroxynitrous acid multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D030421 [linsidomine co-treated with Peroxynitrous Acid] results in increased nitrosation of CACNA1C protein; [Peroxynitrous Acid results in increased metabolism of CACNA1C protein alternative form] which results in decreased phosphorylation of CREB1 protein; Peroxynitrous Acid inhibits the reaction [[Potassium Chloride co-treated with CACNA1C protein alternative form] results in increased phosphorylation of CREB1 protein] PMID:17551092|PMID:20128810 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:2663 amiodarone decreases expression ISO RGD:1550302 E RGD:6480464 20120412 CTD MESH:D000638 Amiodarone results in decreased expression of CACNA1C mRNA PMID:15520326 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:2679 amphetamine increases expression ISO RGD:2245 E RGD:6480464 20191114 CTD MESH:D000661 Amphetamine results in increased expression of CACNA1C mRNA; Amphetamine results in increased expression of CACNA1C protein PMID:15329393 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:27363 zinc atom increases expression ISO RGD:2245 E RGD:6480464 20120515 CTD MESH:D015032 Zinc results in increased expression of CACNA1C mRNA PMID:15159208|PMID:17074742 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:27385 tetrachloromethane increases expression ISO RGD:2245 E RGD:6480464 20190910 CTD MESH:D002251 Carbon Tetrachloride results in increased expression of CACNA1C mRNA PMID:31150632 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:27563 arsenic atom affects methylation EXP E RGD:6480464 20150310 CTD MESH:D001151 Arsenic affects the methylation of CACNA1C gene PMID:25304211 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:27856 acetamide increases expression ISO RGD:2245 E RGD:6480464 20200519 CTD MESH:C030686 acetamide results in increased expression of CACNA1C mRNA PMID:31881176 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:27881 resveratrol decreases expression ISO RGD:1550302 E RGD:6480464 20130212 CTD MESH:C059514 resveratrol results in decreased expression of CACNA1C mRNA PMID:22610192 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:27889 lead(0) affects expression EXP E RGD:6480464 20171114 CTD MESH:D007854 Lead affects the expression of CACNA1C mRNA PMID:28903495 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:27899 cisplatin decreases expression ISO RGD:1550302 E RGD:6480464 20120412 CTD MESH:D002945 Cisplatin results in decreased expression of CACNA1C mRNA PMID:21151649 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1550302 E RGD:6480464 20120412 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of CACNA1C mRNA PMID:19465110 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:2245 E RGD:6480464 20200609 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of CACNA1C mRNA PMID:32109520 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1550302 E RGD:6480464 20120515 CTD MESH:D013749 Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CACNA1C promoter] PMID:19654925 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:28201 rotenone increases expression ISO RGD:2245 E RGD:6480464 20200609 CTD MESH:D012402 Rotenone results in increased expression of CACNA1C mRNA PMID:31585160 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:28201 rotenone multiple interactions ISO RGD:2245 E RGD:6480464 20200609 CTD MESH:D012402 [3-bromo-2-oxopropionic acid co-treated with Rotenone] results in increased expression of CACNA1C mRNA PMID:31585160 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:28748 doxorubicin affects methylation ISO RGD:2245 E RGD:6480464 20180116 CTD MESH:D004317 Doxorubicin affects the methylation of CACNA1C gene PMID:28962528 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:28748 doxorubicin decreases expression EXP E RGD:6480464 20181113 CTD MESH:D004317 Doxorubicin results in decreased expression of CACNA1C mRNA PMID:29803840 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:2904 atenolol increases response to substance EXP E RGD:6480464 20120412 CTD MESH:D001262 CACNA1C gene polymorphism results in increased susceptibility to Atenolol PMID:20031608 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29320 calcium(0) increases transport EXP E RGD:6480464 20120412 CTD MESH:D002118 CACNA1C protein results in increased transport of Calcium PMID:15299022 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29320 calcium(0) increases transport ISO RGD:2245 E RGD:6480464 20120412 CTD MESH:D002118 CACNA1C protein results in increased transport of Calcium PMID:14634047 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29320 calcium(0) multiple interactions EXP E RGD:6480464 20120515 CTD MESH:D002118 [CACNA1C protein co-treated with CACNB3 protein] results in increased transport of Calcium; [CACNA2D4 protein binds to CACNA1C protein binds to CACNB3 protein] which results in increased transport of Calcium; CACNA2D4 protein promotes the reaction [[CACNA1C protein co-treated with CACNB3 protein] results in increased transport of Calcium] PMID:12181424 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29320 calcium(0) multiple interactions ISO RGD:2245 E RGD:6480464 20120412 CTD MESH:D002118 Allethrins inhibits the reaction [CACNA1C protein results in increased transport of Calcium] PMID:14634047 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29678 sodium arsenite affects methylation EXP E RGD:6480464 20171114 CTD MESH:C017947 sodium arsenite affects the methylation of CACNA1C gene PMID:28589171 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20161228 CTD MESH:C017947 sodium arsenite results in decreased expression of CACNA1C mRNA PMID:21776218 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of CACNA1C mRNA PMID:38568856 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29699 tunicamycin increases expression ISO RGD:1550302 E RGD:6480464 20120412 CTD MESH:D014415 Tunicamycin results in increased expression of CACNA1C mRNA PMID:17127020 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of CACNA1C 3' UTR; Benzo(a)pyrene affects the methylation of CACNA1C exon; Benzo(a)pyrene affects the methylation of CACNA1C intron PMID:27901495|PMID:30157460 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29865 benzo[a]pyrene affects methylation ISO RGD:1550302 E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of CACNA1C exon; Benzo(a)pyrene affects the methylation of CACNA1C intron PMID:27901495 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20120918 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of CACNA1C mRNA PMID:22316170 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29865 benzo[a]pyrene increases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in increased methylation of CACNA1C promoter PMID:27901495 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29865 benzo[a]pyrene increases methylation ISO RGD:1550302 E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in increased methylation of CACNA1C intron PMID:27901495 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:29865 benzo[a]pyrene multiple interactions ISO RGD:1550302 E RGD:6480464 20120515 CTD MESH:D001564 Benzo(a)pyrene promotes the reaction [AHR protein binds to CACNA1C promoter] PMID:19654925 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:30185 zinc(0) increases expression ISO RGD:2245 E RGD:6480464 20120515 CTD MESH:D015032 Zinc results in increased expression of CACNA1C mRNA PMID:15159208|PMID:17074742 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:30512 silver atom decreases expression ISO RGD:1550302 E RGD:6480464 20161115 CTD MESH:D012834 Silver results in decreased expression of CACNA1C mRNA PMID:27131904 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:30621 diarsenic trioxide decreases expression ISO RGD:1550302 E RGD:6480464 20191114 CTD MESH:C006632 Arsenic Trioxide results in decreased expression of CACNA1C mRNA PMID:24831965 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:31638 fulvestrant increases methylation EXP E RGD:6480464 20220308 CTD MESH:C070081 Fulvestrant results in increased methylation of CACNA1C gene PMID:31601247 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:31638 fulvestrant multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C070081 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of CACNA1C gene PMID:31601247 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:32234 titanium dioxide decreases methylation ISO RGD:1550302 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in decreased methylation of CACNA1C gene PMID:35295148 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:32234 titanium dioxide increases methylation ISO RGD:1550302 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in increased methylation of CACNA1C gene PMID:35295148 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:32588 potassium chloride multiple interactions EXP E RGD:6480464 20121218 CTD MESH:D011189 [Potassium Chloride co-treated with CACNA1C protein alternative form] results in increased phosphorylation of CREB1 protein; Nifedipine inhibits the reaction [[Potassium Chloride co-treated with CACNA1C protein alternative form] results in increased phosphorylation of CREB1 protein]; Peroxynitrous Acid inhibits the reaction [[Potassium Chloride co-treated with CACNA1C protein alternative form] results in increased phosphorylation of CREB1 protein] PMID:20128810 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:32595 barium(0) increases transport ISO RGD:2245 E RGD:6480464 20120412 CTD MESH:D001464 CACNA1C protein results in increased transport of Barium PMID:17569661 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33192 sodium cyanide increases phosphorylation ISO RGD:1550302 E RGD:6480464 20191112 CTD MESH:D012966 Sodium Cyanide results in increased phosphorylation of CACNA1C protein PMID:31173149 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33192 sodium cyanide multiple interactions ISO RGD:1550302 E RGD:6480464 20191112 CTD MESH:D012966 [Sodium Cyanide results in increased activity of PRKCE protein] which results in increased phosphorylation of CACNA1C protein; Methylene Blue inhibits the reaction [Sodium Cyanide results in increased phosphorylation of CACNA1C protein] PMID:31173149 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33216 bisphenol A affects expression ISO RGD:2245 E RGD:6480464 20191210 CTD MESH:C006780 bisphenol A affects the expression of CACNA1C mRNA PMID:30816183 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20241001 CTD MESH:C006780 bisphenol A results in decreased expression of CACNA1C mRNA PMID:36385337 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33216 bisphenol A decreases expression ISO RGD:1550302 E RGD:6480464 20230207 CTD MESH:C006780 bisphenol A results in decreased expression of CACNA1C mRNA PMID:32156529 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33216 bisphenol A decreases expression ISO RGD:2245 E RGD:6480464 20150310 CTD MESH:C006780 bisphenol A results in decreased expression of CACNA1C mRNA PMID:25181051 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33216 bisphenol A decreases methylation EXP E RGD:6480464 20220308 CTD MESH:C006780 bisphenol A results in decreased methylation of CACNA1C gene PMID:31601247 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33216 bisphenol A increases expression EXP E RGD:6480464 20120412 CTD MESH:C006780 bisphenol A results in increased expression of CACNA1C mRNA PMID:17989879 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33216 bisphenol A increases expression ISO RGD:1550302 E RGD:6480464 20191112 CTD MESH:C006780 bisphenol A results in increased expression of CACNA1C mRNA PMID:30951980|PMID:32370801|PMID:34585602 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33216 bisphenol A increases methylation ISO RGD:1550302 E RGD:6480464 20180116 CTD MESH:C006780 bisphenol A results in increased methylation of CACNA1C promoter PMID:27312807 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33216 bisphenol A multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C006780 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of CACNA1C gene PMID:31601247 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33216 bisphenol A multiple interactions ISO RGD:1550302 E RGD:6480464 20181113 CTD MESH:C006780 [bisphenol A co-treated with Streptozocin] results in decreased expression of CACNA1C mRNA PMID:29935216 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33216 bisphenol A multiple interactions ISO RGD:2245 E RGD:6480464 20160705 CTD MESH:C006780 [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA1C mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1C mRNA PMID:25607892 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:33217 3,3',5,5'-tetrabromobisphenol A increases expression EXP E RGD:6480464 20221101 CTD MESH:C020806 tetrabromobisphenol A results in increased expression of CACNA1C mRNA PMID:35321852 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:34372 4,4'-sulfonyldiphenol affects methylation ISO RGD:1550302 E RGD:6480464 20230207 CTD MESH:C543008 bisphenol S affects the methylation of CACNA1C gene PMID:31683443 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:34372 4,4'-sulfonyldiphenol increases expression ISO RGD:1550302 E RGD:6480464 20191112 CTD MESH:C543008 bisphenol S results in increased expression of CACNA1C mRNA PMID:30951980 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:34567 benzo[e]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene affects the methylation of CACNA1C intron PMID:30157460 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of CACNA1C exon PMID:30157460 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:34572 allethrin multiple interactions ISO RGD:2245 E RGD:6480464 20120412 CTD MESH:D000487 [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of CACNA1C protein; Allethrins inhibits the reaction [CACNA1C protein results in increased transport of Calcium] PMID:14634047|PMID:34896426 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:34575 bisphenol F increases expression ISO RGD:1550302 E RGD:6480464 20191112 CTD MESH:C008745 bisphenol F results in increased expression of CACNA1C mRNA PMID:30951980 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:34631 chlorpyrifos decreases expression ISO RGD:2245 E RGD:6480464 20121009 CTD MESH:D004390 Chlorpyrifos results in decreased expression of CACNA1C mRNA PMID:18668222 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:34687 dibutyl phthalate multiple interactions ISO RGD:2245 E RGD:6480464 20160705 CTD MESH:D003993 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1C mRNA PMID:25607892 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:34873 N-nitrosodiethylamine increases expression ISO RGD:1550302 E RGD:6480464 20160412 CTD MESH:D004052 Diethylnitrosamine results in increased expression of CACNA1C mRNA PMID:24535843 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:34905 paraquat increases expression ISO RGD:2245 E RGD:6480464 20130514 CTD MESH:D010269 Paraquat results in increased expression of CACNA1C mRNA PMID:18198484 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:34905 paraquat multiple interactions ISO RGD:1550302 E RGD:6480464 20230905 CTD MESH:D010269 [Maneb co-treated with Paraquat] results in decreased expression of CACNA1C mRNA PMID:36117858 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:35033 triphenyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C005445 triphenyl phosphate affects the expression of CACNA1C mRNA PMID:37042841 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:35176 zinc sulfate increases expression ISO RGD:2245 E RGD:6480464 20120412 CTD MESH:D019287 Zinc Sulfate results in increased expression of CACNA1C mRNA PMID:17074742 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of CACNA1C mRNA PMID:38568856 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:35456 cadmium dichloride multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D019256 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of CACNA1C mRNA PMID:35301059 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:35456 cadmium dichloride multiple interactions ISO RGD:1550302 E RGD:6480464 20231205 CTD MESH:D019256 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of CACNA1C mRNA PMID:37325564 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:35497 androgen antagonist multiple interactions ISO RGD:2245 E RGD:6480464 20170228 CTD MESH:D000726 [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA1C mRNA PMID:25607892 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:35559 furan increases expression ISO RGD:2245 E RGD:6480464 20170516 CTD MESH:C039281 furan results in increased expression of CACNA1C mRNA PMID:27387713 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:38940 sunitinib decreases activity EXP E RGD:6480464 20170303 CTD MESH:C473478 sunitinib results in decreased activity of CACNA1C protein PMID:23707608 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:38940 sunitinib decreases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in decreased expression of CACNA1C mRNA PMID:31533062 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:38940 sunitinib decreases expression ISO RGD:1550302 E RGD:6480464 20190910 CTD MESH:C473478 Sunitinib results in decreased expression of CACNA1C protein PMID:31025080 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:38940 sunitinib multiple interactions ISO RGD:1550302 E RGD:6480464 20190910 CTD MESH:C473478 PIK3CA protein inhibits the reaction [Sunitinib results in decreased expression of CACNA1C protein] PMID:31025080 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:39098 pyrethrins decreases expression ISO RGD:2245 E RGD:6480464 20230905 CTD MESH:D011722 Pyrethrins results in decreased expression of CACNA1C protein PMID:34896426 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:39481 chloroprene decreases expression ISO RGD:1550302 E RGD:6480464 20130514 CTD MESH:D002737 Chloroprene results in decreased expression of CACNA1C mRNA PMID:23125180 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:39867 valproic acid affects splicing ISO RGD:2245 E RGD:6480464 20180828 CTD MESH:D014635 Valproic Acid affects the splicing of CACNA1C mRNA PMID:29427782 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:39867 valproic acid decreases expression ISO RGD:2245 E RGD:6480464 20180828 CTD MESH:D014635 Valproic Acid results in decreased expression of CACNA1C mRNA PMID:29427782 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:39867 valproic acid decreases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in decreased methylation of CACNA1C gene PMID:29154799 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:39867 valproic acid increases methylation EXP E RGD:6480464 20181016 CTD MESH:D014635 Valproic Acid results in increased methylation of CACNA1C gene PMID:29501571 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:4035 cyhalothrin multiple interactions ISO RGD:2245 E RGD:6480464 20230905 CTD MESH:C037304 [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of CACNA1C protein PMID:34896426 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:4042 cypermethrin multiple interactions ISO RGD:2245 E RGD:6480464 20230905 CTD MESH:C017160 [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of CACNA1C protein PMID:34896426 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:44185 methotrexate decreases expression EXP E RGD:6480464 20151110 CTD MESH:D008727 Methotrexate results in decreased expression of CACNA1C mRNA PMID:24449571 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:44185 methotrexate increases expression EXP E RGD:6480464 20151013 CTD MESH:D008727 Methotrexate results in increased expression of CACNA1C mRNA PMID:21678067 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:46195 paracetamol increases expression ISO RGD:2245 E RGD:6480464 20211207 CTD MESH:D000082 Acetaminophen results in increased expression of CACNA1C mRNA PMID:33387578 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:46195 paracetamol multiple interactions ISO RGD:2245 E RGD:6480464 20160705 CTD MESH:D000082 [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA1C mRNA PMID:25607892 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:47217 arsane affects methylation EXP E RGD:6480464 20150310 CTD MESH:D001151 Arsenic affects the methylation of CACNA1C gene PMID:25304211 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:4791 endosulfan decreases expression ISO RGD:2245 E RGD:6480464 20201103 CTD MESH:D004726 Endosulfan results in decreased expression of CACNA1C mRNA PMID:31464424 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:4811 epoxiconazole increases expression ISO RGD:1550302 E RGD:6480464 20220906 CTD MESH:C109476 epoxiconazole results in increased expression of CACNA1C mRNA PMID:35436446 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:4811 epoxiconazole multiple interactions ISO RGD:2245 E RGD:6480464 20160705 CTD MESH:C109476 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1C mRNA PMID:25607892 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:48843 disodium selenite multiple interactions ISO RGD:1550302 E RGD:6480464 20130514 CTD MESH:D018038 [ptaquiloside co-treated with Sodium Selenite] results in decreased expression of CACNA1C mRNA PMID:23274088 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:49203 torcetrapib increases expression EXP E RGD:6480464 20161213 CTD MESH:C483909 torcetrapib results in increased expression of CACNA1C mRNA PMID:20498617 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:49900 arsenous acid decreases expression ISO RGD:1550302 E RGD:6480464 20191114 CTD MESH:C032793 Arsenic Trioxide results in decreased expression of CACNA1C mRNA PMID:24831965 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:5014 fenvalerate increases expression ISO RGD:2245 E RGD:6480464 20201103 CTD MESH:C017690 fenvalerate results in increased expression of CACNA1C mRNA PMID:30307764 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:5014 fenvalerate multiple interactions ISO RGD:2245 E RGD:6480464 20230905 CTD MESH:C017690 [cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of CACNA1C protein PMID:34896426 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:52497 maneb multiple interactions ISO RGD:1550302 E RGD:6480464 20230905 CTD MESH:D008344 [Maneb co-treated with Paraquat] results in decreased expression of CACNA1C mRNA PMID:36117858 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:53063 2,4,6-trinitrobenzenesulfonic acid increases expression ISO RGD:2245 E RGD:6480464 20150512 CTD MESH:D014302 Trinitrobenzenesulfonic Acid results in increased expression of CACNA1C mRNA; Trinitrobenzenesulfonic Acid results in increased expression of CACNA1C protein PMID:23537331 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:64213 cantharidin decreases expression ISO RGD:1550302 E RGD:6480464 20230704 CTD MESH:D002193 Cantharidin results in decreased expression of CACNA1C mRNA PMID:36907384 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:64310 crizotinib decreases activity EXP E RGD:6480464 20170303 CTD MESH:C551994 crizotinib results in decreased activity of CACNA1C protein PMID:23707608 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:64317 isoprenaline increases expression ISO RGD:2245 E RGD:6480464 20120515 CTD MESH:D007545 Isoproterenol results in increased expression of CACNA1C mRNA PMID:17526999 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:64356 pregabalin affects localization ISO RGD:2245 E RGD:6480464 20170110 CTD MESH:D000069583 Pregabalin affects the localization of CACNA1C protein PMID:22949532 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:6482 linuron multiple interactions ISO RGD:2245 E RGD:6480464 20160705 CTD MESH:D008044 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1C mRNA PMID:25607892 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:65457 astragaloside IV multiple interactions EXP E RGD:6480464 20210504 CTD MESH:C052064 astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein] PMID:33285147 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:6651 malathion increases expression EXP E RGD:6480464 20230606 CTD MESH:D008294 Malathion results in increased expression of CACNA1C mRNA PMID:37047231 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:6809 methamphetamine decreases methylation ISO RGD:1550302 E RGD:6480464 20151215 CTD MESH:D008694 Methamphetamine results in decreased methylation of CACNA1C promoter PMID:26307267 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:6809 methamphetamine increases expression ISO RGD:1550302 E RGD:6480464 20151215 CTD MESH:D008694 Methamphetamine results in increased expression of CACNA1C mRNA; Methamphetamine results in increased expression of CACNA1C protein PMID:26307267 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:6809 methamphetamine increases expression ISO RGD:2245 E RGD:6480464 20230307 CTD MESH:D008694 Methamphetamine results in increased expression of CACNA1C mRNA PMID:35863504 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:6820 methapyrilene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene affects the methylation of CACNA1C intron PMID:30157460 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of CACNA1C exon PMID:30157460 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:6842 methoxychlor affects methylation ISO RGD:2245 E RGD:6480464 20230905 CTD MESH:D008731 Methoxychlor affects the methylation of CACNA1C gene PMID:35440735 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:68554 deferiprone multiple interactions EXP E RGD:6480464 20210504 CTD MESH:C044919 Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein] PMID:33285147 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:68584 ezogabine affects activity EXP E RGD:6480464 20180116 CTD MESH:C101866 ezogabine affects the activity of CACNA1C protein PMID:28641963 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:6872 methylene blue multiple interactions ISO RGD:1550302 E RGD:6480464 20191112 CTD MESH:D008751 Methylene Blue inhibits the reaction [Sodium Cyanide results in increased phosphorylation of CACNA1C protein] PMID:31173149 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:73755 1,2-dimethylhydrazine decreases expression ISO RGD:1550302 E RGD:6480464 20200804 CTD MESH:D019813 1,2-Dimethylhydrazine results in decreased expression of CACNA1C mRNA PMID:22206623 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:7494 nefazodone affects activity EXP E RGD:6480464 20170516 CTD MESH:C051752 nefazodone affects the activity of CACNA1C protein PMID:26821276 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:7565 nifedipine affects response to substance ISO RGD:1550302 E RGD:6480464 20120412 CTD MESH:D009543 CACNA1C protein affects the susceptibility to Nifedipine PMID:18441296 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:7565 nifedipine multiple interactions EXP E RGD:6480464 20121218 CTD MESH:D009543 Nifedipine inhibits the reaction [[Potassium Chloride co-treated with CACNA1C protein alternative form] results in increased phosphorylation of CREB1 protein] PMID:20128810 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:7575 nimodipine multiple interactions ISO RGD:1550302 E RGD:6480464 20161025 CTD MESH:D009553 Nimodipine inhibits the reaction [Iron-Dextran Complex affects the expression of CACNA1C protein] PMID:27095094 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:77733 2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile decreases expression ISO RGD:2245 E RGD:6480464 20140805 CTD MESH:D014700 Verapamil results in decreased expression of CACNA1C mRNA; Verapamil results in decreased expression of CACNA1C protein PMID:19791473 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:77733 2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile increases response to substance EXP E RGD:6480464 20140805 CTD MESH:D014700 CACNA1C gene polymorphism results in increased susceptibility to Verapamil PMID:20031608 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:77733 2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile multiple interactions ISO RGD:1550302 E RGD:6480464 20161025 CTD MESH:D014700 Verapamil inhibits the reaction [Iron-Dextran Complex affects the expression of CACNA1C protein] PMID:27095094 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:77733 2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile multiple interactions ISO RGD:2245 E RGD:6480464 20140805 CTD MESH:D014700 Mevalonic Acid inhibits the reaction [Verapamil results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Verapamil results in decreased expression of CACNA1C protein] PMID:19791473 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:78291 iron dextran affects expression ISO RGD:1550302 E RGD:6480464 20161025 CTD MESH:D007505 Iron-Dextran Complex affects the expression of CACNA1C protein PMID:27095094 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:78291 iron dextran multiple interactions EXP E RGD:6480464 20210504 CTD MESH:D007505 [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein] PMID:33285147 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:78291 iron dextran multiple interactions ISO RGD:1550302 E RGD:6480464 20161025 CTD MESH:D007505 Diltiazem inhibits the reaction [Iron-Dextran Complex affects the expression of CACNA1C protein]; Nimodipine inhibits the reaction [Iron-Dextran Complex affects the expression of CACNA1C protein]; Verapamil inhibits the reaction [Iron-Dextran Complex affects the expression of CACNA1C protein] PMID:27095094 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:79994 CGP 52608 multiple interactions EXP E RGD:6480464 20220607 CTD MESH:C092451 CGP 52608 promotes the reaction [RORA protein binds to CACNA1C gene] PMID:28238834 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:81506 2,3,7,8-Tetrachlorodibenzofuran decreases expression ISO RGD:2245 E RGD:6480464 20200609 CTD MESH:C014211 2,3,7,8-tetrachlorodibenzofuran results in decreased expression of CACNA1C mRNA PMID:32109520 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:81582 2,4-dibromophenyl 2,4,5-tribromophenyl ether affects expression ISO RGD:1550302 E RGD:6480464 20240903 CTD MESH:C477694 2,2',4,4',5-brominated diphenyl ether affects the expression of CACNA1C mRNA PMID:38648751 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:8207 (+)-pilocarpine decreases expression ISO RGD:1550302 E RGD:6480464 20120412 CTD MESH:D010862 Pilocarpine results in decreased expression of CACNA1C protein PMID:17265461 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:8207 (+)-pilocarpine increases expression ISO RGD:1550302 E RGD:6480464 20120412 CTD MESH:D010862 Pilocarpine results in increased expression of CACNA1C protein PMID:17265461 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:8228 pioglitazone multiple interactions ISO RGD:1550302 E RGD:6480464 20180220 CTD MESH:C060836 [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CACNA1C mRNA PMID:27935865 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:82527 Ptaquiloside multiple interactions ISO RGD:1550302 E RGD:6480464 20141111 CTD MESH:C043680 [ptaquiloside co-treated with Sodium Selenite] results in decreased expression of CACNA1C mRNA PMID:23274088 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:82664 iron(0) multiple interactions EXP E RGD:6480464 20210504 CTD MESH:D007501 [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein] PMID:33285147 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:84070 sodium arsenate increases expression ISO RGD:1550302 E RGD:6480464 20170303 CTD MESH:C009277 sodium arsenate results in increased expression of CACNA1C mRNA PMID:21795629 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:8434 prochloraz multiple interactions ISO RGD:2245 E RGD:6480464 20160705 CTD MESH:C045362 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1C mRNA PMID:25607892 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:8450 procymidone multiple interactions ISO RGD:2245 E RGD:6480464 20160705 CTD MESH:C035988 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1C mRNA PMID:25607892 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:88542 Butylparaben multiple interactions ISO RGD:2245 E RGD:6480464 20200407 CTD MESH:C038091 [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA1C mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1C mRNA PMID:25607892 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:9141 silver(0) decreases expression ISO RGD:1550302 E RGD:6480464 20161115 CTD MESH:D012834 Silver results in decreased expression of CACNA1C mRNA PMID:27131904 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:9150 simvastatin decreases expression ISO RGD:2245 E RGD:6480464 20120501 CTD MESH:D019821 Simvastatin results in decreased expression of CACNA1C mRNA; Simvastatin results in decreased expression of CACNA1C protein PMID:19791473 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:9150 simvastatin multiple interactions ISO RGD:2245 E RGD:6480464 20120501 CTD MESH:D019821 Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C protein] PMID:19791473 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:9288 streptozocin increases expression ISO RGD:1550302 E RGD:6480464 20181113 CTD MESH:D013311 Streptozocin results in increased expression of CACNA1C mRNA PMID:29935216 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:9288 streptozocin multiple interactions ISO RGD:1550302 E RGD:6480464 20181113 CTD MESH:D013311 [bisphenol A co-treated with Streptozocin] results in decreased expression of CACNA1C mRNA; [octylphenol co-treated with Streptozocin] results in decreased expression of CACNA1C mRNA PMID:29935216 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:9513 thalidomide decreases expression ISO RGD:1550302 E RGD:6480464 20160119 CTD MESH:D013792 Thalidomide results in decreased expression of CACNA1C mRNA PMID:26006729|PMID:26217789 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:9948 verapamil decreases expression ISO RGD:2245 E RGD:6480464 20120501 CTD MESH:D014700 Verapamil results in decreased expression of CACNA1C mRNA; Verapamil results in decreased expression of CACNA1C protein PMID:19791473 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:9948 verapamil increases response to substance EXP E RGD:6480464 20120412 CTD MESH:D014700 CACNA1C gene polymorphism results in increased susceptibility to Verapamil PMID:20031608 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:9948 verapamil multiple interactions ISO RGD:1550302 E RGD:6480464 20161025 CTD MESH:D014700 Verapamil inhibits the reaction [Iron-Dextran Complex affects the expression of CACNA1C protein] PMID:27095094 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:9948 verapamil multiple interactions ISO RGD:2245 E RGD:6480464 20120501 CTD MESH:D014700 Mevalonic Acid inhibits the reaction [Verapamil results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Verapamil results in decreased expression of CACNA1C protein] PMID:19791473 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:9986 vinclozolin decreases expression ISO RGD:2245 E RGD:6480464 20150825 CTD MESH:C025643 vinclozolin results in decreased expression of CACNA1C mRNA PMID:23034163 10268 CACNA1C calcium voltage-gated channel subunit alpha1 C gene CHEBI:9986 vinclozolin multiple interactions ISO RGD:2245 E RGD:6480464 20160705 CTD MESH:C025643 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1C mRNA PMID:25607892 10291 CASR calcium sensing receptor gene CHEBI:10022 deoxynivalenol multiple interactions ISO RGD:1553551 E RGD:6480464 20150609 CTD MESH:C007262 CASR affects the reaction [deoxynivalenol results in increased secretion of CCK protein] PMID:25787141 10291 CASR calcium sensing receptor gene CHEBI:133151 methyl beta-cyclodextrin multiple interactions EXP E RGD:6480464 20170303 CTD MESH:C108732 methyl-beta-cyclodextrin inhibits the reaction [CASR protein results in increased uptake of Calcium] PMID:21562303 10291 CASR calcium sensing receptor gene CHEBI:145121 SKF-96365 hydrochloride multiple interactions EXP E RGD:6480464 20191114 CTD MESH:C063159 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [CASR protein results in increased uptake of Calcium] PMID:21562303 10291 CASR calcium sensing receptor gene CHEBI:15367 all-trans-retinoic acid increases expression ISO RGD:1553551 E RGD:6480464 20240402 CTD MESH:D014212 Tretinoin results in increased expression of CASR mRNA PMID:36189433 10291 CASR calcium sensing receptor gene CHEBI:15379 dioxygen increases expression ISO RGD:2277 E RGD:6480464 20210406 CTD MESH:D010100 Oxygen deficiency results in increased expression of CASR mRNA; Oxygen deficiency results in increased expression of CASR protein PMID:32956540 10291 CASR calcium sensing receptor gene CHEBI:15379 dioxygen multiple interactions ISO RGD:2277 E RGD:6480464 20210406 CTD MESH:D010100 Chloroquine inhibits the reaction [Oxygen deficiency results in increased expression of CASR mRNA]; Chloroquine inhibits the reaction [Oxygen deficiency results in increased expression of CASR protein] PMID:32956540 10291 CASR calcium sensing receptor gene CHEBI:15746 spermine multiple interactions EXP E RGD:6480464 20120613 CTD MESH:D013096 2-aminoethoxydiphenyl borate inhibits the reaction [Spermine binds to and results in increased activity of CASR protein]; [Spermine binds to and results in increased activity of CASR protein] which results in increased uptake of Calcium; Lanthanum inhibits the reaction [Spermine binds to and results in increased activity of CASR protein]; Spermine binds to and results in increased activity of CASR protein PMID:17041782 10291 CASR calcium sensing receptor gene CHEBI:15746 spermine multiple interactions ISO RGD:2277 E RGD:6480464 20120412 CTD MESH:D013096 NPS R-467 promotes the reaction [Spermine binds to and results in increased activity of CASR protein]; Phenylephrine inhibits the reaction [Spermine binds to and results in increased activity of CASR protein]; Spermine binds to and results in increased activity of CASR protein; Thapsigargin inhibits the reaction [Spermine binds to and results in increased activity of CASR protein] PMID:11071898 10291 CASR calcium sensing receptor gene CHEBI:16595 1D-myo-inositol 1,4,5-trisphosphate multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D015544 [CASR protein mutant form results in increased susceptibility to Calcium] which results in increased abundance of Inositol 1,4,5-Trisphosphate PMID:7874174 10291 CASR calcium sensing receptor gene CHEBI:17347 testosterone decreases expression ISO RGD:1553551 E RGD:6480464 20120412 CTD MESH:D013739 Testosterone results in decreased expression of CASR mRNA PMID:20403060 10291 CASR calcium sensing receptor gene CHEBI:17347 testosterone increases expression ISO RGD:1553551 E RGD:6480464 20120412 CTD MESH:D013739 Testosterone deficiency results in increased expression of CASR mRNA PMID:21045173 10291 CASR calcium sensing receptor gene CHEBI:17347 testosterone multiple interactions ISO RGD:1553551 E RGD:6480464 20120412 CTD MESH:D013739 Testosterone inhibits the reaction [Testosterone deficiency results in increased expression of CASR mRNA] PMID:21045173 10291 CASR calcium sensing receptor gene CHEBI:177802 Cuprizon decreases expression ISO RGD:2277 E RGD:6480464 20210907 CTD MESH:D003471 Cuprizone results in decreased expression of CASR mRNA PMID:27523638 10291 CASR calcium sensing receptor gene CHEBI:177802 Cuprizon increases expression ISO RGD:2277 E RGD:6480464 20210907 CTD MESH:D003471 Cuprizone results in increased expression of CASR mRNA PMID:26577399 10291 CASR calcium sensing receptor gene CHEBI:17823 calcitriol increases expression ISO RGD:2277 E RGD:6480464 20120412 CTD MESH:D002117 Calcitriol results in increased expression of CASR mRNA; Calcitriol results in increased expression of CASR protein PMID:15788476 10291 CASR calcium sensing receptor gene CHEBI:17833 gentamycin increases expression ISO RGD:2277 E RGD:6480464 20161228 CTD MESH:D005839 Gentamicins results in increased expression of CASR protein PMID:16850027 10291 CASR calcium sensing receptor gene CHEBI:17833 gentamycin multiple interactions EXP E RGD:6480464 20161228 CTD MESH:D005839 CASR protein promotes the reaction [Gentamicins results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CASR protein promotes the reaction [Gentamicins results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gentamicins binds to and results in increased activity of CASR protein PMID:17537980 10291 CASR calcium sensing receptor gene CHEBI:22977 cadmium atom multiple interactions ISO RGD:2277 E RGD:6480464 20200915 CTD MESH:D002104 [Cadmium Chloride results in increased abundance of Cadmium] which affects the expression of CASR protein; [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of CASR protein; CASR protein affects the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased cleavage of CASP3 protein]; CASR protein affects the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased cleavage of CASP9 protein]; CASR protein affects the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of AKT1 protein] PMID:27872163|PMID:32599263 10291 CASR calcium sensing receptor gene CHEBI:22984 calcium atom affects expression ISO RGD:2277 E RGD:6480464 20120412 CTD MESH:D002118 Calcium affects the expression of CASR mRNA; Calcium affects the expression of CASR protein PMID:15788476 10291 CASR calcium sensing receptor gene CHEBI:22984 calcium atom decreases response to substance EXP E RGD:6480464 20120412 CTD MESH:D002118 CASR protein mutant form results in decreased susceptibility to Calcium PMID:9011580 10291 CASR calcium sensing receptor gene CHEBI:22984 calcium atom increases activity EXP E RGD:6480464 20120613 CTD MESH:D002118 Calcium results in increased activity of CASR protein PMID:17041782 10291 CASR calcium sensing receptor gene CHEBI:22984 calcium atom increases phosphorylation EXP E RGD:6480464 20120412 CTD MESH:D002118 Calcium results in increased phosphorylation of CASR protein PMID:17376781 10291 CASR calcium sensing receptor gene CHEBI:22984 calcium atom increases response to substance EXP E RGD:6480464 20120412 CTD MESH:D002118 CASR gene mutant form results in increased susceptibility to Calcium; CASR protein mutant form results in increased susceptibility to Calcium PMID:11089548|PMID:11701698|PMID:7874174 10291 CASR calcium sensing receptor gene CHEBI:22984 calcium atom increases uptake EXP E RGD:6480464 20120613 CTD MESH:D002118 CASR protein results in increased uptake of Calcium PMID:21562303 10291 CASR calcium sensing receptor gene CHEBI:22984 calcium atom multiple interactions EXP E RGD:6480464 20120613 CTD MESH:D002118 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [CASR protein results in increased uptake of Calcium]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [CASR protein results in increased uptake of Calcium]; 2-aminoethoxydiphenyl borate inhibits the reaction [Calcium binds to and results in increased activity of CASR protein]; 2-aminoethoxydiphenyl borate inhibits the reaction [CASR protein results in increased uptake of Calcium]; [2-quinoxaline-carboxamide-N-adamantan-1-yl binds to and results in decreased activity of CASR protein] inhibits the reaction [Nickel results in increased abundance of Calcium]; [Calcium binds to and results in increased activity of CASR protein] which results in increased uptake of Calcium; [CASR protein mutant form results in increased susceptibility to Calcium] which results in increased abundance of Inositol 1,4,5-Trisphosphate; [Spermine binds to and results in increased activity of CASR protein] which results in increased uptake of Calcium; bisindolylmaleimide I inhibits the reaction [NPS R-467 promotes the reaction [Calcium results in increased phosphorylation of CASR protein]]; Calcium Chloride promotes the reaction [Calcium results in increased phosphorylation of CASR protein]; CASR mutant form inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; CASR mutant form inhibits the reaction [Calcium results in increased expression of KRT1 protein]; CASR mutant form inhibits the reaction [Calcium results in increased expression of LORICRIN mRNA]; CASR mutant form inhibits the reaction [Calcium results in increased expression of LORICRIN protein]; CASR mutant form inhibits the reaction [Calcium results in increased expression of WNT5A protein]; CASR protein affects the reaction [Nickel results in increased abundance of Calcium]; CASR protein promotes the reaction [TRPC6 protein results in increased uptake of Calcium]; chelerythrine inhibits the reaction [CASR protein results in increased uptake of Calcium]; Flufenamic Acid promotes the reaction [CASR protein results in increased uptake of Calcium]; Lanthanum inhibits the reaction [Calcium binds to and results in increased activity of CASR protein]; Lanthanum inhibits the reaction [CASR protein results in increased uptake of Calcium]; methyl-beta-cyclodextrin inhibits the reaction [CASR protein results in increased uptake of Calcium]; N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine affects the reaction [CASR gene mutant form results in increased susceptibility to Calcium]; N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine promotes the reaction [CASR protein results in increased susceptibility to Calcium]; NPS R-467 promotes the reaction [Calcium results in increased phosphorylation of CASR protein]; Pertussis Toxin inhibits the reaction [CASR protein results in increased uptake of Calcium] PMID:11089548|PMID:17041782|PMID:17376781|PMID:19781536|PMID:21562303|PMID:24658506|PMID:7874174 10291 CASR calcium sensing receptor gene CHEBI:22984 calcium atom multiple interactions ISO RGD:2277 E RGD:6480464 20130312 CTD MESH:D002118 [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Calcium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Calcium binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; [Gadolinium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Magnesium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Neomycin binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; Calcium binds to and results in increased activity of CASR protein; Gadolinium inhibits the reaction [Calcium binds to and results in increased activity of CASR protein] PMID:10231437|PMID:11071898 10291 CASR calcium sensing receptor gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20161025 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of CASR gene PMID:27153756 10291 CASR calcium sensing receptor gene CHEBI:25107 magnesium atom increases expression ISO RGD:2277 E RGD:6480464 20120412 CTD MESH:D008274 Magnesium results in increased expression of CASR mRNA; Magnesium results in increased expression of CASR protein PMID:11563847 10291 CASR calcium sensing receptor gene CHEBI:25107 magnesium atom increases response to substance ISO RGD:1553551 E RGD:6480464 20120412 CTD MESH:D008274 CASR protein results in increased susceptibility to Magnesium PMID:15068510 10291 CASR calcium sensing receptor gene CHEBI:25107 magnesium atom multiple interactions ISO RGD:2277 E RGD:6480464 20130312 CTD MESH:D008274 [Magnesium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Magnesium binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Magnesium binds to and results in increased activity of CASR protein PMID:10231437 10291 CASR calcium sensing receptor gene CHEBI:25812 ozone multiple interactions ISO RGD:2277 E RGD:6480464 20120412 CTD MESH:D010126 [Ozone co-treated with Chlorine] results in decreased expression of CASR mRNA PMID:18636392 10291 CASR calcium sensing receptor gene CHEBI:2637 amikacin increases activity EXP E RGD:6480464 20120412 CTD MESH:D000583 Amikacin results in increased activity of CASR protein PMID:19884751 10291 CASR calcium sensing receptor gene CHEBI:2666 amitriptyline decreases expression ISO RGD:2277 E RGD:6480464 20130416 CTD MESH:D000639 Amitriptyline results in decreased expression of CASR mRNA PMID:22341215 10291 CASR calcium sensing receptor gene CHEBI:27789 1,2-dichloroethane decreases expression ISO RGD:1553551 E RGD:6480464 20200310 CTD MESH:C024565 ethylene dichloride results in decreased expression of CASR mRNA PMID:28960355 10291 CASR calcium sensing receptor gene CHEBI:27881 resveratrol multiple interactions EXP E RGD:6480464 20220510 CTD MESH:C059514 [Plant Extracts co-treated with Resveratrol] results in decreased expression of CASR mRNA PMID:23557933 10291 CASR calcium sensing receptor gene CHEBI:28001 vancomycin increases expression ISO RGD:1553551 E RGD:6480464 20120412 CTD MESH:D014640 Vancomycin results in increased expression of CASR mRNA PMID:18930951 10291 CASR calcium sensing receptor gene CHEBI:28112 nickel atom increases activity EXP E RGD:6480464 20120501 CTD MESH:D009532 Nickel results in increased activity of CASR protein PMID:19781536 10291 CASR calcium sensing receptor gene CHEBI:28112 nickel atom multiple interactions EXP E RGD:6480464 20120501 CTD MESH:D009532 [2-quinoxaline-carboxamide-N-adamantan-1-yl binds to and results in decreased activity of CASR protein] inhibits the reaction [Nickel results in increased abundance of Calcium]; [2-quinoxaline-carboxamide-N-adamantan-1-yl binds to and results in decreased activity of CASR protein] inhibits the reaction [Nickel results in increased expression of ACTA2 mRNA]; [2-quinoxaline-carboxamide-N-adamantan-1-yl binds to and results in decreased activity of CASR protein] inhibits the reaction [Nickel results in increased expression of COL1A1 mRNA]; [2-quinoxaline-carboxamide-N-adamantan-1-yl binds to and results in decreased activity of CASR protein] inhibits the reaction [Nickel results in increased expression of ICAM1 mRNA]; [2-quinoxaline-carboxamide-N-adamantan-1-yl binds to and results in decreased activity of CASR protein] inhibits the reaction [Nickel results in increased expression of IL1B mRNA]; [2-quinoxaline-carboxamide-N-adamantan-1-yl binds to and results in decreased activity of CASR protein] inhibits the reaction [Nickel results in increased expression of TNF mRNA]; [2-quinoxaline-carboxamide-N-adamantan-1-yl binds to and results in decreased activity of CASR protein] which results in decreased susceptibility to Nickel; CASR protein affects the reaction [Nickel results in increased abundance of Calcium] PMID:19781536 10291 CASR calcium sensing receptor gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:2277 E RGD:6480464 20200609 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of CASR mRNA PMID:32109520 10291 CASR calcium sensing receptor gene CHEBI:28201 rotenone increases expression EXP E RGD:6480464 20181016 CTD MESH:D012402 Rotenone results in increased expression of CASR mRNA PMID:29955902 10291 CASR calcium sensing receptor gene CHEBI:28201 rotenone increases expression ISO RGD:2277 E RGD:6480464 20221101 CTD MESH:D012402 Rotenone results in increased expression of CASR protein PMID:35544339 10291 CASR calcium sensing receptor gene CHEBI:28659 phosphorus atom affects abundance EXP E RGD:6480464 20120412 CTD MESH:D010758 CASR protein affects the abundance of Phosphorus PMID:11589681 10291 CASR calcium sensing receptor gene CHEBI:28741 sodium fluoride decreases expression ISO RGD:1553551 E RGD:6480464 20121009 CTD MESH:D012969 Sodium Fluoride results in decreased expression of CASR mRNA PMID:21340527|PMID:27862939 10291 CASR calcium sensing receptor gene CHEBI:28984 aluminium atom multiple interactions ISO RGD:2277 E RGD:6480464 20130312 CTD MESH:D000535 [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Aluminum binds to and results in increased activity of CASR protein PMID:10231437 10291 CASR calcium sensing receptor gene CHEBI:29310 dichlorine multiple interactions ISO RGD:2277 E RGD:6480464 20120412 CTD MESH:D002713 [Ozone co-treated with Chlorine] results in decreased expression of CASR mRNA PMID:18636392 10291 CASR calcium sensing receptor gene CHEBI:29320 calcium(0) affects expression ISO RGD:2277 E RGD:6480464 20120412 CTD MESH:D002118 Calcium affects the expression of CASR mRNA; Calcium affects the expression of CASR protein PMID:15788476 10291 CASR calcium sensing receptor gene CHEBI:29320 calcium(0) decreases response to substance EXP E RGD:6480464 20120412 CTD MESH:D002118 CASR protein mutant form results in decreased susceptibility to Calcium PMID:9011580 10291 CASR calcium sensing receptor gene CHEBI:29320 calcium(0) increases activity EXP E RGD:6480464 20120613 CTD MESH:D002118 Calcium results in increased activity of CASR protein PMID:17041782 10291 CASR calcium sensing receptor gene CHEBI:29320 calcium(0) increases phosphorylation EXP E RGD:6480464 20120412 CTD MESH:D002118 Calcium results in increased phosphorylation of CASR protein PMID:17376781 10291 CASR calcium sensing receptor gene CHEBI:29320 calcium(0) increases response to substance EXP E RGD:6480464 20120412 CTD MESH:D002118 CASR gene mutant form results in increased susceptibility to Calcium; CASR protein mutant form results in increased susceptibility to Calcium PMID:11089548|PMID:11701698|PMID:7874174 10291 CASR calcium sensing receptor gene CHEBI:29320 calcium(0) increases uptake EXP E RGD:6480464 20120613 CTD MESH:D002118 CASR protein results in increased uptake of Calcium PMID:21562303 10291 CASR calcium sensing receptor gene CHEBI:29320 calcium(0) multiple interactions EXP E RGD:6480464 20120613 CTD MESH:D002118 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [CASR protein results in increased uptake of Calcium]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [CASR protein results in increased uptake of Calcium]; 2-aminoethoxydiphenyl borate inhibits the reaction [Calcium binds to and results in increased activity of CASR protein]; 2-aminoethoxydiphenyl borate inhibits the reaction [CASR protein results in increased uptake of Calcium]; [2-quinoxaline-carboxamide-N-adamantan-1-yl binds to and results in decreased activity of CASR protein] inhibits the reaction [Nickel results in increased abundance of Calcium]; [Calcium binds to and results in increased activity of CASR protein] which results in increased uptake of Calcium; [CASR protein mutant form results in increased susceptibility to Calcium] which results in increased abundance of Inositol 1,4,5-Trisphosphate; [Spermine binds to and results in increased activity of CASR protein] which results in increased uptake of Calcium; bisindolylmaleimide I inhibits the reaction [NPS R-467 promotes the reaction [Calcium results in increased phosphorylation of CASR protein]]; Calcium Chloride promotes the reaction [Calcium results in increased phosphorylation of CASR protein]; CASR mutant form inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; CASR mutant form inhibits the reaction [Calcium results in increased expression of KRT1 protein]; CASR mutant form inhibits the reaction [Calcium results in increased expression of LORICRIN mRNA]; CASR mutant form inhibits the reaction [Calcium results in increased expression of LORICRIN protein]; CASR mutant form inhibits the reaction [Calcium results in increased expression of WNT5A protein]; CASR protein affects the reaction [Nickel results in increased abundance of Calcium]; CASR protein promotes the reaction [TRPC6 protein results in increased uptake of Calcium]; chelerythrine inhibits the reaction [CASR protein results in increased uptake of Calcium]; Flufenamic Acid promotes the reaction [CASR protein results in increased uptake of Calcium]; Lanthanum inhibits the reaction [Calcium binds to and results in increased activity of CASR protein]; Lanthanum inhibits the reaction [CASR protein results in increased uptake of Calcium]; methyl-beta-cyclodextrin inhibits the reaction [CASR protein results in increased uptake of Calcium]; N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine affects the reaction [CASR gene mutant form results in increased susceptibility to Calcium]; N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine promotes the reaction [CASR protein results in increased susceptibility to Calcium]; NPS R-467 promotes the reaction [Calcium results in increased phosphorylation of CASR protein]; Pertussis Toxin inhibits the reaction [CASR protein results in increased uptake of Calcium] PMID:11089548|PMID:17041782|PMID:17376781|PMID:19781536|PMID:21562303|PMID:24658506|PMID:7874174 10291 CASR calcium sensing receptor gene CHEBI:29320 calcium(0) multiple interactions ISO RGD:2277 E RGD:6480464 20130312 CTD MESH:D002118 [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Calcium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Calcium binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; [Gadolinium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Magnesium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Neomycin binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; Calcium binds to and results in increased activity of CASR protein; Gadolinium inhibits the reaction [Calcium binds to and results in increased activity of CASR protein] PMID:10231437|PMID:11071898 10291 CASR calcium sensing receptor gene CHEBI:29678 sodium arsenite decreases expression ISO RGD:2277 E RGD:6480464 20230207 CTD MESH:C017947 sodium arsenite results in decreased expression of CASR mRNA PMID:35314868 10291 CASR calcium sensing receptor gene CHEBI:29678 sodium arsenite increases expression ISO RGD:1553551 E RGD:6480464 20240206 CTD MESH:C017947 sodium arsenite results in increased expression of CASR mRNA PMID:37682722 10291 CASR calcium sensing receptor gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of CASR 5' UTR; Benzo(a)pyrene affects the methylation of CASR promoter PMID:27901495 10291 CASR calcium sensing receptor gene CHEBI:29865 benzo[a]pyrene decreases expression ISO RGD:2277 E RGD:6480464 20120613 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of CASR mRNA PMID:21839799 10291 CASR calcium sensing receptor gene CHEBI:29865 benzo[a]pyrene increases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in increased methylation of CASR 3' UTR PMID:27901495 10291 CASR calcium sensing receptor gene CHEBI:30207 phosphorus(.) affects abundance EXP E RGD:6480464 20120412 CTD MESH:D010758 CASR protein affects the abundance of Phosphorus PMID:11589681 10291 CASR calcium sensing receptor gene CHEBI:31206 ammonium chloride affects expression ISO RGD:2277 E RGD:6480464 20120412 CTD MESH:D000643 Ammonium Chloride affects the expression of CASR mRNA PMID:16483693 10291 CASR calcium sensing receptor gene CHEBI:31638 fulvestrant multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C070081 [bisphenol A co-treated with Fulvestrant] results in increased methylation of CASR gene PMID:31601247 10291 CASR calcium sensing receptor gene CHEBI:3312 calcium dichloride increases activity EXP E RGD:6480464 20130312 CTD MESH:D002122 Calcium Chloride results in increased activity of CASR protein PMID:16316325 10291 CASR calcium sensing receptor gene CHEBI:3312 calcium dichloride multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D002122 Calcium Chloride promotes the reaction [Calcium results in increased phosphorylation of CASR protein] PMID:17376781 10291 CASR calcium sensing receptor gene CHEBI:33216 bisphenol A decreases expression ISO RGD:2277 E RGD:6480464 20191210 CTD MESH:C006780 bisphenol A results in decreased expression of CASR mRNA PMID:30816183|PMID:32528016|PMID:34947998 10291 CASR calcium sensing receptor gene CHEBI:33216 bisphenol A increases expression ISO RGD:2277 E RGD:6480464 20250114 CTD MESH:C006780 bisphenol A results in increased expression of CASR mRNA PMID:36779543 10291 CASR calcium sensing receptor gene CHEBI:33216 bisphenol A multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C006780 [bisphenol A co-treated with Fulvestrant] results in increased methylation of CASR gene PMID:31601247 10291 CASR calcium sensing receptor gene CHEBI:33324 strontium atom affects activity EXP E RGD:6480464 20120412 CTD MESH:D013324 Strontium affects the activity of CASR protein PMID:15068510 10291 CASR calcium sensing receptor gene CHEBI:33324 strontium atom increases response to substance EXP E RGD:6480464 20120412 CTD MESH:D013324 CASR protein results in increased susceptibility to Strontium PMID:15068510 10291 CASR calcium sensing receptor gene CHEBI:33336 lanthanum atom multiple interactions EXP E RGD:6480464 20120613 CTD MESH:D007811 Lanthanum inhibits the reaction [Calcium binds to and results in increased activity of CASR protein]; Lanthanum inhibits the reaction [CASR protein results in increased uptake of Calcium]; Lanthanum inhibits the reaction [Spermine binds to and results in increased activity of CASR protein] PMID:17041782|PMID:21562303 10291 CASR calcium sensing receptor gene CHEBI:33375 gadolinium atom multiple interactions ISO RGD:2277 E RGD:6480464 20130312 CTD MESH:D005682 [Gadolinium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Gadolinium binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Gadolinium binds to and results in increased activity of CASR protein; Gadolinium inhibits the reaction [Calcium binds to and results in increased activity of CASR protein] PMID:10231437|PMID:11071898 10291 CASR calcium sensing receptor gene CHEBI:33629 aluminium(0) multiple interactions ISO RGD:2277 E RGD:6480464 20130312 CTD MESH:D000535 [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Aluminum binds to and results in increased activity of CASR protein PMID:10231437 10291 CASR calcium sensing receptor gene CHEBI:34031 1,1-dichloroethene decreases expression ISO RGD:1553551 E RGD:6480464 20170725 CTD MESH:C029297 vinylidene chloride results in decreased expression of CASR mRNA PMID:26682919 10291 CASR calcium sensing receptor gene CHEBI:34687 dibutyl phthalate decreases expression ISO RGD:2277 E RGD:6480464 20120412 CTD MESH:D003993 Dibutyl Phthalate results in decreased expression of CASR mRNA PMID:15620428 10291 CASR calcium sensing receptor gene CHEBI:35456 cadmium dichloride multiple interactions ISO RGD:2277 E RGD:6480464 20200915 CTD MESH:D019256 [Cadmium Chloride results in increased abundance of Cadmium] which affects the expression of CASR protein; [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of CASR protein; CASR protein affects the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased cleavage of CASP3 protein]; CASR protein affects the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased cleavage of CASP9 protein]; CASR protein affects the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of AKT1 protein] PMID:27872163|PMID:32599263 10291 CASR calcium sensing receptor gene CHEBI:3638 chloroquine multiple interactions ISO RGD:2277 E RGD:6480464 20210406 CTD MESH:D002738 Chloroquine inhibits the reaction [Oxygen deficiency results in increased expression of CASR mRNA]; Chloroquine inhibits the reaction [Oxygen deficiency results in increased expression of CASR protein] PMID:32956540 10291 CASR calcium sensing receptor gene CHEBI:41072 3-\{1-[3-(dimethylamino)propyl]-1H-indol-3-yl\}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione multiple interactions EXP E RGD:6480464 20141111 CTD MESH:C070515 bisindolylmaleimide I inhibits the reaction [NPS R-467 promotes the reaction [Calcium results in increased phosphorylation of CASR protein]] PMID:17376781 10291 CASR calcium sensing receptor gene CHEBI:41791 calyculin a multiple interactions EXP E RGD:6480464 20141111 CTD MESH:C059041 calyculin A promotes the reaction [phorbolol myristate acetate results in increased phosphorylation of CASR protein] PMID:17376781 10291 CASR calcium sensing receptor gene CHEBI:42638 flufenamic acid multiple interactions EXP E RGD:6480464 20120613 CTD MESH:D005439 Flufenamic Acid promotes the reaction [CASR protein results in increased uptake of Calcium] PMID:21562303 10291 CASR calcium sensing receptor gene CHEBI:44185 methotrexate decreases expression EXP E RGD:6480464 20151110 CTD MESH:D008727 Methotrexate results in decreased expression of CASR mRNA PMID:24449571 10291 CASR calcium sensing receptor gene CHEBI:46557 zoledronic acid decreases expression EXP E RGD:6480464 20161213 CTD MESH:C088658 zoledronic acid results in decreased expression of CASR mRNA PMID:24714768 10291 CASR calcium sensing receptor gene CHEBI:6030 isoniazide affects expression ISO RGD:2277 E RGD:6480464 20120501 CTD MESH:D007538 Isoniazid affects the expression of CASR mRNA PMID:20623750 10291 CASR calcium sensing receptor gene CHEBI:73755 1,2-dimethylhydrazine decreases expression ISO RGD:2277 E RGD:6480464 20201006 CTD MESH:D019813 1,2-Dimethylhydrazine results in decreased expression of CASR mRNA PMID:32387197 10291 CASR calcium sensing receptor gene CHEBI:7507 neomycin multiple interactions EXP E RGD:6480464 20140805 CTD MESH:D009355 CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Neomycin binds to and results in increased activity of CASR protein PMID:17537980 10291 CASR calcium sensing receptor gene CHEBI:7507 neomycin multiple interactions ISO RGD:2277 E RGD:6480464 20140805 CTD MESH:D009355 [Neomycin binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Neomycin binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Neomycin binds to and results in increased activity of CASR protein PMID:10231437 10291 CASR calcium sensing receptor gene CHEBI:7590 nitrofen increases expression ISO RGD:2277 E RGD:6480464 20190219 CTD MESH:C007350 nitrofen results in increased expression of CASR mRNA; nitrofen results in increased expression of CASR protein PMID:28983729 10291 CASR calcium sensing receptor gene CHEBI:78373 chelerythrine multiple interactions EXP E RGD:6480464 20140805 CTD MESH:C016299 chelerythrine inhibits the reaction [CASR protein results in increased uptake of Calcium] PMID:21562303 10291 CASR calcium sensing receptor gene CHEBI:79516 Nonylphenol decreases expression ISO RGD:2277 E RGD:6480464 20141111 CTD MESH:C025256 nonylphenol results in decreased expression of CASR mRNA PMID:15620428 10291 CASR calcium sensing receptor gene CHEBI:79994 CGP 52608 multiple interactions EXP E RGD:6480464 20220607 CTD MESH:C092451 CGP 52608 promotes the reaction [RORA protein binds to CASR gene] PMID:28238834 10291 CASR calcium sensing receptor gene CHEBI:8093 phenylephrine multiple interactions ISO RGD:2277 E RGD:6480464 20120412 CTD MESH:D010656 Phenylephrine inhibits the reaction [Spermine binds to and results in increased activity of CASR protein] PMID:11071898 10291 CASR calcium sensing receptor gene CHEBI:8502 6-propyl-2-thiouracil decreases expression ISO RGD:2277 E RGD:6480464 20150310 CTD MESH:D011441 Propylthiouracil results in decreased expression of CASR mRNA PMID:24780913|PMID:25825206 10291 CASR calcium sensing receptor gene CHEBI:90690 U-73122 multiple interactions EXP E RGD:6480464 20160105 CTD MESH:C060229 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [CASR protein results in increased uptake of Calcium] PMID:21562303 10291 CASR calcium sensing receptor gene CHEBI:9516 thapsigargin multiple interactions ISO RGD:2277 E RGD:6480464 20120412 CTD MESH:D019284 Thapsigargin inhibits the reaction [Spermine binds to and results in increased activity of CASR protein] PMID:11071898 10291 CASR calcium sensing receptor gene CHEBI:9753 troglitazone increases expression ISO RGD:2277 E RGD:6480464 20120918 CTD MESH:C057693 troglitazone results in increased expression of CASR mRNA PMID:21515302 10305 CD2 CD2 molecule gene CHEBI:125472 N-(6-acetamidohexyl)acetamide decreases expression ISO RGD:10304 E RGD:6480464 20170228 CTD MESH:C014026 hexamethylene bisacetamide results in decreased expression of CD2 mRNA PMID:26941288 10305 CD2 CD2 molecule gene CHEBI:15379 dioxygen multiple interactions ISO RGD:10304 E RGD:6480464 20190312 CTD MESH:D010100 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of CD2 mRNA PMID:30529165 10305 CD2 CD2 molecule gene CHEBI:166473 Dibutyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C065087 di-n-butylphosphoric acid affects the expression of CD2 mRNA PMID:37042841 10305 CD2 CD2 molecule gene CHEBI:16842 formaldehyde increases expression EXP E RGD:6480464 20140408 CTD MESH:D005557 Formaldehyde results in increased expression of CD2 mRNA PMID:23649840 10305 CD2 CD2 molecule gene CHEBI:17627 ferroheme b increases expression ISO RGD:10304 E RGD:6480464 20120814 CTD MESH:D006418 Heme metabolite results in increased expression of CD2 mRNA PMID:19191707 10305 CD2 CD2 molecule gene CHEBI:17833 gentamycin increases expression ISO RGD:2297 E RGD:6480464 20161228 CTD MESH:D005839 Gentamicins results in increased expression of CD2 mRNA PMID:22061828 10305 CD2 CD2 molecule gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20161025 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of CD2 gene PMID:27153756 10305 CD2 CD2 molecule gene CHEBI:25812 ozone multiple interactions ISO RGD:10304 E RGD:6480464 20220809 CTD MESH:D010126 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of CD2 mRNA; [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of CD2 mRNA PMID:34911549 10305 CD2 CD2 molecule gene CHEBI:26355 heme b increases expression ISO RGD:10304 E RGD:6480464 20140805 CTD MESH:D006418 Heme metabolite results in increased expression of CD2 mRNA PMID:19191707 10305 CD2 CD2 molecule gene CHEBI:2682 amphotericin B increases expression EXP E RGD:6480464 20230704 CTD MESH:D000666 Amphotericin B analog results in increased expression of CD2 mRNA PMID:28534445 10305 CD2 CD2 molecule gene CHEBI:27563 arsenic atom increases methylation EXP E RGD:6480464 20171114 CTD MESH:D001151 Arsenic results in increased methylation of CD2 gene PMID:27838757 10305 CD2 CD2 molecule gene CHEBI:27563 arsenic atom multiple interactions EXP E RGD:6480464 20200915 CTD MESH:D001151 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CD2 mRNA PMID:32525701 10305 CD2 CD2 molecule gene CHEBI:27856 acetamide increases expression ISO RGD:2297 E RGD:6480464 20200519 CTD MESH:C030686 acetamide results in increased expression of CD2 mRNA PMID:31881176 10305 CD2 CD2 molecule gene CHEBI:28088 genistein decreases expression ISO RGD:10304 E RGD:6480464 20200804 CTD MESH:D019833 Genistein results in decreased expression of CD2 mRNA PMID:32186404 10305 CD2 CD2 molecule gene CHEBI:28112 nickel atom increases expression EXP E RGD:6480464 20151110 CTD MESH:D009532 Nickel results in increased expression of CD2 mRNA PMID:25583101 10305 CD2 CD2 molecule gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:2297 E RGD:6480464 20220111 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of CD2 mRNA PMID:34747641 10305 CD2 CD2 molecule gene CHEBI:29678 sodium arsenite multiple interactions ISO RGD:10304 E RGD:6480464 20220405 CTD MESH:C017947 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD2 mRNA PMID:34876320 10305 CD2 CD2 molecule gene CHEBI:29852 methylarsonic acid multiple interactions ISO RGD:10304 E RGD:6480464 20220405 CTD MESH:C020300 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD2 mRNA PMID:34876320 10305 CD2 CD2 molecule gene CHEBI:29865 benzo[a]pyrene decreases expression ISO RGD:10304 E RGD:6480464 20120613 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of CD2 mRNA PMID:21569818 10305 CD2 CD2 molecule gene CHEBI:29865 benzo[a]pyrene increases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in increased methylation of CD2 promoter PMID:27901495 10305 CD2 CD2 molecule gene CHEBI:30563 silicon dioxide increases expression ISO RGD:10304 E RGD:6480464 20200310 CTD MESH:D012822 Silicon Dioxide results in increased expression of CD2 mRNA PMID:29341224 10305 CD2 CD2 molecule gene CHEBI:31206 ammonium chloride affects expression ISO RGD:2297 E RGD:6480464 20120412 CTD MESH:D000643 Ammonium Chloride affects the expression of CD2 mRNA PMID:16483693 10305 CD2 CD2 molecule gene CHEBI:3139 bleomycin A2 increases expression ISO RGD:10304 E RGD:6480464 20230307 CTD MESH:D001761 Bleomycin results in increased expression of CD2 mRNA PMID:36087614 10305 CD2 CD2 molecule gene CHEBI:32234 titanium dioxide increases expression ISO RGD:10304 E RGD:6480464 20140211 CTD MESH:C009495 titanium dioxide results in increased expression of CD2 mRNA PMID:23557971 10305 CD2 CD2 molecule gene CHEBI:32506 4,4'-diaminodiphenylmethane decreases expression ISO RGD:10304 E RGD:6480464 20120412 CTD MESH:C009505 4,4'-diaminodiphenylmethane results in decreased expression of CD2 mRNA PMID:18648102 10305 CD2 CD2 molecule gene CHEBI:32509 pirinixic acid increases expression ISO RGD:10304 E RGD:6480464 20120412 CTD MESH:C006253 pirinixic acid results in increased expression of CD2 mRNA PMID:20813756 10305 CD2 CD2 molecule gene CHEBI:33216 bisphenol A decreases expression ISO RGD:2297 E RGD:6480464 20150310 CTD MESH:C006780 bisphenol A results in decreased expression of CD2 mRNA PMID:25181051 10305 CD2 CD2 molecule gene CHEBI:33216 bisphenol A decreases methylation ISO RGD:10304 E RGD:6480464 20180116 CTD MESH:C006780 bisphenol A results in decreased methylation of CD2 promoter PMID:27312807 10305 CD2 CD2 molecule gene CHEBI:33216 bisphenol A increases expression ISO RGD:10304 E RGD:6480464 20230207 CTD MESH:C006780 bisphenol A results in increased expression of CD2 mRNA PMID:32156529|PMID:38701888 10305 CD2 CD2 molecule gene CHEBI:33217 3,3',5,5'-tetrabromobisphenol A decreases expression EXP E RGD:6480464 20200310 CTD MESH:C020806 tetrabromobisphenol A results in decreased expression of CD2 protein PMID:21623697 10305 CD2 CD2 molecule gene CHEBI:33418 graphite affects expression ISO RGD:2297 E RGD:6480464 20181113 CTD MESH:D006108 Graphite affects the expression of CD2 mRNA PMID:29933104 10305 CD2 CD2 molecule gene CHEBI:34372 4,4'-sulfonyldiphenol increases methylation ISO RGD:10304 E RGD:6480464 20220208 CTD MESH:C543008 bisphenol S results in increased methylation of CD2 promoter PMID:33297965 10305 CD2 CD2 molecule gene CHEBI:34575 bisphenol F decreases expression ISO RGD:10304 E RGD:6480464 20241105 CTD MESH:C008745 bisphenol F results in decreased expression of CD2 mRNA PMID:38685157 10305 CD2 CD2 molecule gene CHEBI:35033 triphenyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C005445 triphenyl phosphate affects the expression of CD2 mRNA PMID:37042841 10305 CD2 CD2 molecule gene CHEBI:35064 alpha-Zearalanol increases expression ISO RGD:2297 E RGD:6480464 20240430 CTD MESH:D015029 Zeranol results in increased expression of CD2 mRNA PMID:35163327 10305 CD2 CD2 molecule gene CHEBI:35064 alpha-Zearalanol multiple interactions ISO RGD:2297 E RGD:6480464 20240430 CTD MESH:D015029 [Zeranol co-treated with perfluorooctanoic acid] results in increased expression of CD2 mRNA PMID:35163327 10305 CD2 CD2 molecule gene CHEBI:35549 perfluorooctanoic acid multiple interactions ISO RGD:2297 E RGD:6480464 20240430 CTD MESH:C023036 [Zeranol co-treated with perfluorooctanoic acid] results in increased expression of CD2 mRNA PMID:35163327 10305 CD2 CD2 molecule gene CHEBI:35842 antirheumatic drug decreases expression EXP E RGD:6480464 20161228 CTD MESH:D018501 Antirheumatic Agents results in decreased expression of CD2 mRNA PMID:24449571 10305 CD2 CD2 molecule gene CHEBI:3750 clofibrate increases expression ISO RGD:10304 E RGD:6480464 20120515 CTD MESH:D002994 Clofibrate results in increased expression of CD2 mRNA PMID:17585979 10305 CD2 CD2 molecule gene CHEBI:39478 buta-1,3-diene decreases expression ISO RGD:10304 E RGD:6480464 20180703 CTD MESH:C031763 1,3-butadiene results in decreased expression of CD2 mRNA PMID:29038090 10305 CD2 CD2 molecule gene CHEBI:39481 chloroprene decreases expression ISO RGD:10304 E RGD:6480464 20130514 CTD MESH:D002737 Chloroprene results in decreased expression of CD2 mRNA PMID:23125180 10305 CD2 CD2 molecule gene CHEBI:4027 cyclophosphamide decreases expression ISO RGD:10304 E RGD:6480464 20120515 CTD MESH:D003520 Cyclophosphamide results in decreased expression of CD2 mRNA PMID:21041162 10305 CD2 CD2 molecule gene CHEBI:41879 dexamethasone decreases expression ISO RGD:10304 E RGD:6480464 20120515 CTD MESH:D003907 Dexamethasone results in decreased expression of CD2 mRNA PMID:21041162 10305 CD2 CD2 molecule gene CHEBI:44185 methotrexate decreases expression EXP E RGD:6480464 20121113 CTD MESH:D008727 Methotrexate results in decreased expression of CD2 mRNA PMID:17400583 10305 CD2 CD2 molecule gene CHEBI:45716 vorinostat increases expression ISO RGD:10304 E RGD:6480464 20161213 CTD MESH:C111237 vorinostat results in increased expression of CD2 mRNA PMID:26941288 10305 CD2 CD2 molecule gene CHEBI:46195 paracetamol increases expression EXP E RGD:6480464 20180313 CTD MESH:D000082 Acetaminophen results in increased expression of CD2 mRNA PMID:26690555 10305 CD2 CD2 molecule gene CHEBI:46195 paracetamol multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D000082 [Dietary Carbohydrates co-treated with Acetaminophen] results in decreased expression of CD2 mRNA PMID:17093179 10305 CD2 CD2 molecule gene CHEBI:47217 arsane increases methylation EXP E RGD:6480464 20171114 CTD MESH:D001151 Arsenic results in increased methylation of CD2 gene PMID:27838757 10305 CD2 CD2 molecule gene CHEBI:47217 arsane multiple interactions EXP E RGD:6480464 20200915 CTD MESH:D001151 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CD2 mRNA PMID:32525701 10305 CD2 CD2 molecule gene CHEBI:48765 dimethylarsinic acid increases expression ISO RGD:2297 E RGD:6480464 20120412 CTD MESH:D002101 Cacodylic Acid results in increased expression of CD2 mRNA PMID:16122865 10305 CD2 CD2 molecule gene CHEBI:48765 dimethylarsinic acid multiple interactions ISO RGD:10304 E RGD:6480464 20220405 CTD MESH:D002101 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD2 mRNA PMID:34876320 10305 CD2 CD2 molecule gene CHEBI:48843 disodium selenite increases expression EXP E RGD:6480464 20120412 CTD MESH:D018038 Sodium Selenite results in increased expression of CD2 mRNA PMID:18175754 10305 CD2 CD2 molecule gene CHEBI:50594 carbon nanotube decreases expression ISO RGD:10304 E RGD:6480464 20161228 CTD MESH:D037742 Nanotubes, Carbon analog results in decreased expression of CD2 mRNA; Nanotubes, Carbon results in decreased expression of CD2 mRNA PMID:25554681 10305 CD2 CD2 molecule gene CHEBI:53050 trimellitic anhydride increases expression ISO RGD:10304 E RGD:6480464 20120412 CTD MESH:C015559 trimellitic anhydride results in increased expression of CD2 mRNA PMID:16141432 10305 CD2 CD2 molecule gene CHEBI:6067 isotretinoin increases expression EXP E RGD:6480464 20120412 CTD MESH:D015474 Isotretinoin results in increased expression of CD2 mRNA PMID:20436886 10305 CD2 CD2 molecule gene CHEBI:61057 tacrolimus hydrate multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D016559 Tacrolimus inhibits the reaction [CD2 protein results in increased expression of IL2 protein] PMID:1705513 10305 CD2 CD2 molecule gene CHEBI:72544 flavonoids increases expression ISO RGD:2297 E RGD:6480464 20170303 CTD MESH:D005419 Flavonoids results in increased expression of CD2 mRNA PMID:18035473 10305 CD2 CD2 molecule gene CHEBI:72564 temozolomide decreases expression EXP E RGD:6480464 20210706 CTD MESH:C047246 Temozolomide results in decreased expression of CD2 mRNA PMID:31758290 10305 CD2 CD2 molecule gene CHEBI:73755 1,2-dimethylhydrazine increases expression ISO RGD:10304 E RGD:6480464 20200804 CTD MESH:D019813 1,2-Dimethylhydrazine results in increased expression of CD2 mRNA PMID:22206623 10305 CD2 CD2 molecule gene CHEBI:84070 sodium arsenate multiple interactions EXP E RGD:6480464 20200915 CTD MESH:C009277 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CD2 mRNA PMID:32525701 10305 CD2 CD2 molecule gene CHEBI:84070 sodium arsenate multiple interactions ISO RGD:10304 E RGD:6480464 20220405 CTD MESH:C009277 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD2 mRNA PMID:34876320 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:132267 triptonide increases expression ISO RGD:10355 E RGD:6480464 20210406 CTD MESH:C084079 triptonide results in increased expression of CHRNA4 mRNA PMID:33045310 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:133354 bentonite multiple interactions EXP E RGD:6480464 20161004 CTD MESH:D001546 Bentonite inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] PMID:22750351 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:136608 Theaflavin 3,3'-digallate affects expression EXP E RGD:6480464 20240402 CTD MESH:C585473 theaflavin-3,3'-digallate affects the expression of CHRNA4 mRNA PMID:34925699 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:1391 3,4-methylenedioxymethamphetamine multiple interactions EXP E RGD:6480464 20120918 CTD MESH:D018817 N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] PMID:20132834 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:140621 cisatracurium multiple interactions EXP E RGD:6480464 20180508 CTD MESH:C101584 cisatracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:16931985 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:145170 13-desmethylspirolide C multiple interactions EXP E RGD:6480464 20191105 CTD MESH:C517170 13-desmethylspirolide C binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:26063663 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:15354 choline affects activity ISO RGD:2346 E RGD:6480464 20171010 CTD MESH:D002794 Choline affects the activity of CHRNA4 protein PMID:19047205 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:15354 choline multiple interactions EXP E RGD:6480464 20120515 CTD MESH:D002794 Choline affects the activity of [CHRNA4 protein binds to CHRNB2 protein]; Choline inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]] PMID:14645658 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:15354 choline multiple interactions ISO RGD:10355 E RGD:6480464 20230704 CTD MESH:D002794 Choline inhibits the reaction [Sodium Fluoride results in decreased expression of CHRNA4 mRNA] PMID:36286330 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:15355 acetylcholine affects binding ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D000109 Acetylcholine analog binds to [CHRNA4 protein binds to CHRNB2 protein]; Acetylcholine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:19252481 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:15355 acetylcholine increases response to substance ISO RGD:10355 E RGD:6480464 20120412 CTD MESH:D000109 CHRNA4 protein mutant form results in increased susceptibility to Acetylcholine PMID:16339034 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:15355 acetylcholine multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D000109 1-Butanol affects the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; 2,4,2',4'-tetrachlorobiphenyl inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; 3,5-dibromo-2-(2,4-dibromophenoxy)phenol inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; 4-nonylphenol inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; 4-octylphenol inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; [3,5-dibromo-2-(2,4-dibromophenoxy)phenol co-treated with 2,4,2',4'-tetrachlorobiphenyl] inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; [Estradiol co-treated with Acetylcholine] results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; [Ethinyl Estradiol co-treated with Acetylcholine] results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; [Progesterone co-treated with Acetylcholine] results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]; Acetylcholine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]; Acetylcholine results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]; Aluminum Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]; antimony trioxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]; Atracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Atropine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Bentonite inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]; bisphenol A inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; cisatracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; clothianidin promotes the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; decabromobiphenyl ether inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]; desformylflustrabromine promotes the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dichlorvos inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Diethylstilbestrol inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Ethinyl Estradiol promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Fire Trol 934 inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]; Flame Retardants inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Flame Retardants inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]; Galantamine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; imidacloprid inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Magnesium Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]; Mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]; Pancuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Physostigmine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Rivastigmine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Rocuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Scopolamine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tacrine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tamoxifen inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; tetrabromobisphenol A inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; tetrabromobisphenol A inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]; Tetrachloroethylene inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Toluene inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; triphenyl phosphate inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Ethinyl Estradiol promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]]; Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:11517245|PMID:11711029|PMID:12604691|PMID:14645658|PMID:15733544|PMID:15885267|PMID:16931985|PMID:20132834|PMID:20861069|PMID:21538459|PMID:21905680|PMID:22547355|PMID:22750351|PMID:34628512|PMID:9454827 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:15355 acetylcholine multiple interactions ISO RGD:2346 E RGD:2303194|PMID:15016836 20210901 RGD MESH:D000109 acetylcholine affects binding to Chrna4 protein; acetylcholine competes with [Epibatidine binds to Chrna4 protein] 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:15355 acetylcholine multiple interactions ISO RGD:2346 E RGD:6480464 20130611 CTD MESH:D000109 [CHRNA4 protein co-treated with CHRNB2 protein mutant form] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein co-treated with CHRNB2 protein] affects the reaction [Barium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein co-treated with CHRNB2 protein] affects the reaction [Calcium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein co-treated with CHRNB2 protein] affects the susceptibility to Acetylcholine; [CHRNA4 protein mutant form co-treated with CHRNB2 protein] inhibits the reaction [Barium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein mutant form co-treated with CHRNB2 protein] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine]; [Ethinyl Estradiol co-treated with Acetylcholine] results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; [Mercuric Chloride co-treated with Acetylcholine] affects the activity of [CHRNA4 protein binds to CHRNB2 protein]; [Mercuric Chloride co-treated with Acetylcholine] affects the activity of [CHRNA4 protein binds to CHRNB4 protein]; [pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine; Acetylcholine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [[pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine]; Excitatory Amino Acid Antagonists inhibits the reaction [[pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine]; FG 9041 inhibits the reaction [[pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine]; Mecamylamine inhibits the reaction [[pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine]; Tetrachloroethylene inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Toluene inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Urethane promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:11517245|PMID:11812690|PMID:12130716|PMID:12754307|PMID:15885267|PMID:18385335 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:15367 all-trans-retinoic acid decreases expression ISO RGD:10355 E RGD:6480464 20120412 CTD MESH:D014212 Tretinoin results in decreased expression of CHRNA4 mRNA; Tretinoin results in decreased expression of CHRNA4 protein PMID:17203487 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:15367 all-trans-retinoic acid multiple interactions ISO RGD:10355 E RGD:6480464 20120412 CTD MESH:D014212 Tretinoin promotes the reaction [epibatidine binds to CHRNA4 protein] PMID:17203487 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:15379 dioxygen increases expression ISO RGD:10355 E RGD:6480464 20140114 CTD MESH:D010100 Oxygen deficiency results in increased expression of CHRNA4 mRNA PMID:24205000 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:16236 ethanol affects expression ISO RGD:10355 E RGD:6480464 20190507 CTD MESH:D000431 Ethanol affects the expression of CHRNA4 mRNA PMID:30319688 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:16469 17beta-estradiol affects binding EXP E RGD:6480464 20120412 CTD MESH:D004958 Estradiol binds to CHRNA4 protein PMID:11517245 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:16469 17beta-estradiol multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D004958 [Estradiol co-treated with Acetylcholine] results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:11517245 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:16684 atropine affects binding EXP E RGD:6480464 20120412 CTD MESH:D001285 Atropine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:16684 atropine multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D001285 Atropine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:16684 atropine multiple interactions ISO RGD:2346 E RGD:6480464 20130416 CTD MESH:D001285 Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]]; Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein]] PMID:21791372 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:16716 benzene decreases expression ISO RGD:10355 E RGD:6480464 20220308 CTD MESH:D001554 Benzene results in decreased expression of CHRNA4 mRNA PMID:34624356 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:16794 scopolamine affects binding EXP E RGD:6480464 20120412 CTD MESH:D012601 Scopolamine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:16794 scopolamine multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D012601 Scopolamine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17026 progesterone multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D011374 [Progesterone co-treated with Acetylcholine] results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:11517245 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17300 tetrachloroethene multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D013750 Tetrachloroethylene inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:15885267 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17300 tetrachloroethene multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D013750 Tetrachloroethylene inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:15885267 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17578 toluene multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D014050 Toluene inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:15885267 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17578 toluene multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D014050 Toluene inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:15885267 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17688 (S)-nicotine affects binding EXP E RGD:6480464 20161213 CTD MESH:D009538 Nicotine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:9336329 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17688 (S)-nicotine affects binding ISO RGD:2346 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine analog binds to [CHRNA4 protein binds to CHRNB2 protein]; Nicotine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:15615518|PMID:19252481 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17688 (S)-nicotine affects response to substance ISO RGD:10355 E RGD:6480464 20161213 CTD MESH:D009538 CHRNA4 gene polymorphism affects the susceptibility to Nicotine; CHRNA4 protein affects the susceptibility to Nicotine; CHRNA4 protein mutant form affects the susceptibility to Nicotine PMID:10734154|PMID:10942032|PMID:19404753 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17688 (S)-nicotine decreases expression ISO RGD:10355 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in decreased expression of CHRNA4 mRNA PMID:17135361 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17688 (S)-nicotine decreases expression ISO RGD:2346 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in decreased expression of CHRNA4 mRNA PMID:20060465 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17688 (S)-nicotine increases expression EXP E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in increased expression of CHRNA4 protein PMID:19139119|PMID:20106947 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17688 (S)-nicotine increases expression ISO RGD:10355 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in increased expression of CHRNA4 mRNA; Nicotine results in increased expression of CHRNA4 protein PMID:14500745|PMID:19594327|PMID:29293602|PMID:7756618 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17688 (S)-nicotine increases expression ISO RGD:2346 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in increased expression of CHRNA4 mRNA; Nicotine results in increased expression of CHRNA4 protein PMID:24368670|PMID:28555334|PMID:29486207|PMID:31846720|PMID:34153408 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17688 (S)-nicotine increases response to substance ISO RGD:10355 E RGD:6480464 20161213 CTD MESH:D009538 CHRNA4 protein mutant form results in increased susceptibility to Nicotine PMID:16339034 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17688 (S)-nicotine multiple interactions EXP E RGD:6480464 20161213 CTD MESH:D009538 [CHRNA4 protein binds to CHRNB2 protein] which results in increased susceptibility to Nicotine; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]; Rosiglitazone inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein] PMID:14645658|PMID:18448488|PMID:19139119|PMID:20943775|PMID:34628512|PMID:9336329|PMID:9454827 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17688 (S)-nicotine multiple interactions ISO RGD:10355 E RGD:6480464 20161213 CTD MESH:D009538 [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with Nicotine] inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CHRNA4 protein]; cytisine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Nicotine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CHRNA4 protein]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein] PMID:15551346|PMID:19481067|PMID:19594327|PMID:7756618 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17688 (S)-nicotine multiple interactions ISO RGD:2346 E RGD:6480464 20161213 CTD MESH:D009538 1-(5-azido-6-chloropyridin-3-ylmethyl)-2-nitroiminoimidazolidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine; [Nicotine co-treated with Benzo(a)pyrene] results in decreased expression of [CHRNA4 protein binds to CHRNB2 protein]; Bungarotoxins inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in increased expression of CHRNA4 mRNA]; imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; N-(5-azido-6-chloropyridin-3-ylmethyl)-N'-methyl-N''-nitroguanidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine results in increased expression of [CHRNA4 protein binds to CHRNB2 protein] PMID:10336510|PMID:10377228|PMID:10945867|PMID:11124396|PMID:11150171|PMID:16915382|PMID:28555334|PMID:30247698|PMID:34153408 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17747 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:10355 E RGD:6480464 20210608 CTD MESH:D004051 Diethylhexyl Phthalate inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of CHRNA4 mRNA] PMID:33484791 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:177802 Cuprizon decreases expression ISO RGD:2346 E RGD:6480464 20210907 CTD MESH:D003471 Cuprizone results in decreased expression of CHRNA4 mRNA PMID:26577399 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17963 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine decreases expression ISO RGD:10355 E RGD:6480464 20160510 CTD MESH:D015632 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CHRNA4 protein PMID:19594327 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17963 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine multiple interactions ISO RGD:10355 E RGD:6480464 20160510 CTD MESH:D015632 Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CHRNA4 protein] PMID:19594327 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:17967 urethane multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D014520 Urethane promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:11812690 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18243 dopamine affects binding ISO RGD:2346 E RGD:8549526|PMID:22550286 20210820 RGD MESH:D004298 dopamine binds to Chrna4 protein in rat brain striatal sections 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine affects binding EXP E RGD:6480464 20161213 CTD MESH:D009538 Nicotine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:9336329 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine affects binding ISO RGD:2346 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine analog binds to [CHRNA4 protein binds to CHRNB2 protein]; Nicotine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:15615518|PMID:19252481 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine affects response to substance ISO RGD:10355 E RGD:6480464 20161213 CTD MESH:D009538 CHRNA4 gene polymorphism affects the susceptibility to Nicotine; CHRNA4 protein affects the susceptibility to Nicotine; CHRNA4 protein mutant form affects the susceptibility to Nicotine PMID:10734154|PMID:10942032|PMID:19404753 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine decreases expression ISO RGD:10355 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in decreased expression of CHRNA4 mRNA PMID:17135361 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine decreases expression ISO RGD:2346 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in decreased expression of CHRNA4 mRNA PMID:20060465 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine increases expression EXP E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in increased expression of CHRNA4 protein PMID:19139119|PMID:20106947 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine increases expression ISO RGD:10355 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in increased expression of CHRNA4 mRNA; Nicotine results in increased expression of CHRNA4 protein PMID:14500745|PMID:19594327|PMID:29293602|PMID:7756618 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine increases expression ISO RGD:2346 E RGD:6480464 20161213 CTD MESH:D009538 Nicotine results in increased expression of CHRNA4 mRNA; Nicotine results in increased expression of CHRNA4 protein PMID:24368670|PMID:28555334|PMID:29486207|PMID:31846720|PMID:34153408 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine increases response to substance ISO RGD:10355 E RGD:6480464 20161213 CTD MESH:D009538 CHRNA4 protein mutant form results in increased susceptibility to Nicotine PMID:16339034 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine multiple interactions EXP E RGD:6480464 20161213 CTD MESH:D009538 [CHRNA4 protein binds to CHRNB2 protein] which results in increased susceptibility to Nicotine; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]; Rosiglitazone inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein] PMID:14645658|PMID:18448488|PMID:19139119|PMID:20943775|PMID:34628512|PMID:9336329|PMID:9454827 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine multiple interactions ISO RGD:10355 E RGD:6480464 20161213 CTD MESH:D009538 [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with Nicotine] inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CHRNA4 protein]; cytisine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Nicotine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CHRNA4 protein]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein] PMID:15551346|PMID:19481067|PMID:19594327|PMID:7756618 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine multiple interactions ISO RGD:2346 E RGD:2303194|PMID:15016836 20210901 RGD MESH:D009538 nicotine affects binding to Chrna4 protein; nicotine competes with [Epibatidine binds to Chrna4 protein] 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine multiple interactions ISO RGD:2346 E RGD:2303195|PMID:16129735 20210902 RGD MESH:D009538 nicotine affects binding to Chrna4 protein; nicotine inhibits the reaction [epibatidine affects binding to Chrna4 protein] in rat retina 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:18723 nicotine multiple interactions ISO RGD:2346 E RGD:6480464 20161213 CTD MESH:D009538 1-(5-azido-6-chloropyridin-3-ylmethyl)-2-nitroiminoimidazolidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine; [Nicotine co-treated with Benzo(a)pyrene] results in decreased expression of [CHRNA4 protein binds to CHRNB2 protein]; Bungarotoxins inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in increased expression of CHRNA4 mRNA]; imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; N-(5-azido-6-chloropyridin-3-ylmethyl)-N'-methyl-N''-nitroguanidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine results in increased expression of [CHRNA4 protein binds to CHRNB2 protein] PMID:10336510|PMID:10377228|PMID:10945867|PMID:11124396|PMID:11150171|PMID:16915382|PMID:28555334|PMID:30247698|PMID:34153408 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:188610 Desformylflustrabromine multiple interactions EXP E RGD:6480464 20220104 CTD MESH:C524215 desformylflustrabromine promotes the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:21905680 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:22977 cadmium atom multiple interactions ISO RGD:10355 E RGD:6480464 20231205 CTD MESH:D002104 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of CHRNA4 mRNA PMID:37325564 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:22984 calcium atom multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D002118 [CHRNA4 protein co-treated with CHRNB2 protein mutant form] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein co-treated with CHRNB2 protein] affects the reaction [Calcium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein mutant form co-treated with CHRNB2 protein] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine] PMID:12754307 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:2555 aldicarb multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D000448 Aldicarb results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] PMID:14644616 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:2564 aldrin increases expression ISO RGD:10355 E RGD:6480464 20140107 CTD MESH:D000452 Aldrin results in increased expression of CHRNA4 mRNA PMID:18579281 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:25812 ozone multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D010126 [Ozone co-treated with Chlorine] results in increased expression of CHRNA4 mRNA PMID:18636392 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:26421 pyridines multiple interactions EXP E RGD:6480464 20170110 CTD MESH:D011725 Pyridines binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:21962147 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:27385 tetrachloromethane affects expression ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D002251 Carbon Tetrachloride affects the expression of CHRNA4 mRNA PMID:12734012 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:27563 arsenic atom affects methylation EXP E RGD:6480464 20150310 CTD MESH:D001151 Arsenic affects the methylation of CHRNA4 gene PMID:25304211 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:27568 selenium atom increases expression EXP E RGD:6480464 20120412 CTD MESH:D012643 Selenium results in increased expression of CHRNA4 mRNA PMID:19244175 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:27789 1,2-dichloroethane affects expression ISO RGD:10355 E RGD:6480464 20200310 CTD MESH:C024565 ethylene dichloride affects the expression of CHRNA4 mRNA PMID:28960355 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:27827 paraoxon decreases expression ISO RGD:2346 E RGD:6480464 20130416 CTD MESH:D010261 Paraoxon results in decreased expression of CHRNA4 mRNA; Paraoxon results in decreased expression of CHRNA4 protein PMID:21791372 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:27827 paraoxon multiple interactions ISO RGD:2346 E RGD:6480464 20130416 CTD MESH:D010261 Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]]; Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein]]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein] PMID:21791372 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:27881 resveratrol increases expression EXP E RGD:6480464 20120412 CTD MESH:C059514 resveratrol results in increased expression of CHRNA4 mRNA PMID:12569576 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:27881 resveratrol multiple interactions EXP E RGD:6480464 20220510 CTD MESH:C059514 [Plant Extracts co-treated with Resveratrol] results in decreased expression of CHRNA4 mRNA PMID:23557933 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:27953 physostigmine affects binding EXP E RGD:6480464 20120412 CTD MESH:D010830 Physostigmine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:27953 physostigmine multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D010830 Physostigmine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Physostigmine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Physostigmine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Physostigmine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:14645658|PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:27958 cocaine multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D003042 Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:10336510 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28001 vancomycin increases expression ISO RGD:10355 E RGD:6480464 20120412 CTD MESH:D014640 Vancomycin results in increased expression of CHRNA4 mRNA PMID:18930951 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28088 genistein decreases expression ISO RGD:10355 E RGD:6480464 20200804 CTD MESH:D019833 Genistein results in decreased expression of CHRNA4 mRNA PMID:32186404 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28088 genistein multiple interactions ISO RGD:2346 E RGD:6480464 20130611 CTD MESH:D019833 [Genistein co-treated with Methoxychlor] results in decreased expression of CHRNA4 mRNA PMID:21782745 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28112 nickel atom decreases expression ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D009532 Nickel results in decreased expression of CHRNA4 mRNA PMID:18812211 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:10355 E RGD:6480464 20160210 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of CHRNA4 mRNA PMID:24680724|PMID:26377647 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:10355 E RGD:6480464 20160119 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of CHRNA4 mRNA PMID:26290441 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:10355 E RGD:6480464 20120515 CTD MESH:D013749 Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CHRNA4 promoter] PMID:19654925 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28201 rotenone decreases expression EXP E RGD:6480464 20210810 CTD MESH:D012402 Rotenone results in decreased expression of CHRNA4 mRNA PMID:33512557 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of CHRNA4 mRNA PMID:33212167 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28509 chloroethene increases expression ISO RGD:10355 E RGD:6480464 20130514 CTD MESH:D014752 Vinyl Chloride results in increased expression of CHRNA4 mRNA PMID:18579281 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28619 acrylamide decreases expression ISO RGD:2346 E RGD:6480464 20180410 CTD MESH:D020106 Acrylamide results in decreased expression of CHRNA4 mRNA PMID:28959563 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28741 sodium fluoride decreases expression ISO RGD:10355 E RGD:6480464 20230704 CTD MESH:D012969 Sodium Fluoride results in decreased expression of CHRNA4 mRNA PMID:36286330 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28741 sodium fluoride decreases expression ISO RGD:2346 E RGD:6480464 20120918 CTD MESH:D012969 Sodium Fluoride results in decreased expression of CHRNA4 protein PMID:19900517 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28741 sodium fluoride multiple interactions ISO RGD:10355 E RGD:6480464 20230704 CTD MESH:D012969 Choline inhibits the reaction [Sodium Fluoride results in decreased expression of CHRNA4 mRNA] PMID:36286330 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:28885 butan-1-ol multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D020001 1-Butanol affects the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; 1-Butanol binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [1-Butanol binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Mecamylamine inhibits the reaction [1-Butanol binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:12604691 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:2914 atracurium multiple interactions EXP E RGD:6480464 20120515 CTD MESH:D001279 Atracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:16931985 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:29310 dichlorine multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D002713 [Ozone co-treated with Chlorine] results in increased expression of CHRNA4 mRNA PMID:18636392 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:29320 calcium(0) multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D002118 [CHRNA4 protein co-treated with CHRNB2 protein mutant form] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein co-treated with CHRNB2 protein] affects the reaction [Calcium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein mutant form co-treated with CHRNB2 protein] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine] PMID:12754307 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of CHRNA4 mRNA PMID:38568856 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:29699 tunicamycin increases expression EXP E RGD:6480464 20210608 CTD MESH:D014415 Tunicamycin results in increased expression of CHRNA4 mRNA PMID:33545341 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of CHRNA4 3' UTR PMID:27901495 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:29865 benzo[a]pyrene decreases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in decreased methylation of CHRNA4 promoter PMID:27901495 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:29865 benzo[a]pyrene increases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in increased methylation of CHRNA4 exon PMID:27901495 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:29865 benzo[a]pyrene multiple interactions ISO RGD:10355 E RGD:6480464 20201006 CTD MESH:D001564 [corannulene co-treated with Benzo(a)pyrene] results in increased expression of CHRNA4 mRNA PMID:32417428 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:29865 benzo[a]pyrene multiple interactions ISO RGD:2346 E RGD:6480464 20190219 CTD MESH:D001564 [Nicotine co-treated with Benzo(a)pyrene] results in decreased expression of [CHRNA4 protein binds to CHRNB2 protein] PMID:30247698 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:29866 arsenite(3-) increases expression ISO RGD:10355 E RGD:6480464 20210504 CTD MESH:C015001 arsenite results in increased expression of CHRNA4 mRNA PMID:33053406 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:30563 silicon dioxide decreases expression ISO RGD:2346 E RGD:6480464 20210706 CTD MESH:D012822 Silicon Dioxide results in decreased expression of CHRNA4 mRNA PMID:32721576 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:31206 ammonium chloride affects expression ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D000643 Ammonium Chloride affects the expression of CHRNA4 mRNA PMID:16483693 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:31575 ethylparaben decreases expression EXP E RGD:6480464 20240109 CTD MESH:C012313 ethyl-p-hydroxybenzoate results in decreased expression of CHRNA4 mRNA PMID:37690743 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:31638 fulvestrant increases methylation EXP E RGD:6480464 20220308 CTD MESH:C070081 Fulvestrant results in increased methylation of CHRNA4 gene PMID:31601247 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:31695 indigo carmine multiple interactions ISO RGD:2346 E RGD:6480464 20141111 CTD MESH:D007203 [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein PMID:23429044 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:31823 mercury dichloride multiple interactions ISO RGD:2346 E RGD:6480464 20120814 CTD MESH:D008627 [Mercuric Chloride co-treated with Acetylcholine] affects the activity of [CHRNA4 protein binds to CHRNB2 protein]; [Mercuric Chloride co-treated with Acetylcholine] affects the activity of [CHRNA4 protein binds to CHRNB4 protein] PMID:12130716 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:32234 titanium dioxide decreases methylation ISO RGD:10355 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in decreased methylation of CHRNA4 gene PMID:35295148 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:32595 barium(0) multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D001464 [CHRNA4 protein co-treated with CHRNB2 protein] affects the reaction [Barium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein mutant form co-treated with CHRNB2 protein] inhibits the reaction [Barium results in increased susceptibility to Acetylcholine] PMID:12754307 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:33130 aluminium hydroxide multiple interactions EXP E RGD:6480464 20121009 CTD MESH:D000536 Aluminum Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] PMID:22750351 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:33216 bisphenol A decreases expression ISO RGD:10355 E RGD:6480464 20230207 CTD MESH:C006780 bisphenol A results in decreased expression of CHRNA4 mRNA PMID:32156529 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:33216 bisphenol A decreases expression ISO RGD:2346 E RGD:6480464 20150310 CTD MESH:C006780 bisphenol A results in decreased expression of CHRNA4 mRNA; bisphenol A results in decreased expression of CHRNA4 protein PMID:25181051|PMID:30816183|PMID:32528016|PMID:34947998|PMID:37495067 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:33216 bisphenol A decreases methylation ISO RGD:10355 E RGD:6480464 20180116 CTD MESH:C006780 bisphenol A results in decreased methylation of CHRNA4 promoter PMID:27312807 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:33216 bisphenol A increases expression ISO RGD:10355 E RGD:6480464 20120515 CTD MESH:C006780 bisphenol A results in increased expression of CHRNA4 mRNA PMID:21932408 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:33216 bisphenol A multiple interactions EXP E RGD:6480464 20120412 CTD MESH:C006780 bisphenol A inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:11711029 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:33216 bisphenol A multiple interactions ISO RGD:2346 E RGD:6480464 20250114 CTD MESH:C006780 bisphenol A promotes the reaction [CHRNA4 protein binds to METTL3 protein]; bisphenol A results in decreased expression of and results in increased methylation of CHRNA4 mRNA; METTL3 protein promotes the reaction [bisphenol A results in decreased expression of CHRNA4 protein] PMID:37495067 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:33217 3,3',5,5'-tetrabromobisphenol A multiple interactions EXP E RGD:6480464 20121009 CTD MESH:C020806 tetrabromobisphenol A inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; tetrabromobisphenol A inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] PMID:22547355|PMID:22750351 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:3385 carbachol affects binding ISO RGD:2346 E RGD:6480464 20161213 CTD MESH:D002217 Carbachol binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:15615518 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:3385 carbachol multiple interactions EXP E RGD:6480464 20161213 CTD MESH:D002217 Carbachol inhibits the reaction [decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol inhibits the reaction [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol inhibits the reaction [methyllycaconitine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:14645658 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:3385 carbachol multiple interactions ISO RGD:2346 E RGD:2303194|PMID:15016836 20210901 RGD MESH:D002217 carbachol affects binding to Chrna4 protein; carbachol competes with [Epibatidine binds to Chrna4 protein] 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:3387 carbamazepine affects binding EXP E RGD:6480464 20120412 CTD MESH:D002220 Carbamazepine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:12110613 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:3390 carbaryl multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D012721 Carbaryl results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Carbaryl results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] PMID:14644616 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34031 1,1-dichloroethene decreases expression ISO RGD:10355 E RGD:6480464 20170725 CTD MESH:C029297 vinylidene chloride results in decreased expression of CHRNA4 mRNA PMID:26682919 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34204 2,2',4,4'-tetrachlorobiphenyl multiple interactions EXP E RGD:6480464 20120412 CTD MESH:C035976 2,4,2',4'-tetrachlorobiphenyl inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; [3,5-dibromo-2-(2,4-dibromophenoxy)phenol co-treated with 2,4,2',4'-tetrachlorobiphenyl] inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:20861069 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34372 4,4'-sulfonyldiphenol decreases expression ISO RGD:10355 E RGD:6480464 20191112 CTD MESH:C543008 bisphenol S results in decreased expression of CHRNA4 mRNA PMID:30951980|PMID:33297965 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34432 4-octylphenol multiple interactions EXP E RGD:6480464 20140204 CTD MESH:C080417 4-octylphenol inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:11711029 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34440 4-nonylphenol multiple interactions EXP E RGD:6480464 20120412 CTD MESH:C041594 4-nonylphenol inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:11711029 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34533 Amaranth multiple interactions ISO RGD:2346 E RGD:6480464 20141111 CTD MESH:D000548 [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein PMID:23429044 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34556 bendiocarb multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:C007725 bendiocarb results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] PMID:14644616 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34575 bisphenol F decreases expression ISO RGD:10355 E RGD:6480464 20191112 CTD MESH:C008745 bisphenol F results in decreased expression of CHRNA4 mRNA PMID:30951980|PMID:38685157 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34631 chlorpyrifos increases expression ISO RGD:10355 E RGD:6480464 20230606 CTD MESH:D004390 Chlorpyrifos results in increased expression of CHRNA4 mRNA PMID:37019170 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34682 diazinon affects expression ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D003976 Diazinon affects the expression of CHRNA4 mRNA PMID:18812211 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34690 dichlorvos multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D004006 Dichlorvos inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34696 dieldrin affects expression ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D004026 Dieldrin affects the expression of CHRNA4 mRNA PMID:18812211 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34705 dihydro-beta-erythroidine affects binding ISO RGD:2346 E RGD:6480464 20140708 CTD MESH:D004079 [CHRNA4 protein binds to CHRNB4 protein] which binds to Dihydro-beta-Erythroidine PMID:9687574 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34705 dihydro-beta-erythroidine multiple interactions EXP E RGD:6480464 20140708 CTD MESH:D004079 Carbachol inhibits the reaction [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [1-Butanol binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:12604691|PMID:14645658 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34705 dihydro-beta-erythroidine multiple interactions ISO RGD:10355 E RGD:6480464 20140708 CTD MESH:D004079 Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [3-(2-(pyrrolidinyl)methoxy)pyridine analog results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:16569710|PMID:20100906 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34705 dihydro-beta-erythroidine multiple interactions ISO RGD:2346 E RGD:2303194|PMID:15016836 20210901 RGD MESH:D004079 dihydro-beta-erythroidine affects binding to Chrna4 protein; dihydro-beta-erythroidine competes with [Epibatidine binds to Chrna4 protein] 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34705 dihydro-beta-erythroidine multiple interactions ISO RGD:2346 E RGD:2303195|PMID:16129735 20210902 RGD MESH:D004079 dihydro-beta-erythroidine affects binding to Chrna4 protein; dihydro-beta-erythroidine inhibits the reaction [epibatidine affects binding to Chrna4 protein] in rat retina 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34705 dihydro-beta-erythroidine multiple interactions ISO RGD:2346 E RGD:6480464 20140708 CTD MESH:D004079 [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine; Dihydro-beta-Erythroidine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in increased expression of CHRNA4 mRNA]; Dihydro-beta-Erythroidine inhibits the reaction [[pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine]; Dihydro-beta-Erythroidine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:10945867|PMID:11600638|PMID:16915382|PMID:18385335|PMID:19047205|PMID:28555334 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34873 N-nitrosodiethylamine increases expression ISO RGD:10355 E RGD:6480464 20160412 CTD MESH:D004052 Diethylnitrosamine results in increased expression of CHRNA4 mRNA PMID:24535843 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:34938 propoxur multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D001074 Propoxur results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] PMID:14644616 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:35033 triphenyl phosphate multiple interactions EXP E RGD:6480464 20121009 CTD MESH:C005445 triphenyl phosphate inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] PMID:22750351 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:35456 cadmium dichloride multiple interactions ISO RGD:10355 E RGD:6480464 20231205 CTD MESH:D019256 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of CHRNA4 mRNA PMID:37325564 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:36386 dichloroacetic acid increases expression ISO RGD:10355 E RGD:6480464 20171114 CTD MESH:D003999 Dichloroacetic Acid results in increased expression of CHRNA4 mRNA PMID:28962523 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:36904 elemental selenium increases expression EXP E RGD:6480464 20120412 CTD MESH:D012643 Selenium results in increased expression of CHRNA4 mRNA PMID:19244175 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:38314 pyrazines multiple interactions EXP E RGD:6480464 20170303 CTD MESH:D011719 Pyrazines binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:21962147 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:38604 pyrimidifen decreases expression EXP E RGD:6480464 20210810 CTD MESH:C476509 pyrimidifen results in decreased expression of CHRNA4 mRNA PMID:33512557 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:39163 acetamiprid decreases expression ISO RGD:10355 E RGD:6480464 20201103 CTD MESH:C464485 acetamiprid results in decreased expression of CHRNA4 mRNA PMID:30103633 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:39178 clothianidin multiple interactions EXP E RGD:6480464 20180116 CTD MESH:C480342 clothianidin promotes the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:21538459 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:39867 valproic acid affects expression ISO RGD:10355 E RGD:6480464 20120412 CTD MESH:D014635 Valproic Acid affects the expression of CHRNA4 mRNA PMID:17292431 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:39867 valproic acid increases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in increased methylation of CHRNA4 gene PMID:29154799 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4055 cytisine affects binding EXP E RGD:6480464 20130702 CTD MESH:C004712 cytisine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:9336329 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4055 cytisine affects expression ISO RGD:10355 E RGD:6480464 20130702 CTD MESH:C004712 cytisine affects the expression of CHRNA4 protein PMID:7756618 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4055 cytisine multiple interactions EXP E RGD:6480464 20130702 CTD MESH:C004712 cytisine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; cytisine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; cytisine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; cytisine results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]; Nicotine inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]]; pozanicline inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]] PMID:14645658|PMID:20331614|PMID:9336329|PMID:9454827 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4055 cytisine multiple interactions ISO RGD:10355 E RGD:6480464 20130702 CTD MESH:C004712 cytisine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein] PMID:7756618 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4055 cytisine multiple interactions ISO RGD:2346 E RGD:2303194|PMID:15016836 20210901 RGD MESH:C004712 cytisine affects binding to Chrna4 protein; cytisine competes with [Epibatidine binds to Chrna4 protein] 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4055 cytisine multiple interactions ISO RGD:2346 E RGD:2303195|PMID:16129735 20210902 RGD MESH:C004712 cytisine affects binding to Chrna4 protein; cytisine inhibits the reaction [epibatidine affects binding to Chrna4 protein] in rat retina 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:40909 azoxystrobin decreases expression EXP E RGD:6480464 20210810 CTD MESH:C087670 azoxystrobin results in decreased expression of CHRNA4 mRNA PMID:33512557 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:41774 tamoxifen multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D013629 Tamoxifen inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:11711029 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:41922 diethylstilbestrol multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D004054 Diethylstilbestrol inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:11711029 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:41934 decamethonium multiple interactions EXP E RGD:6480464 20120515 CTD MESH:C033019 Carbachol inhibits the reaction [decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; decamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; decamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:14645658 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4290 1,1-dimethyl-4-phenylpiperazinium iodide multiple interactions EXP E RGD:6480464 20120515 CTD MESH:D004246 Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] PMID:14645658|PMID:9454827 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4290 1,1-dimethyl-4-phenylpiperazinium iodide multiple interactions ISO RGD:2346 E RGD:2303194|PMID:15016836 20210901 RGD MESH:D004246 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrna4 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrna4 protein] 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:42944 galanthamine affects binding EXP E RGD:6480464 20120412 CTD MESH:D005702 Galantamine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:42944 galanthamine multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D005702 Galantamine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4357 deguelin decreases expression EXP E RGD:6480464 20210810 CTD MESH:C107676 deguelin results in decreased expression of CHRNA4 mRNA PMID:33512557 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:43931 methyllycaconitine affects activity ISO RGD:2346 E RGD:6480464 20171010 CTD MESH:C054634 methyllycaconitine affects the activity of CHRNA4 protein PMID:19047205 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:43931 methyllycaconitine multiple interactions EXP E RGD:6480464 20141111 CTD MESH:C054634 Carbachol inhibits the reaction [methyllycaconitine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; methyllycaconitine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; methyllycaconitine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; methyllycaconitine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:14645658 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:43931 methyllycaconitine multiple interactions ISO RGD:2346 E RGD:2303194|PMID:15016836 20210901 RGD MESH:C054634 methyllycaconitine affects binding to Chrna4 protein; methyllycaconitine competes with [Epibatidine binds to Chrna4 protein] 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:45652 succinylcholine multiple interactions EXP E RGD:6480464 20120515 CTD MESH:D013390 Succinylcholine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]] PMID:14645658 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:45980 tacrine increases expression ISO RGD:10355 E RGD:6480464 20120515 CTD MESH:D013619 Tacrine results in increased expression of CHRNA4 protein PMID:8930989 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:45980 tacrine multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D013619 Tacrine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:45980 tacrine multiple interactions ISO RGD:10355 E RGD:6480464 20120515 CTD MESH:D013619 Mecamylamine inhibits the reaction [Tacrine results in increased expression of CHRNA4 protein] PMID:8930989 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:46195 paracetamol affects expression ISO RGD:10355 E RGD:6480464 20120412 CTD MESH:D000082 Acetaminophen affects the expression of CHRNA4 mRNA PMID:17562736 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:46345 5-fluorouracil multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D005472 TP53 protein affects the reaction [Fluorouracil results in decreased expression of CHRNA4 mRNA] PMID:15016801 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:47217 arsane affects methylation EXP E RGD:6480464 20150310 CTD MESH:D001151 Arsenic affects the methylation of CHRNA4 gene PMID:25304211 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4738 EPTC multiple interactions ISO RGD:2346 E RGD:6480464 20141111 CTD MESH:C036251 EPTC results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; EPTC results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] PMID:14644616 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4803 epibatidine affects binding EXP E RGD:6480464 20141111 CTD MESH:C082748 [CHRNB4 protein binds to CHRNA4 protein] which binds to epibatidine; epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:14645658|PMID:9454827 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4803 epibatidine affects binding ISO RGD:10355 E RGD:6480464 20141111 CTD MESH:C082748 epibatidine binds to CHRNA4 protein PMID:17203487 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4803 epibatidine affects binding ISO RGD:2346 E RGD:2303194|PMID:15016836 20210901 RGD MESH:C082748 Epibatidine binds to Chrna4 protein 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4803 epibatidine affects binding ISO RGD:2346 E RGD:2303195|PMID:16129735 20210902 RGD MESH:C082748 epibatidine binds to Chrnb4 protein in the rat retina 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4803 epibatidine affects binding ISO RGD:2346 E RGD:6480464 20141111 CTD MESH:C082748 epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:11124396|PMID:15615518|PMID:21942635 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4803 epibatidine multiple interactions EXP E RGD:6480464 20141111 CTD MESH:C082748 Acetylcholine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Acetylthiocholine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Alcuronium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Choline inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; cytisine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; decamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; epibatidine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; epibatidine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Hexamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Lobeline inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; methyllycaconitine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Pancuronium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Physostigmine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; subecholine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Succinylcholine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]] PMID:14645658|PMID:22060139 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4803 epibatidine multiple interactions ISO RGD:10355 E RGD:6480464 20141111 CTD MESH:C082748 Tretinoin promotes the reaction [epibatidine binds to CHRNA4 protein] PMID:17203487 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4803 epibatidine multiple interactions ISO RGD:2346 E RGD:6480464 20141111 CTD MESH:C082748 2-(1'-methyl-2'-pyrrolidinyl)-7-hydroxy-1,4-benzodioxane inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; epibatidine binds to [CHRNA4 protein co-treated with CHRNB2 protein]; epibatidine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; sazetidine-A analog inhibits the reaction [epibatidine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:10728888|PMID:21905669|PMID:21942635 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4811 epoxiconazole decreases expression ISO RGD:10355 E RGD:6480464 20220906 CTD MESH:C109476 epoxiconazole results in decreased expression of CHRNA4 mRNA PMID:35436446 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:48723 (-)-lobeline multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D008120 [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Lobeline inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Lobeline results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:14645658|PMID:18448488 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4903 17alpha-ethynylestradiol multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D004997 [Ethinyl Estradiol co-treated with Acetylcholine] results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Ethinyl Estradiol promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Ethinyl Estradiol promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]] PMID:11517245|PMID:11711029 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:4903 17alpha-ethynylestradiol multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D004997 [Ethinyl Estradiol co-treated with Acetylcholine] results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:11517245 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:5009 fenoxycarb multiple interactions ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:C052034 fenoxycarb results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; fenoxycarb results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] PMID:14644616 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:50594 carbon nanotube decreases expression ISO RGD:10355 E RGD:6480464 20161228 CTD MESH:D037742 Nanotubes, Carbon analog results in decreased expression of CHRNA4 mRNA; Nanotubes, Carbon results in decreased expression of CHRNA4 mRNA PMID:25620056 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:51348 tetraphene decreases expression ISO RGD:10355 E RGD:6480464 20160119 CTD MESH:C030935 benz(a)anthracene results in decreased expression of CHRNA4 mRNA PMID:26377693 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:53444 potassium dichromate decreases expression ISO RGD:10355 E RGD:6480464 20140610 CTD MESH:D011192 Potassium Dichromate results in decreased expression of CHRNA4 mRNA PMID:23608068 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:55313 alcuronium multiple interactions EXP E RGD:6480464 20120515 CTD MESH:D000443 Alcuronium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Alcuronium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:14645658 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:5693 hexachlorophene decreases expression ISO RGD:10355 E RGD:6480464 20180515 CTD MESH:D006582 Hexachlorophene results in decreased expression of CHRNA4 mRNA PMID:25943520 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:5700 Hexamethonium multiple interactions EXP E RGD:6480464 20141111 CTD MESH:D018738 Hexamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Hexamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:14645658 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:5700 Hexamethonium multiple interactions ISO RGD:10355 E RGD:6480464 20141111 CTD MESH:D018738 Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein] PMID:7756618 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:5870 imidacloprid multiple interactions EXP E RGD:6480464 20180116 CTD MESH:C082359 imidacloprid inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB4 protein] PMID:21538459|PMID:34628512 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:5870 imidacloprid multiple interactions ISO RGD:2346 E RGD:6480464 20180116 CTD MESH:C082359 imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; imidacloprid binds to [CHRNA4 protein co-treated with CHRNB2 protein] PMID:10377228|PMID:10728888 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:6637 magnesium dihydroxide multiple interactions EXP E RGD:6480464 20121009 CTD MESH:D008276 Magnesium Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] PMID:22750351 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:6706 Mecamylamine multiple interactions EXP E RGD:6480464 20141111 CTD MESH:D008464 Mecamylamine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Mecamylamine inhibits the reaction [1-Butanol binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Mecamylamine inhibits the reaction [desnitroimidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Mecamylamine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:12604691|PMID:14645658|PMID:34628512 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:6706 Mecamylamine multiple interactions ISO RGD:10355 E RGD:6480464 20141111 CTD MESH:D008464 Mecamylamine inhibits the reaction [Tacrine results in increased expression of CHRNA4 protein] PMID:8930989 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:6706 Mecamylamine multiple interactions ISO RGD:2346 E RGD:6480464 20141111 CTD MESH:D008464 Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]]; Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein]]; Mecamylamine inhibits the reaction [[pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein] PMID:18385335|PMID:21791372 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:68318 galanthamine Trifluoroacetic acid affects binding EXP E RGD:6480464 20141111 CTD MESH:D005702 Galantamine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:68318 galanthamine Trifluoroacetic acid multiple interactions EXP E RGD:6480464 20141111 CTD MESH:D005702 Galantamine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:6842 methoxychlor multiple interactions ISO RGD:2346 E RGD:6480464 20130611 CTD MESH:D008731 [Genistein co-treated with Methoxychlor] results in decreased expression of CHRNA4 mRNA PMID:21782745 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:68508 diethyl maleate increases expression EXP E RGD:6480464 20210608 CTD MESH:C014476 diethyl maleate results in increased expression of CHRNA4 mRNA PMID:33545341 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:6958 Mivacurium multiple interactions EXP E RGD:6480464 20141111 CTD MESH:C049430 mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:16931985 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:73458 NS-398 increases expression ISO RGD:10355 E RGD:6480464 20130604 CTD MESH:C080955 N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CHRNA4 protein PMID:15551346 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:73458 NS-398 multiple interactions ISO RGD:10355 E RGD:6480464 20130604 CTD MESH:C080955 [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with Nicotine] inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CHRNA4 protein] PMID:15551346 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:74 (S)-anabasine affects binding ISO RGD:2346 E RGD:6480464 20120412 CTD MESH:D000691 Anabasine analog binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:15615518 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:7590 nitrofen decreases expression ISO RGD:2346 E RGD:6480464 20190312 CTD MESH:C007350 nitrofen results in decreased expression of CHRNA4 mRNA PMID:26720608 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:78734 tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate affects binding EXP E RGD:6480464 20140805 CTD MESH:D001285 Atropine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:78734 tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate multiple interactions EXP E RGD:6480464 20140805 CTD MESH:D001285 Atropine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:78734 tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate multiple interactions ISO RGD:2346 E RGD:6480464 20140805 CTD MESH:D001285 Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]]; Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein]] PMID:21791372 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:7907 pancuronium multiple interactions EXP E RGD:6480464 20170303 CTD MESH:D010197 Pancuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Pancuronium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Pancuronium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:14645658|PMID:16931985 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:8069 phenobarbital increases expression ISO RGD:10355 E RGD:6480464 20130514 CTD MESH:D010634 Phenobarbital results in increased expression of CHRNA4 mRNA PMID:23091169 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:80713 Citreoviridin affects expression ISO RGD:10355 E RGD:6480464 20181016 CTD MESH:C014416 citreoviridin affects the expression of CHRNA4 mRNA PMID:30071239 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:81582 2,4-dibromophenyl 2,4,5-tribromophenyl ether increases expression ISO RGD:10355 E RGD:6480464 20181113 CTD MESH:C477694 2,2',4,4',5-brominated diphenyl ether results in increased expression of CHRNA4 mRNA PMID:26254212 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:81794 thifluzamide decreases expression EXP E RGD:6480464 20210810 CTD MESH:C494892 thifluzamide results in decreased expression of CHRNA4 mRNA PMID:33512557 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:82289 Antimony trioxide multiple interactions EXP E RGD:6480464 20141111 CTD MESH:C037554 antimony trioxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] PMID:22750351 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:82411 Brilliant Blue multiple interactions ISO RGD:2346 E RGD:6480464 20170303 CTD MESH:C006796 [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein PMID:23429044 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:82436 decabromodiphenyl ether multiple interactions EXP E RGD:6480464 20141111 CTD MESH:C010902 decabromobiphenyl ether inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] PMID:22750351 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:82538 Sunset Yellow FCF multiple interactions ISO RGD:2346 E RGD:6480464 20141111 CTD MESH:C005842 [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein PMID:23429044 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:83197 picoxystrobin decreases expression EXP E RGD:6480464 20210810 CTD MESH:C556557 picoxystrobin results in decreased expression of CHRNA4 mRNA PMID:33512557 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:84500 varenicline multiple interactions EXP E RGD:6480464 20170303 CTD MESH:D000068580 Varenicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:20207347|PMID:20331614|PMID:20373480|PMID:20388087 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:84500 varenicline multiple interactions ISO RGD:10355 E RGD:6480464 20170303 CTD MESH:D000068580 Varenicline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:20100906 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:84500 varenicline multiple interactions ISO RGD:2346 E RGD:6480464 20170303 CTD MESH:D000068580 Varenicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:16766716 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:84500 varenicline multiple interactions ISO RGD:2346 E RGD:8549526|PMID:22550286 20210820 RGD MESH:D000068580 varenicline binds to Chrna4 protein; varenicline inhibits [alpha-conotoxin MII binds to Chrna4 protein] in rat brain striatal sections 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:8502 6-propyl-2-thiouracil increases expression ISO RGD:2346 E RGD:6480464 20150310 CTD MESH:D011441 Propylthiouracil results in increased expression of CHRNA4 mRNA PMID:24780913 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:8874 rivastigmine affects binding EXP E RGD:6480464 20170303 CTD MESH:C072506 Rivastigmine binds to [CHRNA4 protein binds to CHRNB2 protein] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:8874 rivastigmine multiple interactions EXP E RGD:6480464 20170303 CTD MESH:C072506 Rivastigmine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:15733544 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:8884 rocuronium multiple interactions EXP E RGD:6480464 20120515 CTD MESH:C061870 rocuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] PMID:16931985 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:9288 streptozocin multiple interactions ISO RGD:10355 E RGD:6480464 20210608 CTD MESH:D013311 [Streptozocin co-treated with Dietary Fats] results in decreased expression of CHRNA4 mRNA; Diethylhexyl Phthalate inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of CHRNA4 mRNA] PMID:33484791 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:9381 T-2 toxin decreases expression ISO RGD:10355 E RGD:6480464 20160119 CTD MESH:D013605 T-2 Toxin results in decreased expression of CHRNA4 mRNA PMID:26314264 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:9405 tartrazine multiple interactions ISO RGD:2346 E RGD:6480464 20140311 CTD MESH:D013645 [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein PMID:23429044 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:9747 Triptolide decreases expression ISO RGD:10355 E RGD:6480464 20210706 CTD MESH:C001899 triptolide results in decreased expression of CHRNA4 mRNA PMID:32835833 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:9774 tubocurarine multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D014403 Tubocurarine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Ethinyl Estradiol promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]]; Tubocurarine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:11711029|PMID:14645658|PMID:16931985 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:9774 tubocurarine multiple interactions ISO RGD:10355 E RGD:6480464 20120515 CTD MESH:D014403 Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein] PMID:7756618 10356 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit gene CHEBI:9940 vecuronium bromide multiple interactions EXP E RGD:6480464 20120515 CTD MESH:D014673 Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] PMID:14645658|PMID:16931985 10398866 RNA5SP439 RNA, 5S ribosomal pseudogene 439 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20161228 CTD MESH:C017947 sodium arsenite results in increased expression of RNA5SP439 mRNA PMID:25879800 10398868 EFCAB14P1 EF-hand calcium binding domain 14 pseudogene 1 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20160119 CTD MESH:D019256 Cadmium Chloride results in increased expression of EFCAB14P1 mRNA PMID:26472689 10398876 RNU4-36P RNA, U4 small nuclear 36, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RNU4-36P mRNA PMID:38568856 10398880 RNU6-1060P RNA, U6 small nuclear 1060, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RNU6-1060P mRNA PMID:38568856 10398880 RNU6-1060P RNA, U6 small nuclear 1060, pseudogene gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of RNU6-1060P mRNA PMID:38568856 10398884 HLA-DQB1-AS1 HLA-DQB1 antisense RNA 1 gene CHEBI:44915 propofol increases expression EXP E RGD:6480464 20220809 CTD MESH:D015742 Propofol results in increased expression of HLA-DQB1-AS1 mRNA PMID:35238236 10398903 RNY3P8 RNY3 pseudogene 8 gene CHEBI:81584 2,2',4,4'-Tetrabromodiphenyl ether decreases expression EXP E RGD:6480464 20191112 CTD MESH:C511295 2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of RNY3P8 mRNA PMID:31173147 10398918 RNU6-945P RNA, U6 small nuclear 945, pseudogene gene CHEBI:28619 acrylamide increases expression EXP E RGD:6480464 20210406 CTD MESH:D020106 Acrylamide results in increased expression of RNU6-945P mRNA PMID:32763439 10398929 RNA5SP498 RNA, 5S ribosomal pseudogene 498 gene CHEBI:24527 herbicide increases expression EXP E RGD:6480464 20171010 CTD MESH:D006540 Herbicides results in increased expression of RNA5SP498 mRNA PMID:28711546 10398957 RNU6-388P RNA, U6 small nuclear 388, pseudogene gene CHEBI:24527 herbicide increases expression EXP E RGD:6480464 20171010 CTD MESH:D006540 Herbicides results in increased expression of RNU6-388P mRNA PMID:28711546 10398991 RN7SL97P RNA, 7SL, cytoplasmic 97, pseudogene gene CHEBI:17347 testosterone increases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in increased expression of RN7SL97P mRNA PMID:33359661 10398993 RNU6-173P RNA, U6 small nuclear 173, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of RNU6-173P mRNA PMID:35811015 10398993 RNU6-173P RNA, U6 small nuclear 173, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of RNU6-173P mRNA PMID:35811015 10398993 RNU6-173P RNA, U6 small nuclear 173, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of RNU6-173P mRNA PMID:35811015 10398997 RNU6-925P RNA, U6 small nuclear 925, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of RNU6-925P mRNA PMID:35811015 10398997 RNU6-925P RNA, U6 small nuclear 925, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of RNU6-925P mRNA PMID:35811015 10399005 RN7SL181P RNA, 7SL, cytoplasmic 181, pseudogene gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20220208 CTD MESH:C006780 bisphenol A results in decreased expression of RN7SL181P mRNA PMID:33670352 10399007 HMGN2P47 high mobility group nucleosomal binding domain 2 pseudogene 47 gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of HMGN2P47 mRNA PMID:32234424 10399022 RN7SKP276 RN7SK pseudogene 276 gene CHEBI:16412 lipopolysaccharide decreases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in decreased expression of RN7SKP276 mRNA PMID:35811015 10399022 RN7SKP276 RN7SK pseudogene 276 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SKP276 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of RN7SKP276 mRNA PMID:35811015 10399022 RN7SKP276 RN7SK pseudogene 276 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SKP276 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of RN7SKP276 mRNA PMID:35811015 10399056 RNU6-384P RNA, U6 small nuclear 384, pseudogene gene CHEBI:16236 ethanol increases expression EXP E RGD:6480464 20240604 CTD MESH:D000431 Ethanol results in increased expression of RNU6-384P PMID:37149095 10399073 RN7SL849P RNA, 7SL, cytoplasmic 849, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RN7SL849P mRNA PMID:38568856 10399090 RN7SL189P RNA, 7SL, cytoplasmic 189, pseudogene gene CHEBI:17347 testosterone increases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in increased expression of RN7SL189P mRNA PMID:33359661 10399113 RN7SL165P RNA, 7SL, cytoplasmic 165, pseudogene gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SL165P mRNA PMID:33359661 10399113 RN7SL165P RNA, 7SL, cytoplasmic 165, pseudogene gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of RN7SL165P mRNA PMID:33212167 10399126 RNU6-1004P RNA, U6 small nuclear 1004, pseudogene gene CHEBI:27744 glyphosate increases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in increased expression of RNU6-1004P mRNA PMID:28711546 10399181 RNU6ATAC18P RNA, U6atac small nuclear 18, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of RNU6ATAC18P mRNA PMID:35811015 10399181 RNU6ATAC18P RNA, U6atac small nuclear 18, pseudogene gene CHEBI:24527 herbicide increases expression EXP E RGD:6480464 20171010 CTD MESH:D006540 Herbicides results in increased expression of RNU6ATAC18P mRNA PMID:28711546 10399181 RNU6ATAC18P RNA, U6atac small nuclear 18, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of RNU6ATAC18P mRNA PMID:35811015 10399193 SLC25A36P1 SLC25A36 pseudogene 1 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of SLC25A36P1 mRNA PMID:33212167 10399210 EIF1P5 eukaryotic translation initiation factor 1 pseudogene 5 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of EIF1P5 mRNA PMID:38568856 10399223 RNU6ATAC16P RNA, U6atac small nuclear 16, pseudogene gene CHEBI:16412 lipopolysaccharide decreases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in decreased expression of RNU6ATAC16P mRNA PMID:35811015 10399223 RNU6ATAC16P RNA, U6atac small nuclear 16, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RNU6ATAC16P mRNA PMID:35811015 10399223 RNU6ATAC16P RNA, U6atac small nuclear 16, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RNU6ATAC16P mRNA PMID:35811015 10399286 SDCBP2P1 syndecan binding protein 2 pseudogene 1 gene CHEBI:35456 cadmium dichloride decreases expression EXP E RGD:6480464 20160119 CTD MESH:D019256 Cadmium Chloride results in decreased expression of SDCBP2P1 mRNA PMID:26472689 10399292 RNU6-722P RNA, U6 small nuclear 722, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RNU6-722P mRNA PMID:38568856 10399296 GTF2IP14 general transcription factor IIi pseudogene 14 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of GTF2IP14 mRNA PMID:33212167 10399296 GTF2IP14 general transcription factor IIi pseudogene 14 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20160119 CTD MESH:D019256 Cadmium Chloride results in increased expression of GTF2IP14 mRNA PMID:26472689 10399322 RNU6-1266P RNA, U6 small nuclear 1266, pseudogene gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of RNU6-1266P mRNA PMID:33212167 10399329 UBE2FP3 UBE2F pseudogene 3 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of UBE2FP3 mRNA PMID:33212167 10399333 RN7SL292P RNA, 7SL, cytoplasmic 292, pseudogene gene CHEBI:17347 testosterone increases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in increased expression of RN7SL292P mRNA PMID:33359661 10399369 RNU7-141P RNA, U7 small nuclear 141 pseudogene gene CHEBI:27744 glyphosate decreases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in decreased expression of RNU7-141P mRNA PMID:28711546 10399388 RNU4-15P RNA, U4 small nuclear 15, pseudogene gene CHEBI:16236 ethanol increases expression EXP E RGD:6480464 20240604 CTD MESH:D000431 Ethanol results in increased expression of RNU4-15P PMID:37149095 10399432 RNU6-494P RNA, U6 small nuclear 494, pseudogene gene CHEBI:32914 cetylpyridinium increases expression EXP E RGD:6480464 20240604 CTD MESH:D002594 Cetylpyridinium results in increased expression of RNU6-494P PMID:37149095 10399480 RN7SL14P RNA, 7SL, cytoplasmic 14, pseudogene gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SL14P mRNA PMID:33359661 10399502 RNU7-90P RNA, U7 small nuclear 90 pseudogene gene CHEBI:33216 bisphenol A decreases methylation ISO RGD:1612344 E RGD:6480464 20180116 CTD MESH:C006780 bisphenol A results in decreased methylation of RNU7 promoter PMID:27312807 10399511 RN7SL868P RNA, 7SL, cytoplasmic 868, pseudogene gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SL868P mRNA PMID:33359661 10399549 RN7SL178P RNA, 7SL, cytoplasmic 178, pseudogene gene CHEBI:17347 testosterone increases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in increased expression of RN7SL178P mRNA PMID:33359661 10399559 HSPE1P27 heat shock protein family E (Hsp10) member 1 pseudogene 27 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of HSPE1P27 mRNA PMID:38568856 10399561 RNY4P37 RNY4 pseudogene 37 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of RNY4P37 mRNA PMID:33212167 10399564 RNU2-51P RNA, U2 small nuclear 51, pseudogene gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of RNU2-51P mRNA PMID:38568856 10399566 RNU6-514P RNA, U6 small nuclear 514, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RNU6-514P mRNA PMID:38568856 10399581 MDC1-AS1 MDC1 antisense RNA 1 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of MDC1-AS1 mRNA PMID:34032870 10399596 IGKV1OR9-2 immunoglobulin kappa variable 1/OR9-2 (pseudogene) gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of IGKV1OR9-2 mRNA PMID:35811015 10399596 IGKV1OR9-2 immunoglobulin kappa variable 1/OR9-2 (pseudogene) gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of IGKV1OR9-2 mRNA PMID:35811015 10399597 DUX4L50 double homeobox 4 like 50 (pseudogene) gene CHEBI:31575 ethylparaben increases expression EXP E RGD:6480464 20240109 CTD MESH:C012313 ethyl-p-hydroxybenzoate results in increased expression of DUX4L50 mRNA PMID:37690743 10399642 RN7SL63P RNA, 7SL, cytoplasmic 63, pseudogene gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SL63P mRNA PMID:33359661 10399664 RN7SKP203 RN7SK pseudogene 203 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of RN7SKP203 mRNA PMID:35811015 10399664 RN7SKP203 RN7SK pseudogene 203 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of RN7SKP203 mRNA PMID:35811015 10399688 RN7SL672P RNA, 7SL, cytoplasmic 672, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RN7SL672P mRNA PMID:38568856 10399713 RAP2CP1 RAP2C pseudogene 1 gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of RAP2CP1 mRNA PMID:35811015 10399713 RAP2CP1 RAP2C pseudogene 1 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in increased expression of RAP2CP1 mRNA] PMID:35811015 10399713 RAP2CP1 RAP2C pseudogene 1 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in increased expression of RAP2CP1 mRNA] PMID:35811015 10399717 RNU6-454P RNA, U6 small nuclear 454, pseudogene gene CHEBI:3020 benzalkonium chloride decreases expression EXP E RGD:6480464 20240604 CTD MESH:D001548 Benzalkonium Compounds results in decreased expression of RNU6-454P PMID:37149095 10399735 CARS1P2 cysteinyl-tRNA synthetase 1 pseudogene 2 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of CARS1P2 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of CARS1P2 mRNA PMID:35811015 10399735 CARS1P2 cysteinyl-tRNA synthetase 1 pseudogene 2 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine decreases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in decreased expression of CARS1P2 mRNA PMID:35811015 10399735 CARS1P2 cysteinyl-tRNA synthetase 1 pseudogene 2 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of CARS1P2 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of CARS1P2 mRNA PMID:35811015 10399759 MTCO1P4 MT-CO1 pseudogene 4 gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of MTCO1P4 mRNA PMID:35811015 10399759 MTCO1P4 MT-CO1 pseudogene 4 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of MTCO1P4 mRNA PMID:35811015 10399759 MTCO1P4 MT-CO1 pseudogene 4 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of MTCO1P4 mRNA PMID:38568856 10399759 MTCO1P4 MT-CO1 pseudogene 4 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of MTCO1P4 mRNA PMID:35811015 10399781 RNU6-367P RNA, U6 small nuclear 367, pseudogene gene CHEBI:32914 cetylpyridinium decreases expression EXP E RGD:6480464 20240604 CTD MESH:D002594 Cetylpyridinium results in decreased expression of RNU6-367P PMID:37149095 10399782 RNU6-3P RNA, U6 small nuclear 3, pseudogene gene CHEBI:31835 methylparaben increases expression EXP E RGD:6480464 20200609 CTD MESH:C015358 methylparaben results in increased expression of RNU6-3P mRNA PMID:31745603 10399785 SOD1P1 superoxide dismutase 1 pseudogene 1 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of SOD1P1 mRNA PMID:38568856 10399795 RNU6-667P RNA, U6 small nuclear 667, pseudogene gene CHEBI:27744 glyphosate decreases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in decreased expression of RNU6-667P mRNA PMID:28711546 10399798 RNU1-138P RNA, U1 small nuclear 138, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RNU1-138P mRNA PMID:38568856 10399798 RNU1-138P RNA, U1 small nuclear 138, pseudogene gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of RNU1-138P mRNA PMID:38568856 10399846 MCCC1-AS1 MCCC1 antisense RNA 1 gene CHEBI:28619 acrylamide decreases expression EXP E RGD:6480464 20210406 CTD MESH:D020106 Acrylamide results in decreased expression of MCCC1-AS1 mRNA PMID:32763439 10399876 RN7SL822P RNA, 7SL, cytoplasmic 822, pseudogene gene CHEBI:132448 perfluorohexanesulfonic acid increases expression ISO RGD:6484513 E RGD:6480464 20240206 CTD MESH:C471071 perfluorohexanesulfonic acid results in increased expression of RN7S1 mRNA PMID:37995155 10399881 RNU6-334P RNA, U6 small nuclear 334, pseudogene gene CHEBI:32914 cetylpyridinium increases expression EXP E RGD:6480464 20240604 CTD MESH:D002594 Cetylpyridinium results in increased expression of RNU6-334P PMID:37149095 10399889 RNU6-1278P RNA, U6 small nuclear 1278, pseudogene gene CHEBI:32914 cetylpyridinium increases expression EXP E RGD:6480464 20240604 CTD MESH:D002594 Cetylpyridinium results in increased expression of RNU6-1278P PMID:37149095 10399891 RNU2-62P RNA, U2 small nuclear 62, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RNU2-62P mRNA PMID:38568856 10399891 RNU2-62P RNA, U2 small nuclear 62, pseudogene gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of RNU2-62P mRNA PMID:38568856 10399899 RNU4-79P RNA, U4 small nuclear 79, pseudogene gene CHEBI:31264 benzethonium chloride increases expression EXP E RGD:6480464 20240604 CTD MESH:D001558 Benzethonium results in increased expression of RNU4-79P PMID:37149095 10399899 RNU4-79P RNA, U4 small nuclear 79, pseudogene gene CHEBI:94725 dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium increases expression EXP E RGD:6480464 20240604 CTD MESH:D001558 Benzethonium results in increased expression of RNU4-79P PMID:37149095 10399941 RNU6-1024P RNA, U6 small nuclear 1024, pseudogene gene CHEBI:27744 glyphosate decreases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in decreased expression of RNU6-1024P mRNA PMID:28711546 10399948 VTA1P1 vesicle trafficking 1 pseudogene 1 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of VTA1P1 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of VTA1P1 mRNA PMID:35811015 10399948 VTA1P1 vesicle trafficking 1 pseudogene 1 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of VTA1P1 mRNA PMID:35811015 10399948 VTA1P1 vesicle trafficking 1 pseudogene 1 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of VTA1P1 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of VTA1P1 mRNA PMID:35811015 10399971 RNU2-28P RNA, U2 small nuclear 28, pseudogene gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of RNU2-28P mRNA PMID:38568856 10399993 RN7SL336P RNA, 7SL, cytoplasmic 336, pseudogene gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of RN7SL336P mRNA PMID:33212167 10400000 RNU6-1014P RNA, U6 small nuclear 1014, pseudogene gene CHEBI:31264 benzethonium chloride increases expression EXP E RGD:6480464 20240604 CTD MESH:D001558 Benzethonium results in increased expression of RNU6-1014P PMID:37149095 10400000 RNU6-1014P RNA, U6 small nuclear 1014, pseudogene gene CHEBI:32146 sodium hypochlorite increases expression EXP E RGD:6480464 20240604 CTD MESH:D012973 Sodium Hypochlorite results in increased expression of RNU6-1014P PMID:37149095 10400000 RNU6-1014P RNA, U6 small nuclear 1014, pseudogene gene CHEBI:94725 dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium increases expression EXP E RGD:6480464 20240604 CTD MESH:D001558 Benzethonium results in increased expression of RNU6-1014P PMID:37149095 10400019 RNU6-177P RNA, U6 small nuclear 177, pseudogene gene CHEBI:24527 herbicide decreases expression EXP E RGD:6480464 20171010 CTD MESH:D006540 Herbicides results in decreased expression of RNU6-177P mRNA PMID:28711546 10400033 RNU7-136P RNA, U7 small nuclear 136 pseudogene gene CHEBI:32914 cetylpyridinium decreases expression EXP E RGD:6480464 20240604 CTD MESH:D002594 Cetylpyridinium results in decreased expression of RNU7-136P PMID:37149095 10400046 RNU6-643P RNA, U6 small nuclear 643, pseudogene gene CHEBI:3020 benzalkonium chloride decreases expression EXP E RGD:6480464 20240604 CTD MESH:D001548 Benzalkonium Compounds results in decreased expression of RNU6-643P PMID:37149095 10400048 RNU6-893P RNA, U6 small nuclear 893, pseudogene gene CHEBI:24527 herbicide decreases expression EXP E RGD:6480464 20171010 CTD MESH:D006540 Herbicides results in decreased expression of RNU6-893P mRNA PMID:28711546 10400064 RN7SL197P RNA, 7SL, cytoplasmic 197, pseudogene gene CHEBI:17347 testosterone increases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in increased expression of RN7SL197P mRNA PMID:33359661 10400067 RNU6ATAC35P RNA, U6atac small nuclear 35, pseudogene gene CHEBI:44915 propofol decreases expression EXP E RGD:6480464 20220809 CTD MESH:D015742 Propofol results in decreased expression of RNU6ATAC35P mRNA PMID:35238236 10400094 RNU6-1258P RNA, U6 small nuclear 1258, pseudogene gene CHEBI:27744 glyphosate increases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in increased expression of RNU6-1258P mRNA PMID:28711546 10400103 RN7SL333P RNA, 7SL, cytoplasmic 333, pseudogene gene CHEBI:28619 acrylamide increases expression EXP E RGD:6480464 20210406 CTD MESH:D020106 Acrylamide results in increased expression of RN7SL333P mRNA PMID:32763439 10400103 RN7SL333P RNA, 7SL, cytoplasmic 333, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in increased expression of RN7SL333P mRNA PMID:34032870 10400124 RN7SL316P RNA, 7SL, cytoplasmic 316, pseudogene gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SL316P mRNA PMID:33359661 10400148 RNU6-659P RNA, U6 small nuclear 659, pseudogene gene CHEBI:193591 Didecyldimethylammonium increases expression EXP E RGD:6480464 20221018 CTD MESH:C027118 didecyldimethylammonium results in increased expression of RNU6-659P mRNA PMID:32763356 10400148 RNU6-659P RNA, U6 small nuclear 659, pseudogene gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of RNU6-659P mRNA PMID:38568856 10400156 RNU6-1085P RNA, U6 small nuclear 1085, pseudogene gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of RNU6-1085P mRNA PMID:33212167 10400181 RNU7-172P RNA, U7 small nuclear 172 pseudogene gene CHEBI:27744 glyphosate decreases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in decreased expression of RNU7-172P mRNA PMID:28711546 10400203 RNU6-4P RNA, U6 small nuclear 4, pseudogene gene CHEBI:33216 bisphenol A increases expression EXP E RGD:6480464 20210504 CTD MESH:C006780 bisphenol A results in increased expression of RNU6-4P mRNA PMID:33476716 10400209 RN7SKP228 RN7SK pseudogene 228 gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SKP228 mRNA PMID:33359661 10400220 RNU6-1161P RNA, U6 small nuclear 1161, pseudogene gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of RNU6-1161P mRNA PMID:34032870 10400254 RNU4-60P RNA, U4 small nuclear 60, pseudogene gene CHEBI:27744 glyphosate increases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in increased expression of RNU4-60P mRNA PMID:28711546 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:15443 inulin multiple interactions ISO RGD:1315919 E RGD:6480464 20230502 CTD MESH:D007444 [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of THEM7 mRNA PMID:36331819 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:16412 lipopolysaccharide increases expression ISO RGD:1315919 E RGD:6480464 20161228 CTD MESH:D008070 Lipopolysaccharides results in increased expression of THEM7 mRNA PMID:27339419 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:18246 (1->4)-beta-D-glucan multiple interactions ISO RGD:1315919 E RGD:6480464 20230502 CTD MESH:D002482 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of THEM7 mRNA PMID:36331819 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:190294 calcium silicate increases expression ISO RGD:1315919 E RGD:6480464 20220405 CTD MESH:C031293 calcium silicate results in increased expression of THEM7 mRNA PMID:29279043 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:27385 tetrachloromethane decreases expression ISO RGD:1315919 E RGD:6480464 20200804 CTD MESH:D002251 Carbon Tetrachloride results in decreased expression of THEM7 mRNA PMID:31919559 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:27385 tetrachloromethane multiple interactions ISO RGD:1315919 E RGD:6480464 20181016 CTD MESH:D002251 [PANX1 protein co-treated with Carbon Tetrachloride] affects the expression of THEM7 mRNA PMID:29987408 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:28088 genistein decreases expression ISO RGD:1315919 E RGD:6480464 20200804 CTD MESH:D019833 Genistein results in decreased expression of THEM7 mRNA PMID:32186404 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1315919 E RGD:6480464 20160210 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of THEM7 mRNA PMID:26377647 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1315919 E RGD:6480464 20160119 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of THEM7 mRNA PMID:26290441 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:33216 bisphenol A decreases methylation ISO RGD:1315919 E RGD:6480464 20180116 CTD MESH:C006780 bisphenol A results in decreased methylation of THEM7 promoter PMID:27312807 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:39421 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:1315919 E RGD:6480464 20230502 CTD MESH:C076994 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of THEM7 mRNA; [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of THEM7 mRNA; [perfluorooctane sulfonic acid co-treated with Pectins] results in increased expression of THEM7 mRNA PMID:36331819 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:42588 4-hydroxyphenyl retinamide increases expression ISO RGD:1315919 E RGD:6480464 20180220 CTD MESH:D017313 Fenretinide results in increased expression of THEM7 mRNA PMID:28973697 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:4811 epoxiconazole decreases expression ISO RGD:1315919 E RGD:6480464 20220906 CTD MESH:C109476 epoxiconazole results in decreased expression of THEM7 mRNA PMID:35436446 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:81520 2,3',4,4',5-Pentachlorobiphenyl increases expression ISO RGD:1315919 E RGD:6480464 20200114 CTD MESH:C070055 2,3',4,4',5-pentachlorobiphenyl results in increased expression of THEM7 mRNA PMID:31388691 10400384 THEM7P thioesterase superfamily member 7, pseudogene gene CHEBI:9753 troglitazone increases expression ISO RGD:1315919 E RGD:6480464 20180220 CTD MESH:C057693 troglitazone results in increased expression of THEM7 mRNA PMID:28973697 10400401 RNU6-415P RNA, U6 small nuclear 415, pseudogene gene CHEBI:31835 methylparaben decreases expression EXP E RGD:6480464 20200609 CTD MESH:C015358 methylparaben results in decreased expression of RNU6-415P mRNA PMID:31745603 10400447 SNRPGP19 small nuclear ribonucleoprotein polypeptide G pseudogene 19 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of SNRPGP19 mRNA PMID:33212167 10400475 RNU7-134P RNA, U7 small nuclear 134 pseudogene gene CHEBI:27744 glyphosate decreases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in decreased expression of RNU7-134P mRNA PMID:28711546 10400476 RN7SKP60 RN7SK pseudogene 60 gene CHEBI:15443 inulin multiple interactions ISO RGD:1624517 E RGD:6480464 20230502 CTD MESH:D007444 [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of MIRT2 mRNA PMID:36331819 10400476 RN7SKP60 RN7SK pseudogene 60 gene CHEBI:18246 (1->4)-beta-D-glucan multiple interactions ISO RGD:1624517 E RGD:6480464 20230502 CTD MESH:D002482 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of MIRT2 mRNA PMID:36331819 10400476 RN7SKP60 RN7SK pseudogene 60 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1624517 E RGD:6480464 20190423 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of MIRT2 mRNA PMID:26290441 10400476 RN7SKP60 RN7SK pseudogene 60 gene CHEBI:39421 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:1624517 E RGD:6480464 20230502 CTD MESH:C076994 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of MIRT2 mRNA; [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of MIRT2 mRNA; [perfluorooctane sulfonic acid co-treated with Pectins] results in increased expression of MIRT2 mRNA PMID:36331819 10400476 RN7SKP60 RN7SK pseudogene 60 gene CHEBI:71957 XL147 multiple interactions ISO RGD:1624517 E RGD:6480464 20190423 CTD MESH:C581157 [N-nitroso-tris-chloroethylurea co-treated with XL147] results in increased expression of MIRT2 mRNA PMID:27935865 10400493 LINC00449 long intergenic non-protein coding RNA 449 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in increased expression of LINC00449 mRNA PMID:34032870 10400498 RNU6-306P RNA, U6 small nuclear 306, pseudogene gene CHEBI:27744 glyphosate increases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in increased expression of RNU6-306P mRNA PMID:28711546 10400517 RN7SKP31 RN7SK pseudogene 31 gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SKP31 mRNA PMID:33359661 10400538 RN7SL396P RNA, 7SL, cytoplasmic 396, pseudogene gene CHEBI:2504 aflatoxin B1 decreases expression EXP E RGD:6480464 20200714 CTD MESH:D016604 Aflatoxin B1 results in decreased expression of RN7SL396P mRNA PMID:32234424 10400655 TRIM80P tripartite motif containing 80, pseudogene gene CHEBI:132267 triptonide increases expression ISO RGD:1615479 E RGD:6480464 20210406 CTD MESH:C084079 triptonide results in increased expression of TRIM80 mRNA PMID:33045310 10400655 TRIM80P tripartite motif containing 80, pseudogene gene CHEBI:18246 (1->4)-beta-D-glucan multiple interactions ISO RGD:1615479 E RGD:6480464 20230502 CTD MESH:D002482 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of TRIM80 mRNA PMID:36331819 10400655 TRIM80P tripartite motif containing 80, pseudogene gene CHEBI:27928 parathion increases expression ISO RGD:1615479 E RGD:6480464 20220607 CTD MESH:D010278 Parathion results in increased expression of TRIM80 mRNA PMID:34813904 10400655 TRIM80P tripartite motif containing 80, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in increased expression of TRIM80P mRNA PMID:34032870 10400655 TRIM80P tripartite motif containing 80, pseudogene gene CHEBI:29865 benzo[a]pyrene decreases methylation ISO RGD:1615479 E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in decreased methylation of TRIM80 exon; Benzo(a)pyrene results in decreased methylation of TRIM80 intron PMID:27901495 10400655 TRIM80P tripartite motif containing 80, pseudogene gene CHEBI:33216 bisphenol A decreases methylation ISO RGD:1615479 E RGD:6480464 20180116 CTD MESH:C006780 bisphenol A results in decreased methylation of TRIM80 promoter PMID:27312807 10400655 TRIM80P tripartite motif containing 80, pseudogene gene CHEBI:34372 4,4'-sulfonyldiphenol affects methylation ISO RGD:1615479 E RGD:6480464 20230207 CTD MESH:C543008 bisphenol S affects the methylation of TRIM80 gene PMID:31683443 10400655 TRIM80P tripartite motif containing 80, pseudogene gene CHEBI:39421 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:1615479 E RGD:6480464 20230502 CTD MESH:C076994 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of TRIM80 mRNA PMID:36331819 10400658 PHB1P6 PHB1 pseudogene 6 gene CHEBI:7553 niclosamide decreases expression EXP E RGD:6480464 20230704 CTD MESH:D009534 Niclosamide results in decreased expression of PHB1P6 mRNA PMID:36318118 10400672 BMS1P22 BMS1 pseudogene 22 gene CHEBI:6402 leflunomide decreases expression EXP E RGD:6480464 20180410 CTD MESH:C045463 leflunomide results in decreased expression of BMS1P22 mRNA PMID:28988120 10400701 H3P4 H3 histone pseudogene 4 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of H3P4 mRNA PMID:33212167 10400712 RNU4-39P RNA, U4 small nuclear 39, pseudogene gene CHEBI:32146 sodium hypochlorite decreases expression EXP E RGD:6480464 20240604 CTD MESH:D012973 Sodium Hypochlorite results in decreased expression of RNU4-39P PMID:37149095 10400752 RN7SKP65 RN7SK pseudogene 65 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of RN7SKP65 mRNA PMID:38568856 10400757 RPPH1-3P ribonuclease P RNA component H1, 3 pseudogene gene CHEBI:15379 dioxygen increases expression ISO RGD:1612751 E RGD:6480464 20210323 CTD MESH:D010100 Oxygen deficiency results in increased expression of RPRL2 mRNA PMID:24205000 10400757 RPPH1-3P ribonuclease P RNA component H1, 3 pseudogene gene CHEBI:17747 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1612751 E RGD:6480464 20210323 CTD MESH:D004051 Diethylhexyl Phthalate results in decreased expression of RPRL2 mRNA PMID:19850644 10400757 RPPH1-3P ribonuclease P RNA component H1, 3 pseudogene gene CHEBI:17747 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:1612751 E RGD:6480464 20210323 CTD MESH:D004051 PPARA protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of RPRL2 mRNA] PMID:19850644 10400757 RPPH1-3P ribonuclease P RNA component H1, 3 pseudogene gene CHEBI:50594 carbon nanotube decreases expression ISO RGD:1612751 E RGD:6480464 20210323 CTD MESH:D037742 Nanotubes, Carbon analog results in decreased expression of RPRL2 mRNA; Nanotubes, Carbon results in decreased expression of RPRL2 mRNA PMID:25554681|PMID:25620056 10400765 RNU2-10P RNA, U2 small nuclear 10, pseudogene gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of RNU2-10P mRNA PMID:38568856 10400768 RN7SL138P RNA, 7SL, cytoplasmic 138, pseudogene gene CHEBI:16412 lipopolysaccharide decreases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in decreased expression of RN7SL138P mRNA PMID:35811015 10400768 RN7SL138P RNA, 7SL, cytoplasmic 138, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SL138P mRNA PMID:35811015 10400768 RN7SL138P RNA, 7SL, cytoplasmic 138, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SL138P mRNA PMID:35811015 10400775 RN7SL689P RNA, 7SL, cytoplasmic 689, pseudogene gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of RN7SL689P mRNA PMID:33212167 10400779 SUMO2P18 SUMO2 pseudogene 18 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of SUMO2P18 mRNA PMID:33212167 10400781 NOP56P3 NOP56 ribonucleoprotein pseudogene 3 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of NOP56P3 mRNA PMID:33212167 10400783 RNU6-376P RNA, U6 small nuclear 376, pseudogene gene CHEBI:17824 propan-2-ol increases expression EXP E RGD:6480464 20240604 CTD MESH:D019840 2-Propanol results in increased expression of RNU6-376P PMID:37149095 10400827 RN7SKP106 RN7SK pseudogene 106 gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of RN7SKP106 mRNA PMID:38218311 10400842 RN7SL128P RNA, 7SL, cytoplasmic 128, pseudogene gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of RN7SL128P mRNA PMID:32234424 10400940 LINC01615 long intergenic non-protein coding RNA 1615 gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of LINC01615 intron PMID:30157460 10400940 LINC01615 long intergenic non-protein coding RNA 1615 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of LINC01615 intron PMID:30157460 10400964 CCDC188 coiled-coil domain containing 188 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of CCDC188 mRNA PMID:33212167 10400964 CCDC188 coiled-coil domain containing 188 gene CHEBI:29678 sodium arsenite increases expression ISO RGD:1621006 E RGD:6480464 20240206 CTD MESH:C017947 sodium arsenite results in increased expression of CCDC188 mRNA PMID:37682722 10400964 CCDC188 coiled-coil domain containing 188 gene CHEBI:33216 bisphenol A decreases expression ISO RGD:1563782 E RGD:6480464 20151215 CTD MESH:C006780 bisphenol A results in decreased expression of CCDC188 mRNA PMID:25181051 10400964 CCDC188 coiled-coil domain containing 188 gene CHEBI:7553 niclosamide increases expression EXP E RGD:6480464 20230704 CTD MESH:D009534 Niclosamide results in increased expression of CCDC188 mRNA PMID:36318118 10401000 DACOR1 DNMT1-associated colon cancer repressed lncRNA 1 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in decreased expression of DACOR1 mRNA PMID:29301061 10401179 TREHP1 trehalase pseudogene 1 gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of TREHP1 mRNA PMID:38568856 10401694 SNORA92 small nucleolar RNA, H/ACA box 92 gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of SNORA92 polyA tail PMID:30157460 10401741 MIR34AHG MIR34A host gene gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of MIR34AHG mRNA PMID:35811015 10401741 MIR34AHG MIR34A host gene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in increased expression of MIR34AHG mRNA] PMID:35811015 10401741 MIR34AHG MIR34A host gene gene CHEBI:17243 mono(2-ethylhexyl) phthalate increases expression EXP E RGD:6480464 20230905 CTD MESH:C016599 mono-(2-ethylhexyl)phthalate results in increased expression of MIR34AHG mRNA PMID:36695872 10401741 MIR34AHG MIR34A host gene gene CHEBI:178199 sotorasib multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C000706028 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MIR34AHG mRNA PMID:36139627 10401741 MIR34AHG MIR34A host gene gene CHEBI:28619 acrylamide decreases expression EXP E RGD:6480464 20210406 CTD MESH:D020106 Acrylamide results in decreased expression of MIR34AHG mRNA PMID:32763439 10401741 MIR34AHG MIR34A host gene gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of MIR34AHG intron PMID:30157460 10401741 MIR34AHG MIR34A host gene gene CHEBI:29865 benzo[a]pyrene increases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of MIR34AHG mRNA PMID:32234424 10401741 MIR34AHG MIR34A host gene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in increased expression of MIR34AHG mRNA] PMID:35811015 10401741 MIR34AHG MIR34A host gene gene CHEBI:75998 trametinib multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C560077 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MIR34AHG mRNA PMID:36139627 10401741 MIR34AHG MIR34A host gene gene CHEBI:9495 thiram decreases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in decreased expression of MIR34AHG mRNA PMID:38568856 10401963 LINC00680 long intergenic non-protein coding RNA 680 gene CHEBI:178199 sotorasib multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C000706028 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LINC00680 mRNA PMID:36139627 10401963 LINC00680 long intergenic non-protein coding RNA 680 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of LINC00680 mRNA PMID:33212167 10401963 LINC00680 long intergenic non-protein coding RNA 680 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC00680 mRNA PMID:38568856 10401963 LINC00680 long intergenic non-protein coding RNA 680 gene CHEBI:35456 cadmium dichloride decreases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in decreased expression of LINC00680 mRNA PMID:38568856 10401963 LINC00680 long intergenic non-protein coding RNA 680 gene CHEBI:6402 leflunomide decreases expression EXP E RGD:6480464 20180410 CTD MESH:C045463 leflunomide results in decreased expression of LINC00680 mRNA PMID:28988120 10401963 LINC00680 long intergenic non-protein coding RNA 680 gene CHEBI:75998 trametinib multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C560077 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LINC00680 mRNA PMID:36139627 10402212 MIR3681HG MIR3681 host gene gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of MIR3681HG intron PMID:30157460 10402235 OLFM5P olfactomedin family member 5, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of OLFM5P mRNA PMID:35811015 10402235 OLFM5P olfactomedin family member 5, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of OLFM5P mRNA PMID:35811015 10402243 MIR3945HG MIR3945 host gene gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of MIR3945HG mRNA PMID:35811015 10402243 MIR3945HG MIR3945 host gene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of MIR3945HG mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of MIR3945HG mRNA PMID:35811015 10402243 MIR3945HG MIR3945 host gene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of MIR3945HG mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of MIR3945HG mRNA PMID:35811015 10402251 MIR193BHG MIR193b-365a host gene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of MIR193BHG mRNA PMID:35811015 10402251 MIR193BHG MIR193b-365a host gene gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of MIR193BHG mRNA PMID:33212167 10402251 MIR193BHG MIR193b-365a host gene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine decreases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in decreased expression of MIR193BHG mRNA PMID:35811015 10402251 MIR193BHG MIR193b-365a host gene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of MIR193BHG mRNA PMID:35811015 10402285 CCDC74BP1 coiled-coil domain containing 74B pseudogene 1 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of CCDC74BP1 mRNA PMID:34032870 10402300 VDAC2P4 VDAC2 pseudogene 4 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of VDAC2P4 mRNA PMID:38568856 10402323 MUC20P1 mucin 20, cell surface associated pseudogene 1 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of MUC20P1 mRNA PMID:33212167 10402345 MIR4290HG MIR4290 host gene gene CHEBI:29865 benzo[a]pyrene increases expression EXP E RGD:6480464 20241105 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of MIR4290HG PMID:38036013 10402345 MIR4290HG MIR4290 host gene gene CHEBI:31638 fulvestrant multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C070081 [bisphenol F co-treated with Fulvestrant] results in decreased methylation of MIR4290HG gene PMID:31601247 10402345 MIR4290HG MIR4290 host gene gene CHEBI:34575 bisphenol F multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C008745 [bisphenol F co-treated with Fulvestrant] results in decreased methylation of MIR4290HG gene PMID:31601247 10402643 LYRM4-AS1 LYRM4 antisense RNA 1 gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of LYRM4-AS1 intron PMID:30157460 10402643 LYRM4-AS1 LYRM4 antisense RNA 1 gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of LYRM4-AS1 intron PMID:30157460 10402643 LYRM4-AS1 LYRM4 antisense RNA 1 gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of LYRM4-AS1 intron PMID:30157460 10402643 LYRM4-AS1 LYRM4 antisense RNA 1 gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of LYRM4-AS1 intron PMID:30157460 10402673 PACRG-AS3 PACRG antisense RNA 3 gene CHEBI:22977 cadmium atom multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D002104 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of PACRG-AS3 mRNA PMID:35301059 10402673 PACRG-AS3 PACRG antisense RNA 3 gene CHEBI:35456 cadmium dichloride multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D019256 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of PACRG-AS3 mRNA PMID:35301059 10402683 LINC01623 long intergenic non-protein coding RNA 1623 gene CHEBI:33216 bisphenol A decreases methylation EXP E RGD:6480464 20220308 CTD MESH:C006780 bisphenol A results in decreased methylation of LINC01623 gene PMID:31601247 10402689 LINC01622 long intergenic non-protein coding RNA 1622 gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of LINC01622 intron PMID:30157460 10402689 LINC01622 long intergenic non-protein coding RNA 1622 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of LINC01622 promoter PMID:27901495 10402689 LINC01622 long intergenic non-protein coding RNA 1622 gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of LINC01622 intron PMID:30157460 10402689 LINC01622 long intergenic non-protein coding RNA 1622 gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of LINC01622 intron PMID:30157460 10402702 MIR548XHG MIR548X host gene gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of MIR548XHG intron PMID:30157460 10402712 MIR5689HG MIR5689 host gene gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of MIR5689HG mRNA PMID:34032870 10402712 MIR5689HG MIR5689 host gene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of MIR5689HG mRNA PMID:38568856 10402712 MIR5689HG MIR5689 host gene gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of MIR5689HG mRNA PMID:38568856 10402712 MIR5689HG MIR5689 host gene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of MIR5689HG mRNA PMID:35811015 10402713 LINC01624 long intergenic non-protein coding RNA 1624 gene CHEBI:16412 lipopolysaccharide decreases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in decreased expression of LINC01624 mRNA PMID:35811015 10402713 LINC01624 long intergenic non-protein coding RNA 1624 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01624 mRNA PMID:35811015 10402713 LINC01624 long intergenic non-protein coding RNA 1624 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01624 mRNA PMID:35811015 10402719 UST-AS1 UST antisense RNA 1 gene CHEBI:38940 sunitinib decreases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in decreased expression of UST-AS1 mRNA PMID:31533062 10402981 MFSD13B major facilitator superfamily domain containing 13B (pseudogene) gene CHEBI:132267 triptonide increases expression ISO RGD:1621477 E RGD:6480464 20210406 CTD MESH:C084079 triptonide results in increased expression of MFSD13B mRNA PMID:33045310 10402981 MFSD13B major facilitator superfamily domain containing 13B (pseudogene) gene CHEBI:16836 4-nitrophenol increases expression ISO RGD:1621477 E RGD:6480464 20220111 CTD MESH:C024836 4-nitrophenol results in increased expression of MFSD13B mRNA PMID:34673133 10402981 MFSD13B major facilitator superfamily domain containing 13B (pseudogene) gene CHEBI:17347 testosterone decreases expression ISO RGD:1621477 E RGD:6480464 20211109 CTD MESH:D013739 Testosterone deficiency results in decreased expression of MFSD13B mRNA PMID:33848595 10402981 MFSD13B major facilitator superfamily domain containing 13B (pseudogene) gene CHEBI:17347 testosterone multiple interactions ISO RGD:1621477 E RGD:6480464 20211109 CTD MESH:D013739 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane inhibits the reaction [Testosterone deficiency results in decreased expression of MFSD13B mRNA] PMID:33848595 10402981 MFSD13B major facilitator superfamily domain containing 13B (pseudogene) gene CHEBI:29678 sodium arsenite increases expression ISO RGD:1621477 E RGD:6480464 20240206 CTD MESH:C017947 sodium arsenite results in increased expression of MFSD13B mRNA PMID:37682722 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:27899 cisplatin increases expression EXP E RGD:6480464 20170516 CTD MESH:D002945 Cisplatin results in increased expression of CCDC18-AS1 mRNA PMID:27392435 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:27899 cisplatin multiple interactions EXP E RGD:6480464 20170516 CTD MESH:D002945 [Cisplatin co-treated with jinfukang] results in increased expression of CCDC18-AS1 mRNA PMID:27392435 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:28358 rac-lactic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of CCDC18-AS1 mRNA PMID:30851411 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of CCDC18-AS1 mRNA PMID:34032870 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:38940 sunitinib increases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in increased expression of CCDC18-AS1 mRNA PMID:31533062 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:39867 valproic acid decreases expression EXP E RGD:6480464 20160119 CTD MESH:D014635 Valproic Acid results in decreased expression of CCDC18-AS1 mRNA PMID:26272509 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:39867 valproic acid multiple interactions EXP E RGD:6480464 20161025 CTD MESH:D014635 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC18-AS1 mRNA PMID:27188386 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:5063 fipronil decreases expression EXP E RGD:6480464 20190219 CTD MESH:C082360 fipronil results in decreased expression of CCDC18-AS1 mRNA PMID:28991164 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:5063 fipronil multiple interactions EXP E RGD:6480464 20190219 CTD MESH:C082360 [fipronil co-treated with DEET] results in decreased expression of CCDC18-AS1 mRNA PMID:28991164 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:641 N-methyl-4-phenylpyridinium increases expression EXP E RGD:6480464 20170725 CTD MESH:D015655 1-Methyl-4-phenylpyridinium results in increased expression of CCDC18-AS1 mRNA PMID:24810058 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:7071 N,N-diethyl-m-toluamide multiple interactions EXP E RGD:6480464 20190219 CTD MESH:D003671 [fipronil co-treated with DEET] results in decreased expression of CCDC18-AS1 mRNA PMID:28991164 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:78320 2-hydroxypropanoic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of CCDC18-AS1 mRNA PMID:30851411 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:78510 dorsomorphin multiple interactions EXP E RGD:6480464 20161228 CTD MESH:C516138 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC18-AS1 mRNA PMID:27188386 10411941 CCDC18-AS1 CCDC18 antisense RNA 1 gene CHEBI:91108 SB 431542 multiple interactions EXP E RGD:6480464 20161220 CTD MESH:C459179 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC18-AS1 mRNA PMID:27188386 10411961 LINC01629 long intergenic non-protein coding RNA 1629 gene CHEBI:26523 reactive oxygen species multiple interactions EXP E RGD:6480464 20211109 CTD MESH:D017382 [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in decreased expression of EPB41L1 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in decreased expression of THY1 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in increased expression of MEF2A mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in increased expression of MYPN mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in increased expression of OTOG mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in increased expression of STAB1 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in increased expression of TRIM8 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in increased expression of ZNF672 mRNA; [Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA PMID:33656867 10411961 LINC01629 long intergenic non-protein coding RNA 1629 gene CHEBI:29865 benzo[a]pyrene increases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of LINC01629 mRNA PMID:32234424 10411961 LINC01629 long intergenic non-protein coding RNA 1629 gene CHEBI:4610 dimethylselenide multiple interactions EXP E RGD:6480464 20211109 CTD MESH:C013503 [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in decreased expression of EPB41L1 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in decreased expression of THY1 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in increased expression of MEF2A mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in increased expression of MYPN mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in increased expression of OTOG mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in increased expression of STAB1 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in increased expression of TRIM8 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA] which results in increased expression of ZNF672 mRNA; [Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01629 mRNA PMID:33656867 10411987 DHRSX-IT1 DHRSX intronic transcript 1 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of DHRSX-IT1 mRNA PMID:33212167 10411996 GAS1RR GAS1 adjacent regulatory RNA gene CHEBI:132082 entinostat increases expression EXP E RGD:6480464 20161228 CTD MESH:C118739 entinostat results in increased expression of GAS1RR mRNA PMID:27188386 10411996 GAS1RR GAS1 adjacent regulatory RNA gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of GAS1RR intron PMID:30157460 10411996 GAS1RR GAS1 adjacent regulatory RNA gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in decreased expression of GAS1RR mRNA PMID:38568856 10411996 GAS1RR GAS1 adjacent regulatory RNA gene CHEBI:30621 diarsenic trioxide decreases expression EXP E RGD:6480464 20191114 CTD MESH:C006632 Arsenic Trioxide results in decreased expression of GAS1RR mRNA PMID:26705709 10411996 GAS1RR GAS1 adjacent regulatory RNA gene CHEBI:49900 arsenous acid decreases expression EXP E RGD:6480464 20191114 CTD MESH:C032793 Arsenic Trioxide results in decreased expression of GAS1RR mRNA PMID:26705709 10412374 RPL23AP92 ribosomal protein L23a pseudogene 92 gene CHEBI:33216 bisphenol A increases expression EXP E RGD:6480464 20220208 CTD MESH:C006780 bisphenol A results in increased expression of RPL23AP92 mRNA PMID:33670352 10412396 EIF1P7 eukaryotic translation initiation factor 1 pseudogene 7 gene CHEBI:31835 methylparaben increases expression EXP E RGD:6480464 20200609 CTD MESH:C015358 methylparaben results in increased expression of EIF1P7 mRNA PMID:31745603 10412407 RN7SL832P RNA, 7SL, cytoplasmic 832, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RN7SL832P mRNA PMID:38568856 10412407 RN7SL832P RNA, 7SL, cytoplasmic 832, pseudogene gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of RN7SL832P mRNA PMID:38568856 10412410 RNU6-529P RNA, U6 small nuclear 529, pseudogene gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of RNU6-529P mRNA PMID:33212167 10412420 RN7SL477P RNA, 7SL, cytoplasmic 477, pseudogene gene CHEBI:17347 testosterone increases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in increased expression of RN7SL477P mRNA PMID:33359661 10412444 RN7SL499P RNA, 7SL, cytoplasmic 499, pseudogene gene CHEBI:17347 testosterone increases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in increased expression of RN7SL499P mRNA PMID:33359661 10412445 RN7SL845P RNA, 7SL, cytoplasmic 845, pseudogene gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SL845P mRNA PMID:33359661 10412448 RN7SL569P RNA, 7SL, cytoplasmic 569, pseudogene gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SL569P mRNA PMID:33359661 10412448 RN7SL569P RNA, 7SL, cytoplasmic 569, pseudogene gene CHEBI:34575 bisphenol F decreases expression EXP E RGD:6480464 20210504 CTD MESH:C008745 bisphenol F results in decreased expression of RN7SL569P mRNA PMID:33476716 10412460 RRM1-AS1 RRM1 antisense RNA 1 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of RRM1-AS1 mRNA PMID:34032870 10412464 RN7SL549P RNA, 7SL, cytoplasmic 549, pseudogene gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SL549P mRNA PMID:33359661 10412484 RNU2-63P RNA, U2 small nuclear 63, pseudogene gene CHEBI:27889 lead(0) decreases expression EXP E RGD:6480464 20240206 CTD MESH:D007854 Lead results in decreased expression of RNU2-63P mRNA PMID:37386098 10412484 RNU2-63P RNA, U2 small nuclear 63, pseudogene gene CHEBI:3020 benzalkonium chloride decreases expression EXP E RGD:6480464 20240604 CTD MESH:D001548 Benzalkonium Compounds results in decreased expression of RNU2-63P PMID:37149095 10412487 RN7SL568P RNA, 7SL, cytoplasmic 568, pseudogene gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SL568P mRNA PMID:33359661 10412487 RN7SL568P RNA, 7SL, cytoplasmic 568, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RN7SL568P mRNA PMID:38568856 10412498 MTATP8P2 MT-ATP8 pseudogene 2 gene CHEBI:35549 perfluorooctanoic acid decreases expression EXP E RGD:6480464 20230502 CTD MESH:C023036 perfluorooctanoic acid results in decreased expression of MTATP8P2 mRNA PMID:36326898 10412514 RN7SL470P RNA, 7SL, cytoplasmic 470, pseudogene gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of RN7SL470P mRNA PMID:35811015 10412514 RN7SL470P RNA, 7SL, cytoplasmic 470, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SL470P mRNA PMID:35811015 10412514 RN7SL470P RNA, 7SL, cytoplasmic 470, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SL470P mRNA PMID:35811015 10412526 CST12P cystatin 12, pseudogene gene CHEBI:15367 all-trans-retinoic acid increases expression ISO RGD:1550919 E RGD:6480464 20240402 CTD MESH:D014212 Tretinoin results in increased expression of CST12 mRNA; Tretinoin results in increased expression of CST9 mRNA PMID:36189433 10412526 CST12P cystatin 12, pseudogene gene CHEBI:15367 all-trans-retinoic acid multiple interactions ISO RGD:1550919 E RGD:6480464 20240402 CTD MESH:D014212 [mono-(2-ethylhexyl)phthalate co-treated with Tretinoin] results in increased expression of CST12 mRNA; [mono-(2-ethylhexyl)phthalate co-treated with Tretinoin] results in increased expression of CST9 mRNA PMID:36189433 10412526 CST12P cystatin 12, pseudogene gene CHEBI:17243 mono(2-ethylhexyl) phthalate multiple interactions ISO RGD:1550919 E RGD:6480464 20240402 CTD MESH:C016599 [mono-(2-ethylhexyl)phthalate co-treated with Tretinoin] results in increased expression of CST12 mRNA; [mono-(2-ethylhexyl)phthalate co-treated with Tretinoin] results in increased expression of CST9 mRNA PMID:36189433 10412526 CST12P cystatin 12, pseudogene gene CHEBI:28436 delphinidin decreases expression ISO RGD:1550919 E RGD:6480464 20240604 CTD MESH:C017185 delphinidin results in decreased expression of CST12 mRNA PMID:38291899 10412526 CST12P cystatin 12, pseudogene gene CHEBI:28741 sodium fluoride increases expression ISO RGD:1550919 E RGD:6480464 20180116 CTD MESH:D012969 Sodium Fluoride results in increased expression of CST12 protein PMID:28918527 10412526 CST12P cystatin 12, pseudogene gene CHEBI:32234 titanium dioxide decreases expression ISO RGD:1550919 E RGD:6480464 20250128 CTD MESH:C009495 titanium dioxide results in decreased expression of CST9 mRNA PMID:23557971 10412526 CST12P cystatin 12, pseudogene gene CHEBI:32509 pirinixic acid increases expression ISO RGD:1550919 E RGD:6480464 20250128 CTD MESH:C006253 pirinixic acid results in increased expression of CST9 mRNA PMID:20813756 10412526 CST12P cystatin 12, pseudogene gene CHEBI:33217 3,3',5,5'-tetrabromobisphenol A decreases expression ISO RGD:1550919 E RGD:6480464 20220705 CTD MESH:C020806 tetrabromobisphenol A results in decreased expression of CST12 mRNA PMID:35230478 10412526 CST12P cystatin 12, pseudogene gene CHEBI:46195 paracetamol affects expression ISO RGD:1550919 E RGD:6480464 20151124 CTD MESH:D000082 Acetaminophen affects the expression of CST12 mRNA PMID:17562736 10412583 RN7SKP66 RN7SK pseudogene 66 gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SKP66 mRNA PMID:33359661 10412585 BOLA3P4 bolA family member 3 pseudogene 4 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of BOLA3P4 mRNA PMID:38568856 10412585 BOLA3P4 bolA family member 3 pseudogene 4 gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of BOLA3P4 mRNA PMID:38568856 10412597 EIF1P6 eukaryotic translation initiation factor 1 pseudogene 6 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of EIF1P6 mRNA PMID:33212167 10412597 EIF1P6 eukaryotic translation initiation factor 1 pseudogene 6 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of EIF1P6 mRNA PMID:38568856 10412609 RNU6-612P RNA, U6 small nuclear 612, pseudogene gene CHEBI:30769 citric acid increases expression EXP E RGD:6480464 20240604 CTD MESH:D019343 Citric Acid results in increased expression of RNU6-612P PMID:37149095 10412609 RNU6-612P RNA, U6 small nuclear 612, pseudogene gene CHEBI:32914 cetylpyridinium increases expression EXP E RGD:6480464 20240604 CTD MESH:D002594 Cetylpyridinium results in increased expression of RNU6-612P PMID:37149095 10412624 RN7SKP271 RN7SK pseudogene 271 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of RN7SKP271 mRNA PMID:33212167 10412631 RN7SL455P RNA, 7SL, cytoplasmic 455, pseudogene gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of RN7SL455P mRNA PMID:38568856 10412632 RNU7-113P RNA, U7 small nuclear 113 pseudogene gene CHEBI:27744 glyphosate decreases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in decreased expression of RNU7-113P mRNA PMID:28711546 10413043 MTATP6P1 MT-ATP6 pseudogene 1 gene CHEBI:2825 aristolochic acid A decreases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in decreased expression of MTATP6P1 mRNA PMID:33212167 10413043 MTATP6P1 MT-ATP6 pseudogene 1 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in decreased expression of MTATP6P1 mRNA PMID:38568856 10413043 MTATP6P1 MT-ATP6 pseudogene 1 gene CHEBI:3000 beauvericin decreases expression EXP E RGD:6480464 20180515 CTD MESH:C004456 beauvericin results in decreased expression of MTATP6P1 mRNA PMID:29203277 10413043 MTATP6P1 MT-ATP6 pseudogene 1 gene CHEBI:31835 methylparaben decreases expression EXP E RGD:6480464 20200609 CTD MESH:C015358 methylparaben results in decreased expression of MTATP6P1 mRNA PMID:31745603 10413043 MTATP6P1 MT-ATP6 pseudogene 1 gene CHEBI:33007 chromium(6+) multiple interactions EXP E RGD:6480464 20240702 CTD MESH:C074702 [zinc chromate results in increased abundance of chromium hexavalent ion] which results in increased expression of MTATP6P1 mRNA PMID:38479592 10413043 MTATP6P1 MT-ATP6 pseudogene 1 gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20220208 CTD MESH:C006780 bisphenol A results in decreased expression of MTATP6P1 mRNA PMID:33670352 10413043 MTATP6P1 MT-ATP6 pseudogene 1 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of MTATP6P1 mRNA PMID:38568856 10413043 MTATP6P1 MT-ATP6 pseudogene 1 gene CHEBI:9495 thiram decreases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in decreased expression of MTATP6P1 mRNA PMID:38568856 10413047 RNY1P16 RNY1 pseudogene 16 gene CHEBI:31835 methylparaben increases expression EXP E RGD:6480464 20200609 CTD MESH:C015358 methylparaben results in increased expression of RNY1P16 mRNA PMID:31745603 10413087 RNVU1-32 RNA, variant U1 small nuclear 32 gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of RNVU1-32 mRNA PMID:35811015 10413087 RNVU1-32 RNA, variant U1 small nuclear 32 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RNVU1-32 mRNA PMID:35811015 10413087 RNVU1-32 RNA, variant U1 small nuclear 32 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RNVU1-32 mRNA PMID:35811015 10413109 RNU4-40P RNA, U4 small nuclear 40, pseudogene gene CHEBI:24527 herbicide increases expression EXP E RGD:6480464 20171010 CTD MESH:D006540 Herbicides results in increased expression of RNU4-40P mRNA PMID:28711546 10413123 RNU6-403P RNA, U6 small nuclear 403, pseudogene gene CHEBI:16412 lipopolysaccharide decreases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in decreased expression of RNU6-403P mRNA PMID:35811015 10413123 RNU6-403P RNA, U6 small nuclear 403, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in decreased expression of RNU6-403P mRNA] PMID:35811015 10413123 RNU6-403P RNA, U6 small nuclear 403, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RNU6-403P mRNA PMID:38568856 10413123 RNU6-403P RNA, U6 small nuclear 403, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in decreased expression of RNU6-403P mRNA] PMID:35811015 10413134 HM13-IT1 HM13 intronic transcript 1 gene CHEBI:28216 methylmercury chloride increases expression EXP E RGD:6480464 20170516 CTD MESH:C004925 methylmercuric chloride results in increased expression of HM13-IT1 mRNA PMID:28001369 10413139 RNU6-611P RNA, U6 small nuclear 611, pseudogene gene CHEBI:24527 herbicide decreases expression EXP E RGD:6480464 20171010 CTD MESH:D006540 Herbicides results in decreased expression of RNU6-611P mRNA PMID:28711546 10413139 RNU6-611P RNA, U6 small nuclear 611, pseudogene gene CHEBI:27744 glyphosate decreases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in decreased expression of RNU6-611P mRNA PMID:28711546 10413161 RNU6-179P RNA, U6 small nuclear 179, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RNU6-179P mRNA PMID:38568856 10413163 RNU6-1045P RNA, U6 small nuclear 1045, pseudogene gene CHEBI:34575 bisphenol F increases expression EXP E RGD:6480464 20210504 CTD MESH:C008745 bisphenol F results in increased expression of RNU6-1045P mRNA PMID:33476716 10413179 RN7SL559P RNA, 7SL, cytoplasmic 559, pseudogene gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of RN7SL559P mRNA PMID:35811015 10413179 RN7SL559P RNA, 7SL, cytoplasmic 559, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SL559P mRNA PMID:35811015 10413179 RN7SL559P RNA, 7SL, cytoplasmic 559, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SL559P mRNA PMID:35811015 10413184 RN7SL200P RNA, 7SL, cytoplasmic 200, pseudogene gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of RN7SL200P mRNA PMID:38568856 10413229 RN7SL403P RNA, 7SL, cytoplasmic 403, pseudogene gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SL403P mRNA PMID:33359661 10413242 RNU6-490P RNA, U6 small nuclear 490, pseudogene gene CHEBI:16240 hydrogen peroxide decreases expression EXP E RGD:6480464 20240604 CTD MESH:D006861 Hydrogen Peroxide results in decreased expression of RNU6-490P PMID:37149095 10413242 RNU6-490P RNA, U6 small nuclear 490, pseudogene gene CHEBI:31264 benzethonium chloride decreases expression EXP E RGD:6480464 20240604 CTD MESH:D001558 Benzethonium results in decreased expression of RNU6-490P PMID:37149095 10413242 RNU6-490P RNA, U6 small nuclear 490, pseudogene gene CHEBI:32146 sodium hypochlorite decreases expression EXP E RGD:6480464 20240604 CTD MESH:D012973 Sodium Hypochlorite results in decreased expression of RNU6-490P PMID:37149095 10413242 RNU6-490P RNA, U6 small nuclear 490, pseudogene gene CHEBI:32914 cetylpyridinium decreases expression EXP E RGD:6480464 20240604 CTD MESH:D002594 Cetylpyridinium results in decreased expression of RNU6-490P PMID:37149095 10413242 RNU6-490P RNA, U6 small nuclear 490, pseudogene gene CHEBI:94725 dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium decreases expression EXP E RGD:6480464 20240604 CTD MESH:D001558 Benzethonium results in decreased expression of RNU6-490P PMID:37149095 10413253 RN7SKP26 RN7SK pseudogene 26 gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of RN7SKP26 mRNA PMID:35811015 10413253 RN7SKP26 RN7SK pseudogene 26 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in increased expression of RN7SKP26 mRNA] PMID:35811015 10413253 RN7SKP26 RN7SK pseudogene 26 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in increased expression of RN7SKP26 mRNA] PMID:35811015 10413259 RN7SL399P RNA, 7SL, cytoplasmic 399, pseudogene gene CHEBI:29678 sodium arsenite affects expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite affects the expression of RN7SL399P mRNA PMID:34032870 10413275 RNU6-431P RNA, U6 small nuclear 431, pseudogene gene CHEBI:31835 methylparaben increases expression EXP E RGD:6480464 20200609 CTD MESH:C015358 methylparaben results in increased expression of RNU6-431P mRNA PMID:31745603 10413281 RN7SL751P RNA, 7SL, cytoplasmic 751, pseudogene gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of RN7SL751P mRNA PMID:35811015 10413281 RN7SL751P RNA, 7SL, cytoplasmic 751, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SL751P mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of RN7SL751P mRNA PMID:35811015 10413281 RN7SL751P RNA, 7SL, cytoplasmic 751, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SL751P mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of RN7SL751P mRNA PMID:35811015 10413290 RNU6-807P RNA, U6 small nuclear 807, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of RNU6-807P mRNA PMID:35811015 10413290 RNU6-807P RNA, U6 small nuclear 807, pseudogene gene CHEBI:16469 17beta-estradiol increases expression EXP E RGD:6480464 20171010 CTD MESH:D004958 Estradiol results in increased expression of RNU6-807P mRNA PMID:28711546 10413290 RNU6-807P RNA, U6 small nuclear 807, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of RNU6-807P mRNA PMID:35811015 10413294 RNU6-118P RNA, U6 small nuclear 118, pseudogene gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of RNU6-118P mRNA PMID:34032870 10413340 RNU6-583P RNA, U6 small nuclear 583, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in increased expression of RNU6-583P mRNA PMID:34032870 10413351 RN7SL32P RNA, 7SL, cytoplasmic 32, pseudogene gene CHEBI:16412 lipopolysaccharide decreases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in decreased expression of RN7SL32P mRNA PMID:35811015 10413351 RN7SL32P RNA, 7SL, cytoplasmic 32, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SL32P mRNA PMID:35811015 10413351 RN7SL32P RNA, 7SL, cytoplasmic 32, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SL32P mRNA PMID:35811015 10413384 RNU6-1160P RNA, U6 small nuclear 1160, pseudogene gene CHEBI:17824 propan-2-ol increases expression EXP E RGD:6480464 20240604 CTD MESH:D019840 2-Propanol results in increased expression of RNU6-1160P PMID:37149095 10413400 RNU6-1316P RNA, U6 small nuclear 1316, pseudogene gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of RNU6-1316P mRNA PMID:35811015 10413400 RNU6-1316P RNA, U6 small nuclear 1316, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RNU6-1316P mRNA PMID:35811015 10413400 RNU6-1316P RNA, U6 small nuclear 1316, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RNU6-1316P mRNA PMID:35811015 10413403 RNU6-853P RNA, U6 small nuclear 853, pseudogene gene CHEBI:24527 herbicide increases expression EXP E RGD:6480464 20171010 CTD MESH:D006540 Herbicides results in increased expression of RNU6-853P mRNA PMID:28711546 10413408 RN7SL535P RNA, 7SL, cytoplasmic 535, pseudogene gene CHEBI:16598 DDE increases expression EXP E RGD:6480464 20240702 CTD MESH:D003633 Dichlorodiphenyl Dichloroethylene results in increased expression of RN7SL535P mRNA PMID:38568856 10413428 RN7SKP97 RN7SK pseudogene 97 gene CHEBI:82362 N-Nitrosopyrrolidine decreases expression EXP E RGD:6480464 20200714 CTD MESH:D009242 N-Nitrosopyrrolidine results in decreased expression of RN7SKP97 mRNA PMID:32234424 10413430 RNU6-548P RNA, U6 small nuclear 548, pseudogene gene CHEBI:16236 ethanol increases expression EXP E RGD:6480464 20240604 CTD MESH:D000431 Ethanol results in increased expression of RNU6-548P PMID:37149095 10413445 MTATP8P1 MT-ATP8 pseudogene 1 gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of MTATP8P1 mRNA PMID:38218311 10413475 RNU6-638P RNA, U6 small nuclear 638, pseudogene gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of RNU6-638P mRNA PMID:35811015 10413475 RNU6-638P RNA, U6 small nuclear 638, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RNU6-638P mRNA PMID:35811015 10413475 RNU6-638P RNA, U6 small nuclear 638, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RNU6-638P mRNA PMID:35811015 10413486 RN7SL466P RNA, 7SL, cytoplasmic 466, pseudogene gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20211109 CTD MESH:D013739 Testosterone results in decreased expression of RN7SL466P mRNA PMID:33359661 10413548 RN7SL364P RNA, 7SL, cytoplasmic 364, pseudogene gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of RN7SL364P mRNA PMID:38568856 10413568 RNU6-1062P RNA, U6 small nuclear 1062, pseudogene gene CHEBI:32914 cetylpyridinium increases expression EXP E RGD:6480464 20240604 CTD MESH:D002594 Cetylpyridinium results in increased expression of RNU6-1062P PMID:37149095 10413572 RNU6-37P RNA, U6 small nuclear 37, pseudogene gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of RNU6-37P mRNA PMID:35811015 10413572 RNU6-37P RNA, U6 small nuclear 37, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RNU6-37P mRNA PMID:35811015 10413572 RNU6-37P RNA, U6 small nuclear 37, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RNU6-37P mRNA PMID:35811015 10413596 RNU6-767P RNA, U6 small nuclear 767, pseudogene gene CHEBI:31264 benzethonium chloride decreases expression EXP E RGD:6480464 20240604 CTD MESH:D001558 Benzethonium results in decreased expression of RNU6-767P PMID:37149095 10413596 RNU6-767P RNA, U6 small nuclear 767, pseudogene gene CHEBI:94725 dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium decreases expression EXP E RGD:6480464 20240604 CTD MESH:D001558 Benzethonium results in decreased expression of RNU6-767P PMID:37149095 10413600 RN7SKP269 RN7SK pseudogene 269 gene CHEBI:10429 beta-lapachone increases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in increased expression of RN7SKP269 mRNA PMID:38218311 10413615 RNU6-301P RNA, U6 small nuclear 301, pseudogene gene CHEBI:16236 ethanol decreases expression EXP E RGD:6480464 20240604 CTD MESH:D000431 Ethanol results in decreased expression of RNU6-301P PMID:37149095 10413615 RNU6-301P RNA, U6 small nuclear 301, pseudogene gene CHEBI:193591 Didecyldimethylammonium decreases expression EXP E RGD:6480464 20221018 CTD MESH:C027118 didecyldimethylammonium results in decreased expression of RNU6-301P mRNA PMID:32763356 10413643 RNU6-998P RNA, U6 small nuclear 998, pseudogene gene CHEBI:24527 herbicide decreases expression EXP E RGD:6480464 20171010 CTD MESH:D006540 Herbicides results in decreased expression of RNU6-998P mRNA PMID:28711546 10413643 RNU6-998P RNA, U6 small nuclear 998, pseudogene gene CHEBI:27744 glyphosate decreases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in decreased expression of RNU6-998P mRNA PMID:28711546 10413681 CYP4F26P cytochrome P450 family 4 subfamily F member 26, pseudogene gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of CYP4F26P mRNA PMID:33212167 10413681 CYP4F26P cytochrome P450 family 4 subfamily F member 26, pseudogene gene CHEBI:44915 propofol decreases expression EXP E RGD:6480464 20220809 CTD MESH:D015742 Propofol results in decreased expression of CYP4F26P mRNA PMID:35238236 10413683 RN7SL788P RNA, 7SL, cytoplasmic 788, pseudogene gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of RN7SL788P mRNA PMID:38568856 10413686 RN7SKP56 RN7SK pseudogene 56 gene CHEBI:27744 glyphosate increases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in increased expression of RN7SKP56 mRNA PMID:28711546 10413719 NDUFB4P12 NADH:ubiquinone oxidoreductase subunit B4 pseudogene 12 gene CHEBI:46645 isobutanol multiple interactions EXP E RGD:6480464 20181016 CTD MESH:C040507 [[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFB4P12 mRNA PMID:29432896 10413733 GK-IT1 GK intronic transcript 1 gene CHEBI:29191 hydroxyl multiple interactions EXP E RGD:6480464 20211109 CTD MESH:D017665 [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-IT1 mRNA] which results in increased expression of GK mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-IT1 mRNA PMID:33656867 10413733 GK-IT1 GK intronic transcript 1 gene CHEBI:4610 dimethylselenide multiple interactions EXP E RGD:6480464 20211109 CTD MESH:C013503 [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-IT1 mRNA] which results in increased expression of GK mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-IT1 mRNA PMID:33656867 10413740 RNU6-90P RNA, U6 small nuclear 90, pseudogene gene CHEBI:16240 hydrogen peroxide decreases expression EXP E RGD:6480464 20240604 CTD MESH:D006861 Hydrogen Peroxide results in decreased expression of RNU6-90P PMID:37149095 10413753 RNU4-38P RNA, U4 small nuclear 38, pseudogene gene CHEBI:24527 herbicide increases expression EXP E RGD:6480464 20171010 CTD MESH:D006540 Herbicides results in increased expression of RNU4-38P mRNA PMID:28711546 10413753 RNU4-38P RNA, U4 small nuclear 38, pseudogene gene CHEBI:27744 glyphosate increases expression EXP E RGD:6480464 20240206 CTD MESH:C010974 Glyphosate results in increased expression of RNU4-38P mRNA PMID:28711546 10413755 RNU6-97P RNA, U6 small nuclear 97, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RNU6-97P mRNA PMID:38568856 10413773 RNU6-125P RNA, U6 small nuclear 125, pseudogene gene CHEBI:16240 hydrogen peroxide decreases expression EXP E RGD:6480464 20240604 CTD MESH:D006861 Hydrogen Peroxide results in decreased expression of RNU6-125P PMID:37149095 10413788 RNU6-789P RNA, U6 small nuclear 789, pseudogene gene CHEBI:16240 hydrogen peroxide decreases expression EXP E RGD:6480464 20240604 CTD MESH:D006861 Hydrogen Peroxide results in decreased expression of RNU6-789P PMID:37149095 10413805 RN7SKP80 RN7SK pseudogene 80 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of RN7SKP80 mRNA PMID:33212167 10413805 RN7SKP80 RN7SK pseudogene 80 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RN7SKP80 mRNA PMID:38568856 10413835 RN7SL326P RNA, 7SL, cytoplasmic 326, pseudogene gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of RN7SL326P mRNA PMID:35811015 10413835 RN7SL326P RNA, 7SL, cytoplasmic 326, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in increased expression of RN7SL326P mRNA] PMID:35811015 10413835 RN7SL326P RNA, 7SL, cytoplasmic 326, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in increased expression of RN7SL326P mRNA] PMID:35811015 10413840 RN7SL124P RNA, 7SL, cytoplasmic 124, pseudogene gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of RN7SL124P mRNA PMID:35811015 10413840 RN7SL124P RNA, 7SL, cytoplasmic 124, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SL124P mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of RN7SL124P mRNA PMID:35811015 10413840 RN7SL124P RNA, 7SL, cytoplasmic 124, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RN7SL124P mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of RN7SL124P mRNA PMID:35811015 10449059 SMPD5 sphingomyelin phosphodiesterase 5 (pseudogene) gene CHEBI:16602 trichloroethene increases expression ISO RGD:2323312 E RGD:6480464 20211207 CTD MESH:D014241 Trichloroethylene results in increased expression of SMPD5 mRNA PMID:33387578 10449059 SMPD5 sphingomyelin phosphodiesterase 5 (pseudogene) gene CHEBI:17153 propanal decreases expression EXP E RGD:6480464 20151222 CTD MESH:C005556 propionaldehyde results in decreased expression of SMPD5 mRNA PMID:26079696 10449059 SMPD5 sphingomyelin phosphodiesterase 5 (pseudogene) gene CHEBI:33216 bisphenol A decreases expression ISO RGD:2323312 E RGD:6480464 20160112 CTD MESH:C006780 bisphenol A results in decreased expression of SMPD5 mRNA PMID:25181051|PMID:30816183|PMID:32528016 10449059 SMPD5 sphingomyelin phosphodiesterase 5 (pseudogene) gene CHEBI:34372 4,4'-sulfonyldiphenol increases methylation ISO RGD:1642410 E RGD:6480464 20220208 CTD MESH:C543008 bisphenol S results in increased methylation of SMPD5 promoter PMID:33297965 10449059 SMPD5 sphingomyelin phosphodiesterase 5 (pseudogene) gene CHEBI:34575 bisphenol F decreases expression ISO RGD:1642410 E RGD:6480464 20241105 CTD MESH:C008745 bisphenol F results in decreased expression of SMPD5 mRNA PMID:38685157 10449059 SMPD5 sphingomyelin phosphodiesterase 5 (pseudogene) gene CHEBI:34696 dieldrin affects methylation ISO RGD:1642410 E RGD:6480464 20241105 CTD MESH:D004026 Dieldrin affects the methylation of SMPD5 gene PMID:38995845 10449059 SMPD5 sphingomyelin phosphodiesterase 5 (pseudogene) gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of SMPD5 mRNA PMID:38568856 10449059 SMPD5 sphingomyelin phosphodiesterase 5 (pseudogene) gene CHEBI:35456 cadmium dichloride increases expression ISO RGD:2323312 E RGD:6480464 20210504 CTD MESH:D019256 Cadmium Chloride results in increased expression of SMPD5 mRNA PMID:33453195 10449059 SMPD5 sphingomyelin phosphodiesterase 5 (pseudogene) gene CHEBI:36386 dichloroacetic acid increases expression ISO RGD:1642410 E RGD:6480464 20171114 CTD MESH:D003999 Dichloroacetic Acid results in increased expression of SMPD5 mRNA PMID:28962523 10449059 SMPD5 sphingomyelin phosphodiesterase 5 (pseudogene) gene CHEBI:64163 diquat increases expression ISO RGD:1642410 E RGD:6480464 20230704 CTD MESH:D004178 Diquat results in increased expression of SMPD5 mRNA PMID:36851058 10449059 SMPD5 sphingomyelin phosphodiesterase 5 (pseudogene) gene CHEBI:8502 6-propyl-2-thiouracil increases expression ISO RGD:2323312 E RGD:6480464 20160112 CTD MESH:D011441 Propylthiouracil results in increased expression of SMPD5 mRNA PMID:24780913 10449094 RNA5SP334 RNA, 5S ribosomal pseudogene 334 gene CHEBI:9495 thiram decreases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in decreased expression of RNA5SP334 mRNA PMID:38568856 10449213 CCDC192 coiled-coil domain containing 192 gene CHEBI:28748 doxorubicin increases expression ISO RGD:1623912 E RGD:6480464 20200804 CTD MESH:D004317 Doxorubicin results in increased expression of CCDC192 mRNA PMID:28608983 10449213 CCDC192 coiled-coil domain containing 192 gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20220208 CTD MESH:C006780 bisphenol A results in decreased expression of CCDC192 mRNA PMID:33670352 10449213 CCDC192 coiled-coil domain containing 192 gene CHEBI:34795 3-isobutyl-1-methyl-7H-xanthine multiple interactions EXP E RGD:6480464 20180116 CTD MESH:D015056 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CCDC192 mRNA PMID:28628672 10449213 CCDC192 coiled-coil domain containing 192 gene CHEBI:41879 dexamethasone multiple interactions EXP E RGD:6480464 20180116 CTD MESH:D003907 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CCDC192 mRNA PMID:28628672 10449213 CCDC192 coiled-coil domain containing 192 gene CHEBI:49662 indometacin multiple interactions EXP E RGD:6480464 20180116 CTD MESH:D007213 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CCDC192 mRNA PMID:28628672 10449213 CCDC192 coiled-coil domain containing 192 gene CHEBI:52136 glufosinate decreases expression ISO RGD:1623912 E RGD:6480464 20230905 CTD MESH:C003121 phosphinothricin results in decreased expression of CCDC192 mRNA PMID:34597628 10449213 CCDC192 coiled-coil domain containing 192 gene CHEBI:6651 malathion increases expression EXP E RGD:6480464 20230606 CTD MESH:D008294 Malathion results in increased expression of CCDC192 mRNA PMID:37047231 10449326 TEX13C TEX13 family member C gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20220308 CTD MESH:C006780 bisphenol A results in decreased expression of TEX13C protein PMID:31675489 10449326 TEX13C TEX13 family member C gene CHEBI:33216 bisphenol A decreases expression ISO RGD:1563975 E RGD:6480464 20230627 CTD MESH:C006780 bisphenol A results in decreased expression of TEX13C mRNA PMID:25181051 10449326 TEX13C TEX13 family member C gene CHEBI:33217 3,3',5,5'-tetrabromobisphenol A increases expression EXP E RGD:6480464 20220308 CTD MESH:C020806 tetrabromobisphenol A results in increased expression of TEX13C protein PMID:31675489 10449326 TEX13C TEX13 family member C gene CHEBI:47696 2,4,6-tribromophenol decreases expression EXP E RGD:6480464 20220308 CTD MESH:C004554 2,4,6-tribromophenol results in decreased expression of TEX13C mRNA PMID:31675489 10449326 TEX13C TEX13 family member C gene CHEBI:81584 2,2',4,4'-Tetrabromodiphenyl ether decreases expression EXP E RGD:6480464 20220308 CTD MESH:C511295 2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of TEX13C protein PMID:31675489 10449361 TEX13D TEX13 family member D gene CHEBI:15367 all-trans-retinoic acid increases expression ISO RGD:2299041 E RGD:6480464 20240402 CTD MESH:D014212 Tretinoin results in increased expression of TEX13D mRNA PMID:36189433 10449361 TEX13D TEX13 family member D gene CHEBI:15367 all-trans-retinoic acid multiple interactions ISO RGD:2299041 E RGD:6480464 20240402 CTD MESH:D014212 [mono-(2-ethylhexyl)phthalate co-treated with Tretinoin] results in increased expression of TEX13D mRNA PMID:36189433 10449361 TEX13D TEX13 family member D gene CHEBI:17243 mono(2-ethylhexyl) phthalate multiple interactions ISO RGD:2299041 E RGD:6480464 20240402 CTD MESH:C016599 [mono-(2-ethylhexyl)phthalate co-treated with Tretinoin] results in increased expression of TEX13D mRNA PMID:36189433 10449361 TEX13D TEX13 family member D gene CHEBI:4811 epoxiconazole increases expression ISO RGD:2299041 E RGD:6480464 20220906 CTD MESH:C109476 epoxiconazole results in increased expression of TEX13D mRNA PMID:35436446 10449362 CCDC92B coiled-coil domain containing 92B gene CHEBI:132267 triptonide increases expression ISO RGD:1616364 E RGD:6480464 20210406 CTD MESH:C084079 triptonide results in increased expression of CCDC92B mRNA PMID:33045310 10449362 CCDC92B coiled-coil domain containing 92B gene CHEBI:15367 all-trans-retinoic acid multiple interactions ISO RGD:1616364 E RGD:6480464 20240402 CTD MESH:D014212 [mono-(2-ethylhexyl)phthalate co-treated with Tretinoin] results in decreased expression of CCDC92B mRNA PMID:36189433 10449362 CCDC92B coiled-coil domain containing 92B gene CHEBI:17243 mono(2-ethylhexyl) phthalate multiple interactions ISO RGD:1616364 E RGD:6480464 20240402 CTD MESH:C016599 [mono-(2-ethylhexyl)phthalate co-treated with Tretinoin] results in decreased expression of CCDC92B mRNA PMID:36189433 10449362 CCDC92B coiled-coil domain containing 92B gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of CCDC92B intron PMID:30157460 10449362 CCDC92B coiled-coil domain containing 92B gene CHEBI:29678 sodium arsenite multiple interactions ISO RGD:1616364 E RGD:6480464 20220405 CTD MESH:C017947 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC92B mRNA PMID:34876320 10449362 CCDC92B coiled-coil domain containing 92B gene CHEBI:29852 methylarsonic acid multiple interactions ISO RGD:1616364 E RGD:6480464 20220405 CTD MESH:C020300 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC92B mRNA PMID:34876320 10449362 CCDC92B coiled-coil domain containing 92B gene CHEBI:32234 titanium dioxide increases expression ISO RGD:1616364 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in increased expression of CCDC92B mRNA PMID:35295148 10449362 CCDC92B coiled-coil domain containing 92B gene CHEBI:34905 paraquat decreases expression ISO RGD:1562276 E RGD:6480464 20210907 CTD MESH:D010269 Paraquat results in decreased expression of CCDC92B mRNA PMID:32680482 10449362 CCDC92B coiled-coil domain containing 92B gene CHEBI:48765 dimethylarsinic acid multiple interactions ISO RGD:1616364 E RGD:6480464 20220405 CTD MESH:D002101 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC92B mRNA PMID:34876320 10449362 CCDC92B coiled-coil domain containing 92B gene CHEBI:84070 sodium arsenate multiple interactions ISO RGD:1616364 E RGD:6480464 20220405 CTD MESH:C009277 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC92B mRNA PMID:34876320 10450273 NDUFB4P11 NADH:ubiquinone oxidoreductase subunit B4 pseudogene 11 gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of NDUFB4P11 mRNA PMID:35811015 10450273 NDUFB4P11 NADH:ubiquinone oxidoreductase subunit B4 pseudogene 11 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of NDUFB4P11 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of NDUFB4P11 mRNA PMID:35811015 10450273 NDUFB4P11 NADH:ubiquinone oxidoreductase subunit B4 pseudogene 11 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of NDUFB4P11 mRNA PMID:33212167 10450273 NDUFB4P11 NADH:ubiquinone oxidoreductase subunit B4 pseudogene 11 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of NDUFB4P11 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of NDUFB4P11 mRNA PMID:35811015 10450277 LAPTM4BP2 lysosomal protein transmembrane 4 beta pseudogene 2 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in increased expression of LAPTM4BP2 mRNA PMID:34032870 10450332 RHOXF1P3 Rhox homeobox family member 1 pseudogene 3 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RHOXF1P3 mRNA PMID:38568856 10450361 NDUFA5P11 NADH:ubiquinone oxidoreductase subunit A5 pseudogene 11 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of NDUFA5P11 mRNA PMID:35811015 10450361 NDUFA5P11 NADH:ubiquinone oxidoreductase subunit A5 pseudogene 11 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of NDUFA5P11 mRNA PMID:35811015 10450374 RNFT1P3 ring finger protein, transmembrane 1 pseudogene 3 gene CHEBI:31835 methylparaben decreases expression EXP E RGD:6480464 20200609 CTD MESH:C015358 methylparaben results in decreased expression of RNFT1P3 mRNA PMID:31745603 10450375 MIR3142HG MIR3142 host gene gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of MIR3142HG mRNA PMID:35811015 10450375 MIR3142HG MIR3142 host gene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of MIR3142HG mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of MIR3142HG mRNA PMID:35811015 10450375 MIR3142HG MIR3142 host gene gene CHEBI:2825 aristolochic acid A decreases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in decreased expression of MIR3142HG mRNA PMID:33212167 10450375 MIR3142HG MIR3142 host gene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in increased expression of MIR3142HG mRNA PMID:34032870 10450375 MIR3142HG MIR3142 host gene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of MIR3142HG mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of MIR3142HG mRNA PMID:35811015 10450389 ODF2-AS1 ODF2 antisense RNA 1 gene CHEBI:29678 sodium arsenite affects expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite affects the expression of ODF2-AS1 mRNA PMID:34032870 10450396 MTCO1P12 MT-CO1 pseudogene 12 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP E RGD:6480464 20181016 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of MTCO1P12 mRNA PMID:30096437 10450396 MTCO1P12 MT-CO1 pseudogene 12 gene CHEBI:2825 aristolochic acid A decreases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in decreased expression of MTCO1P12 mRNA PMID:33212167 10450396 MTCO1P12 MT-CO1 pseudogene 12 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in decreased expression of MTCO1P12 mRNA PMID:38568856 10450396 MTCO1P12 MT-CO1 pseudogene 12 gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20220208 CTD MESH:C006780 bisphenol A results in decreased expression of MTCO1P12 mRNA PMID:33670352 10450396 MTCO1P12 MT-CO1 pseudogene 12 gene CHEBI:9495 thiram decreases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in decreased expression of MTCO1P12 mRNA PMID:38568856 10450399 NDUFB4P8 NADH:ubiquinone oxidoreductase subunit B4 pseudogene 8 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of NDUFB4P8 mRNA PMID:33212167 10450416 MTCO2P12 MT-CO2 pseudogene 12 gene CHEBI:2825 aristolochic acid A decreases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in decreased expression of MTCO2P12 mRNA PMID:33212167 10450416 MTCO2P12 MT-CO2 pseudogene 12 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in decreased expression of MTCO2P12 mRNA PMID:38568856 10450416 MTCO2P12 MT-CO2 pseudogene 12 gene CHEBI:31835 methylparaben decreases expression EXP E RGD:6480464 20200609 CTD MESH:C015358 methylparaben results in decreased expression of MTCO2P12 mRNA PMID:31745603 10450416 MTCO2P12 MT-CO2 pseudogene 12 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of MTCO2P12 mRNA PMID:38568856 10450416 MTCO2P12 MT-CO2 pseudogene 12 gene CHEBI:9495 thiram decreases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in decreased expression of MTCO2P12 mRNA PMID:38568856 10450633 RNU6-322P RNA, U6 small nuclear 322, pseudogene gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of RNU6-322P mRNA PMID:33212167 10450704 RNU1-70P RNA, U1 small nuclear 70, pseudogene gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of RNU1-70P mRNA PMID:32234424 10450704 RNU1-70P RNA, U1 small nuclear 70, pseudogene gene CHEBI:4918 O-methyleugenol decreases expression EXP E RGD:6480464 20200714 CTD MESH:C005223 methyleugenol results in decreased expression of RNU1-70P mRNA PMID:32234424 10450710 LINC01077 long intergenic non-protein coding RNA 1077 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01077 mRNA PMID:35811015 10450710 LINC01077 long intergenic non-protein coding RNA 1077 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01077 mRNA PMID:35811015 10450713 IQCA1-AS1 IQCA1 antisense RNA 1 gene CHEBI:2825 aristolochic acid A decreases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in decreased expression of IQCA1-AS1 mRNA PMID:33212167 10755360 SEPTIN14P23 septin 14 pseudogene 23 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20220308 CTD MESH:D019256 Cadmium Chloride results in increased expression of SEPTIN14P23 mRNA PMID:26472689 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:1367 3,3',4,4'-tetrachlorobiphenyl multiple interactions ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C028451 3,4,3',4'-tetrachlorobiphenyl inhibits the reaction [Dietary Fats results in increased expression of AOX3 mRNA] PMID:19467301 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:15379 dioxygen multiple interactions ISO RGD:1622280 E RGD:6480464 20190312 CTD MESH:D010100 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of AOX3 mRNA PMID:30529165 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:15443 inulin multiple interactions ISO RGD:1622280 E RGD:6480464 20230502 CTD MESH:D007444 [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of AOX3 mRNA PMID:36331819 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:16469 17beta-estradiol increases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D004958 Estradiol results in increased expression of AOX3 mRNA PMID:19484750 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:16482 naphthalene decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C031721 naphthalene results in decreased expression of AOX3 mRNA PMID:18757308 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:16602 trichloroethene decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D014241 Trichloroethylene results in decreased expression of AOX3 mRNA PMID:25549359 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:17347 testosterone increases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D013739 Testosterone results in increased expression of AOX3 mRNA PMID:21669218 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:17747 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D004051 [Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in decreased expression of AOX3 mRNA PMID:28433925 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:18246 (1->4)-beta-D-glucan multiple interactions ISO RGD:1622280 E RGD:6480464 20230502 CTD MESH:D002482 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of AOX3 mRNA PMID:36331819 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:25812 ozone multiple interactions ISO RGD:1622280 E RGD:6480464 20220809 CTD MESH:D010126 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of AOX3 mRNA; [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of AOX3 mRNA PMID:27106289|PMID:34911549 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:2663 amiodarone decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D000638 Amiodarone results in decreased expression of AOX3 mRNA PMID:24535564 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:27385 tetrachloromethane decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D002251 Carbon Tetrachloride results in decreased expression of AOX3 mRNA PMID:27339419|PMID:31919559 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:27568 selenium atom increases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D012643 Selenium deficiency results in increased expression of AOX3 mRNA; Selenium results in increased expression of AOX3 mRNA PMID:16170372 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:27789 1,2-dichloroethane decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C024565 ethylene dichloride results in decreased expression of AOX3 mRNA PMID:28189721|PMID:28960355 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:27881 resveratrol multiple interactions ISO RGD:1622280 E RGD:6480464 20200211 CTD MESH:C059514 Resveratrol inhibits the reaction [titanium dioxide results in increased expression of AOX3 mRNA] PMID:31298478 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of AOX3 mRNA PMID:26377647|PMID:28213091 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of AOX3 mRNA; Tetrachlorodibenzodioxin results in increased expression of AOX3 protein PMID:15664268|PMID:19770486|PMID:19933214 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D013749 [Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in decreased expression of AOX3 mRNA; Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to AOX3 gene]; tungstate inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AOX3 protein] PMID:15664268|PMID:28213091|PMID:28433925 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:29678 sodium arsenite decreases expression ISO RGD:1622280 E RGD:6480464 20240206 CTD MESH:C017947 sodium arsenite results in decreased expression of AOX3 mRNA PMID:37682722 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:29865 benzo[a]pyrene decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of AOX3 mRNA PMID:22228805 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:29865 benzo[a]pyrene increases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of AOX3 mRNA PMID:19770486|PMID:21569818 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:29865 benzo[a]pyrene multiple interactions ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D001564 AHR protein affects the reaction [Benzo(a)pyrene affects the expression of AOX3 mRNA] PMID:22228805 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:30512 silver atom increases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D012834 Silver results in increased expression of AOX3 mRNA PMID:27131904 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:32234 titanium dioxide decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C009495 titanium dioxide results in decreased expression of AOX3 mRNA PMID:27760801 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:32234 titanium dioxide increases expression ISO RGD:1622280 E RGD:6480464 20200211 CTD MESH:C009495 titanium dioxide results in increased expression of AOX3 mRNA PMID:31298478 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:32234 titanium dioxide multiple interactions ISO RGD:1622280 E RGD:6480464 20200211 CTD MESH:C009495 Resveratrol inhibits the reaction [titanium dioxide results in increased expression of AOX3 mRNA] PMID:31298478 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:32509 pirinixic acid decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C006253 pirinixic acid results in decreased expression of AOX3 mRNA PMID:18445702|PMID:20813756|PMID:23811191 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:32509 pirinixic acid multiple interactions ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C006253 [pirinixic acid co-treated with PPARA] results in decreased expression of AOX3 mRNA PMID:20813756 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:33216 bisphenol A increases expression ISO RGD:1622280 E RGD:6480464 20191112 CTD MESH:C006780 bisphenol A results in increased expression of AOX3 mRNA PMID:30951980 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:33216 bisphenol A multiple interactions ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C006780 [Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in decreased expression of AOX3 mRNA PMID:28433925 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:34202 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C014024 [Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in decreased expression of AOX3 mRNA PMID:28433925 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:34372 4,4'-sulfonyldiphenol increases expression ISO RGD:1622280 E RGD:6480464 20191112 CTD MESH:C543008 bisphenol S results in increased expression of AOX3 mRNA PMID:30951980 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:34575 bisphenol F increases expression ISO RGD:1622280 E RGD:6480464 20191112 CTD MESH:C008745 bisphenol F results in increased expression of AOX3 mRNA PMID:30951980 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:34837 methidathion decreases expression ISO RGD:1622280 E RGD:6480464 20220607 CTD MESH:C005828 methidathion results in decreased expression of AOX3 mRNA PMID:34813904 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:34873 N-nitrosodiethylamine decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D004052 Diethylnitrosamine results in decreased expression of AOX3 mRNA PMID:24535843 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:35591 pregnenolone 16alpha-carbonitrile decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D011285 Pregnenolone Carbonitrile results in decreased expression of AOX3 mRNA PMID:28903501 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:36386 dichloroacetic acid decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D003999 Dichloroacetic Acid results in decreased expression of AOX3 mRNA PMID:28962523 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:36904 elemental selenium increases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D012643 Selenium deficiency results in increased expression of AOX3 mRNA; Selenium results in increased expression of AOX3 mRNA PMID:16170372 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:38922 dibenzofurans increases expression ISO RGD:1622280 E RGD:6480464 20230704 CTD MESH:D000072318 Dibenzofurans results in increased expression of AOX3 mRNA PMID:34254344 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:39421 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:1622280 E RGD:6480464 20230502 CTD MESH:C076994 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of AOX3 mRNA; [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of AOX3 mRNA; [perfluorooctane sulfonic acid co-treated with Pectins] results in decreased expression of AOX3 mRNA PMID:36331819 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:39867 valproic acid decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D014635 Valproic Acid results in decreased expression of AOX3 mRNA PMID:24535564 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:4031 cyclosporin A decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D016572 Cyclosporine results in decreased expression of AOX3 mRNA PMID:19770486 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:46195 paracetamol affects expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D000082 Acetaminophen affects the expression of AOX3 mRNA PMID:17562736 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:46195 paracetamol decreases expression ISO RGD:1622280 E RGD:6480464 20190910 CTD MESH:D000082 Acetaminophen results in decreased expression of AOX3 mRNA PMID:29246445 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:46195 paracetamol multiple interactions ISO RGD:1622280 E RGD:6480464 20190910 CTD MESH:D000082 PANX1 gene mutant form inhibits the reaction [Acetaminophen results in decreased expression of AOX3 mRNA] PMID:29246445 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:46502 tungstate decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C045951 tungstate results in decreased expression of AOX3 protein PMID:15664268 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:46502 tungstate multiple interactions ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C045951 tungstate inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AOX3 protein] PMID:15664268 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:47032 1,4-dioxane increases expression ISO RGD:1622280 E RGD:6480464 20211109 CTD MESH:C025223 1,4-dioxane results in increased expression of AOX3 mRNA PMID:33693819 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:47519 ketoconazole decreases expression ISO RGD:1622280 E RGD:6480464 20230606 CTD MESH:D007654 Ketoconazole results in decreased expression of AOX3 mRNA PMID:31099283 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:4811 epoxiconazole decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C109476 epoxiconazole results in decreased expression of AOX3 mRNA PMID:22334560 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:50594 carbon nanotube decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D037742 Nanotubes, Carbon analog results in decreased expression of AOX3 mRNA; Nanotubes, Carbon results in decreased expression of AOX3 mRNA PMID:25554681|PMID:25620056 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:6076 itraconazole decreases expression ISO RGD:1622280 E RGD:6480464 20230606 CTD MESH:D017964 Itraconazole results in decreased expression of AOX3 mRNA PMID:31099283 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:65408 andrographolide multiple interactions ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C030419 [andrographolide co-treated with beta-Naphthoflavone] results in increased expression of AOX3 mRNA PMID:19737545 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:6925 microcystin-LR increases expression ISO RGD:1622280 E RGD:6480464 20231031 CTD MESH:C057862 cyanoginosin LR results in increased expression of AOX3 mRNA PMID:37342990 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:77013 beta-naphthoflavone multiple interactions ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D019324 [andrographolide co-treated with beta-Naphthoflavone] results in increased expression of AOX3 mRNA PMID:19737545 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:8069 phenobarbital affects expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D010634 Phenobarbital affects the expression of AOX3 mRNA PMID:23091169 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:8113 phlorizin decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D010695 Phlorhizin results in decreased expression of AOX3 mRNA PMID:22538082 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:81582 2,4-dibromophenyl 2,4,5-tribromophenyl ether affects expression ISO RGD:1622280 E RGD:6480464 20240903 CTD MESH:C477694 2,2',4,4',5-brominated diphenyl ether affects the expression of AOX3 mRNA PMID:38648751 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:81758 cyproconazole decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C093628 cyproconazole results in decreased expression of AOX3 mRNA PMID:22334560 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:81760 difenoconazole decreases expression ISO RGD:1622280 E RGD:6480464 20230905 CTD MESH:C115058 difenoconazole results in decreased expression of AOX3 mRNA PMID:34425431 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:8489 propiconazole decreases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:C045950 propiconazole results in decreased expression of AOX3 mRNA PMID:21278054|PMID:22334560 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:9141 silver(0) increases expression ISO RGD:1622280 E RGD:6480464 20180424 CTD MESH:D012834 Silver results in increased expression of AOX3 mRNA PMID:27131904 10755376 AOX3P aldehyde oxidase 3, pseudogene gene CHEBI:94366 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-1,2,4-triazol-3-one decreases expression ISO RGD:1622280 E RGD:6480464 20230606 CTD MESH:D017964 Itraconazole results in decreased expression of AOX3 mRNA PMID:31099283 10755390 CYP4F60P cytochrome P450 family 4 subfamily F member 60, pseudogene gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of CYP4F60P mRNA PMID:33212167 10755394 SEPTIN14P20 septin 14 pseudogene 20 gene CHEBI:27899 cisplatin multiple interactions EXP E RGD:6480464 20220308 CTD MESH:D002945 [Cisplatin co-treated with jinfukang] results in decreased expression of SEPTIN14P20 mRNA PMID:27392435 10755394 SEPTIN14P20 septin 14 pseudogene 20 gene CHEBI:28358 rac-lactic acid increases expression EXP E RGD:6480464 20220308 CTD MESH:D019344 Lactic Acid results in increased expression of SEPTIN14P20 mRNA PMID:30851411 10755394 SEPTIN14P20 septin 14 pseudogene 20 gene CHEBI:5063 fipronil increases expression EXP E RGD:6480464 20220308 CTD MESH:C082360 fipronil results in increased expression of SEPTIN14P20 mRNA PMID:28991164 10755394 SEPTIN14P20 septin 14 pseudogene 20 gene CHEBI:53620 methylisothiazolinone increases expression EXP E RGD:6480464 20220308 CTD MESH:C011506 2-methyl-4-isothiazolin-3-one results in increased expression of SEPTIN14P20 mRNA PMID:31629900 10755394 SEPTIN14P20 septin 14 pseudogene 20 gene CHEBI:78320 2-hydroxypropanoic acid increases expression EXP E RGD:6480464 20220308 CTD MESH:D019344 Lactic Acid results in increased expression of SEPTIN14P20 mRNA PMID:30851411 10755591 UPK3BP1 uroplakin 3B pseudogene 1 gene CHEBI:31575 ethylparaben increases expression EXP E RGD:6480464 20240109 CTD MESH:C012313 ethyl-p-hydroxybenzoate results in increased expression of UPK3BP1 mRNA PMID:37690743 10755593 PDZPH1P PDZ and pleckstrin homology domains 1, pseudogene gene CHEBI:132471 (+)-schisandrin B multiple interactions ISO RGD:1560925 E RGD:6480464 20220510 CTD MESH:C015499 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of PDZPH1 mRNA] PMID:31150632 10755593 PDZPH1P PDZ and pleckstrin homology domains 1, pseudogene gene CHEBI:16236 ethanol increases expression ISO RGD:1621522 E RGD:6480464 20190507 CTD MESH:D000431 Ethanol results in increased expression of PDZPH1 mRNA PMID:30319688 10755593 PDZPH1P PDZ and pleckstrin homology domains 1, pseudogene gene CHEBI:16602 trichloroethene increases expression ISO RGD:1560925 E RGD:6480464 20220510 CTD MESH:D014241 Trichloroethylene results in increased expression of PDZPH1 mRNA PMID:33387578 10755593 PDZPH1P PDZ and pleckstrin homology domains 1, pseudogene gene CHEBI:27385 tetrachloromethane decreases expression ISO RGD:1560925 E RGD:6480464 20220510 CTD MESH:D002251 Carbon Tetrachloride results in decreased expression of PDZPH1 mRNA PMID:31150632 10755593 PDZPH1P PDZ and pleckstrin homology domains 1, pseudogene gene CHEBI:27385 tetrachloromethane multiple interactions ISO RGD:1560925 E RGD:6480464 20220510 CTD MESH:D002251 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of PDZPH1 mRNA] PMID:31150632 10755593 PDZPH1P PDZ and pleckstrin homology domains 1, pseudogene gene CHEBI:28088 genistein decreases expression ISO RGD:1621522 E RGD:6480464 20200804 CTD MESH:D019833 Genistein results in decreased expression of PDZPH1 mRNA PMID:32186404 10755593 PDZPH1P PDZ and pleckstrin homology domains 1, pseudogene gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1560925 E RGD:6480464 20220510 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of PDZPH1 mRNA PMID:20059583 10755593 PDZPH1P PDZ and pleckstrin homology domains 1, pseudogene gene CHEBI:31941 oxaliplatin increases expression ISO RGD:1560925 E RGD:6480464 20220510 CTD MESH:C030110 Oxaliplatin results in increased expression of PDZPH1 mRNA PMID:25729387 10755593 PDZPH1P PDZ and pleckstrin homology domains 1, pseudogene gene CHEBI:31941 oxaliplatin multiple interactions ISO RGD:1560925 E RGD:6480464 20220510 CTD MESH:C030110 [Oxaliplatin co-treated with Topotecan] results in increased expression of PDZPH1 mRNA PMID:25729387 10755593 PDZPH1P PDZ and pleckstrin homology domains 1, pseudogene gene CHEBI:33216 bisphenol A decreases expression ISO RGD:1560925 E RGD:6480464 20220510 CTD MESH:C006780 bisphenol A results in decreased expression of PDZPH1 mRNA PMID:25181051 10755593 PDZPH1P PDZ and pleckstrin homology domains 1, pseudogene gene CHEBI:63632 topotecan multiple interactions ISO RGD:1560925 E RGD:6480464 20220510 CTD MESH:D019772 [Oxaliplatin co-treated with Topotecan] results in increased expression of PDZPH1 mRNA PMID:25729387 10755593 PDZPH1P PDZ and pleckstrin homology domains 1, pseudogene gene CHEBI:6842 methoxychlor affects methylation ISO RGD:1560925 E RGD:6480464 20230905 CTD MESH:D008731 Methoxychlor affects the methylation of PDZPH1 gene PMID:35440735 10755662 SMURF2P1 SMAD specific E3 ubiquitin protein ligase 2 pseudogene 1 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of SMURF2P1 mRNA PMID:33212167 10755670 CDK2AP2P2 cyclin dependent kinase 2 associated protein 2 pseudogene 2 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of CDK2AP2P2 mRNA PMID:35811015 10755670 CDK2AP2P2 cyclin dependent kinase 2 associated protein 2 pseudogene 2 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of CDK2AP2P2 mRNA PMID:35811015 10768917 GTF2IP7 general transcription factor IIi pseudogene 7 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of GTF2IP7 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of GTF2IP7 mRNA PMID:35811015 10768917 GTF2IP7 general transcription factor IIi pseudogene 7 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of GTF2IP7 mRNA PMID:35811015 10768917 GTF2IP7 general transcription factor IIi pseudogene 7 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of GTF2IP7 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of GTF2IP7 mRNA PMID:35811015 10769049 GTF2IP12 general transcription factor IIi pseudogene 12 gene CHEBI:28619 acrylamide increases expression EXP E RGD:6480464 20210406 CTD MESH:D020106 Acrylamide results in increased expression of GTF2IP12 mRNA PMID:32763439 10769213 GTF2IP13 general transcription factor IIi pseudogene 13 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of GTF2IP13 mRNA PMID:33212167 10769213 GTF2IP13 general transcription factor IIi pseudogene 13 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of GTF2IP13 mRNA PMID:38568856 10769319 CLEC12A-AS1 CLEC12A antisense RNA 1 gene CHEBI:28619 acrylamide increases expression EXP E RGD:6480464 20210406 CTD MESH:D020106 Acrylamide results in increased expression of CLEC12A-AS1 mRNA PMID:32763439 11038749 LINC01460 long intergenic non-protein coding RNA 1460 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of LINC01460 mRNA PMID:33212167 11038760 NOC2LP1 NOC2 like nucleolar associated transcriptional repressor pseudogene 1 gene CHEBI:31575 ethylparaben increases expression EXP E RGD:6480464 20240109 CTD MESH:C012313 ethyl-p-hydroxybenzoate results in increased expression of NOC2LP1 mRNA PMID:37690743 11038760 NOC2LP1 NOC2 like nucleolar associated transcriptional repressor pseudogene 1 gene CHEBI:7553 niclosamide decreases expression EXP E RGD:6480464 20230704 CTD MESH:D009534 Niclosamide results in decreased expression of NOC2LP1 mRNA PMID:36318118 11039061 LINC00863 long intergenic non-protein coding RNA 863 gene CHEBI:16469 17beta-estradiol decreases expression EXP E RGD:6480464 20220308 CTD MESH:D004958 Estradiol results in decreased expression of LINC00863 mRNA PMID:31614463 11039061 LINC00863 long intergenic non-protein coding RNA 863 gene CHEBI:16598 DDE decreases expression EXP E RGD:6480464 20240702 CTD MESH:D003633 Dichlorodiphenyl Dichloroethylene results in decreased expression of LINC00863 mRNA PMID:38568856 11039061 LINC00863 long intergenic non-protein coding RNA 863 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of LINC00863 mRNA PMID:33212167 11039061 LINC00863 long intergenic non-protein coding RNA 863 gene CHEBI:39867 valproic acid decreases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in decreased methylation of LINC00863 gene PMID:29154799 11039061 LINC00863 long intergenic non-protein coding RNA 863 gene CHEBI:5063 fipronil multiple interactions EXP E RGD:6480464 20190219 CTD MESH:C082360 [fipronil co-treated with DEET] results in increased expression of LINC00863 mRNA PMID:28991164 11039061 LINC00863 long intergenic non-protein coding RNA 863 gene CHEBI:7071 N,N-diethyl-m-toluamide multiple interactions EXP E RGD:6480464 20190219 CTD MESH:D003671 [fipronil co-treated with DEET] results in increased expression of LINC00863 mRNA PMID:28991164 11039065 LINC00543 long intergenic non-protein coding RNA 543 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC00543 promoter PMID:30157460 11039065 LINC00543 long intergenic non-protein coding RNA 543 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in decreased expression of LINC00543 mRNA PMID:29301061 11039065 LINC00543 long intergenic non-protein coding RNA 543 gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of LINC00543 mRNA PMID:32234424 11039094 LINC01451 long intergenic non-protein coding RNA 1451 gene CHEBI:28358 rac-lactic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of LINC01451 mRNA PMID:30851411 11039094 LINC01451 long intergenic non-protein coding RNA 1451 gene CHEBI:78320 2-hydroxypropanoic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of LINC01451 mRNA PMID:30851411 11039105 LINC01376 long intergenic non-protein coding RNA 1376 gene CHEBI:28358 rac-lactic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of LINC01376 mRNA PMID:30851411 11039105 LINC01376 long intergenic non-protein coding RNA 1376 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in decreased expression of LINC01376 mRNA PMID:29301061|PMID:34032870 11039105 LINC01376 long intergenic non-protein coding RNA 1376 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LINC01376 mRNA PMID:38568856 11039105 LINC01376 long intergenic non-protein coding RNA 1376 gene CHEBI:78320 2-hydroxypropanoic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of LINC01376 mRNA PMID:30851411 11039126 CASC22 cancer susceptibility 22 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in decreased expression of CASC22 mRNA PMID:29301061 11039174 SEMA3F-AS1 SEMA3F antisense RNA 1 gene CHEBI:28077 rifampicin decreases expression EXP E RGD:6480464 20160412 CTD MESH:D012293 Rifampin results in decreased expression of SEMA3F-AS1 mRNA PMID:24552687 11039187 BFSP2-AS1 BFSP2 antisense RNA 1 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of BFSP2-AS1 promoter PMID:30157460 11039187 BFSP2-AS1 BFSP2 antisense RNA 1 gene CHEBI:35842 antirheumatic drug decreases expression EXP E RGD:6480464 20161228 CTD MESH:D018501 Antirheumatic Agents results in decreased expression of BFSP2-AS1 mRNA PMID:24449571 11039187 BFSP2-AS1 BFSP2 antisense RNA 1 gene CHEBI:44185 methotrexate increases expression EXP E RGD:6480464 20160308 CTD MESH:D008727 Methotrexate results in increased expression of BFSP2-AS1 mRNA PMID:24449571 11039274 GCC2-AS1 GCC2 antisense RNA 1 gene CHEBI:29191 hydroxyl multiple interactions EXP E RGD:6480464 20211109 CTD MESH:D017665 [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GCC2-AS1 mRNA] which results in increased expression of GCC2 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GCC2-AS1 mRNA PMID:33656867 11039274 GCC2-AS1 GCC2 antisense RNA 1 gene CHEBI:4610 dimethylselenide multiple interactions EXP E RGD:6480464 20211109 CTD MESH:C013503 [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GCC2-AS1 mRNA] which results in increased expression of GCC2 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GCC2-AS1 mRNA PMID:33656867 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:132267 triptonide increases expression ISO RGD:1550275 E RGD:6480464 20210406 CTD MESH:C084079 triptonide results in increased expression of CYP2C23 mRNA PMID:33045310 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:1367 3,3',4,4'-tetrachlorobiphenyl multiple interactions ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:C028451 3,4,3',4'-tetrachlorobiphenyl inhibits the reaction [Dietary Fats results in increased expression of CYP2C23 mRNA] PMID:19467301 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:15443 inulin multiple interactions ISO RGD:1550275 E RGD:6480464 20230502 CTD MESH:D007444 [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of CYP2C23 mRNA PMID:36331819 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:15843 arachidonic acid multiple interactions ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D016718 CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK3 protein] PMID:19464254 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:17241 1H-pyrazole decreases expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:C031280 pyrazole results in decreased expression of CYP2C23 mRNA PMID:17945193 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:17300 tetrachloroethene increases expression ISO RGD:1550275 E RGD:6480464 20180116 CTD MESH:D013750 Tetrachloroethylene results in increased expression of CYP2C23 mRNA PMID:28973375 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:17963 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine increases expression ISO RGD:1550275 E RGD:6480464 20180828 CTD MESH:D015632 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CYP2C23 mRNA PMID:29627306 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:232612 Azoxymethane multiple interactions ISO RGD:1550275 E RGD:6480464 20241203 CTD MESH:D001397 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2C23 mRNA PMID:29950665 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:2504 aflatoxin B1 decreases expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D016604 Aflatoxin B1 results in decreased expression of CYP2C23 mRNA PMID:19770486 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:27385 tetrachloromethane decreases expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D002251 Carbon Tetrachloride results in decreased expression of CYP2C23 mRNA PMID:27339419|PMID:31919559 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:27881 resveratrol multiple interactions ISO RGD:1550275 E RGD:6480464 20200211 CTD MESH:C059514 Resveratrol inhibits the reaction [titanium dioxide results in decreased expression of CYP2C23 mRNA] PMID:31298478 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:27999 tolbutamide increases metabolic processing ISO RGD:1550275 E RGD:6480464 20190409 CTD MESH:D014044 CYP2C23 protein results in increased metabolism of Tolbutamide PMID:30503582 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:27999 tolbutamide multiple interactions ISO RGD:1550275 E RGD:6480464 20190409 CTD MESH:D014044 [CYP2C23 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide PMID:30503582 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:28001 vancomycin increases expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D014640 Vancomycin results in increased expression of CYP2C23 mRNA PMID:18930951 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of CYP2C23 mRNA PMID:26377647 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of CYP2C23 mRNA PMID:28213091 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D013749 Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP2C23 gene] PMID:28213091 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:28748 doxorubicin increases expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D004317 Doxorubicin results in increased expression of CYP2C23 mRNA PMID:26873546 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:28748 doxorubicin multiple interactions ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D004317 [Doxorubicin co-treated with Dexrazoxane] results in decreased expression of CYP2C23 mRNA PMID:26873546 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:30563 silicon dioxide decreases expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D012822 Silicon Dioxide results in decreased expression of CYP2C23 mRNA PMID:23221170 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:32234 titanium dioxide decreases expression ISO RGD:1550275 E RGD:6480464 20200211 CTD MESH:C009495 titanium dioxide results in decreased expression of CYP2C23 mRNA PMID:31298478 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:32234 titanium dioxide multiple interactions ISO RGD:1550275 E RGD:6480464 20190702 CTD MESH:C009495 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2C23 mRNA; Resveratrol inhibits the reaction [titanium dioxide results in decreased expression of CYP2C23 mRNA] PMID:29950665|PMID:31298478 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:32509 pirinixic acid decreases expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:C006253 pirinixic acid results in decreased expression of CYP2C23 mRNA; pirinixic acid results in decreased expression of CYP2C23 protein PMID:17405874|PMID:20813756|PMID:23811191 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:32509 pirinixic acid increases expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:C006253 pirinixic acid results in increased expression of CYP2C23 mRNA PMID:17426115 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:32509 pirinixic acid multiple interactions ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:C006253 [pirinixic acid co-treated with PPARA] results in decreased expression of CYP2C23 mRNA; PPARA protein affects the reaction [pirinixic acid results in decreased expression of CYP2C23 mRNA] PMID:17405874|PMID:20813756 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:33216 bisphenol A decreases expression ISO RGD:1550275 E RGD:6480464 20220208 CTD MESH:C006780 bisphenol A results in decreased expression of CYP2C23 mRNA PMID:33221593 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:33216 bisphenol A increases expression ISO RGD:1550275 E RGD:6480464 20230207 CTD MESH:C006780 bisphenol A results in increased expression of CYP2C23 mRNA PMID:32156529 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:34674 dextran sulfate multiple interactions ISO RGD:1550275 E RGD:6480464 20190702 CTD MESH:D016264 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2C23 mRNA PMID:29950665 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:35591 pregnenolone 16alpha-carbonitrile decreases expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D011285 Pregnenolone Carbonitrile results in decreased expression of CYP2C23 mRNA PMID:27413110 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:39421 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:1550275 E RGD:6480464 20230502 CTD MESH:C076994 [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of CYP2C23 mRNA PMID:36331819 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:39478 buta-1,3-diene decreases expression ISO RGD:1550275 E RGD:6480464 20180703 CTD MESH:C031763 1,3-butadiene results in decreased expression of CYP2C23 mRNA PMID:29038090 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:41774 tamoxifen decreases expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D013629 Tamoxifen results in decreased expression of CYP2C23 mRNA PMID:25123088 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:46195 paracetamol affects expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D000082 Acetaminophen affects the expression of CYP2C23 mRNA PMID:17562736 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:46195 paracetamol decreases expression ISO RGD:1550275 E RGD:6480464 20190910 CTD MESH:D000082 Acetaminophen results in decreased expression of CYP2C23 mRNA PMID:29246445 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:46195 paracetamol multiple interactions ISO RGD:1550275 E RGD:6480464 20190910 CTD MESH:D000082 PANX1 gene mutant form inhibits the reaction [Acetaminophen results in decreased expression of CYP2C23 mRNA] PMID:29246445 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:47381 diclofenac decreases expression ISO RGD:1550275 E RGD:6480464 20180313 CTD MESH:D004008 Diclofenac results in decreased expression of CYP2C23 mRNA PMID:26934552 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:50223 (+)-dexrazoxane multiple interactions ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D064730 [Doxorubicin co-treated with Dexrazoxane] results in decreased expression of CYP2C23 mRNA PMID:26873546 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:50594 carbon nanotube decreases expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D037742 Nanotubes, Carbon results in decreased expression of CYP2C23 mRNA PMID:25620056 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:63618 pravastatin decreases expression ISO RGD:1550275 E RGD:6480464 20180220 CTD MESH:D017035 Pravastatin results in decreased expression of CYP2C23 mRNA PMID:27225895 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:63799 4-hydroxytolbutamide multiple interactions ISO RGD:1550275 E RGD:6480464 20190409 CTD MESH:C031014 [CYP2C23 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide PMID:30503582 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:73755 1,2-dimethylhydrazine decreases expression ISO RGD:1550275 E RGD:6480464 20200804 CTD MESH:D019813 1,2-Dimethylhydrazine results in decreased expression of CYP2C23 mRNA PMID:22206623 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:75170 zaragozic acid A decreases expression ISO RGD:1550275 E RGD:6480464 20180220 CTD MESH:C075117 squalestatin 1 results in decreased expression of CYP2C23 mRNA PMID:27225895 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:8069 phenobarbital affects expression ISO RGD:1550275 E RGD:6480464 20171212 CTD MESH:D010634 Phenobarbital affects the expression of CYP2C23 mRNA PMID:23091169 11041837 CYP2C23P cytochrome P450 family 2 subfamily C member 23, pseudogene gene CHEBI:81582 2,4-dibromophenyl 2,4,5-tribromophenyl ether affects expression ISO RGD:1550275 E RGD:6480464 20240903 CTD MESH:C477694 2,2',4,4',5-brominated diphenyl ether affects the expression of CYP2C23 mRNA PMID:38648751 11052114 LY6L lymphocyte antigen 6 family member L gene CHEBI:16469 17beta-estradiol multiple interactions ISO RGD:1597652 E RGD:6480464 20210406 CTD MESH:D004958 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY6L mRNA PMID:32741896 11052114 LY6L lymphocyte antigen 6 family member L gene CHEBI:17347 testosterone multiple interactions ISO RGD:1597652 E RGD:6480464 20210406 CTD MESH:D013739 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY6L mRNA PMID:32741896 11052114 LY6L lymphocyte antigen 6 family member L gene CHEBI:177802 Cuprizon decreases expression ISO RGD:1597652 E RGD:6480464 20210907 CTD MESH:D003471 Cuprizone results in decreased expression of LY6L mRNA PMID:27523638 11052114 LY6L lymphocyte antigen 6 family member L gene CHEBI:34905 paraquat decreases expression ISO RGD:1597652 E RGD:6480464 20210907 CTD MESH:D010269 Paraquat results in decreased expression of LY6L mRNA PMID:32680482 11052114 LY6L lymphocyte antigen 6 family member L gene CHEBI:77006 17beta-estradiol 3-benzoate multiple interactions ISO RGD:1597652 E RGD:6480464 20210406 CTD MESH:C074283 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY6L mRNA PMID:32741896 11081057 ATXN2-AS ATXN2 antisense RNA gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of ATXN2-AS mRNA PMID:32234424 11084732 LINC01630 long intergenic non-protein coding RNA 1630 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01630 mRNA PMID:38568856 11084732 LINC01630 long intergenic non-protein coding RNA 1630 gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of LINC01630 mRNA PMID:32234424 11084732 LINC01630 long intergenic non-protein coding RNA 1630 gene CHEBI:31638 fulvestrant multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C070081 [bisphenol A co-treated with Fulvestrant] results in increased methylation of LINC01630 gene PMID:31601247 11084732 LINC01630 long intergenic non-protein coding RNA 1630 gene CHEBI:33216 bisphenol A multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C006780 [bisphenol A co-treated with Fulvestrant] results in increased methylation of LINC01630 gene PMID:31601247 11084743 LINC01931 long intergenic non-protein coding RNA 1931 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of LINC01931 mRNA PMID:34032870 11084743 LINC01931 long intergenic non-protein coding RNA 1931 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01931 mRNA PMID:29301061 11084743 LINC01931 long intergenic non-protein coding RNA 1931 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of LINC01931 mRNA PMID:35811015 11084824 LIPC-AS1 LIPC antisense RNA 1 gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of LIPC-AS1 intron PMID:30157460 11084824 LIPC-AS1 LIPC antisense RNA 1 gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of LIPC-AS1 intron PMID:30157460 11120594 OSTM1-AS1 OSTM1 antisense RNA 1 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of OSTM1-AS1 intron PMID:30157460 11231739 GASAL1 growth arrest associated lncRNA 1 gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of GASAL1 mRNA PMID:38218311 11231739 GASAL1 growth arrest associated lncRNA 1 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of GASAL1 mRNA PMID:33212167 11231739 GASAL1 growth arrest associated lncRNA 1 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in increased expression of GASAL1 mRNA PMID:34032870 11324 TAGLN transgelin gene CHEBI:10033 warfarin multiple interactions ISO RGD:11323 E RGD:6480464 20141111 CTD MESH:D014859 [Warfarin co-treated with Vitamin K 1] results in decreased expression of TAGLN mRNA PMID:23990204 11324 TAGLN transgelin gene CHEBI:10033 warfarin multiple interactions ISO RGD:3723 E RGD:6480464 20170725 CTD MESH:D014859 [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of TAGLN mRNA PMID:23117658 11324 TAGLN transgelin gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of TAGLN mRNA PMID:38218311 11324 TAGLN transgelin gene CHEBI:116509 diuron decreases expression ISO RGD:3723 E RGD:6480464 20120412 CTD MESH:D004237 Diuron results in decreased expression of TAGLN mRNA PMID:21551480 11324 TAGLN transgelin gene CHEBI:116509 diuron increases expression ISO RGD:3723 E RGD:6480464 20120412 CTD MESH:D004237 Diuron results in increased expression of TAGLN mRNA PMID:21551480 11324 TAGLN transgelin gene CHEBI:132082 entinostat decreases expression EXP E RGD:6480464 20161228 CTD MESH:C118739 entinostat results in decreased expression of TAGLN mRNA PMID:26272509 11324 TAGLN transgelin gene CHEBI:132082 entinostat multiple interactions EXP E RGD:6480464 20161228 CTD MESH:C118739 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TAGLN mRNA PMID:27188386 11324 TAGLN transgelin gene CHEBI:132267 triptonide increases expression ISO RGD:11323 E RGD:6480464 20210406 CTD MESH:C084079 triptonide results in increased expression of TAGLN mRNA PMID:33045310 11324 TAGLN transgelin gene CHEBI:135357 zimeldine decreases expression EXP E RGD:6480464 20170307 CTD MESH:D015031 Zimeldine results in decreased expression of TAGLN mRNA PMID:15342952|PMID:17175557 11324 TAGLN transgelin gene CHEBI:136608 Theaflavin 3,3'-digallate multiple interactions ISO RGD:3723 E RGD:6480464 20240402 CTD MESH:C585473 theaflavin-3,3'-digallate inhibits the reaction [PDGFBB protein results in decreased expression of TAGLN protein] PMID:35903325 11324 TAGLN transgelin gene CHEBI:15354 choline multiple interactions ISO RGD:11323 E RGD:6480464 20121113 CTD MESH:D002794 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of TAGLN mRNA PMID:20938992 11324 TAGLN transgelin gene CHEBI:15367 all-trans-retinoic acid affects expression EXP E RGD:6480464 20120515 CTD MESH:D014212 Tretinoin affects the expression of TAGLN mRNA PMID:15498508 11324 TAGLN transgelin gene CHEBI:15367 all-trans-retinoic acid increases expression EXP E RGD:6480464 20120412 CTD MESH:D014212 Tretinoin results in increased expression of TAGLN mRNA PMID:17069765 11324 TAGLN transgelin gene CHEBI:15367 all-trans-retinoic acid increases expression ISO RGD:3723 E RGD:6480464 20120412 CTD MESH:D014212 Tretinoin results in increased expression of TAGLN mRNA; Tretinoin results in increased expression of TAGLN protein PMID:17151820 11324 TAGLN transgelin gene CHEBI:15367 all-trans-retinoic acid multiple interactions ISO RGD:11323 E RGD:6480464 20191112 CTD MESH:D014212 [bisphenol A co-treated with Tretinoin] results in decreased expression of TAGLN mRNA; [bisphenol F co-treated with Tretinoin] results in decreased expression of TAGLN mRNA PMID:30951980 11324 TAGLN transgelin gene CHEBI:15368 acrolein multiple interactions EXP E RGD:6480464 20210112 CTD MESH:D000171 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of TAGLN mRNA; [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of TAGLN mRNA PMID:32699268 11324 TAGLN transgelin gene CHEBI:15379 dioxygen multiple interactions EXP E RGD:6480464 20140408 CTD MESH:D010100 Oxygen deficiency inhibits the reaction [darinaparsin results in increased expression of TAGLN mRNA] PMID:22535156 11324 TAGLN transgelin gene CHEBI:15743 butanal increases expression EXP E RGD:6480464 20150825 CTD MESH:C018475 butyraldehyde results in increased expression of TAGLN mRNA PMID:26079696 11324 TAGLN transgelin gene CHEBI:16236 ethanol decreases expression EXP E RGD:6480464 20190611 CTD MESH:D000431 Ethanol results in decreased expression of TAGLN mRNA PMID:31059573 11324 TAGLN transgelin gene CHEBI:16236 ethanol multiple interactions EXP E RGD:6480464 20181016 CTD MESH:D000431 [[Gasoline co-treated with Ethanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TAGLN mRNA PMID:29432896 11324 TAGLN transgelin gene CHEBI:16240 hydrogen peroxide increases expression EXP E RGD:6480464 20210810 CTD MESH:D006861 Hydrogen Peroxide results in increased expression of TAGLN mRNA PMID:32949572 11324 TAGLN transgelin gene CHEBI:16243 quercetin increases expression EXP E RGD:6480464 20121009 CTD MESH:D011794 Quercetin results in increased expression of TAGLN mRNA PMID:21632981 11324 TAGLN transgelin gene CHEBI:16243 quercetin increases expression ISO RGD:3723 E RGD:6480464 20170725 CTD MESH:D011794 Quercetin results in increased expression of TAGLN mRNA PMID:23117658 11324 TAGLN transgelin gene CHEBI:16243 quercetin multiple interactions ISO RGD:3723 E RGD:6480464 20170725 CTD MESH:D011794 [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of TAGLN mRNA PMID:23117658 11324 TAGLN transgelin gene CHEBI:164200 triclosan decreases expression EXP E RGD:6480464 20190507 CTD MESH:D014260 Triclosan results in decreased expression of TAGLN mRNA PMID:30510588 11324 TAGLN transgelin gene CHEBI:16469 17beta-estradiol affects expression EXP E RGD:6480464 20121218 CTD MESH:D004958 Estradiol affects the expression of TAGLN mRNA PMID:22574217 11324 TAGLN transgelin gene CHEBI:16469 17beta-estradiol increases expression ISO RGD:3723 E RGD:6480464 20230606 CTD MESH:D004958 Estradiol results in increased expression of TAGLN mRNA PMID:32145629 11324 TAGLN transgelin gene CHEBI:16469 17beta-estradiol multiple interactions EXP E RGD:6480464 20130910 CTD MESH:D004958 [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TAGLN mRNA; [Estradiol co-treated with TGFB1 protein] results in increased expression of TAGLN mRNA PMID:20823114|PMID:30165855 11324 TAGLN transgelin gene CHEBI:16469 17beta-estradiol multiple interactions ISO RGD:3723 E RGD:6480464 20160705 CTD MESH:D004958 [bisphenol A co-treated with Estradiol] results in decreased expression of TAGLN mRNA PMID:26496021 11324 TAGLN transgelin gene CHEBI:16602 trichloroethene decreases expression ISO RGD:3723 E RGD:6480464 20211207 CTD MESH:D014241 Trichloroethylene results in decreased expression of TAGLN mRNA PMID:33387578 11324 TAGLN transgelin gene CHEBI:16643 L-methionine multiple interactions ISO RGD:11323 E RGD:6480464 20121113 CTD MESH:D008715 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of TAGLN mRNA PMID:20938992 11324 TAGLN transgelin gene CHEBI:16842 formaldehyde increases expression EXP E RGD:6480464 20170207 CTD MESH:D005557 Formaldehyde results in increased expression of TAGLN mRNA PMID:27664576 11324 TAGLN transgelin gene CHEBI:17026 progesterone decreases expression EXP E RGD:6480464 20120412 CTD MESH:D011374 Progesterone results in decreased expression of TAGLN mRNA PMID:18037150 11324 TAGLN transgelin gene CHEBI:17234 glucose increases secretion EXP E RGD:6480464 20160822 CTD MESH:D005947 Glucose deficiency results in increased secretion of TAGLN protein PMID:24802182 11324 TAGLN transgelin gene CHEBI:17578 toluene increases expression ISO RGD:3723 E RGD:6480464 20140408 CTD MESH:D014050 Toluene results in increased expression of TAGLN mRNA PMID:22967744 11324 TAGLN transgelin gene CHEBI:17634 D-glucose increases secretion EXP E RGD:6480464 20160822 CTD MESH:D005947 Glucose deficiency results in increased secretion of TAGLN protein PMID:24802182 11324 TAGLN transgelin gene CHEBI:17747 bis(2-ethylhexyl) phthalate increases expression EXP E RGD:6480464 20190910 CTD MESH:D004051 Diethylhexyl Phthalate results in increased expression of TAGLN mRNA PMID:31163220 11324 TAGLN transgelin gene CHEBI:177802 Cuprizon increases expression ISO RGD:3723 E RGD:6480464 20210907 CTD MESH:D003471 Cuprizone results in increased expression of TAGLN mRNA PMID:26577399 11324 TAGLN transgelin gene CHEBI:17833 gentamycin increases expression ISO RGD:3723 E RGD:6480464 20211207 CTD MESH:D005839 Gentamicins results in increased expression of TAGLN mRNA PMID:33387578 11324 TAGLN transgelin gene CHEBI:17967 urethane decreases expression EXP E RGD:6480464 20171114 CTD MESH:D014520 Urethane results in decreased expression of TAGLN mRNA PMID:28818685 11324 TAGLN transgelin gene CHEBI:18067 phylloquinone multiple interactions ISO RGD:11323 E RGD:6480464 20140408 CTD MESH:D010837 [Warfarin co-treated with Vitamin K 1] results in decreased expression of TAGLN mRNA PMID:23990204 11324 TAGLN transgelin gene CHEBI:18088 formononetin decreases expression EXP E RGD:6480464 20240402 CTD MESH:C007768 formononetin results in decreased expression of TAGLN mRNA PMID:37793997 11324 TAGLN transgelin gene CHEBI:188851 Muraglitazar decreases expression ISO RGD:3723 E RGD:6480464 20220104 CTD MESH:C500085 muraglitazar results in decreased expression of TAGLN mRNA PMID:21515302 11324 TAGLN transgelin gene CHEBI:193591 Didecyldimethylammonium decreases expression EXP E RGD:6480464 20221018 CTD MESH:C027118 didecyldimethylammonium results in decreased expression of TAGLN mRNA PMID:32763356 11324 TAGLN transgelin gene CHEBI:207229 dihydroartemisinin affects binding EXP E RGD:6480464 20170303 CTD MESH:C039060 artenimol analog binds to TAGLN protein PMID:26340163 11324 TAGLN transgelin gene CHEBI:22977 cadmium atom multiple interactions ISO RGD:11323 E RGD:6480464 20231205 CTD MESH:D002104 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of TAGLN mRNA PMID:37325564 11324 TAGLN transgelin gene CHEBI:23414 copper(II) sulfate increases expression EXP E RGD:6480464 20120814 CTD MESH:D019327 Copper Sulfate results in increased expression of TAGLN mRNA PMID:19549813 11324 TAGLN transgelin gene CHEBI:23808 dimethylarsinous acid increases expression EXP E RGD:6480464 20170303 CTD MESH:C472511 dimethylarsinous acid results in increased expression of TAGLN mRNA PMID:23876855 11324 TAGLN transgelin gene CHEBI:2504 aflatoxin B1 increases expression EXP E RGD:6480464 20161025 CTD MESH:D016604 Aflatoxin B1 results in increased expression of TAGLN mRNA PMID:27153756 11324 TAGLN transgelin gene CHEBI:25434 bis(2-chloroethyl) sulfide decreases expression EXP E RGD:6480464 20210608 CTD MESH:D009151 Mustard Gas results in decreased expression of TAGLN mRNA PMID:33491125 11324 TAGLN transgelin gene CHEBI:254496 7,12-dimethyltetraphene multiple interactions ISO RGD:3723 E RGD:6480464 20120918 CTD MESH:D015127 [9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of TAGLN protein PMID:22248470 11324 TAGLN transgelin gene CHEBI:25812 ozone multiple interactions EXP E RGD:6480464 20210112 CTD MESH:D010126 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of TAGLN mRNA; [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of TAGLN mRNA; [Volatile Organic Compounds co-treated with Ozone] results in increased oxidation of TAGLN mRNA PMID:32699268 11324 TAGLN transgelin gene CHEBI:2663 amiodarone decreases expression EXP E RGD:6480464 20121113 CTD MESH:D000638 Amiodarone results in decreased expression of TAGLN mRNA PMID:17175557|PMID:17567588 11324 TAGLN transgelin gene CHEBI:2666 amitriptyline decreases expression EXP E RGD:6480464 20121113 CTD MESH:D000639 Amitriptyline results in decreased expression of TAGLN mRNA PMID:15342952|PMID:17175557|PMID:17567588 11324 TAGLN transgelin gene CHEBI:26710 sodium chloride multiple interactions EXP E RGD:6480464 20250114 CTD MESH:D012965 [Sodium Chloride co-treated with Furaldehyde] results in decreased expression of and affects the localization of TAGLN protein; [Sodium Chloride co-treated with Furaldehyde] results in increased expression of TAGLN protein; [Sodium Chloride co-treated with pyrogallol 1,3-dimethyl ether] results in decreased expression of TAGLN protein; [Sodium Chloride co-treated with pyrogallol 1,3-dimethyl ether] results in increased expression of and affects the localization of TAGLN protein PMID:38598786 11324 TAGLN transgelin gene CHEBI:2679 amphetamine increases expression ISO RGD:3723 E RGD:6480464 20191114 CTD MESH:D000661 Amphetamine results in increased expression of TAGLN mRNA PMID:30779732 11324 TAGLN transgelin gene CHEBI:27385 tetrachloromethane increases expression ISO RGD:11323 E RGD:6480464 20200804 CTD MESH:D002251 Carbon Tetrachloride results in increased expression of TAGLN mRNA PMID:31919559 11324 TAGLN transgelin gene CHEBI:27470 folic acid affects expression EXP E RGD:6480464 20120412 CTD MESH:D005492 Folic Acid affects the expression of TAGLN mRNA PMID:17320366 11324 TAGLN transgelin gene CHEBI:27470 folic acid decreases expression EXP E RGD:6480464 20200804 CTD MESH:D005492 Folic Acid results in decreased expression of TAGLN mRNA PMID:27293554 11324 TAGLN transgelin gene CHEBI:27470 folic acid decreases expression ISO RGD:11323 E RGD:6480464 20200804 CTD MESH:D005492 Folic Acid results in decreased expression of TAGLN mRNA PMID:25629700 11324 TAGLN transgelin gene CHEBI:27470 folic acid multiple interactions ISO RGD:11323 E RGD:6480464 20121113 CTD MESH:D005492 [1,2-Dimethylhydrazine co-treated with Folic Acid] results in increased expression of TAGLN mRNA; [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of TAGLN mRNA PMID:20938992|PMID:22206623 11324 TAGLN transgelin gene CHEBI:27563 arsenic atom affects expression EXP E RGD:6480464 20120412 CTD MESH:D001151 Arsenic affects the expression of TAGLN mRNA PMID:18414638 11324 TAGLN transgelin gene CHEBI:2762 antimycin A increases expression EXP E RGD:6480464 20210810 CTD MESH:D000968 Antimycin A results in increased expression of TAGLN mRNA PMID:33512557 11324 TAGLN transgelin gene CHEBI:27684 phenylmercury acetate increases expression EXP E RGD:6480464 20160119 CTD MESH:D010662 Phenylmercuric Acetate results in increased expression of TAGLN mRNA PMID:26272509 11324 TAGLN transgelin gene CHEBI:27684 phenylmercury acetate multiple interactions EXP E RGD:6480464 20161025 CTD MESH:D010662 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA PMID:27188386 11324 TAGLN transgelin gene CHEBI:27732 caffeine increases phosphorylation EXP E RGD:6480464 20221004 CTD MESH:D002110 Caffeine results in increased phosphorylation of TAGLN protein PMID:35688186 11324 TAGLN transgelin gene CHEBI:27810 resorcinol decreases expression EXP E RGD:6480464 20171114 CTD MESH:C031389 resorcinol results in decreased expression of TAGLN mRNA PMID:22623647 11324 TAGLN transgelin gene CHEBI:27881 resveratrol decreases expression ISO RGD:3723 E RGD:6480464 20120918 CTD MESH:C059514 resveratrol results in decreased expression of TAGLN mRNA PMID:20797428 11324 TAGLN transgelin gene CHEBI:27899 cisplatin affects expression EXP E RGD:6480464 20140513 CTD MESH:D002945 Cisplatin affects the expression of TAGLN mRNA PMID:23300844 11324 TAGLN transgelin gene CHEBI:27899 cisplatin decreases expression EXP E RGD:6480464 20170516 CTD MESH:D002945 Cisplatin results in decreased expression of TAGLN mRNA PMID:27392435 11324 TAGLN transgelin gene CHEBI:27899 cisplatin decreases expression ISO RGD:3723 E RGD:6480464 20120412 CTD MESH:D002945 Cisplatin results in decreased expression of TAGLN protein PMID:22023808 11324 TAGLN transgelin gene CHEBI:27899 cisplatin multiple interactions EXP E RGD:6480464 20170516 CTD MESH:D002945 [Cisplatin co-treated with jinfukang] results in decreased expression of TAGLN mRNA PMID:27392435 11324 TAGLN transgelin gene CHEBI:27902 tetracycline decreases expression EXP E RGD:6480464 20121113 CTD MESH:D013752 Tetracycline results in decreased expression of TAGLN mRNA PMID:17175557 11324 TAGLN transgelin gene CHEBI:28001 vancomycin decreases expression ISO RGD:11323 E RGD:6480464 20120412 CTD MESH:D014640 Vancomycin results in decreased expression of TAGLN mRNA PMID:18930951 11324 TAGLN transgelin gene CHEBI:28088 genistein affects expression EXP E RGD:6480464 20160607 CTD MESH:D019833 Genistein affects the expression of TAGLN mRNA PMID:26865667 11324 TAGLN transgelin gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:3723 E RGD:6480464 20120918 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of TAGLN mRNA PMID:22298810|PMID:34747641 11324 TAGLN transgelin gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:3723 E RGD:6480464 20121113 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased expression of TAGLN mRNA PMID:19692669|PMID:21724226|PMID:32109520 11324 TAGLN transgelin gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:11323 E RGD:6480464 20160119 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of TAGLN mRNA PMID:26290441 11324 TAGLN transgelin gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:3723 E RGD:6480464 20130122 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of TAGLN mRNA PMID:20959002|PMID:33387578 11324 TAGLN transgelin gene CHEBI:28201 rotenone increases expression EXP E RGD:6480464 20210810 CTD MESH:D012402 Rotenone results in increased expression of TAGLN mRNA PMID:33512557 11324 TAGLN transgelin gene CHEBI:28216 methylmercury chloride decreases expression EXP E RGD:6480464 20220308 CTD MESH:C004925 methylmercuric chloride results in decreased expression of TAGLN mRNA PMID:34089799 11324 TAGLN transgelin gene CHEBI:28216 methylmercury chloride increases expression EXP E RGD:6480464 20160119 CTD MESH:C004925 methylmercuric chloride results in increased expression of TAGLN mRNA PMID:23179753|PMID:26272509|PMID:28001369 11324 TAGLN transgelin gene CHEBI:28216 methylmercury chloride multiple interactions EXP E RGD:6480464 20161025 CTD MESH:C004925 [NOG protein co-treated with methylmercuric chloride co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA PMID:27188386 11324 TAGLN transgelin gene CHEBI:28384 vitamin K multiple interactions ISO RGD:3723 E RGD:6480464 20170725 CTD MESH:D014812 [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of TAGLN mRNA PMID:23117658 11324 TAGLN transgelin gene CHEBI:28593 quinidine decreases expression EXP E RGD:6480464 20120412 CTD MESH:D011802 Quinidine results in decreased expression of TAGLN mRNA PMID:17567588 11324 TAGLN transgelin gene CHEBI:28680 cytarabine increases expression EXP E RGD:6480464 20121113 CTD MESH:D003561 Cytarabine results in increased expression of TAGLN mRNA PMID:21198554 11324 TAGLN transgelin gene CHEBI:28694 copper atom multiple interactions EXP E RGD:6480464 20120717 CTD MESH:D003300 [NSC 689534 binds to Copper] which results in increased expression of TAGLN mRNA PMID:20971185 11324 TAGLN transgelin gene CHEBI:28748 doxorubicin affects expression EXP E RGD:6480464 20180515 CTD MESH:D004317 Doxorubicin affects the expression of TAGLN protein PMID:29385562 11324 TAGLN transgelin gene CHEBI:28748 doxorubicin affects expression ISO RGD:11323 E RGD:6480464 20120412 CTD MESH:D004317 Doxorubicin affects the expression of TAGLN mRNA PMID:15033991 11324 TAGLN transgelin gene CHEBI:28748 doxorubicin decreases expression EXP E RGD:6480464 20181113 CTD MESH:D004317 Doxorubicin results in decreased expression of TAGLN mRNA PMID:29803840 11324 TAGLN transgelin gene CHEBI:28748 doxorubicin increases expression EXP E RGD:6480464 20120412 CTD MESH:D004317 Doxorubicin results in increased expression of TAGLN mRNA PMID:15870702 11324 TAGLN transgelin gene CHEBI:28885 butan-1-ol multiple interactions EXP E RGD:6480464 20181016 CTD MESH:D020001 [[Gasoline co-treated with 1-Butanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TAGLN mRNA PMID:29432896 11324 TAGLN transgelin gene CHEBI:28971 ampicillin increases expression EXP E RGD:6480464 20121009 CTD MESH:D000667 Ampicillin results in increased expression of TAGLN mRNA PMID:21632981 11324 TAGLN transgelin gene CHEBI:29073 L-ascorbic acid increases expression EXP E RGD:6480464 20120501 CTD MESH:D001205 Ascorbic Acid results in increased expression of TAGLN mRNA PMID:18607632 11324 TAGLN transgelin gene CHEBI:29073 L-ascorbic acid multiple interactions EXP E RGD:6480464 20120501 CTD MESH:D001205 [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of TAGLN mRNA PMID:18607632 11324 TAGLN transgelin gene CHEBI:29287 gold atom decreases expression EXP E RGD:6480464 20230502 CTD MESH:D006046 Gold analog results in decreased expression of TAGLN mRNA PMID:36057382 11324 TAGLN transgelin gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20161228 CTD MESH:C017947 sodium arsenite results in decreased expression of TAGLN mRNA PMID:22714537|PMID:34032870 11324 TAGLN transgelin gene CHEBI:29678 sodium arsenite decreases expression ISO RGD:11323 E RGD:6480464 20161228 CTD MESH:C017947 sodium arsenite results in decreased expression of TAGLN protein PMID:26135927 11324 TAGLN transgelin gene CHEBI:29678 sodium arsenite decreases expression ISO RGD:3723 E RGD:6480464 20190507 CTD MESH:C017947 sodium arsenite results in decreased expression of TAGLN protein PMID:29459688 11324 TAGLN transgelin gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20161228 CTD MESH:C017947 sodium arsenite results in increased expression of TAGLN mRNA PMID:12634122|PMID:38568856 11324 TAGLN transgelin gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20121009 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of TAGLN mRNA PMID:20106945|PMID:21632981 11324 TAGLN transgelin gene CHEBI:29865 benzo[a]pyrene decreases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in decreased methylation of TAGLN 5' UTR; Benzo(a)pyrene results in decreased methylation of TAGLN promoter PMID:27901495 11324 TAGLN transgelin gene CHEBI:29865 benzo[a]pyrene increases expression ISO RGD:11323 E RGD:6480464 20120918 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of TAGLN mRNA PMID:22228805 11324 TAGLN transgelin gene CHEBI:29866 arsenite(3-) increases expression ISO RGD:11323 E RGD:6480464 20241105 CTD MESH:C015001 arsenite results in increased expression of TAGLN protein PMID:37955338 11324 TAGLN transgelin gene CHEBI:30050 gold(0) decreases expression EXP E RGD:6480464 20230502 CTD MESH:D006046 Gold analog results in decreased expression of TAGLN mRNA PMID:36057382 11324 TAGLN transgelin gene CHEBI:30052 copper(0) multiple interactions EXP E RGD:6480464 20120717 CTD MESH:D003300 [NSC 689534 binds to Copper] which results in increased expression of TAGLN mRNA PMID:20971185 11324 TAGLN transgelin gene CHEBI:30512 silver atom decreases expression ISO RGD:11323 E RGD:6480464 20161115 CTD MESH:D012834 Silver results in decreased expression of TAGLN mRNA PMID:27131904 11324 TAGLN transgelin gene CHEBI:30512 silver atom increases expression EXP E RGD:6480464 20180410 CTD MESH:D012834 Silver results in increased expression of TAGLN mRNA PMID:28959546 11324 TAGLN transgelin gene CHEBI:30563 silicon dioxide increases expression EXP E RGD:6480464 20160315 CTD MESH:D012822 Silicon Dioxide analog results in increased expression of TAGLN mRNA PMID:25895662 11324 TAGLN transgelin gene CHEBI:30563 silicon dioxide increases expression ISO RGD:11323 E RGD:6480464 20140715 CTD MESH:D012822 Silicon Dioxide results in increased expression of TAGLN mRNA PMID:23221170 11324 TAGLN transgelin gene CHEBI:30621 diarsenic trioxide multiple interactions EXP E RGD:6480464 20191114 CTD MESH:C006632 Arsenic Trioxide inhibits the reaction [4-aminophenylarsenoxide binds to TAGLN protein] PMID:26598702 11324 TAGLN transgelin gene CHEBI:30703 tetrathiomolybdate(2-) increases expression EXP E RGD:6480464 20240109 CTD MESH:C020809 tetrathiomolybdate results in increased expression of TAGLN mRNA PMID:37290678 11324 TAGLN transgelin gene CHEBI:31206 ammonium chloride affects expression ISO RGD:3723 E RGD:6480464 20120412 CTD MESH:D000643 Ammonium Chloride affects the expression of TAGLN mRNA PMID:16483693 11324 TAGLN transgelin gene CHEBI:3139 bleomycin A2 increases expression ISO RGD:3723 E RGD:6480464 20151215 CTD MESH:D001761 Bleomycin results in increased expression of TAGLN protein PMID:25933445 11324 TAGLN transgelin gene CHEBI:31767 lead diacetate increases expression EXP E RGD:6480464 20240702 CTD MESH:C008261 lead acetate results in increased expression of TAGLN mRNA PMID:38568856 11324 TAGLN transgelin gene CHEBI:31767 lead diacetate increases expression ISO RGD:3723 E RGD:6480464 20130312 CTD MESH:C008261 lead acetate results in increased expression of TAGLN mRNA PMID:22641619 11324 TAGLN transgelin gene CHEBI:31941 oxaliplatin increases expression ISO RGD:3723 E RGD:6480464 20161213 CTD MESH:C030110 oxaliplatin results in increased expression of TAGLN mRNA PMID:25729387 11324 TAGLN transgelin gene CHEBI:31941 oxaliplatin multiple interactions ISO RGD:3723 E RGD:6480464 20161213 CTD MESH:C030110 [oxaliplatin co-treated with Topotecan] results in increased expression of TAGLN mRNA PMID:25729387 11324 TAGLN transgelin gene CHEBI:32181 tamibarotene affects expression EXP E RGD:6480464 20120515 CTD MESH:C061133 tamibarotene affects the expression of TAGLN mRNA PMID:15498508 11324 TAGLN transgelin gene CHEBI:32234 titanium dioxide decreases expression ISO RGD:11323 E RGD:6480464 20140211 CTD MESH:C009495 titanium dioxide results in decreased expression of TAGLN mRNA PMID:23557971 11324 TAGLN transgelin gene CHEBI:32497 thioacetamide increases expression ISO RGD:3723 E RGD:6480464 20220405 CTD MESH:D013853 Thioacetamide results in increased expression of TAGLN mRNA PMID:34492290 11324 TAGLN transgelin gene CHEBI:32506 4,4'-diaminodiphenylmethane increases expression ISO RGD:11323 E RGD:6480464 20120412 CTD MESH:C009505 4,4'-diaminodiphenylmethane results in increased expression of TAGLN mRNA PMID:18648102 11324 TAGLN transgelin gene CHEBI:32509 pirinixic acid increases expression ISO RGD:11323 E RGD:6480464 20140610 CTD MESH:C006253 pirinixic acid results in increased expression of TAGLN mRNA PMID:23811191 11324 TAGLN transgelin gene CHEBI:33007 chromium(6+) multiple interactions EXP E RGD:6480464 20240702 CTD MESH:C074702 [zinc chromate results in increased abundance of chromium hexavalent ion] which results in decreased expression of TAGLN mRNA PMID:38479592 11324 TAGLN transgelin gene CHEBI:33216 bisphenol A affects expression ISO RGD:3723 E RGD:6480464 20150310 CTD MESH:C006780 bisphenol A affects the expression of TAGLN mRNA PMID:25181051 11324 TAGLN transgelin gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20180515 CTD MESH:C006780 bisphenol A results in decreased expression of TAGLN mRNA; bisphenol A results in decreased expression of TAGLN protein PMID:29275510|PMID:29718440|PMID:31675489 11324 TAGLN transgelin gene CHEBI:33216 bisphenol A decreases expression ISO RGD:11323 E RGD:6480464 20240206 CTD MESH:C006780 bisphenol A results in decreased expression of TAGLN mRNA PMID:37105096 11324 TAGLN transgelin gene CHEBI:33216 bisphenol A increases expression EXP E RGD:6480464 20230307 CTD MESH:C006780 bisphenol A results in increased expression of TAGLN protein PMID:34186270|PMID:37567409 11324 TAGLN transgelin gene CHEBI:33216 bisphenol A increases expression ISO RGD:11323 E RGD:6480464 20191112 CTD MESH:C006780 bisphenol A results in increased expression of TAGLN mRNA PMID:30951980 11324 TAGLN transgelin gene CHEBI:33216 bisphenol A increases expression ISO RGD:3723 E RGD:6480464 20120412 CTD MESH:C006780 bisphenol A results in increased expression of TAGLN mRNA PMID:12075121|PMID:32145629 11324 TAGLN transgelin gene CHEBI:33216 bisphenol A increases methylation ISO RGD:3723 E RGD:6480464 20180116 CTD MESH:C006780 bisphenol A results in increased methylation of TAGLN gene PMID:28505145 11324 TAGLN transgelin gene CHEBI:33216 bisphenol A multiple interactions ISO RGD:11323 E RGD:6480464 20191112 CTD MESH:C006780 [bisphenol A co-treated with Tretinoin] results in decreased expression of TAGLN mRNA; [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of TAGLN protein PMID:30951980|PMID:35999755 11324 TAGLN transgelin gene CHEBI:33216 bisphenol A multiple interactions ISO RGD:3723 E RGD:6480464 20160705 CTD MESH:C006780 [bisphenol A co-treated with Estradiol] results in decreased expression of TAGLN mRNA PMID:26496021 11324 TAGLN transgelin gene CHEBI:33217 3,3',5,5'-tetrabromobisphenol A increases expression EXP E RGD:6480464 20220308 CTD MESH:C020806 tetrabromobisphenol A results in increased expression of TAGLN protein PMID:31675489 11324 TAGLN transgelin gene CHEBI:33234 vitamin E increases expression EXP E RGD:6480464 20161228 CTD MESH:D024502 Vitamin E results in increased expression of TAGLN mRNA PMID:19244175 11324 TAGLN transgelin gene CHEBI:3387 carbamazepine affects expression EXP E RGD:6480464 20151013 CTD MESH:D002220 Carbamazepine affects the expression of TAGLN mRNA PMID:25979313 11324 TAGLN transgelin gene CHEBI:34107 1-nitropyrene increases expression EXP E RGD:6480464 20140415 CTD MESH:C032668 1-nitropyrene results in increased expression of TAGLN mRNA PMID:19041380 11324 TAGLN transgelin gene CHEBI:3423 carmustine affects response to substance EXP E RGD:6480464 20120412 CTD MESH:D002330 TAGLN mRNA affects the susceptibility to Carmustine PMID:16365179 11324 TAGLN transgelin gene CHEBI:34317 3,3',4,4',5-pentachlorobiphenyl decreases expression ISO RGD:3723 E RGD:6480464 20120501 CTD MESH:C023035 3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of TAGLN mRNA PMID:19692669 11324 TAGLN transgelin gene CHEBI:34317 3,3',4,4',5-pentachlorobiphenyl increases expression ISO RGD:3723 E RGD:6480464 20140408 CTD MESH:C023035 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of TAGLN mRNA PMID:23196670 11324 TAGLN transgelin gene CHEBI:34372 4,4'-sulfonyldiphenol affects expression ISO RGD:11323 E RGD:6480464 20191112 CTD MESH:C543008 bisphenol S affects the expression of TAGLN mRNA PMID:30951980 11324 TAGLN transgelin gene CHEBI:34372 4,4'-sulfonyldiphenol decreases methylation ISO RGD:11323 E RGD:6480464 20220208 CTD MESH:C543008 bisphenol S results in decreased methylation of TAGLN promoter PMID:33297965 11324 TAGLN transgelin gene CHEBI:34568 Benzo[ghi]perylene increases expression ISO RGD:11323 E RGD:6480464 20160119 CTD MESH:C006718 1,12-benzoperylene results in increased expression of TAGLN mRNA PMID:26377693 11324 TAGLN transgelin gene CHEBI:34575 bisphenol F decreases expression ISO RGD:11323 E RGD:6480464 20241105 CTD MESH:C008745 bisphenol F results in decreased expression of TAGLN mRNA PMID:38685157 11324 TAGLN transgelin gene CHEBI:34575 bisphenol F increases expression EXP E RGD:6480464 20230307 CTD MESH:C008745 bisphenol F results in increased expression of TAGLN protein PMID:34186270 11324 TAGLN transgelin gene CHEBI:34575 bisphenol F increases expression ISO RGD:11323 E RGD:6480464 20191112 CTD MESH:C008745 bisphenol F results in increased expression of TAGLN mRNA PMID:30951980 11324 TAGLN transgelin gene CHEBI:34575 bisphenol F multiple interactions ISO RGD:11323 E RGD:6480464 20191112 CTD MESH:C008745 [bisphenol F co-treated with Tretinoin] results in decreased expression of TAGLN mRNA PMID:30951980 11324 TAGLN transgelin gene CHEBI:34581 Bisphenol B increases expression EXP E RGD:6480464 20230307 CTD MESH:C492482 bisphenol B results in increased expression of TAGLN protein PMID:34186270 11324 TAGLN transgelin gene CHEBI:34674 dextran sulfate multiple interactions ISO RGD:11323 E RGD:6480464 20230207 CTD MESH:D016264 [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of TAGLN protein PMID:35999755 11324 TAGLN transgelin gene CHEBI:34687 dibutyl phthalate decreases expression ISO RGD:3723 E RGD:6480464 20150127 CTD MESH:D003993 Dibutyl Phthalate results in decreased expression of TAGLN mRNA; Dibutyl Phthalate results in decreased expression of TAGLN protein PMID:24893172|PMID:35926758 11324 TAGLN transgelin gene CHEBI:34687 dibutyl phthalate increases expression ISO RGD:11323 E RGD:6480464 20120412 CTD MESH:D003993 Dibutyl Phthalate results in increased expression of TAGLN mRNA PMID:21266533 11324 TAGLN transgelin gene CHEBI:34687 dibutyl phthalate increases expression ISO RGD:3723 E RGD:6480464 20120412 CTD MESH:D003993 Dibutyl Phthalate results in increased expression of TAGLN mRNA PMID:21266533 11324 TAGLN transgelin gene CHEBI:34768 furfural multiple interactions EXP E RGD:6480464 20250114 CTD MESH:D005662 [pyrogallol 1,3-dimethyl ether co-treated with Furaldehyde] results in increased expression of and affects the localization of TAGLN protein; [Sodium Chloride co-treated with Furaldehyde] results in decreased expression of and affects the localization of TAGLN protein; [Sodium Chloride co-treated with Furaldehyde] results in increased expression of TAGLN protein PMID:38598786 11324 TAGLN transgelin gene CHEBI:34795 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:11323 E RGD:6480464 20120412 CTD MESH:D015056 [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of TAGLN mRNA PMID:16054899 11324 TAGLN transgelin gene CHEBI:34873 N-nitrosodiethylamine multiple interactions ISO RGD:3723 E RGD:6480464 20120412 CTD MESH:D004052 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TAGLN mRNA PMID:18164116 11324 TAGLN transgelin gene CHEBI:35038 tris(2-butoxyethyl) phosphate affects expression EXP E RGD:6480464 20180515 CTD MESH:C013320 tris(2-butoxyethyl) phosphate affects the expression of TAGLN mRNA PMID:29024780 11324 TAGLN transgelin gene CHEBI:35064 alpha-Zearalanol multiple interactions ISO RGD:3723 E RGD:6480464 20240430 CTD MESH:D015029 [Zeranol co-treated with perfluorooctanoic acid] results in decreased expression of TAGLN mRNA; [Zeranol co-treated with perfluorooctanoic acid] results in increased expression of TAGLN mRNA PMID:35163327 11324 TAGLN transgelin gene CHEBI:35455 1-naphthyl isothiocyanate increases expression EXP E RGD:6480464 20121113 CTD MESH:D015058 1-Naphthylisothiocyanate results in increased expression of TAGLN mRNA PMID:17175557 11324 TAGLN transgelin gene CHEBI:35455 1-naphthyl isothiocyanate increases expression ISO RGD:3723 E RGD:6480464 20190507 CTD MESH:D015058 1-Naphthylisothiocyanate results in increased expression of TAGLN mRNA PMID:30723492 11324 TAGLN transgelin gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of TAGLN mRNA PMID:38568856 11324 TAGLN transgelin gene CHEBI:35456 cadmium dichloride multiple interactions ISO RGD:11323 E RGD:6480464 20231205 CTD MESH:D019256 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of TAGLN mRNA PMID:37325564 11324 TAGLN transgelin gene CHEBI:35549 perfluorooctanoic acid multiple interactions ISO RGD:3723 E RGD:6480464 20240430 CTD MESH:C023036 [Zeranol co-treated with perfluorooctanoic acid] results in decreased expression of TAGLN mRNA; [Zeranol co-treated with perfluorooctanoic acid] results in increased expression of TAGLN mRNA PMID:35163327 11324 TAGLN transgelin gene CHEBI:35553 perhexiline decreases expression EXP E RGD:6480464 20121113 CTD MESH:D010480 Perhexiline results in decreased expression of TAGLN mRNA PMID:15342952|PMID:17175557 11324 TAGLN transgelin gene CHEBI:35559 furan increases expression ISO RGD:3723 E RGD:6480464 20170516 CTD MESH:C039281 furan results in increased expression of TAGLN mRNA PMID:27387713 11324 TAGLN transgelin gene CHEBI:3647 chlorpromazine decreases expression EXP E RGD:6480464 20121113 CTD MESH:D002746 Chlorpromazine results in decreased expression of TAGLN mRNA PMID:17175557 11324 TAGLN transgelin gene CHEBI:36740 alpha-pinene multiple interactions EXP E RGD:6480464 20210112 CTD MESH:C005451 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of TAGLN mRNA; [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of TAGLN mRNA PMID:32699268 11324 TAGLN transgelin gene CHEBI:3723 citalopram decreases expression EXP E RGD:6480464 20120412 CTD MESH:D015283 Citalopram results in decreased expression of TAGLN mRNA PMID:17567588 11324 TAGLN transgelin gene CHEBI:37537 phorbol 13-acetate 12-myristate decreases expression EXP E RGD:6480464 20120412 CTD MESH:D013755 Tetradecanoylphorbol Acetate results in decreased expression of TAGLN mRNA PMID:15380616 11324 TAGLN transgelin gene CHEBI:3764 clotrimazole increases expression ISO RGD:3723 E RGD:6480464 20230606 CTD MESH:D003022 Clotrimazole results in increased expression of TAGLN mRNA PMID:30047161 11324 TAGLN transgelin gene CHEBI:3766 clozapine decreases expression EXP E RGD:6480464 20121113 CTD MESH:D003024 Clozapine results in decreased expression of TAGLN mRNA PMID:15342952|PMID:17175557 11324 TAGLN transgelin gene CHEBI:38604 pyrimidifen increases expression EXP E RGD:6480464 20210810 CTD MESH:C476509 pyrimidifen results in increased expression of TAGLN mRNA PMID:33512557 11324 TAGLN transgelin gene CHEBI:38757 isoflavones multiple interactions ISO RGD:3723 E RGD:6480464 20170303 CTD MESH:D007529 [9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of TAGLN protein; [ENNG co-treated with Isoflavones] results in increased expression of TAGLN protein PMID:22248470 11324 TAGLN transgelin gene CHEBI:38940 sunitinib decreases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in decreased expression of TAGLN mRNA PMID:31533062 11324 TAGLN transgelin gene CHEBI:39421 perfluorooctane-1-sulfonic acid decreases expression ISO RGD:11323 E RGD:6480464 20180515 CTD MESH:C076994 perfluorooctane sulfonic acid results in decreased expression of TAGLN protein PMID:26178269 11324 TAGLN transgelin gene CHEBI:39421 perfluorooctane-1-sulfonic acid decreases expression ISO RGD:3723 E RGD:6480464 20121009 CTD MESH:C076994 perfluorooctane sulfonic acid results in decreased expression of TAGLN mRNA PMID:22237054 11324 TAGLN transgelin gene CHEBI:39478 buta-1,3-diene decreases expression ISO RGD:11323 E RGD:6480464 20180703 CTD MESH:C031763 1,3-butadiene results in decreased expression of TAGLN mRNA PMID:29038090 11324 TAGLN transgelin gene CHEBI:39483 sodium dichromate increases expression ISO RGD:3723 E RGD:6480464 20150825 CTD MESH:C016104 sodium bichromate results in increased expression of TAGLN mRNA PMID:22561333|PMID:25993096 11324 TAGLN transgelin gene CHEBI:39867 valproic acid affects expression EXP E RGD:6480464 20151013 CTD MESH:D014635 Valproic Acid affects the expression of TAGLN mRNA PMID:25979313 11324 TAGLN transgelin gene CHEBI:39867 valproic acid decreases expression EXP E RGD:6480464 20140909 CTD MESH:D014635 Valproic Acid results in decreased expression of TAGLN mRNA PMID:17175557|PMID:24935251|PMID:28001369|PMID:29154799 11324 TAGLN transgelin gene CHEBI:39867 valproic acid decreases expression ISO RGD:3723 E RGD:6480464 20180828 CTD MESH:D014635 Valproic Acid results in decreased expression of TAGLN mRNA PMID:29427782 11324 TAGLN transgelin gene CHEBI:39867 valproic acid increases expression EXP E RGD:6480464 20161025 CTD MESH:D014635 Valproic Acid results in increased expression of TAGLN mRNA PMID:23179753|PMID:27188386 11324 TAGLN transgelin gene CHEBI:39867 valproic acid increases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in increased methylation of TAGLN gene PMID:29154799 11324 TAGLN transgelin gene CHEBI:40036 amitrole increases expression ISO RGD:3723 E RGD:6480464 20230606 CTD MESH:D000640 Amitrole results in increased expression of TAGLN mRNA PMID:30047161 11324 TAGLN transgelin gene CHEBI:4031 cyclosporin A affects expression EXP E RGD:6480464 20120412 CTD MESH:D016572 Cyclosporine affects the expression of TAGLN mRNA PMID:20106945 11324 TAGLN transgelin gene CHEBI:4031 cyclosporin A decreases expression EXP E RGD:6480464 20120918 CTD MESH:D016572 Cyclosporine results in decreased expression of TAGLN mRNA PMID:22147139 11324 TAGLN transgelin gene CHEBI:4031 cyclosporin A increases expression EXP E RGD:6480464 20150825 CTD MESH:D016572 Cyclosporine results in increased expression of TAGLN mRNA PMID:21632981|PMID:25562108 11324 TAGLN transgelin gene CHEBI:40909 azoxystrobin increases expression EXP E RGD:6480464 20210810 CTD MESH:C087670 azoxystrobin results in increased expression of TAGLN mRNA PMID:33512557 11324 TAGLN transgelin gene CHEBI:41072 3-\{1-[3-(dimethylamino)propyl]-1H-indol-3-yl\}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione decreases expression EXP E RGD:6480464 20141111 CTD MESH:C070515 bisindolylmaleimide I results in decreased expression of TAGLN mRNA PMID:15380616 11324 TAGLN transgelin gene CHEBI:41774 tamoxifen decreases expression EXP E RGD:6480464 20121113 CTD MESH:D013629 Tamoxifen results in decreased expression of TAGLN mRNA PMID:15342952|PMID:17175557|PMID:17567588 11324 TAGLN transgelin gene CHEBI:41879 dexamethasone decreases expression ISO RGD:3723 E RGD:6480464 20120412 CTD MESH:D003907 Dexamethasone results in decreased expression of TAGLN mRNA PMID:14618091 11324 TAGLN transgelin gene CHEBI:41879 dexamethasone multiple interactions ISO RGD:11323 E RGD:6480464 20120412 CTD MESH:D003907 [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of TAGLN mRNA PMID:16054899 11324 TAGLN transgelin gene CHEBI:41922 diethylstilbestrol increases expression ISO RGD:3723 E RGD:6480464 20230606 CTD MESH:D004054 Diethylstilbestrol results in increased expression of TAGLN mRNA PMID:37077353 11324 TAGLN transgelin gene CHEBI:42355 erythromycin A decreases expression EXP E RGD:6480464 20120412 CTD MESH:D004917 Erythromycin results in decreased expression of TAGLN mRNA PMID:17567588 11324 TAGLN transgelin gene CHEBI:42588 4-hydroxyphenyl retinamide increases expression ISO RGD:11323 E RGD:6480464 20180220 CTD MESH:D017313 Fenretinide results in increased expression of TAGLN mRNA PMID:28973697 11324 TAGLN transgelin gene CHEBI:42758 aldehydo-D-glucose increases secretion EXP E RGD:6480464 20160822 CTD MESH:D005947 Glucose deficiency results in increased secretion of TAGLN protein PMID:24802182 11324 TAGLN transgelin gene CHEBI:42839 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine increases expression ISO RGD:3723 E RGD:6480464 20120412 CTD MESH:D011692 Puromycin Aminonucleoside results in increased expression of TAGLN mRNA; Puromycin Aminonucleoside results in increased expression of TAGLN protein PMID:19617259 11324 TAGLN transgelin gene CHEBI:4357 deguelin increases expression EXP E RGD:6480464 20210810 CTD MESH:C107676 deguelin results in increased expression of TAGLN mRNA PMID:33512557 11324 TAGLN transgelin gene CHEBI:44185 methotrexate decreases expression EXP E RGD:6480464 20120412 CTD MESH:D008727 Methotrexate results in decreased expression of TAGLN mRNA PMID:17320366 11324 TAGLN transgelin gene CHEBI:44185 methotrexate decreases expression ISO RGD:11323 E RGD:6480464 20120412 CTD MESH:D008727 Methotrexate results in decreased expression of TAGLN mRNA PMID:17320366 11324 TAGLN transgelin gene CHEBI:45716 vorinostat increases expression EXP E RGD:6480464 20161213 CTD MESH:C111237 vorinostat results in increased expression of TAGLN mRNA PMID:26272509 11324 TAGLN transgelin gene CHEBI:45716 vorinostat multiple interactions EXP E RGD:6480464 20161213 CTD MESH:C111237 [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA PMID:27188386 11324 TAGLN transgelin gene CHEBI:46024 trichostatin A increases expression EXP E RGD:6480464 20160119 CTD MESH:C012589 trichostatin A results in increased expression of TAGLN mRNA PMID:24935251|PMID:26272509 11324 TAGLN transgelin gene CHEBI:46024 trichostatin A increases expression ISO RGD:11323 E RGD:6480464 20150127 CTD MESH:C012589 trichostatin A results in increased expression of TAGLN mRNA PMID:23463510 11324 TAGLN transgelin gene CHEBI:46024 trichostatin A multiple interactions EXP E RGD:6480464 20161025 CTD MESH:C012589 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA PMID:27188386 11324 TAGLN transgelin gene CHEBI:46195 paracetamol affects expression ISO RGD:11323 E RGD:6480464 20120412 CTD MESH:D000082 Acetaminophen affects the expression of TAGLN mRNA PMID:17562736 11324 TAGLN transgelin gene CHEBI:46195 paracetamol decreases expression EXP E RGD:6480464 20121113 CTD MESH:D000082 Acetaminophen results in decreased expression of TAGLN mRNA PMID:17175557|PMID:26690555 11324 TAGLN transgelin gene CHEBI:46195 paracetamol increases expression ISO RGD:11323 E RGD:6480464 20190910 CTD MESH:D000082 Acetaminophen results in increased expression of TAGLN mRNA PMID:29246445 11324 TAGLN transgelin gene CHEBI:46195 paracetamol multiple interactions ISO RGD:11323 E RGD:6480464 20190910 CTD MESH:D000082 PANX1 gene mutant form inhibits the reaction [Acetaminophen results in increased expression of TAGLN mRNA] PMID:29246445 11324 TAGLN transgelin gene CHEBI:46342 undecane increases expression ISO RGD:3723 E RGD:6480464 20120918 CTD MESH:C022884 undecane results in increased expression of TAGLN protein PMID:17337753 11324 TAGLN transgelin gene CHEBI:46345 5-fluorouracil affects response to substance EXP E RGD:6480464 20120515 CTD MESH:D005472 TAGLN protein affects the susceptibility to Fluorouracil PMID:15352031|PMID:16217747 11324 TAGLN transgelin gene CHEBI:46345 5-fluorouracil decreases expression EXP E RGD:6480464 20120412 CTD MESH:D005472 Fluorouracil results in decreased expression of TAGLN protein PMID:15352031 11324 TAGLN transgelin gene CHEBI:46645 isobutanol multiple interactions EXP E RGD:6480464 20181016 CTD MESH:C040507 [[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TAGLN mRNA PMID:29432896 11324 TAGLN transgelin gene CHEBI:46666 crocidolite asbestos decreases expression EXP E RGD:6480464 20180828 CTD MESH:D017638 Asbestos, Crocidolite results in decreased expression of TAGLN mRNA PMID:29523930 11324 TAGLN transgelin gene CHEBI:46790 2-methoxyethanol decreases expression ISO RGD:3723 E RGD:6480464 20240806 CTD MESH:C005219 methyl cellosolve results in decreased expression of TAGLN protein PMID:15928459 11324 TAGLN transgelin gene CHEBI:4710 doxepin decreases expression EXP E RGD:6480464 20120412 CTD MESH:D004316 Doxepin results in decreased expression of TAGLN mRNA PMID:17567588 11324 TAGLN transgelin gene CHEBI:47217 arsane affects expression EXP E RGD:6480464 20140805 CTD MESH:D001151 Arsenic affects the expression of TAGLN mRNA PMID:18414638 11324 TAGLN transgelin gene CHEBI:47499 imipramine decreases expression EXP E RGD:6480464 20120515 CTD MESH:D007099 Imipramine results in decreased expression of TAGLN mRNA PMID:15342952|PMID:17567588 11324 TAGLN transgelin gene CHEBI:47519 ketoconazole decreases expression EXP E RGD:6480464 20121113 CTD MESH:D007654 Ketoconazole results in decreased expression of TAGLN mRNA PMID:17175557 11324 TAGLN transgelin gene CHEBI:47519 ketoconazole increases expression ISO RGD:3723 E RGD:6480464 20230606 CTD MESH:D007654 Ketoconazole results in increased expression of TAGLN mRNA PMID:37077353 11324 TAGLN transgelin gene CHEBI:47696 2,4,6-tribromophenol increases expression EXP E RGD:6480464 20220308 CTD MESH:C004554 2,4,6-tribromophenol results in increased expression of TAGLN mRNA PMID:31675489 11324 TAGLN transgelin gene CHEBI:47780 clomipramine decreases expression EXP E RGD:6480464 20121113 CTD MESH:D002997 Clomipramine results in decreased expression of TAGLN mRNA PMID:17175557 11324 TAGLN transgelin gene CHEBI:4791 endosulfan decreases expression ISO RGD:3723 E RGD:6480464 20180828 CTD MESH:D004726 Endosulfan results in decreased expression of TAGLN mRNA PMID:29391264 11324 TAGLN transgelin gene CHEBI:4903 17alpha-ethynylestradiol affects expression EXP E RGD:6480464 20160607 CTD MESH:D004997 Ethinyl Estradiol affects the expression of TAGLN mRNA PMID:26865667 11324 TAGLN transgelin gene CHEBI:4903 17alpha-ethynylestradiol affects expression ISO RGD:11323 E RGD:6480464 20120412 CTD MESH:D004997 Ethinyl Estradiol affects the expression of TAGLN mRNA PMID:17555576 11324 TAGLN transgelin gene CHEBI:4903 17alpha-ethynylestradiol increases expression ISO RGD:3723 E RGD:6480464 20120412 CTD MESH:D004997 Ethinyl Estradiol results in increased expression of TAGLN mRNA PMID:12075121 11324 TAGLN transgelin gene CHEBI:49703 latrunculin B decreases expression ISO RGD:3723 E RGD:6480464 20191112 CTD MESH:C037068 latrunculin B results in decreased expression of TAGLN mRNA PMID:11035001 11324 TAGLN transgelin gene CHEBI:49900 arsenous acid multiple interactions EXP E RGD:6480464 20191114 CTD MESH:C032793 Arsenic Trioxide inhibits the reaction [4-aminophenylarsenoxide binds to TAGLN protein] PMID:26598702 11324 TAGLN transgelin gene CHEBI:50095 bucladesine multiple interactions EXP E RGD:6480464 20130910 CTD MESH:D003994 [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TAGLN mRNA PMID:20823114 11324 TAGLN transgelin gene CHEBI:50131 5-aza-2'-deoxycytidine affects expression EXP E RGD:6480464 20191114 CTD MESH:C014347 Decitabine affects the expression of TAGLN mRNA PMID:23300844 11324 TAGLN transgelin gene CHEBI:5014 fenvalerate decreases expression ISO RGD:3723 E RGD:6480464 20201103 CTD MESH:C017690 fenvalerate results in decreased expression of TAGLN mRNA PMID:30307764 11324 TAGLN transgelin gene CHEBI:50594 carbon nanotube decreases expression ISO RGD:11323 E RGD:6480464 20161228 CTD MESH:D037742 Nanotubes, Carbon analog results in decreased expression of TAGLN mRNA PMID:25620056 11324 TAGLN transgelin gene CHEBI:5063 fipronil increases expression ISO RGD:3723 E RGD:6480464 20211109 CTD MESH:C082360 fipronil results in increased expression of TAGLN mRNA PMID:34044035 11324 TAGLN transgelin gene CHEBI:50673 methimazole increases expression ISO RGD:3723 E RGD:6480464 20230606 CTD MESH:D008713 Methimazole results in increased expression of TAGLN mRNA PMID:30047161 11324 TAGLN transgelin gene CHEBI:50729 mitoxantrone affects response to substance EXP E RGD:6480464 20120412 CTD MESH:D008942 TAGLN protein affects the susceptibility to Mitoxantrone PMID:16217747 11324 TAGLN transgelin gene CHEBI:5118 fluoxetine decreases expression EXP E RGD:6480464 20121113 CTD MESH:D005473 Fluoxetine results in decreased expression of TAGLN mRNA PMID:15342952|PMID:17175557|PMID:17567588 11324 TAGLN transgelin gene CHEBI:529996 cytochalasin D increases expression ISO RGD:3723 E RGD:6480464 20191112 CTD MESH:D015638 Cytochalasin D results in increased expression of TAGLN mRNA PMID:11035001 11324 TAGLN transgelin gene CHEBI:53001 nickel sulfate decreases expression EXP E RGD:6480464 20160705 CTD MESH:C029938 nickel sulfate results in decreased expression of TAGLN mRNA PMID:22714537 11324 TAGLN transgelin gene CHEBI:5352 Gingerenone A increases expression EXP E RGD:6480464 20240305 CTD MESH:C000604237 gingerenone A results in increased expression of TAGLN mRNA PMID:35326237 11324 TAGLN transgelin gene CHEBI:5613 haloperidol decreases expression EXP E RGD:6480464 20121113 CTD MESH:D006220 Haloperidol results in decreased expression of TAGLN mRNA PMID:17175557 11324 TAGLN transgelin gene CHEBI:6067 isotretinoin increases expression EXP E RGD:6480464 20120412 CTD MESH:D015474 Isotretinoin results in increased expression of TAGLN mRNA PMID:17237267 11324 TAGLN transgelin gene CHEBI:6067 isotretinoin multiple interactions EXP E RGD:6480464 20120412 CTD MESH:D015474 [LAQ824 co-treated with Isotretinoin] results in increased expression of TAGLN mRNA PMID:17237267 11324 TAGLN transgelin gene CHEBI:63632 topotecan increases expression ISO RGD:3723 E RGD:6480464 20160315 CTD MESH:D019772 Topotecan results in increased expression of TAGLN mRNA PMID:25729387 11324 TAGLN transgelin gene CHEBI:63632 topotecan multiple interactions ISO RGD:3723 E RGD:6480464 20160315 CTD MESH:D019772 [oxaliplatin co-treated with Topotecan] results in increased expression of TAGLN mRNA PMID:25729387 11324 TAGLN transgelin gene CHEBI:63921 2-butoxyethanol increases expression ISO RGD:11323 E RGD:6480464 20120412 CTD MESH:C017096 n-butoxyethanol results in increased expression of TAGLN mRNA PMID:19812364 11324 TAGLN transgelin gene CHEBI:6402 leflunomide increases expression EXP E RGD:6480464 20180410 CTD MESH:C045463 leflunomide results in increased expression of TAGLN mRNA PMID:28988120 11324 TAGLN transgelin gene CHEBI:6538 loratadine decreases expression EXP E RGD:6480464 20191114 CTD MESH:D017336 Loratadine results in decreased expression of TAGLN mRNA PMID:15342952|PMID:17567588 11324 TAGLN transgelin gene CHEBI:66104 jaspamide increases expression ISO RGD:11323 E RGD:6480464 20130611 CTD MESH:C057531 jasplakinolide results in increased expression of TAGLN protein PMID:15184395 11324 TAGLN transgelin gene CHEBI:66104 jaspamide increases expression ISO RGD:3723 E RGD:6480464 20191112 CTD MESH:C057531 jasplakinolide results in increased expression of TAGLN mRNA PMID:11035001 11324 TAGLN transgelin gene CHEBI:6716 medroxyprogesterone acetate multiple interactions EXP E RGD:6480464 20130910 CTD MESH:D017258 [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TAGLN mRNA PMID:20823114 11324 TAGLN transgelin gene CHEBI:6773 Mesaconitine increases expression ISO RGD:3723 E RGD:6480464 20231031 CTD MESH:C019470 mesaconitine results in increased expression of TAGLN protein PMID:37182599 11324 TAGLN transgelin gene CHEBI:6820 methapyrilene increases expression ISO RGD:3723 E RGD:6480464 20180116 CTD MESH:D008701 Methapyrilene results in increased expression of TAGLN mRNA PMID:28935588 11324 TAGLN transgelin gene CHEBI:68508 diethyl maleate decreases expression ISO RGD:3723 E RGD:6480464 20121009 CTD MESH:C014476 diethyl maleate results in decreased expression of TAGLN mRNA PMID:21161181 11324 TAGLN transgelin gene CHEBI:69478 cannabidiol decreases expression ISO RGD:11323 E RGD:6480464 20211207 CTD MESH:D002185 Cannabidiol results in decreased expression of TAGLN mRNA PMID:31052254 11324 TAGLN transgelin gene CHEBI:71957 XL147 multiple interactions ISO RGD:11323 E RGD:6480464 20180220 CTD MESH:C581157 [N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of TAGLN mRNA; XL147 inhibits the reaction [N-nitroso-tris-chloroethylurea results in increased expression of TAGLN mRNA] PMID:27935865|PMID:29891994 11324 TAGLN transgelin gene CHEBI:72564 temozolomide affects response to substance EXP E RGD:6480464 20130305 CTD MESH:C047246 TAGLN mRNA affects the susceptibility to temozolomide PMID:16365179 11324 TAGLN transgelin gene CHEBI:72754 bisphenol AF increases expression EXP E RGD:6480464 20250114 CTD MESH:C583074 bisphenol AF results in increased expression of TAGLN protein PMID:34186270 11324 TAGLN transgelin gene CHEBI:73755 1,2-dimethylhydrazine increases expression ISO RGD:11323 E RGD:6480464 20200804 CTD MESH:D019813 1,2-Dimethylhydrazine results in increased expression of TAGLN mRNA PMID:22206623 11324 TAGLN transgelin gene CHEBI:73755 1,2-dimethylhydrazine multiple interactions ISO RGD:11323 E RGD:6480464 20200804 CTD MESH:D019813 [1,2-Dimethylhydrazine co-treated with Folic Acid] results in increased expression of TAGLN mRNA PMID:22206623 11324 TAGLN transgelin gene CHEBI:75393 Y-27632 decreases expression ISO RGD:3723 E RGD:6480464 20191112 CTD MESH:C108830 Y 27632 results in decreased expression of TAGLN mRNA PMID:11035001 11324 TAGLN transgelin gene CHEBI:75984 flecainide decreases expression EXP E RGD:6480464 20131112 CTD MESH:D005424 Flecainide results in decreased expression of TAGLN mRNA PMID:17175557 11324 TAGLN transgelin gene CHEBI:76290 PhIP decreases expression ISO RGD:3723 E RGD:6480464 20140107 CTD MESH:C049584 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of TAGLN mRNA PMID:15059925 11324 TAGLN transgelin gene CHEBI:76290 PhIP increases expression ISO RGD:3723 E RGD:6480464 20140107 CTD MESH:C049584 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of TAGLN mRNA PMID:15215175 11324 TAGLN transgelin gene CHEBI:77013 beta-naphthoflavone decreases expression EXP E RGD:6480464 20140204 CTD MESH:D019324 beta-Naphthoflavone results in decreased expression of TAGLN mRNA PMID:17175557|PMID:32858204 11324 TAGLN transgelin gene CHEBI:77013 beta-naphthoflavone multiple interactions ISO RGD:3723 E RGD:6480464 20140204 CTD MESH:D019324 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TAGLN mRNA PMID:18164116 11324 TAGLN transgelin gene CHEBI:77397 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile decreases expression EXP E RGD:6480464 20140805 CTD MESH:D015283 Citalopram results in decreased expression of TAGLN mRNA PMID:17567588 11324 TAGLN transgelin gene CHEBI:78510 dorsomorphin multiple interactions EXP E RGD:6480464 20161228 CTD MESH:C516138 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TAGLN mRNA; [NOG protein co-treated with methylmercuric chloride co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA; [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA; [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA PMID:27188386 11324 TAGLN transgelin gene CHEBI:79994 CGP 52608 multiple interactions EXP E RGD:6480464 20220607 CTD MESH:C092451 CGP 52608 promotes the reaction [RORA protein binds to TAGLN gene] PMID:28238834 11324 TAGLN transgelin gene CHEBI:8069 phenobarbital decreases expression EXP E RGD:6480464 20121113 CTD MESH:D010634 Phenobarbital results in decreased expression of TAGLN mRNA PMID:17175557 11324 TAGLN transgelin gene CHEBI:80774 tauroursodeoxycholic acid decreases expression ISO RGD:3723 E RGD:6480464 20141111 CTD MESH:C031655 ursodoxicoltaurine results in decreased expression of TAGLN mRNA PMID:15885361 11324 TAGLN transgelin gene CHEBI:81506 2,3,7,8-Tetrachlorodibenzofuran decreases expression ISO RGD:3723 E RGD:6480464 20200609 CTD MESH:C014211 2,3,7,8-tetrachlorodibenzofuran results in decreased expression of TAGLN mRNA PMID:32109520 11324 TAGLN transgelin gene CHEBI:81582 2,4-dibromophenyl 2,4,5-tribromophenyl ether affects expression ISO RGD:11323 E RGD:6480464 20240903 CTD MESH:C477694 2,2',4,4',5-brominated diphenyl ether affects the expression of TAGLN mRNA PMID:38648751 11324 TAGLN transgelin gene CHEBI:81584 2,2',4,4'-Tetrabromodiphenyl ether increases expression EXP E RGD:6480464 20220308 CTD MESH:C511295 2,2',4,4'-tetrabromodiphenyl ether results in increased expression of TAGLN protein PMID:31675489 11324 TAGLN transgelin gene CHEBI:8228 pioglitazone decreases expression EXP E RGD:6480464 20181113 CTD MESH:C060836 Pioglitazone results in decreased expression of TAGLN mRNA PMID:30031879 11324 TAGLN transgelin gene CHEBI:8228 pioglitazone multiple interactions ISO RGD:11323 E RGD:6480464 20180220 CTD MESH:C060836 [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of TAGLN mRNA PMID:27935865 11324 TAGLN transgelin gene CHEBI:82436 decabromodiphenyl ether increases expression EXP E RGD:6480464 20220308 CTD MESH:C010902 decabromobiphenyl ether results in increased expression of TAGLN protein PMID:31675489 11324 TAGLN transgelin gene CHEBI:83197 picoxystrobin increases expression EXP E RGD:6480464 20210810 CTD MESH:C556557 picoxystrobin results in increased expression of TAGLN mRNA PMID:33512557 11324 TAGLN transgelin gene CHEBI:83258 fenamidone increases expression ISO RGD:11323 E RGD:6480464 20180116 CTD MESH:C540355 fenamidone results in increased expression of TAGLN mRNA PMID:27029645 11324 TAGLN transgelin gene CHEBI:85014 2,5-hexanedione decreases expression ISO RGD:3723 E RGD:6480464 20240806 CTD MESH:C011269 2,5-hexanedione results in decreased expression of TAGLN protein PMID:15928459 11324 TAGLN transgelin gene CHEBI:8502 6-propyl-2-thiouracil increases expression ISO RGD:3723 E RGD:6480464 20230606 CTD MESH:D011441 Propylthiouracil results in increased expression of TAGLN mRNA PMID:30047161 11324 TAGLN transgelin gene CHEBI:91108 SB 431542 multiple interactions EXP E RGD:6480464 20161228 CTD MESH:C459179 [LDN 193189 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in decreased expression of TAGLN protein; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TAGLN mRNA; [NOG protein co-treated with methylmercuric chloride co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA; [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA; [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA PMID:27188386|PMID:37664457 11324 TAGLN transgelin gene CHEBI:9123 sertraline decreases expression EXP E RGD:6480464 20120412 CTD MESH:D020280 Sertraline results in decreased expression of TAGLN mRNA PMID:15342952 11324 TAGLN transgelin gene CHEBI:9141 silver(0) decreases expression ISO RGD:11323 E RGD:6480464 20161115 CTD MESH:D012834 Silver results in decreased expression of TAGLN mRNA PMID:27131904 11324 TAGLN transgelin gene CHEBI:9141 silver(0) increases expression EXP E RGD:6480464 20180410 CTD MESH:D012834 Silver results in increased expression of TAGLN mRNA PMID:28959546 11324 TAGLN transgelin gene CHEBI:9195 Soman increases expression ISO RGD:3723 E RGD:6480464 20141111 CTD MESH:D012999 Soman results in increased expression of TAGLN mRNA PMID:19281266 11324 TAGLN transgelin gene CHEBI:9422 tebufenpyrad increases expression EXP E RGD:6480464 20210810 CTD MESH:C429623 4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide results in increased expression of TAGLN mRNA PMID:33512557 11324 TAGLN transgelin gene CHEBI:94402 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine decreases expression EXP E RGD:6480464 20170307 CTD MESH:C084597 chlorcyclizine results in decreased expression of TAGLN mRNA PMID:15342952 11324 TAGLN transgelin gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of TAGLN mRNA PMID:38568856 11324 TAGLN transgelin gene CHEBI:955 2,6-dimethoxyphenol multiple interactions EXP E RGD:6480464 20250114 CTD MESH:C010120 [pyrogallol 1,3-dimethyl ether co-treated with Furaldehyde] results in increased expression of and affects the localization of TAGLN protein; [Sodium Chloride co-treated with pyrogallol 1,3-dimethyl ether] results in decreased expression of TAGLN protein; [Sodium Chloride co-treated with pyrogallol 1,3-dimethyl ether] results in increased expression of and affects the localization of TAGLN protein PMID:38598786 11324 TAGLN transgelin gene CHEBI:9566 thioridazine decreases expression EXP E RGD:6480464 20121113 CTD MESH:D013881 Thioridazine results in decreased expression of TAGLN mRNA PMID:15342952|PMID:17175557 11324 TAGLN transgelin gene CHEBI:9665 triadimefon decreases expression EXP E RGD:6480464 20160210 CTD MESH:C032910 triadimefon results in decreased expression of TAGLN mRNA PMID:26705709 11324 TAGLN transgelin gene CHEBI:9753 troglitazone decreases expression ISO RGD:3723 E RGD:6480464 20120918 CTD MESH:C057693 troglitazone results in decreased expression of TAGLN mRNA PMID:21515302 11324 TAGLN transgelin gene CHEBI:9907 ursodeoxycholic acid decreases expression ISO RGD:3723 E RGD:6480464 20120613 CTD MESH:D014580 Ursodeoxycholic Acid results in decreased expression of TAGLN mRNA PMID:15885361 11324 TAGLN transgelin gene CHEBI:9986 vinclozolin affects expression ISO RGD:3723 E RGD:6480464 20141111 CTD MESH:C025643 vinclozolin affects the expression of TAGLN mRNA PMID:19015723 11324 TAGLN transgelin gene CHEBI:9986 vinclozolin increases expression ISO RGD:3723 E RGD:6480464 20141111 CTD MESH:C025643 vinclozolin results in increased expression of TAGLN mRNA PMID:22570695 11352781 FGF7P3 fibroblast growth factor 7 pseudogene 3 gene CHEBI:16469 17beta-estradiol decreases expression EXP E RGD:6480464 20220308 CTD MESH:D004958 Estradiol results in decreased expression of FGF7P3 mRNA PMID:31614463 11352781 FGF7P3 fibroblast growth factor 7 pseudogene 3 gene CHEBI:30614 benzo[a]pyrene diol epoxide I increases expression EXP E RGD:6480464 20160726 CTD MESH:D015123 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of FGF7P3 mRNA PMID:20382639 11352781 FGF7P3 fibroblast growth factor 7 pseudogene 3 gene CHEBI:38940 sunitinib decreases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in decreased expression of FGF7P3 mRNA PMID:31533062 11352781 FGF7P3 fibroblast growth factor 7 pseudogene 3 gene CHEBI:46024 trichostatin A decreases expression EXP E RGD:6480464 20160726 CTD MESH:C012589 trichostatin A results in decreased expression of FGF7P3 mRNA PMID:24935251 11352787 MISP3 MISP family member 3 gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of MISP3 mRNA PMID:38218311 11352787 MISP3 MISP family member 3 gene CHEBI:132267 triptonide decreases expression ISO RGD:1321061 E RGD:6480464 20210406 CTD MESH:C084079 triptonide results in decreased expression of MISP3 mRNA PMID:33045310 11352787 MISP3 MISP family member 3 gene CHEBI:15367 all-trans-retinoic acid increases expression ISO RGD:1321061 E RGD:6480464 20240402 CTD MESH:D014212 Tretinoin results in increased expression of MISP3 mRNA PMID:36189433 11352787 MISP3 MISP family member 3 gene CHEBI:15367 all-trans-retinoic acid multiple interactions ISO RGD:1321061 E RGD:6480464 20240402 CTD MESH:D014212 [mono-(2-ethylhexyl)phthalate co-treated with Tretinoin] results in increased expression of MISP3 mRNA PMID:36189433 11352787 MISP3 MISP family member 3 gene CHEBI:16469 17beta-estradiol decreases expression EXP E RGD:6480464 20220308 CTD MESH:D004958 Estradiol results in decreased expression of MISP3 mRNA PMID:31614463 11352787 MISP3 MISP family member 3 gene CHEBI:16469 17beta-estradiol multiple interactions EXP E RGD:6480464 20190611 CTD MESH:D004958 [Estradiol co-treated with TGFB1 protein] results in decreased expression of MISP3 mRNA PMID:30165855 11352787 MISP3 MISP family member 3 gene CHEBI:16602 trichloroethene increases expression ISO RGD:1310262 E RGD:6480464 20211207 CTD MESH:D014241 Trichloroethylene results in increased expression of MISP3 mRNA PMID:33387578 11352787 MISP3 MISP family member 3 gene CHEBI:166473 Dibutyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C065087 di-n-butylphosphoric acid affects the expression of MISP3 mRNA PMID:37042841 11352787 MISP3 MISP family member 3 gene CHEBI:17243 mono(2-ethylhexyl) phthalate multiple interactions ISO RGD:1321061 E RGD:6480464 20240402 CTD MESH:C016599 [mono-(2-ethylhexyl)phthalate co-treated with Tretinoin] results in increased expression of MISP3 mRNA PMID:36189433 11352787 MISP3 MISP family member 3 gene CHEBI:17606 diiodine multiple interactions ISO RGD:1321061 E RGD:6480464 20231003 CTD MESH:D007455 [Propylthiouracil co-treated with Iodine deficiency] results in decreased expression of MISP3 mRNA PMID:36706583 11352787 MISP3 MISP family member 3 gene CHEBI:24814 indole-3-methanol affects expression ISO RGD:1310262 E RGD:6480464 20161115 CTD MESH:C016517 indole-3-carbinol affects the expression of MISP3 mRNA PMID:21396975 11352787 MISP3 MISP family member 3 gene CHEBI:254496 7,12-dimethyltetraphene increases expression ISO RGD:1310262 E RGD:6480464 20161025 CTD MESH:D015127 9,10-Dimethyl-1,2-benzanthracene results in increased expression of MISP3 mRNA PMID:19480007 11352787 MISP3 MISP family member 3 gene CHEBI:27899 cisplatin multiple interactions EXP E RGD:6480464 20170516 CTD MESH:D002945 [Cisplatin co-treated with jinfukang] results in increased expression of MISP3 mRNA PMID:27392435 11352787 MISP3 MISP family member 3 gene CHEBI:28619 acrylamide decreases expression EXP E RGD:6480464 20210406 CTD MESH:D020106 Acrylamide results in decreased expression of MISP3 mRNA PMID:32763439 11352787 MISP3 MISP family member 3 gene CHEBI:29865 benzo[a]pyrene decreases expression ISO RGD:1310262 E RGD:6480464 20161115 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of MISP3 mRNA PMID:21839799 11352787 MISP3 MISP family member 3 gene CHEBI:29865 benzo[a]pyrene decreases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in decreased methylation of MISP3 promoter PMID:27901495 11352787 MISP3 MISP family member 3 gene CHEBI:33216 bisphenol A decreases expression ISO RGD:1310262 E RGD:6480464 20220208 CTD MESH:C006780 bisphenol A results in decreased expression of MISP3 mRNA PMID:34947998 11352787 MISP3 MISP family member 3 gene CHEBI:34631 chlorpyrifos increases expression ISO RGD:1321061 E RGD:6480464 20230606 CTD MESH:D004390 Chlorpyrifos results in increased expression of MISP3 mRNA PMID:37019170 11352787 MISP3 MISP family member 3 gene CHEBI:34905 paraquat decreases expression ISO RGD:1310262 E RGD:6480464 20210907 CTD MESH:D010269 Paraquat results in decreased expression of MISP3 mRNA PMID:32680482 11352787 MISP3 MISP family member 3 gene CHEBI:6402 leflunomide decreases expression EXP E RGD:6480464 20180410 CTD MESH:C045463 leflunomide results in decreased expression of MISP3 mRNA PMID:28988120 11352787 MISP3 MISP family member 3 gene CHEBI:8502 6-propyl-2-thiouracil decreases expression ISO RGD:1310262 E RGD:6480464 20161115 CTD MESH:D011441 Propylthiouracil results in decreased expression of MISP3 mRNA PMID:24780913 11352787 MISP3 MISP family member 3 gene CHEBI:8502 6-propyl-2-thiouracil multiple interactions ISO RGD:1321061 E RGD:6480464 20231003 CTD MESH:D011441 [Propylthiouracil co-treated with Iodine deficiency] results in decreased expression of MISP3 mRNA PMID:36706583 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:10429 beta-lapachone increases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in increased expression of NMRAL2P mRNA PMID:38218311 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of NMRAL2P mRNA PMID:35811015 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of NMRAL2P mRNA; S-(1,2-dichlorovinyl)cysteine promotes the reaction [Lipopolysaccharides results in increased expression of NMRAL2P mRNA] PMID:35811015 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:17594 hydroquinone increases expression EXP E RGD:6480464 20190910 CTD MESH:C031927 hydroquinone results in increased expression of NMRAL2P mRNA PMID:29221148|PMID:31256213 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:193591 Didecyldimethylammonium increases expression EXP E RGD:6480464 20221018 CTD MESH:C027118 didecyldimethylammonium results in increased expression of NMRAL2P mRNA PMID:32763356 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:27470 folic acid decreases expression EXP E RGD:6480464 20200804 CTD MESH:D005492 Folic Acid results in decreased expression of NMRAL2P mRNA PMID:21867686 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:27899 cisplatin increases expression EXP E RGD:6480464 20170516 CTD MESH:D002945 Cisplatin results in increased expression of NMRAL2P mRNA PMID:27392435 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:27899 cisplatin multiple interactions EXP E RGD:6480464 20170516 CTD MESH:D002945 [Cisplatin co-treated with jinfukang] results in increased expression of NMRAL2P mRNA PMID:27392435 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:2948 azathioprine increases expression EXP E RGD:6480464 20171114 CTD MESH:D001379 Azathioprine results in increased expression of NMRAL2P mRNA PMID:22623647 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of NMRAL2P mRNA PMID:34032870 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of NMRAL2P mRNA PMID:38568856 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:29866 arsenite(3-) multiple interactions EXP E RGD:6480464 20220405 CTD MESH:C015001 arsenite promotes the reaction [G3BP1 protein binds to NMRAL2P mRNA] PMID:32406909 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:31767 lead diacetate increases expression EXP E RGD:6480464 20240702 CTD MESH:C008261 lead acetate results in increased expression of NMRAL2P mRNA PMID:38568856 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:33216 bisphenol A affects expression EXP E RGD:6480464 20191112 CTD MESH:C006780 bisphenol A affects the expression of NMRAL2P mRNA PMID:30903817 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:33216 bisphenol A increases expression EXP E RGD:6480464 20180515 CTD MESH:C006780 bisphenol A results in increased expression of NMRAL2P mRNA PMID:29275510 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:33216 bisphenol A multiple interactions EXP E RGD:6480464 20180116 CTD MESH:C006780 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of NMRAL2P mRNA PMID:28628672 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:34202 2,2',4,4',5,5'-hexachlorobiphenyl increases expression EXP E RGD:6480464 20240702 CTD MESH:C014024 2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of NMRAL2P mRNA PMID:38568856 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:34575 bisphenol F multiple interactions EXP E RGD:6480464 20180116 CTD MESH:C008745 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of NMRAL2P mRNA PMID:28628672 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:34795 3-isobutyl-1-methyl-7H-xanthine multiple interactions EXP E RGD:6480464 20180116 CTD MESH:D015056 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of NMRAL2P mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of NMRAL2P mRNA PMID:28628672 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:34905 paraquat increases expression EXP E RGD:6480464 20220607 CTD MESH:D010269 Paraquat results in increased expression of NMRAL2P mRNA PMID:35182771 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:4031 cyclosporin A increases expression EXP E RGD:6480464 20210608 CTD MESH:D016572 Cyclosporine results in increased expression of NMRAL2P mRNA PMID:33631201 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:41879 dexamethasone multiple interactions EXP E RGD:6480464 20180116 CTD MESH:D003907 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of NMRAL2P mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of NMRAL2P mRNA PMID:28628672 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of NMRAL2P mRNA PMID:35811015|PMID:36576512 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of NMRAL2P mRNA; S-(1,2-dichlorovinyl)cysteine promotes the reaction [Lipopolysaccharides results in increased expression of NMRAL2P mRNA] PMID:35811015 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:4918 O-methyleugenol increases expression EXP E RGD:6480464 20200714 CTD MESH:C005223 methyleugenol results in increased expression of NMRAL2P mRNA PMID:32234424 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:49553 copper(II) chloride increases expression EXP E RGD:6480464 20240702 CTD MESH:C029892 cupric chloride results in increased expression of NMRAL2P mRNA PMID:38568856 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:49662 indometacin multiple interactions EXP E RGD:6480464 20180116 CTD MESH:D007213 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of NMRAL2P mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of NMRAL2P mRNA PMID:28628672 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:64648 enniatin increases expression EXP E RGD:6480464 20230502 CTD MESH:C100264 enniatins results in increased expression of NMRAL2P mRNA PMID:36016515 11353885 NMRAL2P NmrA like redox sensor 2, pseudogene gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of NMRAL2P mRNA PMID:38568856 11520750 RPL10P15 ribosomal protein L10 pseudogene 15 gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20220208 CTD MESH:C006780 bisphenol A results in decreased expression of RPL10P15 mRNA PMID:33670352 11520755 DHFRP3 dihydrofolate reductase pseudogene 3 gene CHEBI:6651 malathion decreases expression EXP E RGD:6480464 20230606 CTD MESH:D008294 Malathion results in decreased expression of DHFRP3 mRNA PMID:37047231 11520759 MTDHP1 metadherin pseudogene 1 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of MTDHP1 mRNA PMID:33212167 11520768 RPL10P13 ribosomal protein L10 pseudogene 13 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of RPL10P13 mRNA PMID:38568856 11520768 RPL10P13 ribosomal protein L10 pseudogene 13 gene CHEBI:39285 chloropicrin increases expression EXP E RGD:6480464 20160822 CTD MESH:C100187 chloropicrin results in increased expression of RPL10P13 mRNA PMID:26352163 11520768 RPL10P13 ribosomal protein L10 pseudogene 13 gene CHEBI:72564 temozolomide increases expression EXP E RGD:6480464 20210706 CTD MESH:C047246 Temozolomide results in increased expression of RPL10P13 mRNA PMID:31758290 11520772 RPL10P12 ribosomal protein L10 pseudogene 12 gene CHEBI:27881 resveratrol multiple interactions EXP E RGD:6480464 20220510 CTD MESH:C059514 [Plant Extracts co-treated with Resveratrol] results in decreased expression of RPL10P12 mRNA PMID:23557933 11520773 RPL10P6 ribosomal protein L10 pseudogene 6 gene CHEBI:39285 chloropicrin increases expression EXP E RGD:6480464 20160822 CTD MESH:C100187 chloropicrin results in increased expression of RPL10P6 mRNA PMID:26352163 11520777 RPL10P8 ribosomal protein L10 pseudogene 8 gene CHEBI:17347 testosterone decreases expression EXP E RGD:6480464 20160822 CTD MESH:D013739 Testosterone results in decreased expression of RPL10P8 mRNA PMID:21592394 11520777 RPL10P8 ribosomal protein L10 pseudogene 8 gene CHEBI:17347 testosterone multiple interactions EXP E RGD:6480464 20160822 CTD MESH:D013739 [Testosterone co-treated with Calcitriol] results in decreased expression of RPL10P8 mRNA PMID:21592394 11520777 RPL10P8 ribosomal protein L10 pseudogene 8 gene CHEBI:17823 calcitriol decreases expression EXP E RGD:6480464 20160822 CTD MESH:D002117 Calcitriol results in decreased expression of RPL10P8 mRNA PMID:21592394 11520777 RPL10P8 ribosomal protein L10 pseudogene 8 gene CHEBI:17823 calcitriol multiple interactions EXP E RGD:6480464 20160822 CTD MESH:D002117 [Testosterone co-treated with Calcitriol] results in decreased expression of RPL10P8 mRNA PMID:21592394 11520777 RPL10P8 ribosomal protein L10 pseudogene 8 gene CHEBI:29699 tunicamycin increases expression EXP E RGD:6480464 20190312 CTD MESH:D014415 Tunicamycin results in increased expression of RPL10P8 mRNA PMID:29453283 11520777 RPL10P8 ribosomal protein L10 pseudogene 8 gene CHEBI:72564 temozolomide increases expression EXP E RGD:6480464 20210706 CTD MESH:C047246 Temozolomide results in increased expression of RPL10P8 mRNA PMID:31758290 11520778 MTDHP4 metadherin pseudogene 4 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of MTDHP4 mRNA PMID:33212167 11531437 XIAPP3 X-linked inhibitor of apoptosis pseudogene 3 gene CHEBI:7553 niclosamide decreases expression EXP E RGD:6480464 20230704 CTD MESH:D009534 Niclosamide results in decreased expression of XIAPP3 mRNA PMID:36318118 11531439 FKBP1BP1 FKBP prolyl isomerase 1B pseudogene 1 gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of FKBP1BP1 mRNA PMID:35811015 11531439 FKBP1BP1 FKBP prolyl isomerase 1B pseudogene 1 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of FKBP1BP1 mRNA PMID:35811015 11531439 FKBP1BP1 FKBP prolyl isomerase 1B pseudogene 1 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of FKBP1BP1 mRNA PMID:35811015 11537410 NPIPB12 nuclear pore complex interacting protein family member B12 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of NPIPB12 mRNA PMID:33212167 11537411 NPIPB2 nuclear pore complex interacting protein family member B2 gene CHEBI:16236 ethanol multiple interactions EXP E RGD:6480464 20181016 CTD MESH:D000431 [[Gasoline co-treated with Ethanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of NPIPB2 mRNA PMID:29432896 11537411 NPIPB2 nuclear pore complex interacting protein family member B2 gene CHEBI:28885 butan-1-ol multiple interactions EXP E RGD:6480464 20181016 CTD MESH:D020001 [[Gasoline co-treated with 1-Butanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of NPIPB2 mRNA PMID:29432896 11537411 NPIPB2 nuclear pore complex interacting protein family member B2 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of NPIPB2 mRNA PMID:38568856 11537411 NPIPB2 nuclear pore complex interacting protein family member B2 gene CHEBI:29699 tunicamycin increases expression EXP E RGD:6480464 20190312 CTD MESH:D014415 Tunicamycin results in increased expression of NPIPB2 mRNA PMID:29453283 11537411 NPIPB2 nuclear pore complex interacting protein family member B2 gene CHEBI:30812 iron dichloride decreases expression EXP E RGD:6480464 20231003 CTD MESH:C029451 ferrous chloride results in decreased expression of NPIPB2 mRNA PMID:35984750 11537411 NPIPB2 nuclear pore complex interacting protein family member B2 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of NPIPB2 mRNA PMID:38568856 11537411 NPIPB2 nuclear pore complex interacting protein family member B2 gene CHEBI:35549 perfluorooctanoic acid increases expression EXP E RGD:6480464 20230502 CTD MESH:C023036 perfluorooctanoic acid results in increased expression of NPIPB2 mRNA PMID:36326898 11537411 NPIPB2 nuclear pore complex interacting protein family member B2 gene CHEBI:39285 chloropicrin increases expression EXP E RGD:6480464 20171010 CTD MESH:C100187 chloropicrin results in increased expression of NPIPB2 mRNA PMID:28476498 11537411 NPIPB2 nuclear pore complex interacting protein family member B2 gene CHEBI:9516 thapsigargin increases expression EXP E RGD:6480464 20190312 CTD MESH:D019284 Thapsigargin results in increased expression of NPIPB2 mRNA PMID:29453283 11537412 NPIPB10P nuclear pore complex interacting protein family, member B10, pseudogene gene CHEBI:31575 ethylparaben decreases expression EXP E RGD:6480464 20240109 CTD MESH:C012313 ethyl-p-hydroxybenzoate results in decreased expression of NPIPB10P mRNA PMID:37690743 11537413 NPIPB13 nuclear pore complex interacting protein family, member B13 gene CHEBI:30778 gallic acid increases expression EXP E RGD:6480464 20210907 CTD MESH:D005707 Gallic Acid results in increased expression of NPIPB13 mRNA PMID:34408198 11537413 NPIPB13 nuclear pore complex interacting protein family, member B13 gene CHEBI:35033 triphenyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C005445 triphenyl phosphate affects the expression of NPIPB13 mRNA PMID:37042841 11537413 NPIPB13 nuclear pore complex interacting protein family, member B13 gene CHEBI:46666 crocidolite asbestos decreases expression EXP E RGD:6480464 20180828 CTD MESH:D017638 Asbestos, Crocidolite results in decreased expression of NPIPB13 mRNA PMID:29523930 11552590 PEG13 paternally expressed 13 gene CHEBI:15368 acrolein multiple interactions EXP E RGD:6480464 20210112 CTD MESH:D000171 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased expression of PEG13 mRNA; [Acrolein co-treated with methacrylaldehyde co-treated with Ozone] results in increased expression of PEG13 mRNA; [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased expression of PEG13 mRNA PMID:32699268|PMID:32845096 11552590 PEG13 paternally expressed 13 gene CHEBI:17747 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:1615533 E RGD:6480464 20241203 CTD MESH:D004051 [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PEG13 mRNA PMID:39150890 11552590 PEG13 paternally expressed 13 gene CHEBI:25812 ozone multiple interactions EXP E RGD:6480464 20210112 CTD MESH:D010126 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased expression of PEG13 mRNA; [Acrolein co-treated with methacrylaldehyde co-treated with Ozone] results in increased expression of PEG13 mRNA; [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased expression of PEG13 mRNA; [Volatile Organic Compounds co-treated with Ozone] results in increased expression of PEG13 mRNA PMID:32699268|PMID:32845096 11552590 PEG13 paternally expressed 13 gene CHEBI:30512 silver atom decreases expression ISO RGD:1615533 E RGD:6480464 20161115 CTD MESH:D012834 Silver results in decreased expression of PEG13 mRNA PMID:27131904 11552590 PEG13 paternally expressed 13 gene CHEBI:33216 bisphenol A decreases expression ISO RGD:1615533 E RGD:6480464 20220208 CTD MESH:C006780 bisphenol A results in decreased expression of PEG13 mRNA PMID:34585602 11552590 PEG13 paternally expressed 13 gene CHEBI:34372 4,4'-sulfonyldiphenol decreases methylation ISO RGD:1615533 E RGD:6480464 20220208 CTD MESH:C543008 bisphenol S results in decreased methylation of PEG13 exon PMID:33297965 11552590 PEG13 paternally expressed 13 gene CHEBI:34595 Butylbenzyl phthalate multiple interactions ISO RGD:1615533 E RGD:6480464 20241203 CTD MESH:C027561 [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PEG13 mRNA PMID:39150890 11552590 PEG13 paternally expressed 13 gene CHEBI:34687 dibutyl phthalate multiple interactions ISO RGD:1615533 E RGD:6480464 20241203 CTD MESH:D003993 [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PEG13 mRNA PMID:39150890 11552590 PEG13 paternally expressed 13 gene CHEBI:34698 diethyl phthalate multiple interactions ISO RGD:1615533 E RGD:6480464 20241203 CTD MESH:C007379 [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PEG13 mRNA PMID:39150890 11552590 PEG13 paternally expressed 13 gene CHEBI:35459 diisononyl phthalate multiple interactions ISO RGD:1615533 E RGD:6480464 20241203 CTD MESH:C012125 [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PEG13 mRNA PMID:39150890 11552590 PEG13 paternally expressed 13 gene CHEBI:36740 alpha-pinene multiple interactions EXP E RGD:6480464 20210112 CTD MESH:C005451 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased expression of PEG13 mRNA; [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased expression of PEG13 mRNA PMID:32699268 11552590 PEG13 paternally expressed 13 gene CHEBI:46666 crocidolite asbestos decreases expression ISO RGD:1615533 E RGD:6480464 20200915 CTD MESH:D017638 Asbestos, Crocidolite results in decreased expression of PEG13 mRNA PMID:29279043 11552590 PEG13 paternally expressed 13 gene CHEBI:46676 tremolite asbestos decreases expression ISO RGD:1615533 E RGD:6480464 20200915 CTD MESH:C005846 tremolite results in decreased expression of PEG13 mRNA PMID:29279043 11552590 PEG13 paternally expressed 13 gene CHEBI:50594 carbon nanotube decreases expression ISO RGD:1615533 E RGD:6480464 20161228 CTD MESH:D037742 Nanotubes, Carbon analog results in decreased expression of PEG13 mRNA; Nanotubes, Carbon results in decreased expression of PEG13 mRNA PMID:25554681 11552590 PEG13 paternally expressed 13 gene CHEBI:79053 diisobutyl phthalate multiple interactions ISO RGD:1615533 E RGD:6480464 20241203 CTD MESH:C025605 [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PEG13 mRNA PMID:39150890 11552590 PEG13 paternally expressed 13 gene CHEBI:9141 silver(0) decreases expression ISO RGD:1615533 E RGD:6480464 20161115 CTD MESH:D012834 Silver results in decreased expression of PEG13 mRNA PMID:27131904 11553952 ERVK3-1 endogenous retrovirus group K3 member 1 gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of ERVK3-1 mRNA PMID:38218311 11553952 ERVK3-1 endogenous retrovirus group K3 member 1 gene CHEBI:166473 Dibutyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C065087 di-n-butylphosphoric acid affects the expression of ERVK3-1 mRNA PMID:37042841 11553952 ERVK3-1 endogenous retrovirus group K3 member 1 gene CHEBI:2504 aflatoxin B1 increases expression EXP E RGD:6480464 20161213 CTD MESH:D016604 Aflatoxin B1 results in increased expression of ERVK3-1 mRNA PMID:27153756 11553952 ERVK3-1 endogenous retrovirus group K3 member 1 gene CHEBI:2825 aristolochic acid A decreases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in decreased expression of ERVK3-1 mRNA PMID:33212167 11553952 ERVK3-1 endogenous retrovirus group K3 member 1 gene CHEBI:28748 doxorubicin decreases expression EXP E RGD:6480464 20181113 CTD MESH:D004317 Doxorubicin results in decreased expression of ERVK3-1 mRNA PMID:29803840 11553952 ERVK3-1 endogenous retrovirus group K3 member 1 gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20180515 CTD MESH:C006780 bisphenol A results in decreased expression of ERVK3-1 mRNA PMID:29275510 11554226 FBXW7-AS1 FBXW7 antisense RNA 1 gene CHEBI:25812 ozone multiple interactions EXP E RGD:6480464 20211109 CTD MESH:D010126 [[Ozone results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA] which results in increased expression of FBXW7 mRNA; [Ozone results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA PMID:33656867 11554226 FBXW7-AS1 FBXW7 antisense RNA 1 gene CHEBI:29191 hydroxyl multiple interactions EXP E RGD:6480464 20211109 CTD MESH:D017665 [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA] which results in increased expression of FBXW7 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA PMID:33656867 11554226 FBXW7-AS1 FBXW7 antisense RNA 1 gene CHEBI:4610 dimethylselenide multiple interactions EXP E RGD:6480464 20211109 CTD MESH:C013503 [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA] which results in increased expression of FBXW7 mRNA; [[Ozone results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA] which results in increased expression of FBXW7 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA; [Ozone results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA PMID:33656867 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:132471 (+)-schisandrin B multiple interactions ISO RGD:1311793 E RGD:6480464 20190910 CTD MESH:C015499 schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of PRAG1 mRNA] PMID:31150632 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:1391 3,4-methylenedioxymethamphetamine decreases expression ISO RGD:1332292 E RGD:6480464 20161213 CTD MESH:D018817 N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of PRAG1 mRNA PMID:20188158 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:16236 ethanol affects expression ISO RGD:1332292 E RGD:6480464 20190507 CTD MESH:D000431 Ethanol affects the expression of PRAG1 mRNA PMID:30319688 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:16243 quercetin increases expression EXP E RGD:6480464 20170516 CTD MESH:D011794 Quercetin results in increased expression of PRAG1 mRNA PMID:21632981 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:16330 17beta-hydroxy-5alpha-androstan-3-one increases expression EXP E RGD:6480464 20190910 CTD MESH:D013196 Dihydrotestosterone results in increased expression of PRAG1 mRNA PMID:29581250 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of PRAG1 mRNA PMID:35811015 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:164200 triclosan increases expression EXP E RGD:6480464 20190507 CTD MESH:D014260 Triclosan results in increased expression of PRAG1 mRNA PMID:30510588 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:16469 17beta-estradiol affects expression EXP E RGD:6480464 20161101 CTD MESH:D004958 Estradiol affects the expression of PRAG1 mRNA PMID:22574217 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:16469 17beta-estradiol increases expression EXP E RGD:6480464 20161101 CTD MESH:D004958 Estradiol results in increased expression of PRAG1 mRNA PMID:24758408|PMID:31614463 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:16469 17beta-estradiol multiple interactions EXP E RGD:6480464 20161101 CTD MESH:D004958 [Estradiol co-treated with Progesterone] results in decreased expression of PRAG1 mRNA; EGF protein promotes the reaction [Estradiol results in increased expression of PRAG1 mRNA] PMID:20660070|PMID:24758408 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:16602 trichloroethene increases expression ISO RGD:1311793 E RGD:6480464 20211207 CTD MESH:D014241 Trichloroethylene results in increased expression of PRAG1 mRNA PMID:33387578 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:166473 Dibutyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C065087 di-n-butylphosphoric acid affects the expression of PRAG1 mRNA PMID:37042841 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:16842 formaldehyde decreases expression EXP E RGD:6480464 20170516 CTD MESH:D005557 Formaldehyde results in decreased expression of PRAG1 mRNA PMID:20655997 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:17026 progesterone multiple interactions EXP E RGD:6480464 20170516 CTD MESH:D011374 [Estradiol co-treated with Progesterone] results in decreased expression of PRAG1 mRNA PMID:20660070 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:17153 propanal increases expression EXP E RGD:6480464 20170516 CTD MESH:C005556 propionaldehyde results in increased expression of PRAG1 mRNA PMID:26079696 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:178012 FR900359 affects phosphorylation EXP E RGD:6480464 20240305 CTD MESH:C000607068 FR900359 affects the phosphorylation of PRAG1 protein PMID:37730182 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:178199 sotorasib multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C000706028 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PRAG1 mRNA PMID:36139627 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:18246 (1->4)-beta-D-glucan multiple interactions ISO RGD:1332292 E RGD:6480464 20230502 CTD MESH:D002482 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of PRAG1 mRNA PMID:36331819 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:205919 clobetasol decreases expression ISO RGD:1332292 E RGD:6480464 20190910 CTD MESH:D002990 Clobetasol results in decreased expression of PRAG1 mRNA PMID:27462272 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:23414 copper(II) sulfate increases expression EXP E RGD:6480464 20161101 CTD MESH:D019327 Copper Sulfate results in increased expression of PRAG1 mRNA PMID:19549813 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:2504 aflatoxin B1 increases expression ISO RGD:1311793 E RGD:6480464 20180703 CTD MESH:D016604 Aflatoxin B1 results in increased expression of PRAG1 mRNA PMID:25378103 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:27385 tetrachloromethane increases expression ISO RGD:1311793 E RGD:6480464 20190910 CTD MESH:D002251 Carbon Tetrachloride results in increased expression of PRAG1 mRNA PMID:31150632 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:27385 tetrachloromethane increases expression ISO RGD:1332292 E RGD:6480464 20161213 CTD MESH:D002251 Carbon Tetrachloride results in increased expression of PRAG1 mRNA PMID:17484886 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:27385 tetrachloromethane multiple interactions ISO RGD:1311793 E RGD:6480464 20190910 CTD MESH:D002251 schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of PRAG1 mRNA] PMID:31150632 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:27563 arsenic atom affects methylation EXP E RGD:6480464 20170516 CTD MESH:D001151 Arsenic affects the methylation of PRAG1 gene PMID:25304211 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:27684 phenylmercury acetate increases expression EXP E RGD:6480464 20161101 CTD MESH:D010662 Phenylmercuric Acetate results in increased expression of PRAG1 mRNA PMID:26272509 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:27684 phenylmercury acetate multiple interactions EXP E RGD:6480464 20161101 CTD MESH:D010662 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA PMID:27188386 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:27732 caffeine affects phosphorylation EXP E RGD:6480464 20221004 CTD MESH:D002110 Caffeine affects the phosphorylation of PRAG1 protein PMID:35688186 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:27789 1,2-dichloroethane affects expression ISO RGD:1332292 E RGD:6480464 20200310 CTD MESH:C024565 ethylene dichloride affects the expression of PRAG1 mRNA PMID:28960355 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:27856 acetamide increases expression ISO RGD:1311793 E RGD:6480464 20200519 CTD MESH:C030686 acetamide results in increased expression of PRAG1 mRNA PMID:31881176 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:27899 cisplatin increases expression EXP E RGD:6480464 20180220 CTD MESH:D002945 Cisplatin results in increased expression of PRAG1 mRNA PMID:27594783 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1332292 E RGD:6480464 20161213 CTD MESH:D013749 Tetrachlorodibenzodioxin affects the expression of PRAG1 mRNA PMID:26377647 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine decreases phosphorylation ISO RGD:1311793 E RGD:6480464 20170516 CTD MESH:D013749 Tetrachlorodibenzodioxin results in decreased phosphorylation of PRAG1 protein PMID:23298284 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP E RGD:6480464 20161101 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of PRAG1 mRNA PMID:20106945|PMID:21632981|PMID:26238291 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1311793 E RGD:6480464 20211207 CTD MESH:D013749 Tetrachlorodibenzodioxin results in increased expression of PRAG1 mRNA PMID:33387578 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:28201 rotenone increases expression ISO RGD:1332292 E RGD:6480464 20210907 CTD MESH:D012402 Rotenone results in increased expression of PRAG1 mRNA PMID:32937126 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:28619 acrylamide decreases expression ISO RGD:1311793 E RGD:6480464 20180410 CTD MESH:D020106 Acrylamide results in decreased expression of PRAG1 mRNA PMID:28959563 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:28748 doxorubicin decreases expression EXP E RGD:6480464 20181113 CTD MESH:D004317 Doxorubicin results in decreased expression of PRAG1 mRNA PMID:29803840 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:28748 doxorubicin increases expression EXP E RGD:6480464 20181113 CTD MESH:D004317 Doxorubicin results in increased expression of PRAG1 mRNA PMID:30031762 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:28794 coumarin affects phosphorylation EXP E RGD:6480464 20221004 CTD MESH:C030123 coumarin affects the phosphorylation of PRAG1 protein PMID:35688186 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:28885 butan-1-ol multiple interactions EXP E RGD:6480464 20181016 CTD MESH:D020001 [[Gasoline co-treated with 1-Butanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PRAG1 mRNA PMID:29432896 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:2948 azathioprine increases expression EXP E RGD:6480464 20171114 CTD MESH:D001379 Azathioprine results in increased expression of PRAG1 mRNA PMID:22623647 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in increased expression of PRAG1 mRNA PMID:34032870|PMID:38568856 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:29865 benzo[a]pyrene increases expression EXP E RGD:6480464 20161101 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of PRAG1 mRNA PMID:21632981|PMID:22316170|PMID:26238291 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:29865 benzo[a]pyrene increases mutagenesis EXP E RGD:6480464 20161101 CTD MESH:D001564 Benzo(a)pyrene results in increased mutagenesis of PRAG1 gene PMID:25435355 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:30512 silver atom increases expression EXP E RGD:6480464 20180410 CTD MESH:D012834 Silver results in increased expression of PRAG1 mRNA PMID:28959546 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:30563 silicon dioxide increases expression ISO RGD:1332292 E RGD:6480464 20161213 CTD MESH:D012822 Silicon Dioxide results in increased expression of PRAG1 mRNA PMID:23221170 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:30966 glycidol increases expression ISO RGD:1311793 E RGD:6480464 20170516 CTD MESH:C004312 glycidol results in increased expression of PRAG1 mRNA PMID:24915197 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:32234 titanium dioxide decreases methylation ISO RGD:1332292 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in decreased methylation of PRAG1 gene PMID:35295148 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:32234 titanium dioxide increases methylation ISO RGD:1332292 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in increased methylation of PRAG1 gene PMID:35295148 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:32497 thioacetamide increases expression ISO RGD:1311793 E RGD:6480464 20170516 CTD MESH:D013853 Thioacetamide results in increased expression of PRAG1 mRNA PMID:23411599|PMID:34492290 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:33216 bisphenol A decreases expression ISO RGD:1311793 E RGD:6480464 20170516 CTD MESH:C006780 bisphenol A results in decreased expression of PRAG1 mRNA PMID:25181051 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:33216 bisphenol A increases expression ISO RGD:1311793 E RGD:6480464 20191210 CTD MESH:C006780 bisphenol A results in increased expression of PRAG1 mRNA PMID:30816183|PMID:34947998 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:33216 bisphenol A increases expression ISO RGD:1332292 E RGD:6480464 20230207 CTD MESH:C006780 bisphenol A results in increased expression of PRAG1 mRNA PMID:32156529 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:34569 Benzo[k]fluoranthene increases expression ISO RGD:1332292 E RGD:6480464 20161213 CTD MESH:C022921 benzo(k)fluoranthene results in increased expression of PRAG1 mRNA PMID:26377693 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:34631 chlorpyrifos increases expression ISO RGD:1332292 E RGD:6480464 20230606 CTD MESH:D004390 Chlorpyrifos results in increased expression of PRAG1 mRNA PMID:37019170 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:35033 triphenyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C005445 triphenyl phosphate affects the expression of PRAG1 mRNA PMID:37042841 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:35064 alpha-Zearalanol multiple interactions ISO RGD:1311793 E RGD:6480464 20240430 CTD MESH:D015029 [Zeranol co-treated with perfluorooctanoic acid] results in decreased expression of PRAG1 mRNA PMID:35163327 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:35456 cadmium dichloride decreases methylation ISO RGD:1311793 E RGD:6480464 20170516 CTD MESH:D019256 Cadmium Chloride results in decreased methylation of PRAG1 promoter PMID:22457795 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:35549 perfluorooctanoic acid multiple interactions ISO RGD:1311793 E RGD:6480464 20240430 CTD MESH:C023036 [Zeranol co-treated with perfluorooctanoic acid] results in decreased expression of PRAG1 mRNA PMID:35163327 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:35559 furan increases expression ISO RGD:1311793 E RGD:6480464 20170516 CTD MESH:C039281 furan results in increased expression of PRAG1 mRNA PMID:27387713 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:38658 dicrotophos increases expression EXP E RGD:6480464 20170725 CTD MESH:C000944 dicrotophos results in increased expression of PRAG1 mRNA PMID:28302478 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:38940 sunitinib increases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in increased expression of PRAG1 mRNA PMID:31533062 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:39421 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:1332292 E RGD:6480464 20230502 CTD MESH:C076994 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of PRAG1 mRNA PMID:36331819 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:39478 buta-1,3-diene decreases expression ISO RGD:1332292 E RGD:6480464 20180703 CTD MESH:C031763 1,3-butadiene results in decreased expression of PRAG1 mRNA PMID:29038090 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:39867 valproic acid affects expression EXP E RGD:6480464 20161101 CTD MESH:D014635 Valproic Acid affects the expression of PRAG1 mRNA PMID:25979313 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:39867 valproic acid decreases expression ISO RGD:1311793 E RGD:6480464 20180828 CTD MESH:D014635 Valproic Acid results in decreased expression of PRAG1 mRNA PMID:29427782 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:39867 valproic acid increases expression EXP E RGD:6480464 20161101 CTD MESH:D014635 Valproic Acid results in increased expression of PRAG1 mRNA PMID:23179753|PMID:24383497|PMID:24935251|PMID:26272509|PMID:27188386 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:39867 valproic acid increases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in increased methylation of PRAG1 gene PMID:29154799 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:39867 valproic acid multiple interactions EXP E RGD:6480464 20161101 CTD MESH:D014635 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA PMID:27188386 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:39867 valproic acid multiple interactions ISO RGD:1332292 E RGD:6480464 20161213 CTD MESH:D014635 Valproic Acid inhibits the reaction [Dexamethasone results in increased expression of PRAG1 mRNA] PMID:23946490 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:4031 cyclosporin A decreases expression EXP E RGD:6480464 20170516 CTD MESH:D016572 Cyclosporine results in decreased expression of PRAG1 mRNA PMID:27989131 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:4031 cyclosporin A increases expression EXP E RGD:6480464 20161101 CTD MESH:D016572 Cyclosporine results in increased expression of PRAG1 mRNA PMID:20106945|PMID:25562108 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:41607 crotonaldehyde decreases expression EXP E RGD:6480464 20161101 CTD MESH:C012796 2-butenal results in decreased expression of PRAG1 mRNA PMID:20471460 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:41879 dexamethasone increases expression ISO RGD:1332292 E RGD:6480464 20161213 CTD MESH:D003907 Dexamethasone results in increased expression of PRAG1 mRNA PMID:23946490 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:41879 dexamethasone multiple interactions ISO RGD:1332292 E RGD:6480464 20161213 CTD MESH:D003907 Valproic Acid inhibits the reaction [Dexamethasone results in increased expression of PRAG1 mRNA] PMID:23946490 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:42588 4-hydroxyphenyl retinamide increases expression ISO RGD:1332292 E RGD:6480464 20180220 CTD MESH:D017313 Fenretinide results in increased expression of PRAG1 mRNA PMID:28973697 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:46024 trichostatin A increases expression EXP E RGD:6480464 20161101 CTD MESH:C012589 trichostatin A results in increased expression of PRAG1 mRNA PMID:24935251|PMID:26272509 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:46024 trichostatin A multiple interactions EXP E RGD:6480464 20161101 CTD MESH:C012589 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA PMID:27188386 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:46195 paracetamol increases expression EXP E RGD:6480464 20180515 CTD MESH:D000082 Acetaminophen results in increased expression of PRAG1 mRNA PMID:29067470 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine decreases expression EXP E RGD:6480464 20210608 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in decreased expression of PRAG1 mRNA PMID:33725128 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of PRAG1 mRNA PMID:35811015 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:46666 crocidolite asbestos decreases expression EXP E RGD:6480464 20180828 CTD MESH:D017638 Asbestos, Crocidolite results in decreased expression of PRAG1 mRNA PMID:29523930 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:46680 serpentine asbestos decreases expression EXP E RGD:6480464 20180828 CTD MESH:D017632 Asbestos, Serpentine results in decreased expression of PRAG1 mRNA PMID:29523930 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:47217 arsane affects methylation EXP E RGD:6480464 20170516 CTD MESH:D001151 Arsenic affects the methylation of PRAG1 gene PMID:25304211 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:4791 endosulfan increases expression ISO RGD:1311793 E RGD:6480464 20180828 CTD MESH:D004726 Endosulfan results in increased expression of PRAG1 mRNA PMID:29391264 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:4811 epoxiconazole increases expression ISO RGD:1332292 E RGD:6480464 20220906 CTD MESH:C109476 epoxiconazole results in increased expression of PRAG1 mRNA PMID:35436446 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:53050 trimellitic anhydride increases expression ISO RGD:1332292 E RGD:6480464 20161213 CTD MESH:C015559 trimellitic anhydride results in increased expression of PRAG1 mRNA PMID:19042947 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:53444 potassium dichromate decreases expression ISO RGD:1332292 E RGD:6480464 20161213 CTD MESH:D011192 Potassium Dichromate results in decreased expression of PRAG1 mRNA PMID:23608068 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:6402 leflunomide increases expression EXP E RGD:6480464 20180410 CTD MESH:C045463 leflunomide results in increased expression of PRAG1 mRNA PMID:28988120 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:6842 methoxychlor affects methylation ISO RGD:1311793 E RGD:6480464 20230905 CTD MESH:D008731 Methoxychlor affects the methylation of PRAG1 gene PMID:35440735 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:73755 1,2-dimethylhydrazine increases expression ISO RGD:1332292 E RGD:6480464 20200804 CTD MESH:D019813 1,2-Dimethylhydrazine results in increased expression of PRAG1 mRNA PMID:22206623 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:75249 potassium chromate decreases expression EXP E RGD:6480464 20170516 CTD MESH:C027373 potassium chromate(VI) results in decreased expression of PRAG1 mRNA PMID:22714537 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:75998 trametinib multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C560077 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of PRAG1 mRNA PMID:36139627 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:78510 dorsomorphin multiple interactions EXP E RGD:6480464 20161228 CTD MESH:C516138 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA; [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA; [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA PMID:27188386 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:8502 6-propyl-2-thiouracil affects expression ISO RGD:1311793 E RGD:6480464 20170516 CTD MESH:D011441 Propylthiouracil affects the expression of PRAG1 mRNA PMID:24780913 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:8502 6-propyl-2-thiouracil increases expression ISO RGD:1311793 E RGD:6480464 20180703 CTD MESH:D011441 Propylthiouracil results in increased expression of PRAG1 mRNA PMID:25825206 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:85990 panobinostat increases expression EXP E RGD:6480464 20161228 CTD MESH:C496932 panobinostat results in increased expression of PRAG1 mRNA PMID:26272509 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:85990 panobinostat multiple interactions EXP E RGD:6480464 20161228 CTD MESH:C496932 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA PMID:27188386 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:8922 Rutecarpine decreases expression EXP E RGD:6480464 20250114 CTD MESH:C028632 rutecarpine results in decreased expression of PRAG1 mRNA PMID:34955744 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:91108 SB 431542 multiple interactions EXP E RGD:6480464 20161228 CTD MESH:C459179 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA; [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA; [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA PMID:27188386 11554295 PRAG1 PEAK1 related, kinase-activating pseudokinase 1 gene CHEBI:9141 silver(0) increases expression EXP E RGD:6480464 20180410 CTD MESH:D012834 Silver results in increased expression of PRAG1 mRNA PMID:28959546 11556256 NCOA4P2 nuclear receptor coactivator 4 pseudogene 2 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of NCOA4P2 mRNA PMID:33212167 11556267 MAPK8IP1P2 mitogen-activated protein kinase 8 interacting protein 1 pseudogene 2 gene CHEBI:39867 valproic acid increases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in increased methylation of MAPK8IP1P2 gene PMID:29154799 11560514 PRXL2AP2 peroxiredoxin like 2A pseudogene 2 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of PRXL2AP2 mRNA PMID:33212167 11561989 LINC01777 long intergenic non-protein coding RNA 1777 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of LINC01777 promoter PMID:27901495 11561989 LINC01777 long intergenic non-protein coding RNA 1777 gene CHEBI:39867 valproic acid decreases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in decreased methylation of LINC01777 gene PMID:29154799 11562003 LINC01634 long intergenic non-protein coding RNA 1634 gene CHEBI:29865 benzo[a]pyrene decreases methylation EXP E RGD:6480464 20201006 CTD MESH:D001564 Benzo(a)pyrene results in decreased methylation of LINC01634 promoter PMID:27901495 11562062 LINC01724 long intergenic non-protein coding RNA 1724 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01724 mRNA PMID:38568856 11562073 LINC01716 long intergenic non-protein coding RNA 1716 gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of LINC01716 intron PMID:30157460 11562073 LINC01716 long intergenic non-protein coding RNA 1716 gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of LINC01716 intron PMID:30157460 11562073 LINC01716 long intergenic non-protein coding RNA 1716 gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of LINC01716 intron PMID:30157460 11562087 LINC01684 long intergenic non-protein coding RNA 1684 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01684 mRNA PMID:38568856 11562143 LINC01698 long intergenic non-protein coding RNA 1698 gene CHEBI:28201 rotenone increases expression EXP E RGD:6480464 20181016 CTD MESH:D012402 Rotenone results in increased expression of LINC01698 mRNA PMID:29955902 11562156 LINC01798 long intergenic non-protein coding RNA 1798 gene CHEBI:164200 triclosan increases expression EXP E RGD:6480464 20190507 CTD MESH:D014260 Triclosan results in increased expression of LINC01798 mRNA PMID:30510588 11562156 LINC01798 long intergenic non-protein coding RNA 1798 gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of LINC01798 intron PMID:30157460 11562156 LINC01798 long intergenic non-protein coding RNA 1798 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of LINC01798 intron PMID:30157460 11562170 LINC01733 long intergenic non-protein coding RNA 1733 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01733 mRNA PMID:38568856 11562268 LINC01659 long intergenic non-protein coding RNA 1659 gene CHEBI:164200 triclosan decreases expression EXP E RGD:6480464 20190507 CTD MESH:D014260 Triclosan results in decreased expression of LINC01659 mRNA PMID:30510588 11562326 ACBD3-AS1 ACBD3 antisense RNA 1 gene CHEBI:25812 ozone multiple interactions EXP E RGD:6480464 20211109 CTD MESH:D010126 [[Ozone results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA] which results in increased expression of ACBD3 mRNA; [Ozone results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA PMID:33656867 11562326 ACBD3-AS1 ACBD3 antisense RNA 1 gene CHEBI:29191 hydroxyl multiple interactions EXP E RGD:6480464 20211109 CTD MESH:D017665 [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA] which results in increased expression of ACBD3 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA PMID:33656867 11562326 ACBD3-AS1 ACBD3 antisense RNA 1 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of ACBD3-AS1 mRNA PMID:34032870 11562326 ACBD3-AS1 ACBD3 antisense RNA 1 gene CHEBI:4610 dimethylselenide multiple interactions EXP E RGD:6480464 20211109 CTD MESH:C013503 [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA] which results in increased expression of ACBD3 mRNA; [[Ozone results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA] which results in increased expression of ACBD3 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA; [Ozone results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA PMID:33656867 11562349 LINC01736 long intergenic non-protein coding RNA 1736 gene CHEBI:16412 lipopolysaccharide decreases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in decreased expression of LINC01736 mRNA PMID:35811015 11562349 LINC01736 long intergenic non-protein coding RNA 1736 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01736 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of LINC01736 mRNA PMID:35811015 11562349 LINC01736 long intergenic non-protein coding RNA 1736 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine decreases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in decreased expression of LINC01736 mRNA PMID:35811015 11562349 LINC01736 long intergenic non-protein coding RNA 1736 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01736 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of LINC01736 mRNA PMID:35811015 11562365 LINC01720 long intergenic non-protein coding RNA 1720 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC01720 intron PMID:30157460 11562365 LINC01720 long intergenic non-protein coding RNA 1720 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01720 mRNA PMID:29301061 11562365 LINC01720 long intergenic non-protein coding RNA 1720 gene CHEBI:72564 temozolomide decreases expression EXP E RGD:6480464 20210706 CTD MESH:C047246 Temozolomide results in decreased expression of LINC01720 mRNA PMID:31758290 11562436 LINC01719 long intergenic non-protein coding RNA 1719 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01719 mRNA PMID:35811015 11562436 LINC01719 long intergenic non-protein coding RNA 1719 gene CHEBI:28748 doxorubicin decreases expression EXP E RGD:6480464 20181113 CTD MESH:D004317 Doxorubicin results in decreased expression of LINC01719 mRNA PMID:29803840 11562436 LINC01719 long intergenic non-protein coding RNA 1719 gene CHEBI:30563 silicon dioxide decreases expression EXP E RGD:6480464 20221004 CTD MESH:D012822 Silicon Dioxide results in decreased expression of LINC01719 mRNA PMID:34973136 11562436 LINC01719 long intergenic non-protein coding RNA 1719 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01719 mRNA PMID:35811015 11562447 LINC01754 long intergenic non-protein coding RNA 1754 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC01754 promoter PMID:30157460 11562447 LINC01754 long intergenic non-protein coding RNA 1754 gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of LINC01754 promoter PMID:30157460 11562447 LINC01754 long intergenic non-protein coding RNA 1754 gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of LINC01754 promoter PMID:30157460 11562468 LINC01770 long intergenic non-protein coding RNA 1770 gene CHEBI:28358 rac-lactic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of LINC01770 mRNA PMID:30851411 11562468 LINC01770 long intergenic non-protein coding RNA 1770 gene CHEBI:78320 2-hydroxypropanoic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of LINC01770 mRNA PMID:30851411 11562517 LINC01753 long intergenic non-protein coding RNA 1753 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC01753 intron PMID:30157460 11562575 LINC01783 long intergenic non-protein coding RNA 1783 gene CHEBI:29865 benzo[a]pyrene multiple interactions EXP E RGD:6480464 20241105 CTD MESH:D001564 [AHR gene mutant form affects the susceptibility to Benzo(a)pyrene] which results in decreased expression of LINC01783 PMID:38036013 11562575 LINC01783 long intergenic non-protein coding RNA 1783 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LINC01783 mRNA PMID:38568856 11562575 LINC01783 long intergenic non-protein coding RNA 1783 gene CHEBI:39867 valproic acid increases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in increased methylation of LINC01783 gene PMID:29154799 11562623 LINC01790 long intergenic non-protein coding RNA 1790 gene CHEBI:34567 benzo[e]pyrene decreases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in decreased methylation of LINC01790 intron PMID:30157460 11562623 LINC01790 long intergenic non-protein coding RNA 1790 gene CHEBI:6820 methapyrilene decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in decreased methylation of LINC01790 intron PMID:30157460 11562633 LINC01787 long intergenic non-protein coding RNA 1787 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in decreased expression of LINC01787 mRNA PMID:29301061 11562633 LINC01787 long intergenic non-protein coding RNA 1787 gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of LINC01787 mRNA PMID:32234424 11562633 LINC01787 long intergenic non-protein coding RNA 1787 gene CHEBI:4918 O-methyleugenol decreases expression EXP E RGD:6480464 20200714 CTD MESH:C005223 methyleugenol results in decreased expression of LINC01787 mRNA PMID:32234424 11562647 LINC01647 long intergenic non-protein coding RNA 1647 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01647 mRNA PMID:38568856 11562647 LINC01647 long intergenic non-protein coding RNA 1647 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LINC01647 mRNA PMID:38568856 11562647 LINC01647 long intergenic non-protein coding RNA 1647 gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of LINC01647 mRNA PMID:38568856 11562680 LINC01744 long intergenic non-protein coding RNA 1744 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LINC01744 mRNA PMID:38568856 11562725 LINC01743 long intergenic non-protein coding RNA 1743 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC01743 intron PMID:30157460 11562725 LINC01743 long intergenic non-protein coding RNA 1743 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in decreased expression of LINC01743 mRNA PMID:29301061 11562725 LINC01743 long intergenic non-protein coding RNA 1743 gene CHEBI:31638 fulvestrant multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C070081 [bisphenol F co-treated with Fulvestrant] results in increased methylation of LINC01743 gene PMID:31601247 11562725 LINC01743 long intergenic non-protein coding RNA 1743 gene CHEBI:34575 bisphenol F multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C008745 [bisphenol F co-treated with Fulvestrant] results in increased methylation of LINC01743 gene PMID:31601247 11562733 LINC01635 long intergenic non-protein coding RNA 1635 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01635 mRNA PMID:35811015 11562733 LINC01635 long intergenic non-protein coding RNA 1635 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01635 mRNA PMID:35811015 11562733 LINC01635 long intergenic non-protein coding RNA 1635 gene CHEBI:53620 methylisothiazolinone increases expression EXP E RGD:6480464 20200714 CTD MESH:C011506 2-methyl-4-isothiazolin-3-one results in increased expression of LINC01635 mRNA PMID:31629900 11562758 LINC01748 long intergenic non-protein coding RNA 1748 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01748 mRNA PMID:38568856 11562832 LINC01639 long intergenic non-protein coding RNA 1639 gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of LINC01639 intron PMID:30157460 11562902 PSG8-AS1 PSG8 antisense RNA 1 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in increased expression of PSG8-AS1 mRNA PMID:29301061 11562967 LINC01730 long intergenic non-protein coding RNA 1730 gene CHEBI:16598 DDE increases expression EXP E RGD:6480464 20240702 CTD MESH:D003633 Dichlorodiphenyl Dichloroethylene results in increased expression of LINC01730 mRNA PMID:38568856 11562967 LINC01730 long intergenic non-protein coding RNA 1730 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of LINC01730 mRNA PMID:33212167 11563019 LINC01808 long intergenic non-protein coding RNA 1808 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01808 mRNA PMID:38568856 11563044 LINC01781 long intergenic non-protein coding RNA 1781 gene CHEBI:2825 aristolochic acid A decreases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in decreased expression of LINC01781 mRNA PMID:33212167 11563044 LINC01781 long intergenic non-protein coding RNA 1781 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01781 mRNA PMID:29301061 11563044 LINC01781 long intergenic non-protein coding RNA 1781 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of LINC01781 intron PMID:30157460 11563044 LINC01781 long intergenic non-protein coding RNA 1781 gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of LINC01781 intron PMID:30157460 11563044 LINC01781 long intergenic non-protein coding RNA 1781 gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of LINC01781 intron PMID:30157460 11563058 LINC01655 long intergenic non-protein coding RNA 1655 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01655 mRNA PMID:38568856 11563327 LINC01768 long intergenic non-protein coding RNA 1768 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01768 mRNA PMID:35811015 11563327 LINC01768 long intergenic non-protein coding RNA 1768 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of LINC01768 mRNA PMID:35811015 11563327 LINC01768 long intergenic non-protein coding RNA 1768 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01768 mRNA PMID:35811015 11563340 LINC01740 long intergenic non-protein coding RNA 1740 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01740 mRNA PMID:35811015 11563340 LINC01740 long intergenic non-protein coding RNA 1740 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of LINC01740 mRNA PMID:35811015 11563340 LINC01740 long intergenic non-protein coding RNA 1740 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01740 mRNA PMID:35811015 11563348 UCA1-AS1 UCA1 antisense RNA 1 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of UCA1-AS1 mRNA PMID:34032870 11563371 LINC01776 long intergenic non-protein coding RNA 1776 gene CHEBI:33216 bisphenol A increases methylation EXP E RGD:6480464 20220308 CTD MESH:C006780 bisphenol A results in increased methylation of LINC01776 gene PMID:31601247 11563379 TMEM269 transmembrane protein 269 gene CHEBI:132267 triptonide increases expression ISO RGD:1557285 E RGD:6480464 20210406 CTD MESH:C084079 triptonide results in increased expression of TMEM269 mRNA PMID:33045310 11563379 TMEM269 transmembrane protein 269 gene CHEBI:178199 sotorasib multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C000706028 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TMEM269 mRNA PMID:36139627 11563379 TMEM269 transmembrane protein 269 gene CHEBI:17833 gentamycin increases expression ISO RGD:1563015 E RGD:6480464 20211207 CTD MESH:D005839 Gentamicins results in increased expression of TMEM269 mRNA PMID:33387578 11563379 TMEM269 transmembrane protein 269 gene CHEBI:27856 acetamide increases expression ISO RGD:1563015 E RGD:6480464 20200519 CTD MESH:C030686 acetamide results in increased expression of TMEM269 mRNA PMID:31881176 11563379 TMEM269 transmembrane protein 269 gene CHEBI:27899 cisplatin decreases expression EXP E RGD:6480464 20170516 CTD MESH:D002945 Cisplatin results in decreased expression of TMEM269 mRNA PMID:27392435 11563379 TMEM269 transmembrane protein 269 gene CHEBI:27899 cisplatin multiple interactions EXP E RGD:6480464 20170516 CTD MESH:D002945 [Cisplatin co-treated with jinfukang] results in decreased expression of TMEM269 mRNA PMID:27392435 11563379 TMEM269 transmembrane protein 269 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of TMEM269 mRNA PMID:33212167 11563379 TMEM269 transmembrane protein 269 gene CHEBI:28619 acrylamide decreases expression ISO RGD:1563015 E RGD:6480464 20180410 CTD MESH:D020106 Acrylamide results in decreased expression of TMEM269 mRNA PMID:28959563 11563379 TMEM269 transmembrane protein 269 gene CHEBI:28619 acrylamide increases expression EXP E RGD:6480464 20210406 CTD MESH:D020106 Acrylamide results in increased expression of TMEM269 mRNA PMID:32763439 11563379 TMEM269 transmembrane protein 269 gene CHEBI:33216 bisphenol A increases methylation ISO RGD:1563015 E RGD:6480464 20180116 CTD MESH:C006780 bisphenol A results in increased methylation of TMEM269 gene PMID:28505145 11563379 TMEM269 transmembrane protein 269 gene CHEBI:33216 bisphenol A multiple interactions ISO RGD:1563015 E RGD:6480464 20230307 CTD MESH:C006780 [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of TMEM269 mRNA PMID:36041667 11563379 TMEM269 transmembrane protein 269 gene CHEBI:34372 4,4'-sulfonyldiphenol multiple interactions ISO RGD:1563015 E RGD:6480464 20230307 CTD MESH:C543008 [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of TMEM269 mRNA PMID:36041667 11563379 TMEM269 transmembrane protein 269 gene CHEBI:34575 bisphenol F multiple interactions ISO RGD:1563015 E RGD:6480464 20230307 CTD MESH:C008745 [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of TMEM269 mRNA PMID:36041667 11563379 TMEM269 transmembrane protein 269 gene CHEBI:34631 chlorpyrifos decreases expression ISO RGD:1557285 E RGD:6480464 20230606 CTD MESH:D004390 Chlorpyrifos results in decreased expression of TMEM269 mRNA PMID:37019170 11563379 TMEM269 transmembrane protein 269 gene CHEBI:35456 cadmium dichloride increases expression ISO RGD:1563015 E RGD:6480464 20210504 CTD MESH:D019256 Cadmium Chloride results in increased expression of TMEM269 mRNA PMID:33453195 11563379 TMEM269 transmembrane protein 269 gene CHEBI:75998 trametinib multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C560077 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of TMEM269 mRNA PMID:36139627 11563408 LINC01792 long intergenic non-protein coding RNA 1792 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LINC01792 mRNA PMID:38568856 11563479 NTRAS non-coding transcript regulating alternative splicing gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of NTRAS mRNA PMID:33212167 11563487 LINC01772 long intergenic non-protein coding RNA 1772 gene CHEBI:181914 Aflatoxin B2 alpha decreases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in decreased methylation of LINC01772 promoter PMID:30157460 11563487 LINC01772 long intergenic non-protein coding RNA 1772 gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of LINC01772 promoter PMID:30157460 11563487 LINC01772 long intergenic non-protein coding RNA 1772 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of LINC01772 promoter PMID:30157460 11563487 LINC01772 long intergenic non-protein coding RNA 1772 gene CHEBI:34567 benzo[e]pyrene decreases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in decreased methylation of LINC01772 promoter PMID:30157460 11563487 LINC01772 long intergenic non-protein coding RNA 1772 gene CHEBI:6820 methapyrilene decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in decreased methylation of LINC01772 promoter PMID:30157460 11563554 LINC01801 long intergenic non-protein coding RNA 1801 gene CHEBI:178199 sotorasib multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C000706028 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LINC01801 mRNA PMID:36139627 11563554 LINC01801 long intergenic non-protein coding RNA 1801 gene CHEBI:38940 sunitinib increases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in increased expression of LINC01801 mRNA PMID:31533062 11563554 LINC01801 long intergenic non-protein coding RNA 1801 gene CHEBI:75998 trametinib multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C560077 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LINC01801 mRNA PMID:36139627 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:10429 beta-lapachone increases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in increased expression of IGFL2-AS1 mRNA PMID:38218311 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:16598 DDE decreases expression EXP E RGD:6480464 20240702 CTD MESH:D003633 Dichlorodiphenyl Dichloroethylene results in decreased expression of IGFL2-AS1 mRNA PMID:38568856 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:2504 aflatoxin B1 increases expression EXP E RGD:6480464 20200714 CTD MESH:D016604 Aflatoxin B1 results in increased expression of IGFL2-AS1 mRNA PMID:32234424 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:28842 octadecanoic acid increases expression EXP E RGD:6480464 20210706 CTD MESH:C031183 stearic acid results in increased expression of IGFL2-AS1 mRNA PMID:32347412 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in decreased expression of IGFL2-AS1 mRNA PMID:38568856 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in increased expression of IGFL2-AS1 mRNA PMID:29301061 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:29865 benzo[a]pyrene increases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of IGFL2-AS1 mRNA PMID:32234424 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:31767 lead diacetate decreases expression EXP E RGD:6480464 20240702 CTD MESH:C008261 lead acetate results in decreased expression of IGFL2-AS1 mRNA PMID:38568856 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:31835 methylparaben decreases expression EXP E RGD:6480464 20240702 CTD MESH:C015358 methylparaben results in decreased expression of IGFL2-AS1 mRNA PMID:38568856 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:33216 bisphenol A decreases expression EXP E RGD:6480464 20240702 CTD MESH:C006780 bisphenol A results in decreased expression of IGFL2-AS1 mRNA PMID:38568856 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:34372 4,4'-sulfonyldiphenol decreases expression EXP E RGD:6480464 20240702 CTD MESH:C543008 bisphenol S results in decreased expression of IGFL2-AS1 mRNA PMID:38568856 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:34575 bisphenol F decreases expression EXP E RGD:6480464 20240702 CTD MESH:C008745 bisphenol F results in decreased expression of IGFL2-AS1 mRNA PMID:38568856 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:35549 perfluorooctanoic acid decreases expression EXP E RGD:6480464 20240109 CTD MESH:C023036 perfluorooctanoic acid results in decreased expression of IGFL2-AS1 mRNA PMID:37738295 11563568 IGFL2-AS1 IGFL2 antisense RNA 1 gene CHEBI:49553 copper(II) chloride decreases expression EXP E RGD:6480464 20240702 CTD MESH:C029892 cupric chloride results in decreased expression of IGFL2-AS1 mRNA PMID:38568856 11563636 LINC01632 long intergenic non-protein coding RNA 1632 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01632 mRNA PMID:35811015 11563636 LINC01632 long intergenic non-protein coding RNA 1632 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01632 mRNA PMID:38568856 11563636 LINC01632 long intergenic non-protein coding RNA 1632 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of LINC01632 mRNA PMID:35811015 11563636 LINC01632 long intergenic non-protein coding RNA 1632 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01632 mRNA PMID:35811015 11563658 LINC01702 long intergenic non-protein coding RNA 1702 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in decreased expression of LINC01702 mRNA PMID:29301061 11563687 LINC01638 long intergenic non-protein coding RNA 1638 gene CHEBI:17243 mono(2-ethylhexyl) phthalate decreases expression EXP E RGD:6480464 20230905 CTD MESH:C016599 mono-(2-ethylhexyl)phthalate results in decreased expression of LINC01638 mRNA PMID:36695872 11563748 LINC01762 long intergenic non-protein coding RNA 1762 gene CHEBI:181914 Aflatoxin B2 alpha decreases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in decreased methylation of LINC01762 intron PMID:30157460 11563748 LINC01762 long intergenic non-protein coding RNA 1762 gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of LINC01762 intron PMID:30157460 11563773 LINC01707 long intergenic non-protein coding RNA 1707 gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of LINC01707 intron PMID:30157460 11563773 LINC01707 long intergenic non-protein coding RNA 1707 gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of LINC01707 intron PMID:30157460 11563773 LINC01707 long intergenic non-protein coding RNA 1707 gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of LINC01707 intron PMID:30157460 11563796 LINC01711 long intergenic non-protein coding RNA 1711 gene CHEBI:28201 rotenone increases expression EXP E RGD:6480464 20181016 CTD MESH:D012402 Rotenone results in increased expression of LINC01711 mRNA PMID:29955902 11563796 LINC01711 long intergenic non-protein coding RNA 1711 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01711 mRNA PMID:38568856 11563796 LINC01711 long intergenic non-protein coding RNA 1711 gene CHEBI:33216 bisphenol A increases expression EXP E RGD:6480464 20200519 CTD MESH:C006780 bisphenol A results in increased expression of LINC01711 mRNA PMID:31715268 11563796 LINC01711 long intergenic non-protein coding RNA 1711 gene CHEBI:39867 valproic acid increases methylation EXP E RGD:6480464 20180410 CTD MESH:D014635 Valproic Acid results in increased methylation of LINC01711 gene PMID:29154799 11563800 LINC01692 long intergenic non-protein coding RNA 1692 gene CHEBI:34372 4,4'-sulfonyldiphenol increases methylation EXP E RGD:6480464 20220308 CTD MESH:C543008 bisphenol S results in increased methylation of LINC01692 gene PMID:31601247 11563826 LINC01807 long intergenic non-protein coding RNA 1807 gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of LINC01807 intron PMID:30157460 11563866 LINC01633 long intergenic non-protein coding RNA 1633 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01633 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01633 mRNA PMID:35811015 11563866 LINC01633 long intergenic non-protein coding RNA 1633 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01633 mRNA PMID:38568856 11563866 LINC01633 long intergenic non-protein coding RNA 1633 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of LINC01633 mRNA PMID:35811015 11563866 LINC01633 long intergenic non-protein coding RNA 1633 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01633 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01633 mRNA PMID:35811015 11563873 LINC01752 long intergenic non-protein coding RNA 1752 gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of LINC01752 promoter PMID:30157460 11563879 LINC01683 long intergenic non-protein coding RNA 1683 gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of LINC01683 promoter PMID:30157460 11563879 LINC01683 long intergenic non-protein coding RNA 1683 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC01683 promoter PMID:30157460 11563892 LINC01789 long intergenic non-protein coding RNA 1789 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01789 mRNA PMID:29301061 11563915 LINC01705 long intergenic non-protein coding RNA 1705 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01705 mRNA PMID:35811015 11563915 LINC01705 long intergenic non-protein coding RNA 1705 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01705 mRNA PMID:38568856 11563915 LINC01705 long intergenic non-protein coding RNA 1705 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LINC01705 mRNA PMID:38568856 11563915 LINC01705 long intergenic non-protein coding RNA 1705 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of LINC01705 mRNA PMID:35811015 11563915 LINC01705 long intergenic non-protein coding RNA 1705 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01705 mRNA PMID:35811015 11563915 LINC01705 long intergenic non-protein coding RNA 1705 gene CHEBI:9495 thiram increases expression EXP E RGD:6480464 20240702 CTD MESH:D013893 Thiram results in increased expression of LINC01705 mRNA PMID:38568856 11563924 LINC01686 long intergenic non-protein coding RNA 1686 gene CHEBI:16412 lipopolysaccharide increases expression EXP E RGD:6480464 20221101 CTD MESH:D008070 Lipopolysaccharides results in increased expression of LINC01686 mRNA PMID:35811015 11563924 LINC01686 long intergenic non-protein coding RNA 1686 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in increased expression of LINC01686 mRNA] PMID:35811015 11563924 LINC01686 long intergenic non-protein coding RNA 1686 gene CHEBI:16842 formaldehyde decreases expression EXP E RGD:6480464 20200317 CTD MESH:D005557 Formaldehyde results in decreased expression of LINC01686 mRNA PMID:27905399 11563924 LINC01686 long intergenic non-protein coding RNA 1686 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Lipopolysaccharides results in increased expression of LINC01686 mRNA] PMID:35811015 11563928 LINC01697 long intergenic non-protein coding RNA 1697 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01697 mRNA PMID:38568856 11563928 LINC01697 long intergenic non-protein coding RNA 1697 gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of LINC01697 mRNA PMID:32234424 11563928 LINC01697 long intergenic non-protein coding RNA 1697 gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of LINC01697 intron PMID:30157460 11563928 LINC01697 long intergenic non-protein coding RNA 1697 gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of LINC01697 intron PMID:30157460 11563967 LINC01750 long intergenic non-protein coding RNA 1750 gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of LINC01750 mRNA PMID:32234424 11563967 LINC01750 long intergenic non-protein coding RNA 1750 gene CHEBI:5063 fipronil multiple interactions EXP E RGD:6480464 20190219 CTD MESH:C082360 [fipronil co-treated with DEET] results in decreased expression of LINC01750 mRNA PMID:28991164 11563967 LINC01750 long intergenic non-protein coding RNA 1750 gene CHEBI:7071 N,N-diethyl-m-toluamide multiple interactions EXP E RGD:6480464 20190219 CTD MESH:D003671 [fipronil co-treated with DEET] results in decreased expression of LINC01750 mRNA PMID:28991164 11564006 LINC01687 long intergenic non-protein coding RNA 1687 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01687 mRNA PMID:38568856 11564028 LINC01786 long intergenic non-protein coding RNA 1786 gene CHEBI:25812 ozone multiple interactions EXP E RGD:6480464 20211109 CTD MESH:D010126 [[Ozone results in increased oxidation of dimethylselenide] which results in increased expression of LINC01786 mRNA] which results in increased expression of SCNN1D mRNA; [Ozone results in increased oxidation of dimethylselenide] which results in increased expression of LINC01786 mRNA PMID:33656867 11564028 LINC01786 long intergenic non-protein coding RNA 1786 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of LINC01786 mRNA PMID:33212167 11564028 LINC01786 long intergenic non-protein coding RNA 1786 gene CHEBI:28619 acrylamide decreases expression EXP E RGD:6480464 20210406 CTD MESH:D020106 Acrylamide results in decreased expression of LINC01786 mRNA PMID:32763439 11564028 LINC01786 long intergenic non-protein coding RNA 1786 gene CHEBI:29191 hydroxyl multiple interactions EXP E RGD:6480464 20211109 CTD MESH:D017665 [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC01786 mRNA] which results in increased expression of SCNN1D mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC01786 mRNA PMID:33656867 11564028 LINC01786 long intergenic non-protein coding RNA 1786 gene CHEBI:4610 dimethylselenide multiple interactions EXP E RGD:6480464 20211109 CTD MESH:C013503 [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC01786 mRNA] which results in increased expression of SCNN1D mRNA; [[Ozone results in increased oxidation of dimethylselenide] which results in increased expression of LINC01786 mRNA] which results in increased expression of SCNN1D mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC01786 mRNA; [Ozone results in increased oxidation of dimethylselenide] which results in increased expression of LINC01786 mRNA PMID:33656867 11564052 LINC01710 long intergenic non-protein coding RNA 1710 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01710 mRNA PMID:38568856 11564061 LINC01703 long intergenic non-protein coding RNA 1703 gene CHEBI:34567 benzo[e]pyrene decreases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in decreased methylation of LINC01703 promoter PMID:30157460 11564061 LINC01703 long intergenic non-protein coding RNA 1703 gene CHEBI:6820 methapyrilene decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in decreased methylation of LINC01703 promoter PMID:30157460 11564090 LINC01778 long intergenic non-protein coding RNA 1778 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01778 mRNA PMID:35811015 11564090 LINC01778 long intergenic non-protein coding RNA 1778 gene CHEBI:2825 aristolochic acid A increases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in increased expression of LINC01778 mRNA PMID:33212167 11564090 LINC01778 long intergenic non-protein coding RNA 1778 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01778 mRNA PMID:35811015 11564204 LINC01806 long intergenic non-protein coding RNA 1806 gene CHEBI:28358 rac-lactic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of LINC01806 mRNA PMID:30851411 11564204 LINC01806 long intergenic non-protein coding RNA 1806 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in decreased expression of LINC01806 mRNA PMID:38568856 11564204 LINC01806 long intergenic non-protein coding RNA 1806 gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of LINC01806 promoter PMID:30157460 11564204 LINC01806 long intergenic non-protein coding RNA 1806 gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of LINC01806 promoter PMID:30157460 11564204 LINC01806 long intergenic non-protein coding RNA 1806 gene CHEBI:78320 2-hydroxypropanoic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of LINC01806 mRNA PMID:30851411 11564219 LINC01679 long intergenic non-protein coding RNA 1679 gene CHEBI:26523 reactive oxygen species multiple interactions EXP E RGD:6480464 20211109 CTD MESH:D017382 [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01679 mRNA] which results in increased expression of CELF3 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01679 mRNA] which results in increased expression of PGPEP1 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01679 mRNA] which results in increased expression of PSMB11 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01679 mRNA] which results in increased expression of ZNF37A mRNA; [Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01679 mRNA PMID:33656867 11564219 LINC01679 long intergenic non-protein coding RNA 1679 gene CHEBI:4610 dimethylselenide multiple interactions EXP E RGD:6480464 20211109 CTD MESH:C013503 [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01679 mRNA] which results in increased expression of CELF3 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01679 mRNA] which results in increased expression of PGPEP1 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01679 mRNA] which results in increased expression of PSMB11 mRNA; [[Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01679 mRNA] which results in increased expression of ZNF37A mRNA; [Reactive Oxygen Species results in increased oxidation of dimethylselenide] which results in increased expression of LINC01679 mRNA PMID:33656867 11564243 LINC01727 long intergenic non-protein coding RNA 1727 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in decreased expression of LINC01727 mRNA PMID:29301061 11564243 LINC01727 long intergenic non-protein coding RNA 1727 gene CHEBI:32234 titanium dioxide decreases methylation ISO RGD:2314650 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in decreased methylation of NKX2-2OS gene PMID:35295148 11564243 LINC01727 long intergenic non-protein coding RNA 1727 gene CHEBI:32234 titanium dioxide increases methylation ISO RGD:2314650 E RGD:6480464 20241001 CTD MESH:C009495 titanium dioxide results in increased methylation of NKX2-2OS promoter PMID:35295148 11564292 LINC01796 long intergenic non-protein coding RNA 1796 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LINC01796 mRNA PMID:38568856 11564309 LINC01701 long intergenic non-protein coding RNA 1701 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01701 mRNA PMID:35811015 11564309 LINC01701 long intergenic non-protein coding RNA 1701 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01701 mRNA PMID:35811015 11565208 LINC01816 long intergenic non-protein coding RNA 1816 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LINC01816 mRNA PMID:38568856 11565208 LINC01816 long intergenic non-protein coding RNA 1816 gene CHEBI:38940 sunitinib decreases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in decreased expression of LINC01816 mRNA PMID:31533062 11565225 LINC01822 long intergenic non-protein coding RNA 1822 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01822 mRNA PMID:38568856 11565225 LINC01822 long intergenic non-protein coding RNA 1822 gene CHEBI:29865 benzo[a]pyrene increases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in increased expression of LINC01822 mRNA PMID:32234424 11565233 LINC01831 long intergenic non-protein coding RNA 1831 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20190409 CTD MESH:C017947 sodium arsenite results in decreased expression of LINC01831 mRNA PMID:29301061 11565233 LINC01831 long intergenic non-protein coding RNA 1831 gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of LINC01831 mRNA PMID:32234424 11565239 LINC01821 long intergenic non-protein coding RNA 1821 gene CHEBI:181914 Aflatoxin B2 alpha decreases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in decreased methylation of LINC01821 intron PMID:30157460 11565253 LINC01819 long intergenic non-protein coding RNA 1819 gene CHEBI:164200 triclosan increases expression EXP E RGD:6480464 20190507 CTD MESH:D014260 Triclosan results in increased expression of LINC01819 mRNA PMID:30510588 11565278 LINC01820 long intergenic non-protein coding RNA 1820 gene CHEBI:28358 rac-lactic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of LINC01820 mRNA PMID:30851411 11565278 LINC01820 long intergenic non-protein coding RNA 1820 gene CHEBI:78320 2-hydroxypropanoic acid increases expression EXP E RGD:6480464 20190910 CTD MESH:D019344 Lactic Acid results in increased expression of LINC01820 mRNA PMID:30851411 11565291 LINC01148 long intergenic non-protein coding RNA 1148 gene CHEBI:31638 fulvestrant multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C070081 [bisphenol A co-treated with Fulvestrant] results in increased methylation of LINC01148 gene PMID:31601247 11565291 LINC01148 long intergenic non-protein coding RNA 1148 gene CHEBI:33216 bisphenol A multiple interactions EXP E RGD:6480464 20220308 CTD MESH:C006780 [bisphenol A co-treated with Fulvestrant] results in increased methylation of LINC01148 gene PMID:31601247 11565303 LINC01823 long intergenic non-protein coding RNA 1823 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01823 mRNA PMID:38568856 11565324 LINC01814 long intergenic non-protein coding RNA 1814 gene CHEBI:34372 4,4'-sulfonyldiphenol decreases expression EXP E RGD:6480464 20210504 CTD MESH:C543008 bisphenol S results in decreased expression of LINC01814 mRNA PMID:33476716 11565338 LINC01345 long intergenic non-protein coding RNA 1345 gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of LINC01345 mRNA PMID:38218311 11565421 LINC01829 long intergenic non-protein coding RNA 1829 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LINC01829 mRNA PMID:38568856 11565963 LINC01836 long intergenic non-protein coding RNA 1836 gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of LINC01836 mRNA PMID:38218311 11565970 LINC01842 long intergenic non-protein coding RNA 1842 gene CHEBI:2504 aflatoxin B1 decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in decreased methylation of LINC01842 intron PMID:30157460 11565970 LINC01842 long intergenic non-protein coding RNA 1842 gene CHEBI:34567 benzo[e]pyrene decreases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in decreased methylation of LINC01842 intron PMID:30157460 11565970 LINC01842 long intergenic non-protein coding RNA 1842 gene CHEBI:6820 methapyrilene decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in decreased methylation of LINC01842 intron PMID:30157460 11565983 PGR-AS1 PGR antisense RNA 1 gene CHEBI:16469 17beta-estradiol increases expression EXP E RGD:6480464 20220308 CTD MESH:D004958 Estradiol results in increased expression of PGR-AS1 mRNA PMID:31614463 11565995 LINC01841 long intergenic non-protein coding RNA 1841 gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of LINC01841 intron PMID:30157460 11565995 LINC01841 long intergenic non-protein coding RNA 1841 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC01841 intron PMID:30157460 11565995 LINC01841 long intergenic non-protein coding RNA 1841 gene CHEBI:34567 benzo[e]pyrene decreases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in decreased methylation of LINC01841 intron PMID:30157460 11565995 LINC01841 long intergenic non-protein coding RNA 1841 gene CHEBI:6820 methapyrilene decreases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in decreased methylation of LINC01841 intron PMID:30157460 11568708 LINC01942 long intergenic non-protein coding RNA 1942 gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of LINC01942 mRNA PMID:38218311 11568708 LINC01942 long intergenic non-protein coding RNA 1942 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01942 mRNA PMID:38568856 11568725 TBC1D3D TBC1 domain family member 3D gene CHEBI:28119 2,3,7,8-tetrachlorodibenzodioxine multiple interactions EXP E RGD:6480464 20180828 CTD MESH:D013749 [Tetrachlorodibenzodioxin co-treated with 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide] results in decreased expression of TBC1D3D mRNA PMID:29704546 11568725 TBC1D3D TBC1 domain family member 3D gene CHEBI:33216 bisphenol A increases expression EXP E RGD:6480464 20231003 CTD MESH:C006780 bisphenol A results in increased expression of TBC1D3D mRNA PMID:37244401 11568725 TBC1D3D TBC1 domain family member 3D gene CHEBI:35033 triphenyl phosphate affects expression EXP E RGD:6480464 20240604 CTD MESH:C005445 triphenyl phosphate affects the expression of TBC1D3D mRNA PMID:37042841 11568805 LINC01888 long intergenic non-protein coding RNA 1888 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01888 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01888 mRNA PMID:35811015 11568805 LINC01888 long intergenic non-protein coding RNA 1888 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP E RGD:6480464 20221101 CTD MESH:C039961 S-(1,2-dichlorovinyl)cysteine results in increased expression of LINC01888 mRNA PMID:35811015 11568805 LINC01888 long intergenic non-protein coding RNA 1888 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01888 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01888 mRNA PMID:35811015 11568822 LINC01950 long intergenic non-protein coding RNA 1950 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LINC01950 mRNA PMID:38568856 11568845 LINC01937 long intergenic non-protein coding RNA 1937 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01937 mRNA PMID:38568856 11568888 LINC01883 long intergenic non-protein coding RNA 1883 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC01883 polyA tail PMID:30157460 11568944 LINC01238 long intergenic non-protein coding RNA 1238 gene CHEBI:10429 beta-lapachone decreases expression EXP E RGD:6480464 20241001 CTD MESH:C014638 beta-lapachone results in decreased expression of LINC01238 mRNA PMID:38218311 11568944 LINC01238 long intergenic non-protein coding RNA 1238 gene CHEBI:164200 triclosan increases expression EXP E RGD:6480464 20190507 CTD MESH:D014260 Triclosan results in increased expression of LINC01238 mRNA PMID:30510588 11568944 LINC01238 long intergenic non-protein coding RNA 1238 gene CHEBI:181914 Aflatoxin B2 alpha increases methylation EXP E RGD:6480464 20211109 CTD MESH:C029753 aflatoxin B2 results in increased methylation of LINC01238 intron PMID:30157460 11568944 LINC01238 long intergenic non-protein coding RNA 1238 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC01238 intron PMID:30157460 11568944 LINC01238 long intergenic non-protein coding RNA 1238 gene CHEBI:2825 aristolochic acid A decreases expression EXP E RGD:6480464 20210608 CTD MESH:C000228 aristolochic acid I results in decreased expression of LINC01238 mRNA PMID:33212167 11568944 LINC01238 long intergenic non-protein coding RNA 1238 gene CHEBI:34567 benzo[e]pyrene increases methylation EXP E RGD:6480464 20190219 CTD MESH:C026487 benzo(e)pyrene results in increased methylation of LINC01238 intron PMID:30157460 11568944 LINC01238 long intergenic non-protein coding RNA 1238 gene CHEBI:53620 methylisothiazolinone increases expression EXP E RGD:6480464 20200714 CTD MESH:C011506 2-methyl-4-isothiazolin-3-one results in increased expression of LINC01238 mRNA PMID:31629900 11568944 LINC01238 long intergenic non-protein coding RNA 1238 gene CHEBI:6820 methapyrilene increases methylation EXP E RGD:6480464 20190219 CTD MESH:D008701 Methapyrilene results in increased methylation of LINC01238 intron PMID:30157460 11569033 LINC01852 long intergenic non-protein coding RNA 1852 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01852 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of LINC01852 mRNA PMID:35811015 11569033 LINC01852 long intergenic non-protein coding RNA 1852 gene CHEBI:178199 sotorasib multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C000706028 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LINC01852 mRNA PMID:36139627 11569033 LINC01852 long intergenic non-protein coding RNA 1852 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LINC01852 mRNA; [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of LINC01852 mRNA PMID:35811015 11569033 LINC01852 long intergenic non-protein coding RNA 1852 gene CHEBI:75998 trametinib multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C560077 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LINC01852 mRNA PMID:36139627 11569073 LINC01915 long intergenic non-protein coding RNA 1915 gene CHEBI:2504 aflatoxin B1 increases methylation EXP E RGD:6480464 20190219 CTD MESH:D016604 Aflatoxin B1 results in increased methylation of LINC01915 polyA tail PMID:30157460 11569073 LINC01915 long intergenic non-protein coding RNA 1915 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LINC01915 mRNA PMID:38568856 11569081 LINC01910 long intergenic non-protein coding RNA 1910 gene CHEBI:29865 benzo[a]pyrene affects methylation EXP E RGD:6480464 20190219 CTD MESH:D001564 Benzo(a)pyrene affects the methylation of LINC01910 promoter PMID:30157460 11569124 LINC01886 long intergenic non-protein coding RNA 1886 gene CHEBI:29678 sodium arsenite increases expression EXP E RGD:6480464 20240702 CTD MESH:C017947 sodium arsenite results in increased expression of LINC01886 mRNA PMID:38568856 11569139 LINC01943 long intergenic non-protein coding RNA 1943 gene CHEBI:35456 cadmium dichloride increases expression EXP E RGD:6480464 20240702 CTD MESH:D019256 Cadmium Chloride results in increased expression of LINC01943 mRNA PMID:38568856 11569139 LINC01943 long intergenic non-protein coding RNA 1943 gene CHEBI:53620 methylisothiazolinone increases expression EXP E RGD:6480464 20200714 CTD MESH:C011506 2-methyl-4-isothiazolin-3-one results in increased expression of LINC01943 mRNA PMID:31629900 11569153 LINC01896 long intergenic non-protein coding RNA 1896 gene CHEBI:28216 methylmercury chloride decreases expression EXP E RGD:6480464 20170516 CTD MESH:C004925 methylmercuric chloride results in decreased expression of LINC01896 mRNA PMID:28001369 11569153 LINC01896 long intergenic non-protein coding RNA 1896 gene CHEBI:39867 valproic acid decreases expression EXP E RGD:6480464 20170516 CTD MESH:D014635 Valproic Acid results in decreased expression of LINC01896 mRNA PMID:28001369 11569188 LINC01954 long intergenic non-protein coding RNA 1954 gene CHEBI:16469 17beta-estradiol increases expression EXP E RGD:6480464 20220308 CTD MESH:D004958 Estradiol results in increased expression of LINC01954 mRNA PMID:31614463 11569188 LINC01954 long intergenic non-protein coding RNA 1954 gene CHEBI:2504 aflatoxin B1 decreases expression EXP E RGD:6480464 20200714 CTD MESH:D016604 Aflatoxin B1 results in decreased expression of LINC01954 mRNA PMID:32234424 11569188 LINC01954 long intergenic non-protein coding RNA 1954 gene CHEBI:29865 benzo[a]pyrene decreases expression EXP E RGD:6480464 20200714 CTD MESH:D001564 Benzo(a)pyrene results in decreased expression of LINC01954 mRNA PMID:32234424 11569188 LINC01954 long intergenic non-protein coding RNA 1954 gene CHEBI:4918 O-methyleugenol decreases expression EXP E RGD:6480464 20200714 CTD MESH:C005223 methyleugenol results in decreased expression of LINC01954 mRNA PMID:32234424 11569188 LINC01954 long intergenic non-protein coding RNA 1954 gene CHEBI:82362 N-Nitrosopyrrolidine decreases expression EXP E RGD:6480464 20200714 CTD MESH:D009242 N-Nitrosopyrrolidine results in decreased expression of LINC01954 mRNA PMID:32234424 11569268 LINC01857 long intergenic non-protein coding RNA 1857 gene CHEBI:16412 lipopolysaccharide multiple interactions EXP E RGD:6480464 20221101 CTD MESH:D008070 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01857 mRNA PMID:35811015 11569268 LINC01857 long intergenic non-protein coding RNA 1857 gene CHEBI:46650 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP E RGD:6480464 20221101 CTD MESH:C039961 [S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of LINC01857 mRNA PMID:35811015 11569283 LINC01881 long intergenic non-protein coding RNA 1881 gene CHEBI:27563 arsenic atom increases methylation EXP E RGD:6480464 20171114 CTD MESH:D001151 Arsenic results in increased methylation of LINC01881 gene PMID:27838757 11569283 LINC01881 long intergenic non-protein coding RNA 1881 gene CHEBI:29678 sodium arsenite decreases expression EXP E RGD:6480464 20211012 CTD MESH:C017947 sodium arsenite results in decreased expression of LINC01881 mRNA PMID:34032870 11569283 LINC01881 long intergenic non-protein coding RNA 1881 gene CHEBI:38397 perfluorononanoic acid increases expression EXP E RGD:6480464 20220111 CTD MESH:C101816 perfluoro-n-nonanoic acid results in increased expression of LINC01881 mRNA PMID:32588087 11569283 LINC01881 long intergenic non-protein coding RNA 1881 gene CHEBI:38940 sunitinib increases expression EXP E RGD:6480464 20191210 CTD MESH:C473478 Sunitinib results in increased expression of LINC01881 mRNA PMID:31533062 11569283 LINC01881 long intergenic non-protein coding RNA 1881 gene CHEBI:47217 arsane increases methylation EXP E RGD:6480464 20171114 CTD MESH:D001151 Arsenic results in increased methylation of LINC01881 gene PMID:27838757 11569316 LINC01929 long intergenic non-protein coding RNA 1929 gene CHEBI:29678 sodium